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Antipsychotic treatment response is unpredictable and variable, and there are 
currently no reliable neurobiological assessment methods to predict treatment 
efficacy. Previous research suggests that psychosis is associated with several 
brain abnormalities and that some of these may be associated with poorer 
treatment response.  
This thesis investigated the association between brain function (salience attribution 
during fMRI and perfusion) and treatment response at 4 and 12 weeks in 
antipsychotic-naïve patients with their first episode of psychosis. Twenty-five first 
episode psychosis patients took part in a longitudinal, open-label intervention 
study, undergoing neuroimaging at baseline and again after treatment with an 
antipsychotic medication. Matched healthy controls were recruited and underwent 
two scans across a similar period. Treatment response in patients was assessed 
using the Positive and Negative Syndrome Scale. Seventeen patients were 
classed as responders and eight were non-responders. These groups were 
compared with each other and with healthy controls to explore differences in 
neurobiological measures associated with treatment response.  
A good response was associated with higher implicit adaptive salience scores at 
baseline. Successful treatment also appeared to be associated with significant 
decreases in implicit aberrant salience, which was seen in responders but not 
non-responders. There were also differences in neural activation patterns of 
responders and non-responders, with greater adaptive salience activation in the 
insula and midbrain in four-week responders than in non-responders before and 
after treatment, respectively. Responders and non-responders also differed in 
terms of resting cerebral blood flow (rCBF), with responders showing higher 
cerebellar and thalamic rCBF at baseline compared with non-responders. 
Furthermore, higher baseline thalamic rCBF was positively correlated with lower 
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positive PANSS scores at follow up, suggesting an association between thalamic 
perfusion and response. Neurobiological differences between responders and 
non-responders were more marked than those between patients and controls.  
Heterogeneity in terms of response to treatment may reflect differences in the 
underlying neurobiology. Such results may inform personalised treatment of 
psychosis, allowing antipsychotic medication to be selected based on 
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1.1.1. Early conceptualisations  
The nonspecific concept of “madness” as wild, chaotic or bizarre behaviour has been a 
part of human culture for many hundreds, if not thousands, of years. With the birth of 
psychiatry in the 1800s as a medical discipline, disordered individuals were mainly 
confined in asylums or hospitals. There were few treatments and few categorisations of 
different subtypes of mental illness. Over the past century, classification of mental 
illness has yielded a range of disorders outlined in diagnostic manuals, such as the 
International Statistical Classification of Diseases and Health Problems (ICD-10; World 
Health Organisation, 2011) and the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5; American Psychiatric Association, 2013). Many mental illnesses are 
now recognised to be commonly occurring and representing a major contribution to the 
global burden of disease (Kessler et al. 2009). 
Early attempts to subdivide 'insanity' into different disorders began in the 19th century. 
The current conception of schizophrenia was developed from early observational work 
of Emil Kraepelin in the 1800s. At this time, Kraepelin laid out an early classification of 
mental disorders in the 6th edition of Psychiatrie (Kraepelin, 1899), identifying what he 
called ‘dementia praecox’ in a number of his patients. This was differentiated from 
manic-depressive illness (encompassing a range of current mood disorders including 
bipolar and major depression) and Kraepelin emphasized the cognitive impairments he 
observed, highlighting the presence of a progressive deterioration over time in such 
patients. Interestingly, Kraepelin saw dementia praecox as primarily the outcome of 
brain disease, a theory that was fiercely contested in the following decades. However, 




Later psychiatrists have focused less on the cognitive symptoms and turned instead to 
the positive symptoms (experiences that are present when normally they would not be) 
and negative symptoms (experiences that represent a loss or impairment of normal 
function or experience). In the early 20th century, Eugen Bleuler revised and expanded 
on Kraepelin’s concept of dementia praecox, and coined the term ‘schizophrenia’ and 
believed that dementia, or progressive deterioration, was not inevitable. He 
emphasized a splitting of psychic functioning (the “split mind” of this term) as a core 
symptom, via which the unity of the personality is lost. Primary symptoms were seen to 
be blunted affect, loosening of associations, ambivalence, and autism. Delusions and 
hallucinations were seen as secondary. In the 1950s, Kurt Schneider also proposed a 
hierarchy of symptoms, with a greater emphasis on delusions and hallucinations. The 
importance of positive symptoms in the diagnosis of schizophrenia still dominates 
today, although more recently cognitive impairments have again begun to assume 
importance and attention (Keefe, 2008).  
Conceptualising mental disorders as discrete illness categories, with commonly 
occurring signs and symptoms that differentiate them from other psychiatric illnesses, 
allows for the development of specific treatment and care management strategies. 
Diagnostic categories indicate specific psychological and pharmacological treatments, 
and guide research into new treatments. However, recent research takes account of 
the complexity and heterogeneity within diagnostic categories. As I shall lay out in this 
thesis, research is beginning to move even further beyond treatments targeted at 
groups of individuals with a shared diagnosis towards personalised treatment, in which 
individual underlying neurobiological and physiological dysfunctions are specifically 
targeted.  
1.1.2. Diagnosis, prevalence and prognosis 
Schizophrenia is a severe mental illness (SMI) affecting just under 1% of the population 
worldwide. It is found in all cultures and geographical regions, and is recognised as a 
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major cause of chronic disability in adults (Perala et al., 2007). Onset is usually in 
adolescence and early adulthood, but is preceded by a period of prodromal subclinical 
symptomatology. Schizophrenia encompasses a range of symptoms not attributable to 
organic pathology, reactions to drugs or severe anxiety. Symptoms can be divided into 
positive psychotic symptoms (delusions, hallucinations, and formal thought disorder) 
and negative symptoms (avolition, apathy, asociality, flattened affect, anhedonia, and 
poverty of thought/speech), alongside neurocognitive deficits. Diagnosis is made 
clinically using operationally defined criteria outlined in the ICD-10 and DSM-IV, and 
there are presently no diagnostic tests available. Psychotic symptoms may however be 
present in several other psychiatric disorders; these are differentiated by several 
factors, including associated substance use, and whether depression or mania are 
present (Van Os and Kapur, 2009).  
This thesis focuses solely on psychotic symptoms within the context of schizophrenia 
(including the diagnoses of schizoaffective and schizophreniform disorders). Still, it 
should be considered that there is considerable heterogeneity of clinical presentations 
even within schizophrenia. Furthermore, prognosis and long-term outcomes of 
schizophrenia are also heterogeneous, with many factors influencing outcome, 
including duration of untreated psychosis (DUP) and socio-environmental factors. This 
makes it difficult to predict the course, outcome of treatment, and long-term prognosis 
of an individual presenting with psychotic symptoms. Although outcome is variable, in 
contrast to accepted pessimism regarding prognosis in psychosis, symptomatic 
remission and recovery are more common than previously suggested (Revier et al., 
2015). However, social recovery appears to be much less common, with fewer 
improvements seen in terms of work and relationships. It is increasingly acknowledged 
that experiencing psychosis does not necessarily indicate that an individual will go on 
to experience chronic schizophrenia. Whilst some patients may remain continuously ill 
or experience further episodes of illness between periods of relative health, others 
experience full recovery after a single episode (Revier et al., 2015).  
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Outcomes, including long-term prognosis and response to antipsychotic treatment are 
variable and unpredictable. Understanding the pathophysiology underlying 
schizophrenia may be helpful in discovering prognostic biomarkers to improve 
prediction of outcomes. This thesis aims to improve understanding of the heterogeneity 
in response to antipsychotic treatment in a sample of first episode psychosis patients. 
Improving prognostic prediction amongst such patients will inform care and 
management of their disorder, potentially allowing greater personalisation of treatment 
and improving outcomes. SMI, such as schizophrenia, have both short- and long-term 
adverse effects on behaviour and function, which are not only damaging to the 
individual and their families, but also represent a significant cost to society (Mangalore 
and Knapp, 2007). Therefore, research to improve the treatment and management of 
the disorder has clear benefits to public health, as well as on a personal level to relieve 
the suffering of those with the disorder.  
1.1.3. Risk factors 
Despite advances in our understanding of schizophrenia, the precise cause of the 
disorder is still unclear, with potential psychosocial, genetic, and biological mechanisms 
of aetiology posited. Generally, a more holistic biopsychosocial model has been 
developed, acknowledging the interplay between these different factors. In particular, 
interactions between genes and the environment have been investigated, although 
challenges remain in elucidating the role of such interactions in the disease aetiology 
(Van Os et al. 2008). 
Obstetric factors, including complications during pregnancy and birth, have been 
implicated in vulnerability for schizophrenia (Cannon et al., 2002), potentially increasing 
the risk of disrupted neurodevelopment. Neurodevelopmental models of schizophrenia 
propose that normal brain development is disrupted in utero with subsequent 
disruptions during critical stages of early childhood and adolescence (Murray et al., 
2008; Owen et al., 2011). Consistent with this, neurological soft signs (that indicate 
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non-specific cerebral dysfunction) are seen in excess in schizophrenia (Dazzan et al., 
2008), and may indicate a more severe, chronic illness course (Varambally et al., 
2012). Further, several brain morphological abnormalities, present before illness onset, 
have been associated with schizophrenia, including ventricular enlargement, reduced 
cortical folding, and lack of normal brain asymmetry, and these may result from 
neurodevelopmental insults (Pantelis et al., 2005). Unfortunately, antipsychotic 
medication complicates the interpretation of brain changes, as observed 
neurobiological alterations could result from the effects of antipsychotics rather than 
being primary to the disease process (see chapter 1.5).  
Genetics represent a further risk factor for schizophrenia. Relatives of those with the 
disorder are at an increased risk of developing the disorder compared with the general 
population. Moreover, first-degree relatives are at greater risk than second-degree 
relatives (Ban, 2004). Twin studies also support a role for genes, with higher 
concordance rates between monozygotic twins than between dizygotic twins (Kringlen, 
2000). These results, alongside heritability estimates of around 80%, suggest a strong 
genetic component to the disorder, yet no one causative gene has been implicated. 
Rather, genetic studies support complex interactions amongst multiple genes (Owen et 
al., 2005). Indeed, genome wide association studies (GWAS) have, in some cases, 
identified over 100 genes that appear to confer risk for schizophrenia (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014). Many genes identified 
by GWAS are biologically plausible, involving neurotransmitter systems that are 
implicated in the aetiology of schizophrenia, such as glutamate, and inflammatory 
pathways of the immune system (Jia et al., 2010).  
Whilst genetics play an important role in the aetiology of schizophrenia, the 
environment also appears to influence risk for the disorder. Trauma and adversity, 
including urbanicity (Pederson and Mortensen, 2001), childhood maltreatment (Sideli et 
al., 2012), and substance abuse, particularly cannabis (Bowers et al., 2001; Di Forti et 
al., 2015) are all associated with schizophrenia. More recently, research has focused 
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on how environmental factors act on genetic vulnerabilities in an interactive way to 
increase risk of psychosis (e.g. Krabbendam and van Os, 2005; Fisher et al., 2014; 
Uher, 2014). Similarly, investigations of interactions between the environment and 
biological vulnerabilities may shed light on the complex aetiological mechanisms 
underlying schizophrenia. For example, stressful life events may interact with 
underlying abnormalities in the biological stress response system (the HPA axis), 
increasing risk for psychosis further than each does alone (Mondelli, 2014; Ajnakina et 
al., 2014). 
Therefore, a complex array of biological, genetic, and psychosocial risk factors likely 
act together to increase the risk of psychosis. The timing at which each factor exerts an 
influence probably differs. Early in development, genetics and obstetric complications 
may set up a predisposition or vulnerability. This vulnerability is likely further modified 
throughout development, sometimes influenced by trauma or adversity during 
childhood, leading to neurobiological alterations that further increase risk. Further risk 
factors during adolescence, including social anxiety, stress and isolation, and abuse of 
drugs, may place further strain on already disordered neurobiology.  
Whilst many different factors may play a role in aetiology, one theory suggests that 
they lead to similar neurobiological dysfunction. Dysfunction within the dopamine 
system (discussed in detail in chapter 1.3) has been termed the ‘final common 
pathway’ on which various aetiological factors converge to produce the symptoms of 
psychosis (Howes and Kapur, 2009). The dopamine theory of schizophrenia has been 
incredibly influential in our understanding of the emergence of psychotic symptoms, 
and is supported by evidence from a variety of sources. Recent modifications to the 
theory consider the potential role of other neurotransmitters in the aetiology of 
schizophrenia, and potentially different patterns of underlying neurobiological 




1.2. Neurobiological factors in schizophrenia aetiology 
Whilst the precise aetiological mechanisms of schizophrenia remain unclear, research 
has revealed numerous underlying neurobiological alterations in individuals with the 
disorder. In particular, the dopamine system has been strongly implicated and the 
dopamine hypothesis remains the dominant theory regarding the neurobiological 
pathophysiology of schizophrenia.  
1.2.1. The dopamine system 
Dopamine is a catecholamine synthesised from tyrosine, which is obtained in the diet, 
and is a precursor in the synthesis of the other catecholamines (noradrenaline and 
adrenaline). Following its release into the synapse, dopamine is catabolised by 
monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT) to form 
homovanillic acid (HVA). Reuptake occurs via energy-dependent Na+ cotransport at 
the dopamine transporter (DAT), found mainly in the extrasynaptic region of the axon 
terminal. 
Dopamine is found throughout the brain, with cell bodies in the midbrain (e.g. 
substantia nigra and ventral tegmental area), hypothalamus and the olfactory bulb. 
Midbrain projections to the forebrain are extensive, with connections to the dorsal and 
ventral striatum, cortical regions (prefrontal cortex, anterior cingulate, perirhinal, and 









Figure 1: Dopamine pathways in the brain  
Four main dopamine pathways are recognised: the mesolimbic, mesocortical, nigrostriatal, and 
tuberinfundibular pathways. (Adapted from Dichter et al. (2012)). 
 
 
There are several important dopamine pathways (Figure 1), which have been attributed 
different functions.  
 Mesolimbic: connecting ventral tegmental area (VTA) to nucleus accumbens, 
amygdala, hippocampus, and medial prefrontral cortex (PFC). The mesolimbic 
pathway is implicated in reward and reinforcement, and dysregulation in this 
pathway may underlie the positive symptoms of schizophrenia. 
 Mesocortical: connecting VTA and frontal cortex. The mesocortical pathway is 
implicated in motivational and emotional responses, and dysregulation of this 
pathway may underlie the negative symptoms of schizophrenia.  
 Nigrostriatal: connecting substantia nigra and striatum. The nigrostriatal 
pathway is implicated in motor control. It is thought that actions of antipsychotic 
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medications in this region underlie extra-pyramidal side effects and other motor 
disorders associated with the treatment of schizophrenia. 
 Tuberinfundibular: connecting hypothalamus and pituitary gland. This system 
regulates prolactin levels. The effects of antipsychotics on this pathway are 
thought to lead to prolactin-related side effects, such as prolactinaemia. 
Within these pathways, five types of dopamine receptors are found, which can be 
divided into two families according to their distribution, pharmacology, and the 
mechanism that follows receptor activation. The D1-like receptor family includes 
receptors D1 and D5, which are widespread through the brain including in the striatum, 
nucleus accumbens, limbic areas, and the thalamus. The D2-like family includes 
receptors D2, D3, and D4, which are found in the striatum (particularly D2), prefrontal 
cortex, cingulate, temporal cortex, entorhinal cortex, amygdala and ventral tegmental 
area. The hypothalamic D2 receptors in particular have been implicated in the action of 
antipsychotic medications and therefore hypothesised to be important in the 
pathogenesis of schizophrenia.  
1.2.2 The dopamine hypothesis  
The original dopamine theory suggested that schizophrenia resulted from a 
hyperdopaminergic state, primarily in the striatum and nucleus accumbens. The theory 
was founded in work that characterized dopamine pathways in the brain and the effects 
of antipsychotics on this neurotransmitter system (Carlsson and Lindqvist, 1963). 
Potential hyperdopaminergia was consistent with the observation that positive 
symptoms appeared to reduce following the administration of D2 receptor blockers 
(Angrist and Gershon, 1970). Furthermore, it was observed that the clinical dosage of 
antipsychotic drugs correlated with the degree of D2 receptor blockade they exhibited 
(Creese et al. 1976; Seeman and Lee 1975). Additionally, many drugs that increase 
dopamine levels (such as amphetamine) are associated with psychotic experiences 
(Tost et al., 2010). These observations, alongside others, lent support to the initial 
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formulation of the dopamine hypothesis by van Rossum in the 1960s (van Rossum, 
1966).  
However, there were some aspects of psychosis and its treatment that were not well 
explained by the original dopamine hypothesis. For example, whilst antipsychotics 
targeting D2 receptors reduced positive symptoms, they did not greatly affect negative 
or cognitive symptoms, and it appeared unlikely that these resulted from mesolimbic 
hyperdopaminergia. Furthermore, drugs that enhance dopamine signalling, such as 
amphetamine, led to exacerbations of symptoms in patients with psychosis at doses 
that did not induce psychosis in healthy individuals (Lieberman et al., 1987). These 
findings suggested that the pathophysiology underlying psychosis was more 
complicated than the original theory suggested and so the dopamine theory was 
reformulated (Davis et al. 1991). This reformulation posited that negative and cognitive 
symptoms resulted from dysfunction in D1 receptor signalling in the PFC. The theory 
posited that, rather than a global hyperdopaminergia, dopamine signalling was 
dysregulated, leading to hypodopaminergia in some regions, such as the PFC.  
The reformulated dopamine theory was supported by preclinical studies illustrating the 
importance of D1 receptors in PFC function (Goldman-Rakic et al., 2000), as well as by 
functional imaging in humans showing altered PFC activation in schizophrenia (Knable 
and Weinberger, 1997). In particular, imaging suggests a role of D1 receptors in 
cognitive function in schizophrenia (Abi-Dargham et al., 2002). Molecular imaging 
techniques, such as positron emission tomography (PET) and single photon emission 
computed tomography (SPECT), provide further evidence. Such studies have reported 
increased dopamine function in schizophrenia, particularly the striatum (e.g. Laruelle et 
al., 1996; Abi-Dargham et al., 1998). However, some also probed prefrontal dopamine, 
showing an upregulation of D1 receptors in this region, which may signify a long-term 
dopamine deficit in this region (Abi-Dargham, 2003). Increased mesolimbic dopamine 
function may result from dysfunctional mesocortical dopamine function. In healthy 
individuals, normal cortical function inhibits subcortical dopamine via reciprocal 
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interactions between regions, such as the striatum and the PFC. In schizophrenia, this 
inhibition may no longer be present (i.e. there is disinhibition) due to a dysfunction of 
the mesocortical dopamine system. As a result, mesolimbic dopamine function may 
increase (Weinberger, 1987).  
Therefore, rather than a simple hyperdopaminergic model, the current view is that 
dopamine signalling may be dysregulated, whereby subcortical (mesolimbic) signalling 
is increased and cortical (mesocortical) afferents to the PFC show reduced activation, 
resulting in positive and negative/cognitive symptom profiles, respectively.  
1.2.3 The role of other neurotransmitters in schizophrenia 
Whilst disrupted dopamine signalling has received the most attention in schizophrenia 
research, the importance of other neurotransmitter systems has more recently been 
recognised. A hypothesis of dopamine dysfunction is no longer thought sufficient to 
explain the symptoms of psychosis or the effect of antipsychotic medications to reduce 
symptoms. In particular, the role of serotonin and glutamate has received increasing 
attention. Indeed, it is becoming increasingly clear that each neurotransmitter system 
should not be considered in isolation. Rather, the disorder is likely determined by a 
complex pattern of changes within a number of neurotransmitter systems and brain 
regions. 
1.2.3.1 Serotonin 
Two major lines of research support the assertion that serotonin plays a role in the 
neuropathology of schizophrenia. Initially, it was observed that certain hallucinogens, 
such as LSD, elicit psychotic symptoms in healthy individuals (Paparelli et al., 2011). 
Serotonin was implicated in the action of LSD, with studies reporting direct agonist 
action at serotonin receptors in the central nervous system (Anden et al. 1968). More 
specifically, animal studies implicated the serotonin-2 receptor, as this subtype 
appeared to mediate the psychotomimetic properties of hallucinogens (Nichols, 2004). 
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The role of serotonin-2 receptors was further supported by post-mortem studies 
reporting reduced serotonin receptors in the prefrontal cortex in the brains of patients 
with schizophrenia (Mita et al., 1986).  
The second major factor influencing theories of serotonin function in schizophrenia 
related to the development of the second-generation antipsychotics (SGAs). Whilst 
research with hallucinogenic drugs had implicated serotonin in schizophrenia, drugs 
that target serotonin alone do not treat the psychotic symptoms (Kapur and Mamo, 
2003). However, the introduction of clozapine, and subsequent SGAs, suggested that 
serotonergic action complemented action at other receptors, including dopamine, to 
endow a substance with antipsychotic properties. More details regarding mechanisms 
of action of antipsychotic medications can be found in chapter 1.4 (page 29).  
1.2.3.2 Glutamate 
More recently, a potential role for glutamate in psychosis has been posited (Olney et al. 
1999). This hypothesis is rooted in observations from the 1950s that drugs that target 
the NMDA receptor, such as phenycyclidine (PCP) and ketamine, have psychotogenic 
properties in humans, (Moghaddam and Javitt, 2012). Such substances not only induce 
positive symptoms, but also negative symptoms (Krystal et al., 1994). Whilst increased 
glutamate levels by ketamine increase associated psychotic symptomatology, the 
effects are ameliorated by antipsychotics, which act to reduce glutamate levels. This 
suggests that glutamate plays a role in response to antipsychotic treatment (Kargieman 
et al., 2008). Indeed, it is suggested that glutamate dysfunction, as opposed to 
dysregulation of other neurotransmitter systems, may underlie treatment-resistance in 
certain individuals (Stone et al., 2007).  
Pharmacological evidence for a role of glutamate has been further supported by 
neuroimaging research. For example, single photon emission tomography has used 
tracers to show limited NMDA availability in the hippocampus is related to increased 
severity of symptoms (Pilowsky et al. 2006). Proton magnetic resonance spectroscopy 
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(1H-MRS) can probe glutamate levels in the brain and a recent study using this 
technique reported higher levels of glutamate in the anterior cingulate cortex of FEP, 
which was associated with increased scores on the PANSS negative symptom 
subscale (Egerton et al., 2012). However, whilst 1H-MRS has shown altered glutamate 
signalling, patterns of change are variable (Merritt et al., 2014). Therefore, 
neuroimaging evidence supports the presence of glutamatergic abnormalities in 
schizophrenia, but the precise patterns of pathophysiology and the mechanisms by 




1.3. Dopamine and the aberrant salience model of psychosis 
The dopamine hypothesis of psychosis provided a partial explanation of the biological 
basis of psychotic symptoms, but did not account for the phenomenological experience 
of the disorder. To overcome this, Kapur (2003) proposed a framework that attempted 
to bridge the gap between the brain and the mind in psychosis. The framework drew on 
evidence that dopamine plays a role in reward processing and the attribution of 
salience to stimuli. Not only does such an account relate the phenomenology of 
psychosis to the biological dysfunctions reported in psychosis, it also can provide a 
framework to explain the effects of pharmacological treatment of the symptoms. The 
sections that follow outline the role of dopamine in reward and salience, before 
describing the aberrant salience hypothesis of schizophrenia. Lastly, the chapter 
outlines the measurement and investigation of aberrant salience in schizophrenia.  
1.3.1 Reward and motivational salience 
Pleasant or positively reinforcing stimuli are referred to as rewards or rewarding. 
However, a more accurate description would suggest that reward is a “composite 
psychological process requiring multiple brain systems” (Berridge and Kringelback, 
2008, p20). Indeed, it is purported to consist of three components: ‘liking’ (the hedonic 
pleasurable experience of reward), ‘wanting’ (incentive motivational aspects of reward), 
and ‘learning’ (representations and associations related to rewarding or punishing 
stimuli based on past experiences) (Berridge and Kringelbach, 2008). Preclinical 
studies suggest opioid systems underlie the hedonic aspects of reward, whilst wanting 
and learning are associated with dopaminergic signalling. Here, the focus will be 
specifically on ‘wanting’ (i.e. motivational aspects of reward processing) in 
schizophrenia, and associated dopaminergic signalling.  
Incentive motivational processes involve stimuli capturing attention and driving 
behaviour, whilst incorporating current physiological state and previously learned 
associations to determine context-appropriate behaviour (Berridge, 2012). This process 
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prioritises stimuli in the environment, such that limited cognitive resources can be 
appropriately allocated by focusing on the important components of what is generally a 
busy sensory environment. Stimuli that capture attention (salient stimuli) may be either 
internal or external, and once ‘tagged’ as important they drive the individual to either 
approach the stimulus, if this is rewarding, or avoid the stimulus, if it is punishing. Thus, 
salient stimuli capture attention, driving goal-directed thought and behaviour.  
Research suggests that the importance or salience of stimuli is signalled by dopamine. 
Early animal research reported that when animals are implanted with electrodes in 
dopamine-rich regions, they self-stimulate repeatedly, in preference to food and sex 
(Olds, 1958). Further evidence for a role of dopamine in reward is derived from 
research on addiction. For example, a number of addictive drugs act to increase 
dopamine levels, potentially contributing to their ability to create dependence (Wise and 
Hoffman, 1992). Furthermore, separation of the neural substrates for the different 
components of reward implicate a specific role for dopamine in motivation for rewards. 
For example, dopamine depletion in the nucleus accumbens leads to decreased 
investigatory or instrumental responses, but does not affect consummatory responses 
in animals (Berridge and Robinson, 1998). Thus, a dopamine-depleted mouse will not 
work for access to food by pressing a lever, but if the food is freely accessible then the 
mouse will eat it. This suggests that dopamine mediates the ‘wanting’ (motivational) 
component of reward, but does not impact on the pleasurable aspects of a rewarding 
stimulus (the ‘liking’ components).  
Seminal work by Schultz and colleagues (1997) showed recordings of dopamine 
neuron activation in response to environmental stimuli from individual cells in primates. 
Dopamine neurons showed phasic activation in response to unpredicted or novel 
rewards. However, when reward was fully predicted by a predictive stimulus 
(conditioned stimulus, CS+), dopamine was no longer released on presentation of the 
reward. Rather, the CS+ now elicited a phasic dopamine response (Schultz et al., 
1997). Thus, mesocorticolimbic dopamine signalling may represent prediction (the 
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mismatch between expectation and receipt of a reward) rather than signalling reward 
per se. The size of a prediction error depends on several factors, including the 
uncertainty, magnitude, and timing of reward. Behaviour and cognition are adjusted 
according to the size of the dopamine response, which is determined by the size of the 
prediction error. A larger dopamine response signals a more salient stimulus, and 
increases the likelihood that it will direct attention and behaviour.  
Dopamine may not solely signal reward, but is also implicated in aversive signalling, 
although this remains a topic of debate (Schultz, 2010). Phasic dopamine responses to 
aversive stimuli have been recorded in rats (e.g. Mantz, 1989), and some suggest that 
factors other than reward, like novelty, may be more important (Winton-Brown et al., 
2014). However, novelty may be intrinsically rewarding, as animals have been shown 
to orient to both aversive and rewarding novel stimuli (Heinz et al., 2009).  
In summary, dopamine has been implicated in the signalling of incentive motivational 
aspects of reward. Dopamine is released in a phasic manner in response to important, 
novel stimuli (or CS+). These signals ensure attention is paid to the stimuli (whether 
external or internal) and subsequently drive behaviour. The aberrant salience 
hypothesis, outlined in the next section, suggests that these processes may be altered 
in psychosis.  
1.3.2 Aberrant salience hypothesis of psychosis 
Whilst research has suggested that dopamine is dysregulated in psychosis, it was not 
previously clear how this related to the subjective experience of symptoms in the 
disorder. Any complete understanding of psychosis requires that neurobiological-level 
explanations of symptomatology are integrated with psychological and 
phenomenological descriptions of psychosis (Jensen and Kapur, 2009).  
The aberrant salience hypothesis (Figure 2) was proposed as a framework to resolve 
this issue (Kapur, 2003). Motivational salience was posited as the intermediate process 
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connecting brain disturbances (specifically dopamine dysfunction) to symptoms, thus 
linking biological explanations with the psychological experience of the disease. The 
theory suggests that normal processes of attributing salience to stimuli, outlined above, 
are disrupted in psychosis because of abnormal dopamine signalling.  
 
Figure 2: The aberrant salience hypothesis  
Illustration of the aberrant salience theory, showing how symptoms develop due to altered 
dopamine signalling (orange), how antipsychotics affect these processes (blue), and the negative 
consequences of medication or stopping treatment (red). Numbers indicate the chronology of the 
events. (Adapted from Kapur et al., 2005).  
 
The aberrant salience theory proposes that mistaken attributions can occur when 
dopamine signalling is disrupted, as this would in turn disrupt the normal processes of 
salience attribution. In a hyperdopaminergic state, phasic dopamine responses, which 
are normally elicited by important novel stimuli, would be elicited chaotically due to the 
disruption in dopamine firing (Kapur et al., 2005). This would lead to aberrant attribution 
of salience to neutral stimuli, such that irrelevant stimuli are imbued with significance 
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and meaning. Thus, neutral stimuli may attract attention, and influence behaviour and 
cognition inappropriately when associated with a dopamine burst, which ‘labels’ them 
as important. This has been termed “aberrant salience” (Kapur, 2003), and may 
underlie the positive symptoms of psychosis, particularly delusions (Roiser et al., 
2009). Conversely, “adaptive salience” is the process of correctly attributing importance 
to stimuli that are novel or significant, for example if they are predictive of reward. 
Adaptive salience may too be disrupted in psychosis, leading to negative symptoms, 
such as amotivation, blunt affect, and withdrawal (Roiser et al., 2009).  
The aberrant salience hypothesis is consistent with clinical reports of the experience of 
schizophrenia. In the prodromal period, accounts describe a subjective feeling of 
increased aberrant salience. Individuals have described a feeling that many stimuli 
begin to attract their attention and seem to hold significance, although they were 
previously unimportant. This ‘delusional mood’ does not constitute overt psychosis, and 
a further stage is required to understand how this develops into the delusions and 
hallucinations that characterise the disorder. Indeed, the presence of aberrant salience 
and its associated neural correlates have been observed in the general population, 
associated with subclinical psychotic symptoms (Van Os et al. 2009). Further, aberrant 
salience has been observed in people at ultra-high risk for psychosis, prior to transition 
to psychosis (Roiser et al. 2013). 
To explain how experiences of heightened saliency develop into acute psychotic 
symptoms, impairments in reasoning may also be necessary. This framework has been 
particularly applied to the development of delusions. Howes and Kapur (2009) 
suggested that delusions arise when an individual attempts to explain their unusual 
subjective experiences of heightened saliency. They are therefore the explanations that 
an individual develops to understand the experienced importance in connection to 
previously ignored stimuli. This is consistent with the idiosyncratic nature of delusions, 
as people incorporate their experiences and culture into their explanations. It may also 
serve to explain the development of hallucinations, in which salience is aberrantly 
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attributed to internal representations of memories and percepts (Kapur, 2003). 
Furthermore, the feelings of threat and anxiety related to these sorts of experiences 
may be associated with dopamine dysfunction in limbic regions such as the amygdala 
(Pankow, 2012).  
Antipsychotic medications have also been incorporated within the salience attribution 
framework. Kapur (2003) proposed that the ‘shared psychological effect’ of all 
antipsychotics was to dampen salience through the dopamine antagonism that 
reverses hyperdopaminergia underlying psychotic symptoms. Rather than acting 
directly on thoughts or ideas therefore, antipsychotics simply alter dopaminergic 
signalling, producing a context in which new aberrant salience attributions are less 
likely to form, and in which previously formed attributions are able to extinguish. This is 
consistent with subjective reports that following treatment delusional beliefs decrease 
in their significance and importance, and so have less influence on daily function (e.g. 
Winkleman, 1954, cited in Kapur, 2003). In addition, relapse often occurs when 
antipsychotic treatment is stopped, consistent with a model in which the return of 
dysregulated dopamine signalling reintroduces a context in which aberrant salience 
attributions are more likely to form (Gitlin et al. 2001). Thus, treatment may temporarily 
dampen salience associated with disrupted dopamine but does not fundamentally alter 
the pathophysiology underlying psychosis. 
Whilst the salience attribution theory can effectively explain the mechanisms by which 
dopamine dysfunction leads to positive symptoms (particularly delusions), it is less able 
to account for the origin of negative and cognitive symptoms. It is possible that 
dopamine dysfunction plays a role in symptoms such as avolition and anhedonia. Here, 
hypodopaminergia would lead to a failure to assign importance to novel and important 
stimuli (i.e. a failure of adaptive salience). Furthermore, antipsychotic treatment can 
produce a ‘deficit-like syndrome’, which may be caused by a further dampening of 
adaptive salience attribution (Kapur, 2003). As described above, neurotransmitters 
other than dopamine may also play a role, particularly glutamate, which interacts with 
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dopamine in complex and still not entirely understood ways. Further work is required to 
elucidate the mechanisms by which neurotransmitters interact with one another, and 
how this might relate to the processes of salience attribution.  
1.3.3 Measuring salience  
Various methodologies have been used to investigate motivational salience processes. 
Many studies have used classical conditioning paradigms, the most widely used of 
which is the monetary incentive delay task (MID) (Knutson et al. 2001). In this task, 
reaction times to cued targets determine rewards, with several trial conditions usually 
composed of certain or uncertain outcomes (a gain, neutral or a loss). The task can 
provide behavioural indices of reward processing in the form of hit rates or reaction 
times, as well as neural activation associated with reward anticipation and receipt. 
Other methods have also been used to investigate reward learning and its importance 
in schizophrenia, such as associative causal learning tasks (Corlett et al. 2004) and 
cued-reinforcement reaction time tasks (Murray et al. 2008).  
The task that will be used in this thesis, the Salience Attribution Task (SAT), was 
developed by Roiser and colleagues (2009) to specifically probe motivational salience. 
The SAT is a speeded-response task with monetary rewards, providing measures of 
adaptive and aberrant salience (full details provided in Methods, page 109). Four 
stimuli are used, characterized by colour and form, with the probability of reinforcement 
dependent on just one of these (task-relevant), but not the other (task-irrelevant). By 
comparing the responses for the task-relevant and task-irrelevant dimensions, 
measures of adaptive and aberrant motivational salience can be estimated.  
Adaptive salience within this paradigm is defined as the ability of an individual to 
differentiate between low and high probability cues, and attach importance to stimuli 
predictive of reward. Aberrant salience provides a measure of whether participants 
erroneously differentiate between cues that are equally associated with reward, such 
that importance is attributed to a neutral cue. Both of these measures are assessed by 
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reaction times (implicitly) and a visual analogue scale (explicitly). Unlike studies using 
the MID, the SAT specifically tests salience attributions, and can provide behavioural 
and neural measures of both aberrant and adaptive salience processes. This is an 
advantage in studies of schizophrenia, because both adaptive and aberrant salience 
processes may be altered in the disorder and this may be seen at both behavioural and 
neural levels, as I will outline in the following sections.  
1.3.4 Studies of salience attribution 
Since the aberrant salience theory was proposed, several studies have investigated 
salience attribution and reward processing using behavioural and fMRI paradigms. In 
the following sections, I outline the evidence for abnormalities in reward processing of 
individuals with psychosis. Studies are organised according to the patient population in 
which they were carried out (prodromal, drug-naïve/unmedicated psychosis, first 
episode psychosis, and chronic schizophrenia) to illustrate the abnormalities seen at 
different stages in the course of schizophrenia.  
1.3.4.1 Studies in patients with chronic schizophrenia 
Studies investigating neural activation underlying incentive salience processing in 
chronic, medicated patients with schizophrenia consistently report abnormalities in 
striatal, hippocampal, and frontal regions (Koch et al., 2010; Walter et al., 2009; Simon 
et al., 2010; Waltz et al., 2010; Diaconescu et al., 2011; Gradin et al., 2011/2013; Dowd 
and Barch, 2012; da Silva Alves et al., 2013). Whilst similar networks of regions are 
activated in anticipation of, or response to, reward in patients, certain regions show 
decreased activation compared with healthy controls. For example, Gradin and 
colleagues (2013) reported activation in the striatum, amygdala-hippocampal complex, 
and midbrain of healthy controls, and functional connectivity between the insula and 
anterior cingulate cortex during reward learning. In patients, activation was detected in 
the insula and anterior cingulate cortex, but not in the other regions. Moreover, the 
same study reported reduced functional connectivity between the insula and anterior 
22 
 
cingulate. In a study of 10 patients with schizophrenia and 12 healthy controls who 
underwent two scans during the MID task, lower activation in patients compared with 
healthy controls in the superior temporal cortex and posterior cingulate was reported 
during reward anticipation (da Silva Alves et al., 2013).  
The specificity of salience processing deficits to schizophrenia is not clear, but is 
supported to some degree by studies comparing different disorders. Comparing 
instrumental reward learning in patients with schizophrenia or depression versus 
healthy controls, abnormalities have been reported in patients with both disorders 
(Gradin et al., 2011). However, the patterns of abnormality differed. In depression, 
there was reduced prediction error related to anhedonia in the striatum and midbrain. In 
schizophrenia, prediction error signals were reduced in the caudate, thalamus, insula 
and amygdala-hippocampal complex, with the degree of disruption correlated with 
positive symptom severity, but not negative symptoms.  
Elsewhere, the lack of differential activation in patients with chronic schizophrenia to 
high, neutral or low probability rewards has been noted. A study of 17 patients with 
schizophrenia and 17 healthy controls completing the MID task found that whilst 
healthy controls showed greater activation for gains compared with losses in medial 
prefrontal cortex (PFC), temporal cortex, and the amygdala, activation in patients failed 
to differentiate between these (Waltz et al., 2010). Similarly, Koch and colleagues 
(2010) reported that whilst fronto-parietal activation in healthy controls reduces as the 
predictability of stimuli improved, this was not seen in patients. Another study found 
that both patients and healthy controls explicitly acquired conditioning during an 
appetitive conditioning paradigm with monetary rewards, with activation in the striatum, 
hippocampus, and PFC in response to the CS+ (Diaconescu et al., 2011). However, 
patients also activated these regions in response to the CS-, showing an inability to 
differentiate between rewarded and unrewarded stimuli. Furthermore, galvanic skin 
recordings showed that patients (unlike controls) did not implicitly differentiate between 
the CS+ and the CS-.  
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One study failed to find any differences between patients with schizophrenia and 
healthy controls (Simon et al., 2010). However, all 15 patients were treated with an 
SGA, which may act to ‘normalise’ neural activation underlying salience processing. 
Nonetheless, the authors reported a negative correlation between ventral striatal 
activation during reward anticipation and symptoms of apathy in the patients. Another 
study found no significant differences between activation in 16 olanzapine-treated 
patients with schizophrenia and 16 healthy controls in the ventral striatum, ventral 
tegmental area, and the anterior cingulate cortex during reward expectation (Walter et 
al., 2009). However, anterior cingulate activation increased with increased probability of 
reward in healthy controls only and activation in this region in patients was negatively 
correlated with positive symptoms.  
1.3.4.2 Studies in patients with first episode psychosis 
Studies in patients with chronic schizophrenia are subject to several confounders, 
including illness duration and antipsychotic treatment. Progressive functional 
deterioration over illness course may influence reward processing and so studies have 
investigated early stages of the disorder (Corlett et al., 2007; Murray et al., 2008; 
Roiser et al., 2009), albeit still in medicated patients .  
In a study of first episode psychosis (FEP) patients, Corlett and colleagues reported 
reductions in activation of right PFC when expectations were violated, the degree of 
which was related to delusions. Results from Murray and colleagues (2008) support 
other studies where patients failed to differentiate between high probability and neutral 
or low probability reward cues. Lower activation was found in patients compared with 
healthy controls in the midbrain, striatum, and limbic regions in response to high 
probability cues. Activation in these same regions was higher in patients compared with 
healthy controls in response to neutral cues. Similarly, there was a behavioural trend 
for patients to respond in a similar way to high probability as they did neutral cues, 
rather than increasing reaction times to high probability cues as expected.  
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In a behavioural study using the SAT, first episode psychosis patients exhibited 
decreased adaptive salience compared with healthy controls, but comparable levels of 
aberrant salience (Roiser et al., 2009). However, higher levels of aberrant salience 
were related to delusions within the patient group. A later study using fMRI to study 
salience processing in a group of healthy controls during the SAT (Roiser et al., 2010) 
reported activation in a network of structures associated with salience attribution, 
including the VTA, thalamus, ventral striatum, and PFC. Thalamic and PFC activation 
levels were related to adaptive salience in these healthy participants. Interestingly, the 
dorsolateral PFC and the medial temporal gyrus responded differentially to cues that 
were rewarded equally, but only where participants responded to them as if they were 
differentially rewarded (i.e. aberrant salience attribution). In those with greater aberrant 
salience, when responding to cues incorrectly (as if they were differently associated 
with reward), greater activation in the dorsolateral PFC and less activation in the medial 
temporal gyrus was seen (Roiser et al., 2010). Thus, brain regions responsible for 
incentive motivation processing erroneously differentiate between cues that are not 
differentially rewarded, and this is associated with behavioural aberrant salience.  
1.3.4.3 Studies in antipsychotic-naïve or unmedicated patients with psychosis 
Studies in medicated patients are confounded by the effects of treatment, complicating 
interpretation. To dissect the effects of antipsychotic medication from alterations 
primary to the disease pathophysiology, studies have investigated reward processing in 
antipsychotic-naïve or unmedicated patients with psychosis (Juckel et al., 2006a; 
Schlagenhauf et al., 2009; Esslinger et al., 2012; Nielsen et al., 2012). This can reveal 
changes that are present in the disorder, prior to any medication effects.  
All studies in unmedicated patients reported lower activation in the ventral striatum in 
response to reward-indicating cues (Juckel et al., 2006a; Esslinger et al., 2012; Nielsen 
et al., 2012) or during successful versus unsuccessful loss avoidance (Schlagenhauf et 
al., 2009). This supports the existence of reward-processing abnormalities in psychosis 
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before antipsychotic treatment commences.  
The largest of these studies compared activation during a MID task in 31 antipsychotic-
naïve patients and 31 healthy controls, reporting reduced activation to salient cues, not 
only in the ventral striatum, but also in the ventral tegmentum, and anterior cingulate 
cortex (Nielsen et al., 2012). However, only reduced activation in the ventral striatum 
was correlated with positive symptom scores. Altered ventral striatal activation has 
been shown to relate to positive symptoms in another study comparing 27 unmedicated 
patients and 27 healthy controls (Esslinger et al., 2012). Furthermore, a relationship 
between delusional psychopathology and activation in the medial PFC has been 
reported elsewhere (Schlagenhauf et al., 2009), where smaller differences in activation 
between successful and unsuccessful loss avoidance related to higher delusional 
scores.  
Conversely, Juckel and colleagues (2006a) reported an association between reduced 
left ventral striatal activation and negative symptom severity, although there was also a 
trend to a correlation with positive symptoms. However, this was in a small group of 
just 10 patients, some of whom had been previously medicated.  
1.3.4.4 Studies in subclinical or at risk groups  
Whilst studies in antipsychotic-naïve or unmedicated psychosis suggest that altered 
reward processing is present early in the disorder prior to antipsychotic treatment, 
studies in ultra-high risk (UHR) individuals, schizotypy, and first-degree relatives 
suggest that abnormal salience attribution can be detected even before onset of frank 
psychosis. This may suggest that abnormal salience processing plays a role in the 
aetiology of the disorder or may be a risk factor in itself.  
Using fMRI and [18F]fluorodopa positron emission tomography (PET), 18 unmedicated 
UHR individuals and 18 healthy controls were assessed for neural activation during the 
SAT task and for dopamine synthesis capacity (Roiser and colleagues 2013). Higher 
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levels of aberrant salience in UHR correlated with delusional symptomatology and were 
associated with ventral striatal activation to irrelevant stimulus features. There was also 
a negative relationship between striatal dopamine synthesis capacity and hippocampal 
activation to irrelevant stimuli features, whilst the relationship was positive in controls. 
These findings were consistent with those of another study in UHR individuals reporting 
a trend to decreased ventral striatal activation compared with healthy controls during a 
MID task (Juckel et al., 2012).  
Similarly, a study of non-psychotic individuals with schizotypal beliefs reported 
prediction error abnormalities in striatal and frontal regions (Corlett et al., 2012). 
Individuals who did not learn appropriately about the predictive cues (and so found 
violations of predictive relationships less surprising) had reduced striatal prediction 
error activation. Reduced activation was related to schizotypal beliefs and the degree 
of associated distress. Furthermore, decreased ventral striatal activation to reward-
indicating cues has been shown in first-degree relatives of patients with schizophrenia 
(Grimm et al., 2014). This suggests that such abnormalities form part of the risk for 
psychosis, but other factors play a role in the development of the disorder.  
1.3.5 Chapter summary and conclusions 
The reward and salience literature supports the assertion that salience attribution and 
reward processing are disrupted in psychosis. Studies in chronic patients show 
reduced activation in reward regions, such as the striatum, hippocampus and anterior 
cingulate cortex. Additionally, activation differentiating between high probability and 
neutral reward cues is not seen in patients, as it is in healthy controls. It seems that 
patients do not correctly assign importance to cues to reflect how often they are 
associated with reward. This is consistent with the aberrant salience hypothesis, in 
which patients are purported to attribute salience inappropriately to neutral stimuli.  
FEP studies corroborate with these findings, suggesting that the effects of prolonged 
illness are not solely responsible for differences seen between patients and healthy 
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controls. Furthermore, studies in patients who are unmedicated or antipsychotic-naïve 
similarly show reduced activation in regions underlying reward processing, particularly 
the ventral striatum. The aberrant salience theory would predict abnormalities in 
regions of disrupted dopaminergic signalling in psychosis, such as the ventral striatum, 
which forms part of a cortico-ventral basal ganglia network of dopamine-rich structures 
and associated projection sites (Haber, 2011).  
Results in patient studies suggest that rather than simple hypo or hyperactivation in 
response to reward cues, it is the appropriateness of activation that is important, i.e., 
differential activation for high, neutral, and low probability cues. This is consistent with 
the revised dopamine hypothesis, which suggests chaotic, dysregulated dopamine 
firing in psychosis, rather than simple hyperdopaminergia in the mesolimbic dopamine 
pathways. It is possible that antipsychotics act to dampen salience by reducing 
dopamine levels in the mesolimbic system, in turn reducing the ‘noise’ in this pathway 
and allowing phasic dopamine responses to important stimuli to signal salience 
appropriately.  
Finally, findings from UHR individuals, individuals with schizotypy, and first-degree 
relatives, suggest that abnormalities in reward processing and salience attribution are 
present prior to treatment with antipsychotic medications, and may confer a degree of 
risk in developing the disorder. These alterations may relate to underlying alterations in 
dopamine signalling. Disentangling the effects of chronic disease treated with 
antipsychotics from those that are primary to the disorder is an important test of the 
aberrant salience hypothesis, which would suggest that abnormalities are present prior 
to and independently of treatment. UHR were also reported to have unimpaired 
adaptive salience (i.e., they are able to discriminate high and low probability rewards). 
However, decreased adaptive salience has been reported in patients (Roiser et al., 
2009). This may reflect an effect of antipsychotics, which in the original aberrant 
salience hypothesis were proposed to dampen mesolimbic dopamine, which would 
alter both aberrant and adaptive salience levels. Furthermore, investigating how altered 
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reward processing in UHR relates to later transition to psychosis is key to 
understanding the aetiology of schizophrenia. This could inform preventative 
management techniques, perhaps allowing treatment prior to onset of frank psychotic 
symptoms, avoiding many adverse effects on function associated with an acute 
psychotic episode.  
The current project offers a unique opportunity to assess salience attribution in a group 
of minimally treated/antipsychotic-naïve patients. This provides a test of the aberrant 
salience hypothesis, by investigating whether abnormal salience attribution is present 
at first episode, prior to treatment. The project will additionally assess the ability of 
salience to change with treatment, by looking at the longitudinal effects of medication 
on measures of salience attribution and in relation to response to treatment. 
Understanding the changes induced by current medications on salience processing will 
help us to elucidate mechanisms of successful treatment and potentially identify new 




1.4 Antipsychotic medication  
1.4.1 Treatments for psychosis 
Prior to the 1950s, various biological and pharmacological treatments were used in 
attempts to treat the symptoms associated with schizophrenia, including prescribing 
cocaine, manganese or castor oil, and inducing coma through hypoglycaemia 
(Lehmann and Ban, 1997). Such treatments were rarely efficacious and often risked 
severe side effects. The serendipitous discovery of the antipsychotic effect of 
chlorpromazine in the 1950s dramatically altered the treatment of schizophrenia. The 
discovery that this antihistamine compound had antipsychotic effects when 
administered to patients with schizophrenia catalysed vast improvement in disturbed 
behaviour on psychiatric wards, and fuelled research into drug development for other 
psychoactive substances (Ban, 2007).  
Today, several antipsychotic medications are available for prescription in the treatment 
of schizophrenia. They are generally divided into typical or first-generation 
antipsychotics (FGAs), and atypical or second-generation antipsychotics (SGAs). 
Despite variation in mechanisms of action, the dopamine system appears to be a 
common therapeutic target for all currently prescribed antipsychotics. 
Chlorpromazine was the first of the FGA class, which includes flupenthixol, haloperidol, 
thiothixene, and zoclopenthixol, many of which are potent D2 receptor blockers 
(antagonists). FGAs are more associated with extrapyramidal side effects, other motor 
side effects (such as tardive dyskinesia and akathisia), and hyperprolactinaemia than 
are SGAs (Gardner et al., 2005). Whilst generally accepted to reduce positive 
symptoms associated with schizophrenia, FGAs appear to have little effect on negative 
or cognitive symptoms in the disorder (Gardner et al., 2005). Nonetheless, it is 
increasingly recognised that these symptom domains are central to the disorder, and 
that their treatment is a desirable and necessary component of recovery.  
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SGAs differ from FGAs by effecting reductions in positive symptoms, alongside a 
reduced risk of extrapyramidal side effects. The first of this class was clozapine, which 
remains the most efficacious treatment for patients who have shown poor treatment 
response to other antipsychotic medications (Mcilwain et al., 2011). However, the risk 
of life-threatening side effects, such as agranulocytosis, has restricted the use of 
clozapine. Several other SGA were subsequently introduced, including aripiprazole, 
amisulpride, quetiapine, and risperidone, which are more commonly prescribed in 
practice.  
It is possible that the use of pharmacological agents to treat psychotic symptoms 
associated with schizophrenia has facilitated the implementation of community-based 
clinical care, although other political and economic reasons also likely played a role 
(Ban, 2007). Nonetheless, despite the reported efficacy of these drugs, their 
mechanisms of action are not fully elucidated, perhaps partly due to the complexity of 
their pharmacological mechanisms. Furthermore, as mentioned earlier in this thesis, 
there is a consistent proportion of patients in whom existing antipsychotics do not 
alleviate symptoms.  
1.4.2 Mechanisms of action 
1.4.2.1 First generation antipsychotics  
The primary site of action for FGAs is the dopamine D2 receptor, with the majority 
exhibiting D2 antagonism (Stahl, 2013). As outlined in Section 1.2.1, page 7, several 
dopamine pathways exist throughout the brain. FGA action on these different pathways 
determine both the antipsychotic efficacy and the associated side effects of the 
compounds.  
One key site of antipsychotic action is the D2 receptor within the mesolimbic pathway, 
which is posited by the dopamine theory as the source of positive psychotic symptoms 
resulting from excess dopamine. D2 antagonism here blocks the binding of dopamine 
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with D2 receptors, leading to an effective decrease in dopamine hyperactivity. Action 
within the mesolimbic pathway may also lead to a worsening of negative symptoms. 
For example, the mesolimbic pathway is associated with ‘pleasure’ or ‘reward’ in the 
normally functioning brain. D2 blockade might therefore block mechanisms of reward 
and reinforcement, leading to anhedonia, apathy, and amotivation.  
However, FGAs are not selective for the mesolimbic system, as D2 receptors are found 
across the other dopaminergic pathways. Action at other sites underlies side effects 
associated with this class of drug. For example, cognitive symptoms experienced by 
many individuals diagnosed with schizophrenia may be worsened by FGA treatment 
due to blockade of D2 receptors in the frontal cortex (part of the mesocortical dopamine 
pathway). Extra-pyramidal side effects and other movement disorders are commonly 
associated with FGAs. These side effects mimic the symptoms of Parkinson’s disease 
(such as bradykinesia, stiffness, and tremor) and result from D2 blockade in the 
nigrostriatal pathway, which forms part of the extrapyramidal nervous system. 
Prolonged blockade of the nigrostriatal system can lead to tardive dyskinesia. This 
disorder is characterised by abnormal, involuntary facial and tongue movements, such 
as grimacing and tongue protrusion. It is thought that chronic nigrostriatal D2 blockade 
leads to upregulation and receptor supersensitivity. Whilst early removal of treatment 
can allow a reversal of tardive dyskinesia, continued treatment can cause the problem 
to become irreversible, even after the treatment is discontinued. Lastly, D2 receptor 
blockade in the tuberinfundibular pathway can lead to hyperprolactineamia, particularly 
in women in which it can interfere with menstruation and fertility.  
FGAs cause D2 blockade at similar levels throughout the brain, and the degree of 
binding at particular sites determines whether therapeutic or adverse effects are 
experienced. Roughly 80% of D2 receptors in the mesolimbic pathway must be 
occupied for an individual to experience therapeutic effects (Stahl, 2013). However, in 
the dorsal striatum an occupancy of above 80% leads to motor side effects. Thus, a 
balance must be achieved between these two thresholds to achieve maximal 
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therapeutic effect without intolerable side effects (Figure 3). For FGAs, this therapeutic 
window is narrow, with a high risk of side effects at a dose necessary to pass the 
therapeutic threshold.  
 
Figure 3: Therapeutic window offered by A) FGAs and B) SGAs  
Treatment with antipsychotics must balance the therapeutic effects with the side effects. A) With 
FGAs, simple dopamine D2 receptor antagonism means that the thresholds for each of these 
are close, giving a narrow window within which an optimal balance can be found. B) With SGAs, 
D2 receptor antagonism is balanced by 5-HT2A antagonism, which eases side effects and 
widens the therapeutic window. This ensures antipsychotic efficacy with a lower risk of side 




1.4.2.2 Second generation antipsychotics 
Like FGAs, many SGAs have D2 antagonistic properties, from which it is thought 
antipsychotic efficacy arises. However, in addition to these properties, they have 
broader receptor profiles, with action at serotonin (5-HT) receptors. Interactions with 5-
HT, in particular 5-HT2A, receptors may account for the reduced risk of side effects that 
are typically associated with FGAs. In fact, the ability of an antipsychotic to reduce 
positive symptoms with a low risk of extra pyramidal side effects or 
hyperprolactineamia is loosely what classifies a drug as a SGA (Stahl, 2013). Due to 
these properties, they are often preferred over FGAs.  
Serotonin is a neurotransmitter found throughout the brain. It is synthesised from 
tryptophan and taken up into synaptic vesicles before use in neurotransmission. 
Numerous 5-HT receptor types exist, the most important in this context being the 5-
HT2A type. 5-HT2A receptors are postsynaptic and found in many brain regions, 
including parts of the neocortex such as prefrontal and parietal regions. These 
receptors enable downstream modulation of dopamine in the striatum, via effects on 
glutamate signalling. Serotonin enhances glutamate in the brainstem, leading to GABA 
release, which is inhibitory and reduces dopamine release in the striatum. Thus, the 
effect of SGA antagonism at 5-HT2A receptors is disinhibition of dopamine, as the 
inhibiting action of serotonin via glutamate and GABA is itself inhibited. This action on 
dopamine may reduce the risk of extra pyramidal side effects. Furthermore, direct and 
indirect action of serotonin on the nigrostriatal and tuberinfundibular pathways further 
eases side effects seen with FGAs. 
The more complex and nuanced modulation of dopamine levels by SGAs likely 
underlies their ability to treat psychotic symptoms whilst avoiding side effects by 
balancing D2 antagonism with 5-HT2A antagonism. Furthermore, the degree of D2 and 
5-HT2A antagonism differs across brain regions. There is decreased dopamine in the 
mesolimbic pathway reducing positive symptoms, and disinhibited dopamine in the 
34 
 
nigrostriatal and tuberinfundibular pathways, lessening side effects. Competition 
between these mechanisms and regional differences allows dopamine receptor 
blockade to remain between 60–80% (depending on brain region) and thus reduces the 
antipsychotic effect threshold. This provides a larger therapeutic window than is 
possible with FGAs (Figure 3).  
1.4.2.3 Amisulpride 
Most patients included in the study that will form this thesis were prescribed 
amisulpride to treat psychotic symptoms as part of the OPTiMiSE clinical trial (see 
Methods, page 109). Amisulpride is a SGA, used to treat psychosis in schizophrenia 
and bipolar disorder, as well as dysthymia at lower doses. Amisulpride has effects on 
the dopaminergic and serotoninergic systems, with highest affinity for the D2 receptor, 
although it also acts as a D3 antagonist with lower affinity. It is usually prescribed at 
doses of between 400 – 1200mg/day for psychotic symptoms. At this dose, the drug 
has postsynaptic effects, inhibiting dopaminergic neurotransmission.  
Amisulpride has been shown to be as effective as risperidone, haloperidol and other 
common antipsychotics, predominantly decreasing positive symptoms of schizophrenia 
but also showing an effect on negative and affective components of the illness (Curran 
and Perry, 2002). The choice of amisulpride in the current project was made on the 
basis of its relatively selective action on the dopamine system, and low affinity for other 
neurotransmitters thus simplifying interpretation of its effects.  
1.4.3 Efficacy  
There is some evidence that SGAs offer benefits over FGAs. At times, SGAs have 
been proposed to offer greater efficacy, particularly for cognitive and negative 
symptoms, and to give greater improvements in functioning and quality of life, as well 
as fewer extra-pyramidal side effects than FGAs (Miyamoto et al., 2005). However, 
meta-analysis suggests that this is not true of all SGAs, although amisulpride, 
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clozapine, olanzapine, and risperidone do all appear to show greater efficacy than 
FGAs (Leucht et al., 2009). Further, Leucht and colleagues (2009) did not find any 
specific benefit for SGAs in their efficacy to treat negative symptoms. There do seem to 
be benefits regarding reduced extra-pyramidal side effects, but other side effects such 
as weight gain and sedation can be more problematic for patients prescribed SGAs.   
A more recent meta-analysis by the same group pooled data from 212 trials 
(comprising 43,049 patients) and found all drugs to be more effective than placebo, but 
that the traditional division between FGAs and SGAs was not necessarily supported 
(Leucht et al., 2013). They suggested that different drugs offer benefits in different 
domains, regardless of generation. Therefore, treating clinicians should consider these 
different domains in choosing drugs for individual patients, dependent on needs.  
This brings greater individualisation to the prescription of antipsychotic medications, but 
it does not go far enough in offering tailored or personalised treatments. Some degree 
of trial and error is likely still required to find the optimal treatment for each individual. It 
would be more beneficial to be able to choose a drug based on need, using underlying 
biological factors to predict likely response and side effects. A better understanding of 
the effects of individual antipsychotics, their mechanisms of action, and the biological 
markers associated with response is therefore necessary.  
1.4.4 Current treatment guidelines 
Treatment guidelines in the UK are available from the National Institute for Health and 
Care Excellence (NICE), British Association of Psychopharmacology (BAP) and in the 
Maudsley Prescribing Guidelines. NICE guidelines for the treatment of schizophrenia 
(NICE, 2014) provide recommendations for the management and care of those 
diagnosed with this disorder within the psychosis pathway, under the section of 
psychosis and schizophrenia in adults.  
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These recommendations stress the need for early intervention in the disorder, with the 
choice of antipsychotic for a first episode based on collaborative consideration by the 
patient and clinical professional of the risks and benefits of the drug concerned. This 
includes consideration of metabolic, extrapyramidal, cardiovascular and hormonal side 
effects. Clozapine is recommended as a choice to be considered following the 
unsuccessful trial of at least two other antipsychotics at adequate doses, one of which 
must have been another SGA.  
1.4.4.1 Early Intervention in Psychosis 
In recent decades, many medical research fields have moved from focusing on curative 
treatments to preventative interventions. Intervening early is likely beneficial to both 
patients and society, reducing the overall cost of treatment, as well as the impact on 
the life and health of the patient, preventing the development of chronic, long-term 
disability.  In psychiatry, a similar move to early intervention has occurred, although its 
application to psychosis has developed only in the last decade (Christy et al., 2014). 
Studies suggest that intervening during a ‘critical period’ with both pharmacological and 
psychological therapies may lead to better long-term outcomes (Birchwood et al., 
1998). Longer duration of untreated psychosis (DUP) has previously been associated 
with poorer outcome (Bottlender et al., 2003), reinforcing the idea that intervening early 
in the disorder could improve prognosis, although whether these effects are substantial 
or sustained remains unclear (Marshall and Rathbone, 2011). 
Initially, development of services for early intervention in psychosis occurred in 
Australia and the USA. However, the UK Department of Health recognised the need for 
early identification, assessment, and phase-specific treatment (DoH, 1999) and NICE 
guidelines on schizophrenia recommended their implementation across England and 
Wales (NICE, 2002). The NHS planned numerous services across these regions, and 
as of 2010, 145 such services were operating across the UK (Bird, 2010). Current 
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NICE guidelines recommend that early intervention is accessible to all those with first 
episode psychosis (NICE, 2014).  
Whilst early detection and treatment may be beneficial for long-term outcomes, 
success is limited by the treatments available. For example, even if disorder is 
identified early in course, time might be wasted trialling numerous different 
antipsychotics. Individuals with psychosis do not always respond to the first 
antipsychotic tried, and may have to trial several in order to find one that is effective, 
with up to 40% not responding to their first treatment (Barnes et al., 2011; see also 
chapters 1.6 and 1.7). It would therefore be beneficial if one could predict treatment 
response before an antipsychotic is tried, and choose based on the underlying 
neurobiological pathology seen in individual patients. This would allow the 
implementation of effective early intervention, hopefully preventing much of the 




1.5 Neurobiological alterations associated with antipsychotic medications 
Whilst our understanding of the neurobiology of schizophrenia has advanced, precise 
mechanisms and patterns of brain pathophysiology associated with this disease remain 
unclear. Neuroimaging studies report evidence for several structural and functional 
brain abnormalities in those with schizophrenia. However, whilst some of these 
changes are likely related to underlying disease vulnerability or subsequent disease 
progression, increasing evidence suggests brain structural and functional changes 
observed in this disorder are partly related to antipsychotic treatment (Navari and 
Dazzan, 2009; Ho et al., 2011; Davis et al., 2005; Vita and de Peri, 2007). Therefore, 
disentangling alterations primary to the disorder from the short- and long-term effects 
on brain structure and function induced by treatment remains a challenge. Recognition 
that antipsychotics affect brain structure and function, alongside the growth of 
pharmacological imaging, has led to the effects of antipsychotic medications on the 
brain being researched in their own right (Gerretsen et al. 2009).  
Studies have investigated the brains in patients with chronic schizophrenia, who, as 
mentioned in previous chapters, are likely to have been previously or currently treated, 
many for a long period. Therefore, more recent studies have investigated UHR, first 
episode, and antipsychotic-naïve patients, removing the confounding factor of chronic 
illness and treatment. A subset of studies has mapped longitudinal antipsychotic-
induced alterations in brain structure or function following antipsychotic treatment. More 
rarely, healthy control populations have been administered single-dose antipsychotic 
medications. These completely remove the confound of disease-related 
pathophysiology, providing a ‘clean’ sample in which to test the effects of the 
antipsychotic medication. However, they naturally are limited in their generalizability to 
clinical populations.  
Here, I outline findings from the literature regarding the neurobiological alterations 
associated with schizophrenia and with antipsychotic medications. I begin by briefly 
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reviewing structural brain changes associated with schizophrenia, followed by studies 
that have investigated antipsychotic-induced structural changes. Following this, I 
review literature regarding measures pertinent to the current study: regional cerebral 
blood flow (rCBF) and fMRI BOLD data, in particular relating to salience processing.  
1.5.1 Brain structure 
1.5.1.1 Structural brain changes in schizophrenia  
One of the earliest and most robust structural brain findings reported in schizophrenia 
is enlarged ventricles (Johnstone et al., 1976). Numerous recent studies support 
findings of decreased volume of grey matter accompanied by an enlargement of the 
ventricles (e.g. Wright et al., 2000). Other changes implicated include decreased 
volume of medial temporal lobe structures, such as the hippocampus and the 
amygdala (Wright et al., 2000; Honea et al, 2005), and the frontal lobes, particularly the 
prefrontal cortex (Fornito et al. 2009).  
Many of these changes were first reported in chronic schizophrenia, limiting both their 
generalizability and their interpretation. However, studies in FEP patients report brain 
changes early in the disease course, including decreased whole brain grey matter 
accompanied by increased ventricular volumes (Vita et al., 2006; Steen et al., 2006). 
Similar alterations are reported before the onset of acute psychosis in those at ultra-
high risk of psychosis with prodromal symptoms (Pantelis et al., 2003).  
A meta-analysis comparing chronic and FEP patients, reported decreased thalamic, 
amygdala, insula, and anterior cingulate cortex volumes in all patients, with more 
widespread cortical changes in chronic patients (Ellison-Wright et al., 2008). More 
recently, the prominence of structural changes in the insula, thalamus, and anterior 
cingulate cortex has been supported by other meta-analyses of structural changes in 
schizophrenia (Bora et al., 2011; Crow et al., 2013). Other meta-analyses have 
suggested longitudinal changes in brain structure with decreases in whole brain gray 
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matter, frontal gray matter, and frontal, parietal, and temporal white matter, alongside 
increased ventricular volumes (Olabi et al., 2011; Kempton et al., 2010). Furthermore, 
those at genetic high risk for schizophrenia also have altered grey matter volumes, 
including bigger left medial frontal gyri and smaller thalamus/putamen compared with 
controls (Cooper et al., 2014). These results suggest that there may be structural brain 
differences between the early and later stages of illness in schizophrenia, with 
potentially progressive cortical changes. It is possible that some of the progressive 
changes may be partly due to antipsychotic treatment.  
1.5.1.2 Antipsychotic effects on brain structure 
Studies of FEP patients, particularly those who are antipsychotic-naïve, compared with 
chronic patients can reveal structural changes present before treatment that may 
represent primary disease pathophysiology. However, such studies have produced 
inconsistent results (Vita and de Peri, 2007). Changes reported by some, but 
disconfirmed by others, include reduced whole brain volume, as well as regional 
reductions in frontal and temporal cortices, superior temporal gyrus, hippocampus and 
caudate nucleus (Vita and de Peri, 2007). Generally, results in FEP are less robust and 
reproducible than those in more chronic, treated cohorts, potentially suggesting 
progressive processes of altered structure, leading to stable and pervasive changes in 
chronic disease. A recent meta-analysis comparing brain structure in medicated and 
antipsychotic-naïve patients (Hajima et al., 2012), reported a decrease in total grey 
matter volume in medicated patients, associated with longer illness and higher 
antipsychotic dose. However, antipsychotic-naïve patients had more pronounced 
decreases in caudate and thalamic volumes. Nonetheless, there was less extensive 
grey matter loss in those naïve to treatment, again suggesting progressive changes 
across illness course.  
Cross-sectional comparisons of treated patients with unmedicated or antipsychotic-
naïve patients have shown decreased cortical grey matter in frontal and temporal 
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regions in patients treated with FGAs (Dazzan et al., 2005), although others have 
reported cortical thinning in both treated and antipsychotic-naïve patients compared 
with healthy controls (Narr et al., 2005). Cross-sectional comparisons of the differential 
effects of FGAs and SGAs on the brain suggest FGA treatment is associated with 
increased basal ganglia volumes and decreased cortical volumes, whereas SGA 
treatment is not associated with increased BG volume (Vita and de Peri, 2007; Navari 
and Dazzan, 2009). These differential effects of FGAs and SGAs may be evident even 
within the first month of treatment. Garver and colleagues (2005) found increased 
cortical grey matter in patients treated with SGAs that was not seen in patients treated 
with haloperidol for 28 days. 
Longitudinal studies can investigate the timing of structural changes. Several studies 
investigating brain structure over a course of treatment with SGAs have reported no 
changes, perhaps reflecting a protective action of these drugs on brain volume (Navari 
and Dazzan, 2009). However, there are reports of white matter changes following SGA 
treatment. A recent study of 35 FEP patients, with little or no previous exposure to 
antipsychotic medication, reported a loss of white matter integrity in parietal and 
occipital regions after 12 weeks of treatment with either risperidone or aripiprazole 
(Szeszko et al., 2014).  
Increased basal ganglia volume has been associated with both FGA and SGA 
treatment in some longitudinal studies (Massana et al., 2005), with higher doses 
associated with larger changes in volume. Whilst other studies have not found 
increases in this region following SGA treatment, it is possible that the conflicting 
results are due to dose. Risperidone prescribed in the study by Massana et al. (2005) 
was at a much higher dose than in other studies. At such high doses, risperidone is 
likely to induce particularly high D2 receptor occupancy, and an increased risk of extra-
pyramidal side effects, essentially acting similarly to FGAs (Nyberg et al., 1999). Others 
suggest that switching from FGA to SGA treatment actually leads to decreased basal 
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ganglia volumes (Scheepers et al., 2001), and the action of SGAs following a switch 
from FGAs may be to normalise brain volumes (Navari and Dazzan, 2009).  
In summary, global and regional volume changes are associated with antipsychotic 
treatment, but the nature of changes observed depends on antipsychotic generation. 
Further work is necessary to elucidate the precise patterns of change for different 
antipsychotic treatments, as well as to relate these to clinical changes and response to 
treatment.  
1.5.2 Functional activation  
1.5.2.1 Altered fMRI BOLD signal in schizophrenia 
Functional brain activation can be measured within a variety of modalities and 
paradigms, both at rest or during a task. This review of the literature will concentrate on 
studies measuring fMRI BOLD during a task. There is much heterogeneity in tasks 
used, allowing fMRI to probe brain function underlying a wide variety of abilities. 
However, this means that observed functional abnormalities or differences between 
groups depend on the task context (regional abnormalities may only be detectable 
during a particular task), and this can limit comparability across studies.  
In patients with schizophrenia, various functional activation abnormalities are reported 
during tasks that test motor skills, working memory, word fluency, emotional and social 
processing, and decision-making (Gur et al., 2010). Such abnormalities may represent 
failure to activate to a task. For example, studies report a lack of amygdala activation 
during identification of emotional expressions in patients with schizophrenia, with 
associated decreased accuracy (Phillips et al., 1999). Alternatively, over-activity is 
reported. For example, in an oddball study requiring participants to respond to targets 
and novel stimuli, patients exhibited increased activation in sensory and frontal areas 
underlying visuo-spatial processing (Gur et al., 2007). More recently, connectivity 
between brain regions has been a focus and studies show various abnormalities in 
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patients compared with healthy controls in networks across a range of experimental 
paradigms (Fornito et al., 2012). Together, this vast literature provides strong evidence 
for a broad range of functional abnormalities associated with schizophrenia.  
In this project, functional activation during a salience task is investigated. Salience 
activation in healthy controls, and abnormalities seen in patients were outlined in 
chapter 1.3 (section 1.3.4, page 21) and will therefore not be repeated at length again 
here. Briefly, the literature provides evidence for abnormal salience processing in 
psychosis. Reward-related regions, including the hippocampus and anterior cingulate 
cortex, but particularly the ventral striatum, are repeatedly found to be under-activated 
during reward tasks (e.g. Smieskova et al., 2015). Additionally, failure to differentially 
activate reward regions for high versus low probability cues is observed. These 
differences are reported in FEP and chronic patients, suggesting they are stable 
deficits throughout the illness, and not necessarily induced by antipsychotic 
medications or progressive changes due to chronicity (Diaconescu et al., 2011). 
Furthermore, UHR patients also show abnormalities in reward and salience processing 
prior to onset or treatment, further supporting the existence of altered salience 
processing as a primary dysfunction in psychosis. Abnormal reward activation could 
create abnormal salience attributions to external (and internal) cues, potentially 
providing a mechanism by which psychotic symptoms such as delusions develop, 
according to the aberrant salience hypothesis (Kapur, 2003).  
Hence, a range of functional abnormalities, including dysfunctional salience 
processing, are observed across the course of schizophrenia, within various task 
paradigms. Variability in results may result from differences in duration of illness and 
antipsychotic treatment history. At present, not enough is known about the effects of 
antipsychotic medications on functional activation in relevant task domains. 
Furthermore, it is possible that such effects may differ between those responding to 
treatment and those who do not. In the next section, functional changes following 
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antipsychotic treatment are briefly reviewed, before studies specifically exploring 
effects of medication on salience activation are reviewed in more detail.  
1.5.2.2 Effects of antipsychotics on fMRI BOLD signal 
Several reviews have collated evidence regarding antipsychotic effects on fMRI BOLD 
activation during a task (Davis et al., 2005; Roder et al., 2010, 2013; Liemburg et al., 
2012), but there are no meta-analyses, reflecting the vast heterogeneity in 
methodology. Studies have implemented longitudinal, cross-sectional or mixed 
designs, in patients with varying degrees of previous antipsychotic exposure and 
disease chronicity. Tasks used include those testing working memory, motor abilities, 
emotional processing, verbal fluency, and other attentional or visual abilities. Several 
studies have also implemented reward or salience paradigms, and were discussed in 
depth in section 1.3.4. Table 1 provides an overview of all the studies identified and 
their main findings.  
Studies investigating antipsychotic effects on fMRI BOLD in patients are subject to 
several methodological issues, such as heterogeneity of symptomatology, differences 
in previous antipsychotic exposure, and different stages of illness. This is problematic 
because it means that the baseline state of the brain is not homogenous within groups, 
calling into doubt whether differences between groups are due to the antipsychotic 
medication received or due to other illness factors. Whilst study of antipsychotic-naïve 
patients can solve some of these issues, such samples are challenging to recruit in 
large numbers. Therefore, some researchers have complemented patient studies with 
studies in healthy individuals, which provide opportunities to investigate antipsychotic 
effects independently of any underlying pathophysiological process, previous 
antipsychotic exposure or symptoms changes that may occur following treatment. 
Whilst the generalizability of these studies to the clinic is limited, they provide 
complementary information to patients studies, and for this reason, I also describe 
studies in healthy controls where relevant below.  
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Table 1: Studies investigating the effects of antipsychotic medications on fMRI BOLD activation during a task 
 
Authors Task Study design Participants (n) and medication Main findings 
a) Working memory     
Honey et al., 1999 N-back  Longitudinal Schizophrenia (20): All treated with 
FGA at baseline; 10 remained on FGA, 
10 switched to risperidone for 6 weeks 
Healthy controls (10)    
Treatment with risperidone led to higher activation 
than continued typical treatment in frontal-parietal, 
supplementary motor area, and right dlPFC. 
Schlösser et al., 2003 N-back  Cross-
sectional 
Schizophrenia (12): Treated with 
haloperidol (6) or a SGA (6) 
Healthy controls (6) 
Haloperidol versus healthy control: increased path 
coefficients between left parietal and left dlPFC; 
right vlPFC and dlPFC; and right vlPFC and left 
cerebellum. 
SGA versus healthy control: increased path 
coefficient between thalamus and right vlPFC; left 
and right dlPFC; and left and right parietal cortex. 
 




Schizophrenia (30): Antipsychotic free 
at baseline, then treated for 8 weeks 
with olanzapine 
Healthy controls (0) 
Those with the Met allele showed improved 
working memory performance and prefrontal cortex 
physiology after treatment. 
 
Meisenzahl et al., 2006 N-back Longitudinal Schizophrenia (12): Untreated at 
baseline, then treated for 12 weeks with 
quetiapine 
Healthy controls (12) 
Treatment led to increased activation in the left 
vlPFC. 
 
Surguladze et al., 2007 N-back Cross-
sectional  
Schizophrenia (32): 16 treated with 
FGA depot, 16 treated with risperidone 
depot 
Healthy controls (8) 
FGA-treated versus healthy controls: greater 
activation of mPFC in patients (failure to show task-
dependent decreases). Less activation in vlPFC of 
patients with increased load.  
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Surguladze et al., 2007 
(cont’d) 
   FGA-treated versus risperidone-treated: greater 
activation of mPFC in patients (failure to show task-
dependent decreases). 
Risperidone-treated versus healthy controls: no 
significant differences. 




Longitudinal Schizophrenia (10): 8 treated with SGA 
at baseline, 1 treated with benperidol, 1 
antipsychotic-naïve; all treated for 7–8 
weeks with SGA 
Healthy controls (15)  
Treatment led to changes in bilateral 
frontotemporal regions at increased load, including 
inferior frontal gyrus and superior temporal gyrus.   
Schlagenhauf et al., 2008a N-back Longitudinal Schizophrenia (10): All treated with 
FGA at baseline, then treated for 4 or 
more weeks with olanzapine  
Healthy controls (10) 
In 0-back condition: increased activation in bilateral 
dlPFC after treatment.  
 
Schlagenhauf et al., 2010 N-back Longitudinal Schizophrenia (11): All treated with 
FGA at baseline, then treated for mean 
24.4 days with aripiprazole 
Healthy controls (11) 
At baseline, patients showed lower activation in the 
dorsal ACC, activation here was not significantly 
different from healthy controls after treatment.  




Schizophrenia (45): 1 untreated, 38 
treated with FGA, 6 treated with SGA 
Healthy controls (19) 
FGA-treated versus SGA-treated: At increased 
load, SGA showed increased left MFG activation, 
FGA showed decreased activation in this same 
region.  





Schizophrenia (23): All untreated at 
baseline, then treated for 10 weeks with 
SGA  
Healthy controls (33) 
Patients showed a significantly smaller reduction in 
activation with practice in left dlPFC and bilateral 
superior parietal cortex. 
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b) Motor  
Braus et al., 1999 Finger-tap Cross-
sectional 
Schizophrenia (13): 13 treated with 
FGA; 10 treated with clozapine; 3 
treated with risperidone; 14 
antipsychotic-naïve 
Healthy controls (15) 
 
(ROI analysis of bilateral motor cortex and 
supplementary motor area). 
Antipsychotic-naïve versus healthy control: no 
significant differences. 
Antipsychotic-treated versus healthy control: lower 
supplementary motor area activation 
Stephan et al., 2001 Finger-tap Longitudinal Schizophrenia (6): All antipsychotic-
naïve or free at baseline, then treated 
for 3 weeks with olanzapine 
Healthy controls (6) 
(Investigating functional connectivity in the 
cerebellum) 
Schizophrenia versus healthy control: higher 
connectivity at baseline, which normalised with 
treatment.  
Muller et al., 2002a Finger-tap Cross-
sectional 
Schizophrenia (30): 10 untreated, 10 
treated with haloperidol, 10 treated with 
olanzapine 
Healthy controls (10) 
Untreated versus healthy control: higher activation 
in the motor cortex, cerebellum and basal ganglia. 
Haloperidol versus healthy control: lower activation 
in the basal ganglia. 
Olanzapine versus healthy control: lower activation 
in the motor cortex. 
Muller et al., 2002b Finger-tap Cross-
sectional  
Schizophrenia (30): 10 untreated, 10 
treated with haloperidol, 10 treated with 
olanzapine 
Healthy controls (10) 
Untreated versus all other groups: higher activation 
in ipsilateral pallidum.  
c) Emotional processing 
    
Fahim et al., 2005 Emotion 
induction 
Longitudinal Schizophrenia (12): All untreated at 
baseline, then treated for 23 weeks with 
quetiapine 
Healthy controls (0) 
T1>T2 – right pons and bilateral midbrain 
T2>T1 – right dlPFC, ACC, anterior temporal pole, 




Stip et al., 2005 Emotional 
induction 
Longitudinal Schizophrenia (12): All untreated at 
baseline, then treated for mean 5.9 
months with quetiapine  
Healthy controls (0) 
T1>T2 – left pons and medulla oblongata.  
T2>T1 – right medial prefrontal gyrus and left OFG. 
 
Blasi et al., 2009 Implicit/ 
explicit face 
matching 
Longitudinal  Schizophrenia (12): All antipsychotic 
naïve or free at baseline, then treated 
for 8 weeks with olanzapine 
Healthy controls (12) 
Schizophrenia versus healthy controls: patients 
showed greater left amygdala activation during 
both implicit and explicit processing. Patients 
showed lower activation of right vlPFC during 
implicit processing. 
Baseline versus follow up: Patients had reduced 
left amygdala activation after treatment during both 
implicit and explicit processing. Patients had 
increased right vlPFC activation after treatment 
during implicit processing.   




Schizophrenia (32): 16 treated with a 
FGA depot, 16 treated with risperidone 
depot 
Healthy controls (16) 
Fearful faces – 
FGA-treated versus risperidone-treated: FGA 
showed greater activation of vmPFC, risperidone 
showed greater activation of the left amygdala 
Happy faces –  
FGA-treated versus risperidone-treated: FGA 
showed greater activation of the vmPFC, 
risperidone showed greater activation of the right 
cerebellum. 
d) Other     




Schizophrenia (15): 7 antipsychotic-
naïve, 8 treated with quetiapine 
Healthy controls (0)  
Drug-naïve versus healthy control: healthy controls 
had higher activation in the left inferior frontal 
cortex. 
Drug-naïve versus quetiapine-treated: quetiapine 











Schizophrenia (11): All untreated at 
baseline, then treated with a mix of 
FGA and SGA for 4 weeks 
Healthy controls (16) 
(ROI analysis in the dlPFC and ACC). 
After treatment there were no changes in the 
dlPFC; activation was increased in ACC. 
 




Schizophrenia (30): 10 treated with 
FGA, 10 treated with olanzapine, 10 
treated with risperidone 
Healthy controls (0) 
Pre-pulse inhibition elicited activation in network 
including insular, inferior frontal cortex and 
thalamus in SGA-treated but not FGA-treated 
patients. 
 





Schizophrenia (9): All untreated at 
baseline, then treated with various 
antipsychotics for at least 4 weeks 
Healthy controls (9) 
T1>T2 in bilateral intraparietal sulcus, superior 
temporal sulcus, vmPFC, insular regions, left 
dlPFC, and right ACC. 
T2>T1 in bilateral cerebellum, left frontal eye fields, 
supplementary eye field, and right ACC. 




Longitudinal Schizophrenia (14): 5 antipsychotic-
naïve, 9 with average 5.57 days 
treatment at baseline, then treated for 
12 weeks with either risperidone or 
aripiprazole 
Healthy controls (14) 
(ROI analysis in caudate, putamen, globus pallidus 
and thalamus). 
At baseline, patients had greater activation in right 
globus pallidus and bilateral thalamus. After 
treatment, activation of the right globus pallidus 
reduced and this was correlated with improved 
performance and reduced thought disturbance.  
 
dlPFC = dorsolateral prefrontal cortex; vlPFC = ventrolateral PFC; vmPFC = ventromedial PFC; ACC = anterior cingulate cortex; OFG = orbital frontal gyrus; MFG = 









a) Working memory 
The process by which information is held in mind, manipulated, and incorporated with 
information stored in long-term memory is known as working memory (Baddeley and 
Hitch, 1974). Working memory deficits have been widely reported in schizophrenia, 
particularly alterations in the fronto-parietal networks underlying normal working 
memory performance (Royer et al., 2009; Pae et al., 2008; Glahn et al., 2005). 
Furthermore, worse working memory performance has been associated with altered 
dopaminergic signalling in the dorsolateral PFC in schizophrenia (Abi-Dargham et al., 
2002). Indeed, working memory performance appears to rely on dopaminergic and 
serotoninergic signalling (Jakab and Goldman-Rakic, 1998), which as discussed earlier 
may both be disrupted in schizophrenia.  
Since these neurotransmitter systems are also known primary targets of antipsychotic 
drugs, it is important to establish how working memory is affected by antipsychotic 
action. Deficits in this cognitive function are seen throughout the course of 
schizophrenia. Deficits in at risk mental state groups may predict psychosis onset 
(Pukrop et al., 2007), suggesting that working memory impairments play a role in 
aetiology. However, evidence suggests that antipsychotic medications do have a 
modulatory effect, possibly different for FGA and SGA treatments. FGA treatment is 
associated with lower activation in the PFC at higher cognitive loads, whilst higher 
activation in this region has been seen in SGA-treated patients at high cognitive load 
(Ettinger et al., 2011). However, some studies have reported no changes in working 
memory activation when patients are switched from FGA to SGA treatment 
(Schlagenhauf et al., 2008). Potentially, this was due to a short follow up two weeks 
after the switch, which may not allow enough time for activation changes to occur. 
However, in the same study cross-sectional comparisons with healthy individuals 
showed lower dorsolateral PFC activation in patients during olanzapine treatment, 
which was not present during previous treatment with haloperidol. This may reflect 
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greater neural efficiency with olanzapine. Other studies report SGA-related alterations 
in working memory-related activation in frontal-parietal, prefrontal, and posterior 
parietal regions (Honey et al., 1999; Meisenzahl et al., 2006; Wolf et al., 2007; Ettinger 
et al., 2011), although working memory performance is often unchanged.  
Two studies, including one by our group, have studied effects of antipsychotic 
medications in healthy controls during working memory performance (Dodds et al., 
2009; Goozee et al., 2015). In a study investigating the effects of 400mg sulpiride (a 
dopamine D2 receptor antagonist), neural activation following the drug did not differ to 
that following placebo (Dodds et al., 2009). There was also no correlation between 
neural activation and performance. However, activation was related to drug plasma 
level in the putamen, with lower drug plasma levels associated with higher neural 
activation when participants were required to manipulate stimuli rather than just recall 
them. In our study, 17 healthy men completed the n-back after placebo, haloperidol, 
and aripiprazole, in a randomised, blinded crossover design (Goozee et al., 2015). We 
found differential effects of the two drugs on working memory function. Aripiprazole 
worsened performance but had no effect on neural activation, whilst haloperidol did not 
affect performance but led to lower activation in parietal and frontal cortices, and the 
putamen compared with both the other conditions.  
b) Motor function  
Motor function deficits are widely reported in schizophrenia (Liddle et al., 1987; Dickinson 
et al., 2007; Morrens et al., 2007) and may underlie other cognitive dysfunctions 
(Salthouse, 1996). Disordered activation may accompany these performance deficits 
(Wenz et al., 1994; Mattay et al., 1997; Northoff et al., 1999), but the role of antipsychotic 
treatment in such changes is ambiguous as patients are often treated at the time they 
are studied. In untreated individuals with schizophrenia, Muller and colleagues (2002a/b) 
reported greater activation in cortical and subcortical regions compared with healthy 
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controls. However, others have reported no difference when comparing antipsychotic-
naïve patients and healthy controls (Braus et al., 2000).  
Motor tasks reliably activate cortico-striatal-thalamo-cortical loops (Alexander et al. 
1990), and dopaminergic signalling is key to motor function. Considering the role of 
dopamine in the pathophysiology of schizophrenia and that of antipsychotic medications 
on this neurotransmitter system, understanding the effects of antipsychotics on motor 
function is important in elucidating the aetiology of such deficits, and in understanding 
and improving their treatment with antipsychotic drugs.  
SGAs may be less likely than FGAs to induce motor deficits, with switches from a FGA 
to SGA associated with improved motor performance (Ahn et al., 2009; Cuesta et al., 
2009; Keefe et al., 2007; Cuesta et al., 2001). Furthermore, a meta-analysis shows little 
effect of FGA on motor function, but improvements with SGA treatment (Woodward et 
al., 2005). Such differences may be expected given the differing mechanisms of action 
of FGA and SGA, and the association of FGA with extra-pyramidal and other motor side 
effects. Nonetheless, some suggest that the degree of superiority of SGAs is small, and 
that methodological issues, such as small sample sizes and choice of comparator dose, 
confound the results (Davidson et al., 2009).  
Cross-sectional comparisons of FGA and SGA treatment are rarely consistent. Two 
related studies investigating motor activation following haloperidol or olanzapine 
treatment reported decreased activation compared with healthy controls in the basal 
ganglia following treatment with haloperidol (Muller et al., 2002a/b). However, olanzapine 
was associated with decreased motor cortex activation. Conversely, another study found 
FGA but not SGA treatment led to lower activation in cortical regions (Braus et al., 1999). 
Longitudinal studies suggest treatment with olanzapine normalises baseline differences 
between healthy controls and patients, for example reversing lower activation in the 
sensorimotor cortex after eight weeks of treatment (Bertolino et al., 2004). As such, whilst 
the literature supports the modulation of motor performance and activation deficits in 
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schizophrenia by antipsychotic medications, the precise pattern of changes and effects 
of different antipsychotic medications remain to be elucidated.  
Studies of motor performance in healthy individuals suggest impaired motor 
performance following SGA administration (Beuzen et al., 1999; Wezenberg et al., 
2007; de Bruijn et al., 2006; Morrens et al., 2007). The FGA haloperidol appears not to 
affect performance in healthy controls, but does appear to lead to decreased motor 
activation in several motor regions, including the supplementary motor area, primary 
somatosensory cortex, premotor cortex, putamen, thalamus and cerebellum (Tost et 
al., 2006). However, in a study carried out by our group, greater activation in temporal, 
parietal, and frontal regions was seen following haloperidol, than after either placebo or 
aripiprazole. The only region of reduced activation was in the right caudate. Neural 
activation following aripiprazole did not differ from that following placebo. These 
differences may be accounted for by the differences in task used or by sample size. 
Our study was larger, and so whilst lower activation was seen in a few participants, 
increased activation may be more common but may go undetected in a smaller 
sample. Regardless, with so few studies it is difficult to draw more certain conclusions.  
c) Emotional processing 
Individuals diagnosed with psychotic illnesses often have associated impairments in 
social functioning, which may relate to other cognitive and emotional deficits, such as 
blunted affect (Kirkpatrick et al., 2001), facial emotional processing deficits (Tsoi et al., 
2008), reduced facial expression during social interactions (Mattes et al., 1995), and 
abnormalities in emotional perception (Edwards et al., 2001). 
Several studies report abnormal activation patterns to emotion stimuli in schizophrenia, 
although results depend on the precise tasks used, as well as whether patients are 
treated or not at the time of study. Dysfunctions in emotion perception and expression 
have been related to abnormal amygdala activity in schizophrenia (Blasi et al., 2009). A 
meta-analysis has suggested the presence of activation abnormalities across a range of 
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regions during emotional processing, including less extensive activation of bilateral 
amygdala, parahippocampal gyrus and fusiform gyrus, right superior frontal gyrus, and 
lentiform nucleus in patients with schizophrenia compared with healthy controls (Li et al., 
2010). Furthermore, during the task patients activated the left insula whilst controls did 
not.  
As emotional deficits, such as blunted affect, are difficult to treat and may relate to 
poorer functional outcomes (Stip et al., 2005), it is important to understand how they 
are modulated by antipsychotic treatment. Comparing emotion induction in 16 patients 
treated with FGA depot (a mixture, including haloperidol decanoate and flupentixol 
decanoate) with 16 patients treated with SGA depot (risperidone long-acting injection), 
activation was related to the type of treatment received (Surguladze et al., 2011). For 
example, during presentation of fearful faces, FGA-treated patients had higher 
activation of ventromedial PFC than SGA-treated patients. However, SGA-treated 
patients showed greater activation of the left amygdala than the other patient group. 
Longitudinal studies of emotion induction report decreased activation in subcortical 
regions of the midbrain, and increases in cortical, particularly frontal, regions, such as 
the dorsolateral PFC, anterior cingulate, and orbital frontal gyrus following five months 
treatment with quetiapine (Fahim et al., 2005; Stip et al., 2005). Another study reported 
decreased amygdala activation (making patients more like healthy controls) following 8 
weeks of olanzapine treatment in patients with schizophrenia (Blasi et al., 2009). FGAs 
and SGAs likely have differential effects. Thus, whilst antipsychotics likely modulate 
emotion processing in subcortical and cortical regions, the effects seen may depend on 
the antipsychotic type. Furthermore, some results are inconsistent and the precise 
patterns of change are yet to be elucidated.  
d) Other tasks 
The effects of antipsychotics on several other tasks have been investigated in 
schizophrenia. Some show a normalizing effect of SGA treatment, for example on 
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verbal fluency (Jones et al., 2004) and attentional control tasks (Ikuta et al., 2014), 
making patients more like healthy controls. Many longitudinal studies report changes in 
frontal regions following antipsychotic treatment. For example, increased anterior 
cingulate cortex activation was seen following 4 weeks of treatment with FGA and 
SGAs during a response-selection task (Snitz et al., 2005). Similarly, activation during 
visual saccades following four weeks of antipsychotic treatment with risperidone, 
ziprasidone or haloperidol was increased in ventromedial PFC, insular regions, left 
dorsolateral PFC, and right anterior cingulate cortex, whilst decreases were seen in 
bilateral cerebellum, left frontal eye fields, and supplementary eye fields (Keedy et al., 
2009). In a study of pre-pulse inhibition, the effects of different treatments (FGA versus 
risperidone) were investigated (Kumari et al., 2002), reporting that activation in a 
network of insular, inferior frontal, and thalamic regions was activated during the task in 
SGA-treated and not FGA-treated patients.  
These studies use widely varying methodologies and tasks, making it difficult to 
integrate their results. However, together the literature suggests that antipsychotic 
medications modulate various cognitive functions and their underlying neural activation 
patterns and that these alterations differ depending on the antipsychotic administered.  
1.5.2.3 Effects of antipsychotics on measures of salience  
Given the potential role of salience in the development of core symptoms of 
schizophrenia (delusions and hallucinations), investigating the effects of antipsychotics 
on these processes is incredibly important. Studying whether measures of salience are 
affected by antipsychotic medications, whether patients more closely resemble healthy 
controls after treatment, and whether these changes are related to changes in 
psychotic symptoms, provides a test of the importance of aberrant salience in the 
pathology of the disorder. Very few previous studies (Table 2) have investigated the 
effects of antipsychotics on salience in this way, and most of those that have, used 
reward tasks rather than tasks providing measures of salience attribution (as in the 
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SAT). Only one recent task has used the SAT to conduct cross-sectional analyses of 
the effects of treatment on measures of salience (Smieskova et al., 2015).  
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Participants (n) and medication Main findings 
Juckel et al., 2006 MID Cross-
sectional 
Schizophrenia (20): 10 FGA-treated; 
10 SGA-treated. 
Healthy controls (10) 
(ROI analysis in the bilateral ventral striatum). 
Healthy controls showed increased activation to 
reward anticipation. SGA-treated showed 
increased activation in left ventral striatum only. 
FGA-treated failed to show any increase in 
activation.  




Schizophrenia (30): 13 FGA-treated 
or a mix of FGA and SGA; 17 SGA-
treated. 
Healthy controls (0) 
(ROI analysis in the bilateral ventral striatum). 
Patients treated only with SGA showed higher right 
ventral striatal activation to reward anticipation 
than other patients.  





Schizophrenia (10): FGA-treated at 
baseline and then switched to 
olanzapine for at least 4 weeks. 
Healthy controls (10) 
Healthy controls had higher ventral striatal 
activation during reward anticipation than patients 
when FGA-treated at baseline.  
After olanzapine treatment, patients showed a 
significant activation of the ventral striatum and did 
not differ from healthy controls.   
Nielsen et al., 2012 MID Longitudinal Schizophrenia (23): Antipsychotic-
naïve at baseline, then treated for at 
least 6 weeks with amisulpride.  
Healthy controls (24) 
At baseline, patients had lower activation in the 
ventral striatum during reward anticipation. 
After amisulpride treatment, patients had 
increased activation in the ventral striatum and no 
longer differed from healthy controls.  
Increased activation in ventral striatum was 




Smieskova et al., 2015 SAT Cross-
sectional 
Schizophrenia (29): 17 unmedicated 
FEP; 12 SGA-treated (plus 34 with at 
risk mental state).  
Healthy controls (19) 
Compared with healthy controls, unmedicated 
patients had lower activation during adaptive 
salience in the left dorsal cingulate gyrus.  
 
Compared with healthy controls, medicated 
patients had lower activation during adaptive 
salience in the right insula.  
 
In unmedicated patients, the severity of 
hallucinations and delusions was negatively 
correlated with activation in the insula and anterior 
cingulate cortex during adaptive salience.   
 
MID = monetary incentive delay; ROI = region of interest; FGA = first generation antipsychotic; SGA = second generation antipsychotic 
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Five studies have investigated reward or salience processing in schizophrenia within a 
pharmacological imaging paradigm. Most were cross-sectional comparisons (Juckel et 
al., 2006b; Kirsch et al., 2007; Schlagenhauf et al., 2008b; Smieskova et al., 2015) and 
only one was longitudinal (Nielsen et al., 2012). Two further studies investigated the 
effects of antipsychotic administration on reward in healthy individuals without 
psychosis (Abler et al., 2007; Bernacer et al., 2013). 
The ventral striatum is a key area to reward and salience processing. Both healthy 
controls and SGA-treated patients exhibit activation here to reward-indicating cues 
during the MID task (Juckel et al., 2006b). However, in the same study, FGA-treated 
patients failed to activate the ventral striatum under the same conditions, and this was 
associated with negative symptoms. Similarly, ventral striatal activation in patients 
became more similar to that of heathy controls following a switch from FGA to SGA 
(olanzapine) (Schlagenhauf et al., 2008b). Furthermore, in a simple conditioning task in 
patients with schizophrenia (treated with either FGA only, a mixture of FGA and SGA or 
SGA only) cross-sectional region of interest analyses in the bilateral ventral striatum 
revealed greater activation during reward anticipation in patients treated with SGA only 
compared with the other patient groups (Kirsch et al., 2007). In the only study to use 
the SAT to measure salience, medicated and unmedicated patients with FEP differed 
from healthy controls in different brain regions (Smieskova et al., 2015). Unmedicated 
patients had lower activation during adaptive salience in the left dorsal cingulate gyrus, 
whereas in medicated patients lower activation associated with adaptive salience in the 
right insula was observed. There were no differences seen in activation during aberrant 
salience processing.  
The only study to investigate the longitudinal effects of antipsychotic medication on 
reward processes studied 23 antipsychotic-naïve patients with schizophrenia and 24 
healthy individuals completing the MID (Nielsen et al., 2012). Patients were scanned 
twice; at baseline and then following six weeks or a period of 2 weeks at a stable dose 
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of amisulpride. Before treatment, abnormal reward activation was seen, with lower 
activation in patients than healthy controls in the bilateral ventral striatum. At follow up, 
patients had an increased level of activation in this same region, and were no longer 
significantly different from healthy individuals, suggesting that the antipsychotic 
medication had acted to normalise reward activation. Furthermore, increased activation 
in the ventral striatum was positively correlated with improvements in positive 
symptoms, consistent with the idea that normalisation of reward-related activation was 
associated with a reduction in psychotic symptoms.  
Two studies investigated the effects of antipsychotics on reward and salience in 
healthy controls (Abler et al., 2007; Bernacer et al., 2013). Bernacer and colleagues 
(2013) investigated the effects of methamphetamine on reward-related processing in 
the ventral striatum and ventromedial PFC. They found that psychotic symptoms 
induced by this drug correlated significantly with altered activation in the ventromedial 
PFC, and these effects were not modulated by pre-treatment with the antipsychotic 
amisulpride.   
In a double-blind study using a crossover design to investigate fMRI BOLD during a 
delayed incentive task, eight healthy controls were compared after placebo and single-
dose olanzapine (Abler et al., 2007). The authors reported reduced activation in the 
ventral striatum, anterior cingulate cortex, and inferior frontal regions after olanzapine. 
There were also slowed reaction times to cues more highly predictive of reward. The 
analysis showed that whilst reductions in some regions appeared to be due to an 
overall drug effect, the results in the ventral striatum were specific to the attribution of 
salience, as the reduction represented a loss of differential activation to high versus low 
probability of reward rather than a general reduction. It is possible that different effects 
are seen in patients and healthy controls because drugs act on a different neural 
substrate, i.e. normal functioning activation in healthy controls. Possibly a U-shaped 
curve of optimal functioning may underlie incentive salience processing. Thus, in 
healthy controls, functioning of the ventral striatum is optimal for incentive salience 
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processing, but treatment with an atypical antipsychotic alters this functioning to 
beyond the optimal range. In patients, ventral striatal activation is decreased and thus 
suboptimal for salience processing. In such a case, atypical antipsychotic treatment 
alters functioning such that it is within the optimal range by increasing the activation in 
this region.  
There are limited studies of antipsychotic effects on salience and reward-related 
activation in schizophrenia. The few studies undertaken suggest an important role of 
the ventral striatum, in which dysfunctional activation may be improved with SGA, but 
not necessarily with FGA treatment. The current study provides a further opportunity to 
replicate these results, using a powerful longitudinal design, in a group of minimally-
treated first episode psychosis patients. Furthermore, it is the first to use such a design 
to investigate the effects of antipsychotics on activation during the SAT, a task that 
provides explicit and implicit measures of aberrant and adaptive salience.  
1.5.3 Brain perfusion  
Functional neuroimaging attempts to measure neuronal activation. However, the BOLD 
response actually comprises several parameters, including cerebral blood volume 
(CBV), blood oxygenation (CMRO2), and cerebral blood flow (CBF), and provides only 
a proxy of neuronal activation. This complicates the interpretation of results somewhat. 
However, perfusion imaging methods, such as arterial spin labelling (ASL), allow just 
one of these parameters, CBF, to be investigated. This removes the influence of other 
parameters, such as CBV and CMRO2, and provides a quantitative measure of brain 
activity in ml blood per 100mg of tissue per minute.  
CBF is the blood flow through a volume of tissue in a set period of time. It is visualised 
using either an exogenous tracer (as in bolus-tracking) or an endogenous tracer (as in 
ASL). Early functional neuroimaging studies used bolus-tracking methods, injecting 
compounds such as Gadolinium into the blood stream. These compounds alter the 
local magnetic susceptibility of blood, and this can be detected by a signal change, and 
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thus tracked as the bolus moves through the cerebral vasculature. ASL allows 
quantitative measurement of CBF using magnetically labelled arterial blood water as an 
endogenous tracer (Detre et al. 1992). Therefore, this technique does not require any 
injected compounds, meaning it is non-invasive and repeatable. This is particularly 
useful in psychopharmacological paradigms in which several images can provide a 
time course of changes across treatment (see Methods, page 131, for more details).  
Cerebral blood flow can be measured during a task or at rest (resting cerebral blood 
flow, rCBF), the latter of which provides a measure of basal brain activity. Importantly, 
rCBF appears to correlate with other measures of brain function. It is closely correlated 
with neuronal metabolic measures (Raichle, 1976), and ASL techniques reveal 
correlations between rCBF and regional brain activity measured using other techniques 
(Uludag et al., 2004).  
There is mounting evidence that antipsychotic medications alter rCBF, with reports that 
this may be linked to symptom amelioration (Pinkham et al., 2011). Regions that have 
been linked to psychosis elsewhere in the literature are often found to show altered 
patterns of rCBF in studies investigating antipsychotic effects (Miller et al., 2001; Lahti 
et al., 2003). Studies in patients have investigated chronic use across weeks, months, 
or longer but studies in healthy controls suggest that rCBF may be sensitive even to 
early antipsychotic action. Indeed, effects have been identified after single-dose 
administration, and what is more, these changes may be specific to antipsychotic type 
(Handley et al., 2013). Understanding these changes can aid interpretation of other 
brain changes, such as structural alterations, by providing the physiological 
mechanisms by which these may occur (Scheepers et al., 2001).  
I have published a systematic review and meta-analysis of the literature (Goozee et al., 
2014, Appendix A), which collates previous findings regarding the effects of 
antipsychotics on CBF and any relationships with treatment response. This paper 
concluded that antipsychotics appear to have an effect on rCBF, which differs 
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depending on antipsychotic generation. FGAs tend to have subcortical effects, while 
SGAs more often lead to alterations in cortical regions. The review and a small, 
exploratory meta-analysis implicated rCBF in the frontal cortex and basal ganglia as 
particularly affected by antipsychotic treatment. However, in the review I also noted that 
few studies use a priori definitions of treatment response, which makes it difficult to 
predict outcomes to antipsychotic treatment using measures of rCBF. There was also a 
high level of heterogeneity between studies in terms of patient samples, methods, and 
treatment administered. These considerations helped to inform the use of cASL in the 
current study, to investigate the potential for rCBF to predict symptomatic improvement.  
Given the literature outlined above, rCBF is a good candidate biomarker for 
antipsychotic treatment effects and treatment response. I therefore use ASL in the 
current study, to investigate the effects of antipsychotic medication on rCBF at rest in 
our sample of FEP patients.  
1.5.4 Chapter summary and conclusions 
A wide range of neurobiological measures have been investigated to try to understand 
how antipsychotic treatment affects the brain. Neurobiological alterations have been 
observed in schizophrenia using various techniques, showing structural and functional 
differences compared with healthy controls. The research reviewed in this chapter 
suggests that some of these changes may be due to treatment. Indeed, antipsychotic 
medications can alter both brain structure and function, and differential effects are often 
seen for different antipsychotics. Whilst FGA and SGA broadly affect these parameters 
in different ways, it might even be possible to differentiate the effects of specific types 
of antipsychotic within these categories, with the mechanisms of action and receptor 
affinities determining the changes seen.  
Such studies allow us to see the ways in which the brain changes under treatment. 
Moreover, such findings provide a basis from which brain measures might potentially 
allow prediction of treatment response. Understanding the differences in the effects of 
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antipsychotics on the brains of patients who respond to antipsychotic medications and 
those who do not, can provide insight into the precise mechanisms of effective 
treatment. Furthermore, baseline brain measures may be used for prediction of later 
response. Together, these findings can help us to better understand current treatments 
and how they work, identify potential new treatment targets (particularly for those who 
do not respond to treatments currently in use), and they could guide treatment, allowing 




1.6 Prediction of antipsychotic treatment response 
Antipsychotic medications are the first choice of treatment for psychosis and at a group 
level, antipsychotics exhibit efficacy compared with placebo for treating the symptoms of 
psychosis (Leucht et al., 2013). However, at the individual level, response to treatment 
is variable. As many as 40% of patients do not respond to the first antipsychotic (Barnes, 
2011), and it is not currently possible to predict later response at first presentation in 
clinical services. Therefore, treatment is carried out in a “trial and error” manner, with no 
objective ways to predict whether a particular patient will respond or not (Piquette-Miller 
and Grant, 2007). Furthermore, given current reliance on relatively subjective clinical 
assessments, both diagnostic accuracy and treatment plans for patients with 
schizophrenia are likely influenced by cultural and value judgements (Fulford et al., 
2005). Whilst antipsychotics have been compared to identify which should be trialled first 
(Johnsen et al., 2010), this approach only accounts for effectiveness at a group-level, 
and does not consider that different individuals may benefit from different antipsychotics.  
Approaching antipsychotic treatment in this way can be problematic for several reasons. 
Inevitably, a proportion of patients will remain treatment resistant or partially responsive, 
with residual symptoms and distress associated with poorly managed psychotic 
symptoms. Prolonged distress may have a greater impact on function as they trial 
several antipsychotic medications before finding a treatment that works for them. 
Additionally, this costs services extra time and money; treating residual symptoms and 
also dealing with associated morbidity, mortality, and adverse drug reactions or side 
effects (Piquette-Miller and Grant, 2007). Furthermore, this approach stunts 
development of new treatments. Elucidating the biological variation underlying treatment 
resistance and poor response may improve treatment for patients, reduce costs for 
services, and provide potential new treatment targets.  
Understanding neurobiological heterogeneity in response to treatment in schizophrenia 
could provide objective predictive biomarkers. If heterogeneity in treatment response 
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reflects differences in aetiology, then understanding differences in individual biological 
factors underlying variability may provide the basis for developing predictive ‘tools’. This 
could inform aetiological mechanisms, as well as diagnostics and therapeutics, 
supporting improved treatment management, patient stratification, and personalised 
treatment planning (Gerretsen et al., 2009).  
Several factors have been associated with outcome in schizophrenia, and research to 
identify prognostic predictors has explored clinical, psychosocial, and biological factors 
with some success. However, many studies still consider these predictive relationships 
at a group-level, providing only general (rather than individual) knowledge about what 
kinds of patients are likely to benefit from particular treatments. In contrast, recent 
development of machine-learning techniques holds promise for individual-level 
prediction, which could therefore allow truly personalised investigations of likely 
treatment outcome (Mourao-Miranda et al. 2012).  
This chapter outlines clinical and biological factors that have been associated with 
treatment outcome or used as prognostic predictors. Clinical, genomic, and proteomic 
research will be mentioned only briefly, allowing space for a full discussion of 
neuroimaging biomarkers of treatment response. However, first, I will discuss the 
concept of remission in schizophrenia, as this is central to the assessment of response 
to treatment, the focus of this thesis.  
1.6.1 Expectations for prognosis and outcome in schizophrenia 
For much of its history, schizophrenia has been identified as a progressive, deteriorative 
or serially relapsing disease (Levine et al., 2011). According to this view, sufferers could 
expect little, if any, recovery of social relations and occupational function, or even 
resolution of symptoms. Such a diagnosis was deemed a ‘life sentence’; a chronic illness 
usually to be managed within the asylum system.  
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The introduction of pharmacological treatments and community care, as well as long-
term prospective studies of illness course, have altered this state of affairs. Greater 
optimism and hope for recovery (a previously neglected concept in schizophrenia) were 
fostered by results showing heterogeneity in outcome of the disorder (e.g. Liberman et 
al., 2002; Morgan et al., 2014). Certainly, some patients develop chronic illness. 
However, many recover, enjoy long periods of remission, and learn to adapt to their 
illness, recovering much of their previous functional capacity. Furthermore, early 
identification and treatment aims to curtail much of the disruption associated with 
uncontrolled symptoms. Possibly, the change from asylum-centric care to community-
based case management did not simply result from availability of new pharmacologic 
treatments but also reflected (and encouraged) a change in attitude towards the 
possibility of recovery.  
1.6.2 Recovery in schizophrenia 
Definitions of recovery, and the related concept of remission, differ depending on the 
perspective taken. Patients, clinicians, and researchers may approach the subject with 
their own priorities, although their definitions will probably overlap to some degree.  
Whilst clinicians and researchers are likely to focus on symptoms, patients’ personal 
definitions are likely to be broader and more idiosyncratic. Reviews of studies looking at 
personal definitions of recovery find various commonalities or themes across individual 
definitions. Leamy and colleagues (2011) identified five recovery processes in personal 
accounts of recovery. These include connectedness, hope and optimism, identity, 
meaning in life, and empowerment. However, in black and ethnic minority samples, 
spirituality and stigma appear more important.   
The focus for recovery clinically often tends to be on the remission of symptoms. Clinical 
definitions of remission and recovery are important to be able to determine suitable 
treatments, manage treatments according to need, and identify unmet need. They are 
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likely to include symptom reduction, relapse prevention, avoidance of hospital 
admittance, and return to work.  
Within psychiatric research the definition of recovery tends to differ from these other two 
perspectives. A definition or operationalization of remission and recovery for research 
needs to be quantifiable, standardized to be applicable across a range of study contexts, 
valid, reliable, and generalizable. To investigate treatment response, there needs to be 
a treatment goal, which is standardised and appropriate for use by different researchers 
or in different studies and samples, to allow comparisons of treatments. Within research, 
definitions of recovery and response are often reached by consensus to enable the 
efficacy of treatments to be determined, and to compare outcomes or treatments. 
Consensus criteria for remission in schizophrenia are outlined and discussed below 
(Andreasen et al., 2005).  
Of course, an important aspect of translational research is ensuring that 
operationalizations of treatment response are clinically relevant, and relate to personal 
priorities of patients, i.e. they should indicate improved functioning and not just symptom 
reduction unrelated to other relevant outcomes. However, remission can be seen as a 
necessary although insufficient step towards recovery, which is a longer-term state that 
encompasses improvements in social and occupational function, quality of life, and the 
like (Andreasen et al., 2005). Therefore, it is an appropriate treatment goal for research. 
1.6.3 Consensus definition for research 
Until recently, a lack of standardised remission criteria was a problem for research into 
outcomes in schizophrenia. It limited the ability to compare findings across studies using 
different criteria and it made findings difficult to interpret as it could be unclear what the 
remission criteria meant clinically. In 2005, the Remission in Schizophrenia Working 
Group developed specified criteria to overcome this (Andreasen et al., 2005). 
Subsequently, these criteria have been applied in numerous settings and in many 
studies. In addition, they have been shown to relate to social and occupational 
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functioning, with patients defined as ‘remitted’ doing better in other functional domains 
than those defined as ‘non-remitted’ (Emsley, 2011). These standardised criteria 
address a number of problems that were previously encountered in research that aimed 
to assess response to treatment.  
Prior to the consensus criteria, early studies tended to use general descriptive criteria, 
such as ‘mild illness’ versus ‘active psychosis’. However, the judgement of the category 
to which an individual should be assigned was not objective, and may have differed 
between different studies or even different raters within a study.  
Definitions of remission that were subsequently developed for research focused on the 
reduction of (usually positive) symptoms. This accompanied the development of 
assessments such as the Scale for Assessment of Positive Symptoms (SAPS), the Scale 
for Assessment of Negative Symptoms (SANS), and the Positive and Negative 
Syndrome Scale for Schizophrenia (PANSS). There are two main approaches to using 
symptom scores to assess response to treatment. Firstly, change scores may be used 
to indicate the level to which a treatment has reduced (or otherwise) a symptom score. 
This method has the benefit of providing a continuous measure of treatment response, 
and can be used where the groups of treatment responders or non-responders suffer 
from a small sample size. However, a limitation with this approach is the variability in 
baseline scores, as well as how to define the extent of change needed for a clinically 
significant change. Is it possible for two individuals to have a decrease in PANSS score 
of the same magnitude, but to differ vastly in the severity of their illness following this 
change if one individual was much more ill to begin with than the other. Therefore, the 
second alternative approach that has been proposed is to use threshold levels of illness 
severity, below which remission is ‘achieved’ (Leucht et al., 2006). This is the procedure 
used in applying the Andreasen remission criteria.  
Within the Andreasen remission criteria, eight PANSS items are used to define 
remission: delusions (P1), conceptual disorganisation (P2), hallucinations (P3), blunted 
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affect (N1), passive/apathetic social withdrawal (N4), lack of spontaneity and flow of 
conversation (N6), mannerisms and posturing (G5), and unusual thought content (G9). 
Remission is achieved with a score of three or less (‘mildly present and does not interfere 
with daily life functioning’) on all eight items. Importantly, these criteria have been shown 
to relate to several broader clinical outcomes, such as quality of life, occupational 
function, social function, and subjective wellbeing (Helldin et al., 2007; Emsley et al., 
2007; Nasrallah and Lasser, 2006). The consensus group also considered the long term 
and potentially relapsing course schizophrenia can take, and so suggested that 
remission was achieved when these items remained mild or less for six months. In this 
study, we did not use the six months criteria, as patients were medicated for 4 weeks, a 
period during which it is suggested most response to antipsychotic treatment occurs 
(Kinon et al., 2010). Furthermore, response at 4 weeks has been shown to reliably 
predict later response up to 12 months (Leucht et al., 2007; Kinon et al., 2010).  
In this thesis, both change scores on the PANSS and the Andreasen remission criteria 
are used to assess treatment response. Thus, remission of symptoms according to the 
Andreasen criteria constitutes a ‘responder’. Meanwhile, failure of symptoms to remit 
constitutes a ‘non-responder’. Using this categorisation of patients, we can compare 
responders and non-responders in a number of ways to try to determine the 
neurobiological basis of treatment response (and non-response). The aim is therefore to 
use various biological parameters to predict to which category a patient will belong 
(responder or non-responder). However, due to relatively small numbers of non-
responders, we also use percent change scores to provide a continuous measure of 
treatment response, where categorical comparisons may be underpowered. Continuous 
variables will allow prediction of response to treatment, by exploring relationships 
between neurobiological factors and the degree of response to treatment.  
A vast number of potential clinical and biological predictors of treatment response, 
including genetic, proteomic, and neuroimaging, have been investigated. Predicting 
response to treatment using neuroimaging is a recently emerging field in psychiatry, and 
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is the approach chosen in the current project. In the next section, I will outline the 
evidence for predictive biomarkers of treatment response in psychosis, concentrating 
primarily on neuroimaging.  
1.6.4 Factors predicting response to treatment 
The observation that not all patients respond well to antipsychotic medications naturally 
leads to the question of why this might be. Understanding the factors that determine 
response to treatment could be beneficial in a number of ways, not least because it might 
allow prediction of treatment response. Furthermore, the ability to determine who will 
respond to a treatment, and who will not, before treatment commences is vital if the aims 
of personalised medicine in psychiatry are to be met.  
It is worth bearing in mind that two broad categories of studies exist that attempt to predict 
outcomes. Some studies use clinical and biological predictors for prognosis to predict 
longer term, broader outcomes that relate to general functioning. Others use a narrower, 
more specific concept of treatment response, such as symptom reductions or the 
Andreasen remission criteria, as I have outlined above.  
1.6.4.1 Clinical predictors of treatment response 
Demographic and clinical factors were the first to be investigated as potential predictors 
of antipsychotic treatment response. A review suggests that insight, early treatment 
response, and duration of untreated psychosis (DUP) may all be particularly important 
for outcomes in psychosis (Emsley et al., 2008). These factors might mediate outcome 
via numerous pathways, for example determining compliance with treatment, 
engagement with services or other non-specific factors.  
Where relationships between clinical factors and antipsychotic response have been 
explored, a good response has been associated with good premorbid adjustment and 
shorter DUP (Schennach et al., 2012). Whilst many studies have identified an early 
good response to treatment as predictive of subsequent good response (e.g. Levine 
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and Leucht, 2012; Giegling et al., 2012; Ruberg et al., 2011), it is possible that this 
prediction is only reliable in the short-term, and does not hold for longer-term outcomes 
(Schennach et al., 2012).  
A common characteristic of clinical predictors is that they deal with group-level 
prediction. On the whole, patients with a longer DUP tend to do worse than those with 
a shorter DUP. However, if we are faced with a patient in the clinic, and asses their 
DUP, we cannot use this measure to predict reliably how well this particular individual 
will fare following treatment or in response to a particular antipsychotic medication. 
There is no precise relationship between a certain cut off length of DUP and good or 
poor treatment response. Clinical factors tend to be imprecise, allowing only 
probabilistic statements about risk of a good or poor response. Neurobiological factors 
in combination with machine learning methods hold the promise of more precise, 
individualised prediction.  
1.6.4.2 Biomarkers of treatment response 
The term biomarker is used across health and medical disciplines, and it has been 
defined in a number of ways. Strimbu and Tavel (2010) define biomarkers as follows:  
“The term “biomarker” … refers to a broad subcategory of medical signs – that is, 
objective indications of medical state observed from outside the patient – which can 
be measured accurately and reproducibly. Medical signs stand in contrast to medical 
symptoms, which are limited to those indications of health or illness perceived by 
patients themselves.” 
The authors stress the difference between biomarkers and clinical endpoints. The latter 
are the aim of treatment, incorporating the subjective sense of wellbeing and symptom 
experience of the patient. Biomarkers on the other hand do not necessarily correspond 
to the clinical state of the patient, but are often surrogate endpoints whereby they 
reliably and accurately predict a clinical endpoint. Another earlier definition from the 
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National Institutes of Health Biomarkers Definitions Working Group (2001) defined a 
biomarker as:  
“A characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention.” 
These definitions suggest that a substance, structure, or process that can be 
objectively measured in the body to predict disease or outcome of treatment can be 
classed as a biomarker. Therefore, any medical signs, from pulse and blood pressure, 
through gene and blood factors, to brain volumes or activations may be used as 
predictive biomarkers if they can be shown to reliably and accurately predict treatment 
outcomes.  
References to biomarkers do not always relate to the prediction of treatment response. 
In a review, Prata and colleagues (2014) collate examples of biomarkers that can be 
defined as ‘predictive’, ‘prognostic’, ‘monitoring’, and ‘diagnostic’. Predictive biomarkers 
are particularly useful in the current context. Predictive biomarkers are biological 
variables that “predict a response to a specific therapy, be it psychological or 
pharmacological, to help determine the optimal treatment in a stratified or personalized 
manner before it is commenced”. In the current project, I investigate potential predictive 
imaging biomarkers with the broader view to informing a personalized approach to 
antipsychotic treatment. 
Within psychiatry, there are currently no objective diagnostic or prognostic biological 
tests. However, several genetic, proteomic, and neurobiological markers are being 






1.6.4.3 Genomic and proteomic predictors of antipsychotic treatment response 
The role of genes in schizophrenia has been extensively researched, and genetic 
factors have emerged as important not only in the development of psychosis, but also 
in the variability of response to treatment (Reynolds, 2012). Studies of monozygotic 
twins suggest a genetic influence on response to treatment, with monozygotic twins 
showing strong concordance in response to clozapine (Vojvoda et al., 1996) and 
olanzapine (Mata et al., 2001). Most genetic studies have used candidate gene 
approaches, which are hypothesis-driven investigations of genes for proteins that are 
either known, or thought, to play a role in the drug action. Thus, genes involved in both 
the dopamine and serotonin systems have been widely researched. For example, the 
DRD2 gene, coding for the dopamine D2 receptor, has been shown to relate to 
response to haloperidol (Schafer et al., 2001). Similarly, polymorphisms at genes 
encoding serotonin receptors have been related to antipsychotic treatment response, 
and may be more important in the remission of negative than positive symptoms 
(Reynolds et al., 2005/2006).  
Genetic studies are subject to many of the same criticisms as neuroimaging studies of 
the effects of antipsychotics on the brain. They suffer from small sample sizes, and 
heterogeneity in patients’ diagnoses and drug histories (Nnadi and Malhotra, 2007). 
However, in drug-naïve patients, polymorphisms at a promoter region of the DRD2 
gene have been related to speed of response to SGAs (Lencz et al., 2006).  
Proteomic alterations are also reported in schizophrenia, and provide another source of 
potential biomarkers to predict treatment response to antipsychotic medications (Guest 
et al., 2013). Some promising findings are reported, despite challenges to proteomic 
analyses (including the inaccessibility of the live human brain for proteomic 
interrogation, the potential inability to detect central changes in the periphery, etc.; 
Martins-de-Souza et al., 2012). Analysis of serum prolactin levels show a relationship 
between higher levels and better outcomes following five years of treatment 
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(Shrivastav et al., 2012). Furthermore, several proteins important in inflammatory and 
hormonal pathways have been shown to predict improvements in positive (e.g. IL-16, 
C-reactive protein, and prolactin) and negative (e.g. insulin) symptoms (Schwarz et al., 
2012).  
The hope for proteomic analyses is that they will reveal molecular tests to identify 
responders to specific medications. As such, personalised medicine approaches could 
be developed based on simple laboratory tests, for example blood samples, to 
determine which antipsychotic medication a patient is likely to benefit from. However, it 
has been suggested that different levels of biological analyses must be integrated, not 
only genetic and proteomic, but also transcriptomic and metabolic, to develop a 
systems biology approach that will better equip clinicians and researchers to predict 
treatment response outcomes in patients (Guest et al., 2013).  
1.6.4.4 Imaging predictors of antipsychotic treatment response 
Neuroimaging is emerging as a promising source of biomarkers of antipsychotic 
treatment response, with potential for clinical translation (Dazzan et al., 2015). Whilst 
genetics and proteomic biomarkers have the benefits of objectivity, low cost, and 
reliability, they also suffer from small effect sizes and low prevalence, limiting their 
clinical application (Prata et al., 2014). Brain imaging has been shown to have larger 
effect sizes with replicable results (although this is largely as diagnostic biomarkers). 
Coupled with machine-learning approaches, imaging offers the potential of an 
automated, accurate tool with which treatment response could be predicted. However, 
whilst recent research efforts have revealed associations between various brain 
measures and response to treatment, it remains to be clarified which measures are of 
greatest predictive value, and thus have value in clinical management.  
To identify biomarkers with a high predictive accuracy and generalizability requires 
large scale, multisite studies (Kempton and McGuire, 2014). Larger sample sizes would 
ensure studies are adequately powered, and would also enable analyses of subgroups 
76 
 
within the heterogeneous umbrella of schizophrenia. Furthermore, studies across 
multiple sites can increase the generalizability of results, whilst ensuring standardized 
procedures are used at all sites. However, it has often been difficult to pool data from 
different studies, as both samples and methods are greatly heterogeneous.  
1.6.4.4.1 Structural imaging predictors of treatment response 
Structural biomarkers have been widely researched for many years, and whilst a 
greater degree of structural abnormality has been associated with a broadly worse 
outcome, no clear associations have been shown with response to treatment (Lawrie et 
al., 2011).  
An early review and meta-analysis found a lack of significant association between brain 
structure and treatment response (Friedman et al., 1992). However, the authors 
highlighted the influence of heterogeneity in samples and methods from different 
studies, suggesting the need for greater standardization. More recent studies have 
combined structural measures with clinical variables, for example reporting that a 
greater degree of baseline psychopathology predicts a better response to treatment, 
but that patients with enlarged ventricles are more variable in both symptomatology 
and response to treatment (Mauri et al., 1994). A recent review by Dazzan and 
colleagues (2015) collated results from studies that investigated the relationship 
between structural MRI parameters and outcome in FEP, finding alterations in medial 
temporal and prefrontal cortical areas to be promising neuroanatomical markers of poor 
response to treatment.  
Often studies investigate specific brain regions in relation to treatment response with 
variable results. For example, some have reported a relationship between larger 
hippocampal volumes and a good response to risperidone (Savas et al., 2002), but 
others have failed to find any relationship with olanzapine treatment (Molina et al., 
2003a). The prefrontal cortex has also been investigated, particularly in relation to 
clozapine response. An early study reported no relationship between improvements on 
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the BPRS and frontal or prefrontal volumes in treatment-resistant patients with 
schizophrenia switched from typical antipsychotics to clozapine (Lauriello et al., 1998). 
However, Molina and colleagues (2003b) studied 25 treatment-resistant patients with 
schizophrenia following clozapine treatment and reported that greater improvements in 
negative symptoms were related to increased volume of the prefrontal cortex, whilst the 
best predictor of improvement of positive symptoms was temporal volume.  
Early studies are subject to methodological limitations, such as heterogeneous 
samples, with many participants having previous exposure to antipsychotic medication. 
Given the evidence that antipsychotic medication alters brain structure (refer back to 
chapter 1.5), the baseline scan in such patients is likely affected by their previous 
treatment. Furthermore, chronicity and duration of illness may be a further 
consideration, as neurodegeneration or progressive pathological processes may 
introduce further variance and confounding factors into the sample. As elsewhere, 
these complications are avoided by implementing studies in antipsychotic-naïve or 
minimally treated patients experiencing their first episode of psychosis.  
An early study of 70 patients with FEP reported that a longer time to remission was 
associated with abnormalities in the lateral and third ventricle (Lieberman et al., 1993). 
Another study of 26 FEP patients investigated early treatment response to haloperidol 
in a voxel-wide search, reporting that improved positive and negative symptoms after 
just one week correlated with cortical grey matter (GM) volumes (Zipursky et al., 1998). 
However, GM was also influenced by the dose (greater GM associated with lower 
doses), highlighting the importance of considering dose when analysing and 
interpreting pharmacological brain imaging findings. Specific cortical regions have been 
found to predict outcome in some studies. Prasad and colleagues (2005) found that 
functional outcomes were predicted by dorsolateral PFC volumes in 27 antipsychotic-
naïve FEP patients. Prefrontal regions were also implicated in another study, where 
poor outcome was associated with smaller left prefrontal volumes (Kasparek et al., 
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2009). However, this relationship between PFC and outcome has not been replicated 
by all studies (Molina et al., 2003b).  
Other studies have investigated subcortical regions. Li and colleagues (2012) reported 
a significant increase in GM volume in the right putamen of 42 medication-naïve FEP 
patients treated for 6 weeks with various antipsychotic medications. These changes 
during treatment positively correlated with a reduction in positive symptoms but this 
methodology did not use baseline brain scans to predict later outcome. However, larger 
striatothalamic volume has been associated with a good response in females but not 
males (Fung et al., 2014), although remission rates for men in this study were generally 
low.  
Studies have also attempted to investigate brain structure measures other than simply 
volumetric changes. For example, greater frontal cortical asymmetry was found in FEP 
patients who later showed symptomatic improvements (Szeszko et al., 2012). 
Furthermore, in the same study a larger temporal cortex thickness was associated with 
a shorter time to response. Cortical gyrification has also been investigated, with FEP 
patients who did not respond after 12 weeks of treatment showing decreased 
gyrification in frontotemporal regions and the insula compared with responders at 
baseline (Palaniyappan et al., 2013).   
It is possible that baseline differences in brain structure are not necessarily strongly 
predictive of clinical outcome, but that dynamic changes during the course of illness are 
important. For example, greater progressive grey matter loss during the first year of 
illness has been associated with worse outcome at 5 years, specifically greater severity 
of negative symptoms and less likelihood of living independently (Cahn et al., 2006). 
Consistent with this, a greater extent of progressive reduction in frontal white matter 
and associated ventricular enlargement in patients with schizophrenia has been shown 
to relate to worse outcomes for patients (Ho et al., 2003). Once again, negative 
symptoms were implicated rather than positive.  
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Classical analyses of neuroimaging data suffer from several problems, including multiple 
testing, the failure to treat the brain as distributed networks rather than localised nodes 
of specialist function, and acting at population-level rather than the individual. Deficits in 
schizophrenia are likely to represent distributed, subtle alterations in the functioning of 
such networks, rather than focal lesions (Orru et al., 2012). Furthermore, generalising 
group-level results to individuals is problematic, as it treats patients as though they are 
homogeneous, ignoring potential variation amongst individuals. Recent techniques 
derived from pattern recognition methods, such as support vector machine learning 
(SVM) are now being investigated to address some of these problems. Pattern 
recognition techniques model brain activity as activation within distributed networks, 
which act in concert to guide behaviour (Zhang et al., 2012). This multivariate technique 
treats the data as spatial or spatio-temporal patterns, and is sensitive to correlations 
between voxels. Moreover, it can be used at an individual level, and is being studied for 
the purpose of diagnostic and prognostic prediction.  
SVM may provide further clinical utility where it can predict prognosis (e.g. transition to 
psychosis in UHR individuals) or outcomes to treatment, if it can do so with a high 
degree of accuracy. Studies have shown promise for SVM to predict transition to 
psychosis using structural MRI (Koutsouleris et al., 2009; 2012), by differentiating those 
who transition to psychosis and those who do not, as well as differentiating each of 
these groups from healthy controls. One study has applied SVM to structural MRI to 
predict later outcomes for FEP patients (Mourao-Miranda et al., 2011). In this study, 
100 patients were scanned at their first presentation. They were followed up on 
average 6.2 years later, and categorised into good and poor outcome according to their 
illness course type (poor outcome characterised by continuous illness and good 
outcome characterised by episodic illness). The authors reported that patients later 
categorised as having a continuous course could be distinguished at baseline from 
patients with a later episodic course with 70% accuracy. The regions that contributed to 
the classification most including the cingulate, parahippocampal gyri, basal ganglia, 
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and thalami. These results suggest that when patients first present, patterns in MRI 
data can be used to predict later outcomes at the individual level, with relatively high 
levels of accuracy. This study suggests that MRI data has potential value as a predictor 
of later outcome in individual patients. No studies so far have used SVM with structural 
imaging to predict treatment response, defined a priori.  
Studies already carried out hold promise that SVM could be used to discriminate 
treatment responders from non-responders. However, it is still a relatively novel 
approach and as such further work is necessary to determine which modalities provide 
the greatest accuracy of prediction. However, this technique is likely to have high 
clinical translation value as predicting response to treatment creates the possibility that 
individual brain scans could be used to design personalised treatment plans based on 
individual neurobiological profiles (MacQueen, 2010).  
In summary, results from studies investigating the relationship between brain structure 
and treatment response vary. Inconsistencies may result from methodological 
differences, whilst some studies suggest that dynamic changes rather than static 
baseline structure are more important in prediction. However, given the failure to find 
accurate, replicable, and reliable structural predictors of treatment response, many 
researchers have turned to functional imaging, which is emerging as a promising 
source of predictive biomarkers (Lawrie et al., 2011). 
1.6.4.4.2 Functional imaging predictors of treatment response 
Various imaging techniques can probe different aspects of brain function. To date, the 
technique most widely used to predict antipsychotic treatment response is PET, 
although other perfusion, functional and chemical imaging techniques have also been 
used, such as ASL, fMRI BOLD, and MRS.  
Using PET, Kapur and colleagues (2001) used CGI scores to designate 22 
antipsychotic-naïve or minimally treated patients as responders (CGI ≤ 2) or non-
81 
 
responders (CGI ≥ 3) after two weeks of haloperidol treatment. They reported greater 
D2 receptor occupancy in responders than in non-responders, and suggested an 
optimal cut-off of 65% occupancy to differentiate between the two. This was consistent 
with a much earlier study reporting increased D2 receptor occupancy during treatment 
with raclopride was associated with a greater percentage reduction of BPRS 
(Nordstrom et al., 1993). Elsewhere, in 14 patients with recent onset psychosis, 2 
weeks treatment with either risperidone or olanzapine lead to changes in PANSS 
positive scores that correlated with D2 receptor occupancy in striatal but not extra-
striatal areas (Agid et al., 2007). However, occupancy related to neither negative 
symptoms nor baseline severity of symptoms. Both of these studies related functional 
changes after treatment initiation to treatment response. This does not provide a 
predictive measure that can be assessed prior to treatment initiation. However, these 
studies do suggest that response to antipsychotic medications is characterised by 
particular patterns of brain function, and elucidating such differences may reveal 
differing pathophysiology underlying disorders in those who respond well to current 
antipsychotics and those who do not. 
Using a cross-sectional design, 12 treatment-resistant, 12 responders (determined 
using the Andreasen (2005) criteria), and 12 healthy controls were compared using 
PET (Demjaha et al., 2012). Patients were medicated with various different drugs but 
none were on clozapine. The authors reported elevated dopamine synthesis capacity in 
the striatum of responders compared with non-responders, as well as healthy controls. 
In contrast, non-responders did not differ from healthy controls. These results suggest 
that elevated dopamine in responders is targeted by current treatments. However, non-
responders may have a different underlying pathophysiology, which affects systems 
other than dopamine and is not altered by current medications. This study is consistent 
with another that found elevated synaptic dopamine at baseline to predict good 
treatment response after 6 weeks of naturalistic treatment with antipsychotics (Abi-
Dargham et al., 2000).  
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Fewer studies have investigated the utility of fMRI BOLD to predict treatment response 
in psychosis. A study of stable and medicated patients with schizophrenia, reported 
that greater activation in the dorsolateral PFC and cerebellum at higher cognitive loads 
during the n-back was associated with symptomatic improvement following CBT 
(Kumari et al., 2009). Other studies have shown a relationship between working 
memory-related activation and symptomatic improvement following antipsychotic 
medication. In patients treated with typical antipsychotics who were switched to 6 
weeks risperidone, increased PFC activation during the n-back was related to improved 
negative symptoms (Honey et al., 1999). Similarly, increased ventrolateral PFC 
activation following 12 weeks of quetiapine has been associated with improvements in 
negative symptoms (Meisenzahl et al., 2006). However, again these studies do not 
predict outcomes using baseline measures and so are of limited predictive use.  
To my knowledge, only two studies have predicted antipsychotic treatment response at 
baseline prior to treatment using fMRI (Van Veelen et al., 2011; Nejad et al., 2013). 
Van Veelan and colleagues investigated the relationship between dorsolateral PFC 
activation during working memory and treatment response to atypical antipsychotics, 
reporting that left dorsolateral PFC dysfunction in patients compared with controls was 
mainly due to non-responders, whereas responders did not differ from healthy controls 
in this region. Furthermore, reduced practice effects in the dorsolateral PFC at baseline 
predicted poor outcome at 10 weeks. In another study of working memory activation, 
Nejad and colleagues investigated functional connectivity in antipsychotic-naïve 
patients with FEP before and after 7 months of treatment with quetiapine (Nejad et al., 
2013). They discovered a frontoparietal network that accurately predicted improvement 
in negative symptoms, and recognised the potential of using such information to stratify 
patients for treatment. Only one published study has investigated response to 
antipsychotic treatment (clozapine) in patients with schizophrenia using SVM and a 
measure of brain function. Responders and non-responders were discriminated using 
EEG with an accuracy of 86% (Khodayari-Rostamabad et al., 2010), suggesting that 
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functional imaging methods may hold promise as predictive biomarkers in machine 
learning approaches.  
Studies have also investigated the use of brain perfusion to predict treatment response. 
Four studies have looked at rCBF in this manner (Rodriguez et al., 1996, 1997; Lahti et 
al., 2009; Ertugrul et al., 2009). These are described in detail in my paper included in 
Section 1.5.3. To summarise, various regions including the basal ganglia (including 
ventral striatum), thalamus, hippocampus, and frontal and parietal cortices have been 
implicated in prediction of treatment response. In these regions, baseline perfusion 
differences between patients and healthy controls are seen primarily in those who later 
respond to treatment, whereas non-responders do not differ from controls. 
Furthermore, over treatment the differences in these regions decreases in responders, 
such that they become more similar to healthy controls. Baseline thalamic and 
prefrontal perfusion (as a ratio of perfusion in the homolateral cerebellar hemisphere) 
predicted response correctly in 78.9% of cases (Rodriguez et al., 1997). 
Frontal/thalamic rCBF values have also been shown to predict percentage change in 
PANSS score after eight weeks of clozapine. Thus, previous research suggests that 
perfusion provides a promising potential predictive biomarker of treatment response. 
However, many studies have used patients with previous exposure to antipsychotics, 
making it difficult to assess whether the effects seen result from treatment withdrawal, 
chronic antipsychotic use, or the study drug.  
In summary, PET studies have repeatedly shown a relationship between dopaminergic 
function and treatment response in psychosis. Research is yet to fully elucidate the 
potential for fMRI BOLD measures to predict response to treatment. Choosing relevant 
fMRI BOLD tasks is clearly important, to ensure that these tap a function that is 
impaired in patients with psychosis. Furthermore, we would expect functional activation 
that has been related to dopaminergic signalling to have greater potential as a 
predictive biomarker, given the results seen from PET imaging. Perfusion imaging 
offers further potential predictive biomarkers, although relatively few studies have been 
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carried out to date. In this study, I investigate salience processing, which is impaired in 
schizophrenia, and is thought to be caused by dysregulated dopamine firing and which 
is improved by current antipsychotic treatments (Kapur et al., 2005). I also investigate 
the ability of cerebral blood flow to predict treatment response in FEP minimally-treated 
patients. A strength of this work is the use of multiple imaging modalities in the same 
sample, at the same time points. This may provide a further predictive model in which 
these measures could be combined.  
1.6.5 Multimodal imaging 
The studies outlined above have investigated the potential of one particular brain 
imaging measure to predict treatment response. It is possible that the use of multiple 
modalities will improve prediction or be useful to stratify patients for clinical trials 
(Kempton and McGuire, 2014). It is easy to implement multiple modalities within an 
MRI scan by scanning the patient with different sequences. Some sites may also be 
able to implement both MRI and PET scans in the same patients, providing a variety of 
different, simultaneous, functional and structural measures. In a study using MRS and 
PET imaging of the same patients, elevated levels of glutamate in the anterior cingulate 
gyrus and normal presynaptic dopamine synthesis were associated with a poor 
response (Demjaha et al., 2014). Using two imaging techniques allows combinations of 
various factors (e.g. structural and perfusion alterations) that relate to a worse 
response to be identified. As suggested elsewhere, this could allow identification of 
poor responders, elucidating multimodal neurobiological predictions of treatment 
response, as well as providing insight into the relationship between imaging 
parameters in determining response to treatment (Kempton and McGuire, 2014).  
1.6.6 Chapter summary and conclusions 
In conclusion, the major implication from the evidence outlined in this chapter is that 
there are differences between the brains of responders and non-responders to 
antipsychotic medications, and that it might be possible to predict response using brain 
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imaging and multivariate approaches such as machine learning. The implication is that 
once predictive biomarkers of antipsychotic treatment response are fully elucidated 
they could be applied clinically, stratifying patients according to their likely response or 
personalising treatment by selecting an antipsychotic based on the results of a brain 




1.7 Conclusions and study rationale 
The current literature reveals strong evidence that there are alterations in brain 
structure and function in schizophrenia, which may represent pathophysiology 
underlying the symptoms seen in the disorder. These neuropathological substrates 
represent targets for antipsychotic medications. Furthermore, increasing evidence 
suggests antipsychotic medications alter neurobiology, including brain structure, 
cerebral blood flow, and neural activation. It remains to be determined which 
neurobiological alterations are primary to the disease pathophysiology and which are 
secondary, resulting for example from antipsychotic treatment. Some neurobiological 
changes have been observed in responders but not in non-responders, and so 
understanding these alterations is key to elucidating factors underlying good (or poor) 
treatment response. This could inform mechanistic explanations for the remission of 
psychotic symptoms. In addition, identifying baseline differences in brain function and 
perfusion may allow prediction of later response to antipsychotic treatment. Given that 
response to treatment in this disorder is heterogeneous, a better understanding of brain 
changes related to the disorder and its treatment is warranted.  
The objective of this study is to evaluate the effect of antipsychotic medications on 
brain perfusion (using cASL) and task-related neural activation (using fMRI). 
Furthermore, the study aims to elucidate whether any neurobiological markers of 
treatment response may be useful in the prediction of good or poor response to 
treatment. In addition, it provides a context within which the salience theory of 
psychosis can be investigated prospectively, illuminating the effects of antipsychotic 
medication on reward processing.  
The work is carried out in patients experiencing their first episode of psychosis, in the 
early stages of the disorder (with a duration of untreated psychosis of less than two 
years), who are relatively naïve to antipsychotic treatment, and who are just initiating 
treatment with an antipsychotic according to the same, standardised protocol.  
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1.7.1 Aims and Objectives 
This thesis aims to achieve the following: 
1. Establish whether baseline differences in resting brain perfusion (measured 
with ASL), task-related activation (measured using fMRI during the SAT), and 
behavioural measures of salience attribution differ between antipsychotic-naïve 
or minimally treated FEP patients and healthy controls.  
2. Establish whether four weeks treatment with amisulpride elicits an effect on 
resting brain perfusion, brain activation during the salience attribution task, and 
behavioural measures of salience attribution in patients. 
3. Investigate how amisulpride-related alterations in resting brain perfusion and 
activation, relate to demographic, clinical, and behavioural measures of 
salience attribution. 
4. Establish whether baseline measures of brain perfusion, task-related activation, 
and behavioural measures relate to subsequent treatment response at four and 
12 weeks.  
The long-term aim of such research is to elucidate the presence of individual variations 
in neurobiology that may act as reliable biomarkers for treatment response and thus 





Based on the reviewed literature, I hypothesised the following:  
Good clinical response to the antipsychotic amisulpride (compared to poor response) 
will be associated with the following neurobiological changes:  
At baseline –  
a) Decreased dorsal striatal perfusion and increased frontal and hippocampal 
perfusion; 
b) Aberrant salience attribution associated with increased ventral striatal and 
dorsolateral prefrontal cortex activation. 
At four-week follow-up –  
c) There will be an increase in resting dorsal striatal perfusion and a decrease 
in frontal and hippocampal perfusion; 
d) There will be a normalization of aberrant salience processing and of the 
associated brain activation alterations.  
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2. METHODS  
2.1 Study design 
Minimally-treated or antipsychotic-naïve first episode psychosis (FEP) patients took 
part in a longitudinal, open-label intervention study, in which they underwent 
neuroimaging at baseline and again after treatment with an antipsychotic medication. 
The majority of patients (n=22) were recruited as part of OPTiMiSE (see below) to be 
treated with amisulpride under a standardised protocol. Other patients (n=3) were 
recruited as part of TreatFEP, in which they received naturalistic antipsychotic 
treatment, chosen by their clinical team. Healthy controls were recruited from the same 
catchment area to match patients in age, gender, ethnicity, and educational level.  
2.1.1 OPTiMiSE clinical trial 
The majority of data for this project were collected within the phase four clinical trial, 
‘Optimization of Treatment and Management of Schizophrenia in Europe’ (OPTiMiSE). 
The aims of the trial are to provide evidence-based guidelines for drug therapy in FEP, 
to optimize current treatments, and to elucidate potential pathways for new treatments. 
To achieve these aims, a series of clinical studies and integrated experimental designs 
with imaging and genomic technologies are being used.  
OPTiMiSE is a collaboration between 24 sites across Europe, and is funded by an FP7 
grant of the European Commission. Eighteen European Psychiatric Institutes formed a 
consortium with the aim to recruit 350 antipsychotic-naïve or minimally treated (less 
than two weeks) patients at their first episode of schizophrenia over a period of six 
years. The Institute of Psychiatry, Psychology and Neuroscience is the Leader of the 
Work Package 1, which aimed to use structural MRI techniques in the optimisation of 
treatment. Structural MRI could be used both to exclude ‘organic’ psychosis and to aid 
prediction of treatment response based on underlying neuroanatomy. The patient 
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sample recruited at two UK sites (South London and Maudsley NHS Foundation Trust; 
SLAM (King’s College London, KCL); and West London Mental Health NHS Trust; 
WLMHT) form the sample for the current project. The data for the current project were 
collected during Pharmacological Phase I of the OPTiMiSE protocol, the procedures for 
which are outlined below. Only patients at these two UK sites also underwent BOLD 
fMRI and arterial spin labelling in addition to structural scanning. 
2.1.2 TreatFEP  
Three patients recruited to the TreatFEP study were also included in my sample. The 
patient sample for this study was similar to OPTiMiSE in all aspects except a few subtle 
differences. These patients were not put on trial medication, but were about to be or 
had just (less than two weeks previously) been prescribed an antipsychotic by their 
clinical team. This study also did not limit the duration of untreated psychosis to two 
years, so patients may have been ill for longer than those recruited to OPTiMiSE (see 
detailed exclusion criteria below). TreatFEP patients underwent the same MRI 
procedure, and clinical and demographic information was collected at baseline and 
follow up with the same instruments. Inclusion of these patients increased the sample 
size and therefore increased the power of the analyses carried out.  
2.1.3 Ethical approvals 
Local ethical approval for OPTiMiSE at the Kings College London site was granted by 
the Psychiatry, Nursing & Midwifery Research Ethics Subcommittee (ref: 2011/052) 
and a separate approval was granted for neuroimaging protocols (ref(s): patients – 
R&D2011/050; healthy individuals - PNM/10/11-3). The West London Mental Health 
NHS Trust ethical approval was granted by London West Mental Health R&D 
Consortium (ref: MAREW1401). The TreatFEP study titled ‘The neurobiology of 
schizophrenia and its relationship to treatment response’ was granted ethical approval 





A total of 47 participants were recruited to take part, of which 25 were patients and 22 
were healthy controls.  
2.2.1 Case definition and ascertainment 
Cases were recruited from South London and the Maudsley (SLAM) Foundation Trust 
NHS Mental Health Services, including early intervention services, home treatment 
teams, liaison mental health teams and psychiatric wards. Recruitment was carried out 
over 4 years (from 2011 to 2015). Services were surveyed regularly by phone, email or 
face-to-face contact for new referrals meeting the inclusion criteria.  
Further cases were recruited from West London Mental Health NHS Trust (WMLHT) by 
an OPTiMiSE study team working in this area. For these patients, the West London 
team carried out all recruitment, screening, and clinical assessments. However, all MRI 
scans were carried out at the SLAM (KCL) site at both baseline and follow up, such 
that patients were all scanned at all time points by the same scanner.  
Participants were aged between 18 and 45, were residents of a London borough within 
the SLAM or WLMHT catchment areas, and during the recruitment period presented to 
local psychiatric services with a functional psychotic illness for the first time. As soon 
after first presentation as possible, when agreed upon by the responsible clinician 
(regarding ability to be interviewed and capacity to consent) potential participants 
underwent a full screening assessment to ascertain whether they met the specific 
inclusion criteria shown in Table 3.  
Although patients were not excluded if they received evidence-based psychological 
therapies (e.g. CBT, family therapy), no patients were receiving this at the time of the 
study, although attended less-structured activity groups (for example to support 
management of social anxiety). 
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2.2.2 Healthy individual definition and ascertainment 
Healthy individuals were recruited from within the same SLAM catchment area as 
patients by advertisements placed in local gyms, a local youth club, and online. Healthy 
participants were matched to the patient sample for age, gender, ethnicity, and 
educational level, and were excluded if they had a past diagnosis of neurological or 
psychiatric disorder. 
Table 3: Participant inclusion criteria  
 
  Inclusion criteria Exclusion criteria 
All 
- Age 18–45 years;  
- Written informed consent. 
- Presence of any contraindication to 
MRI scanning (e.g. implanted metallic 
object or electronic device) 
Patients 
- Diagnosis: DSM-IV schizophrenia, 
schizophreniform or schizoaffective 
disorder (on the basis of the Mini 
International Neuropsychiatric Interview 
Plus, M.I.N.I. Plus; Sheehan et al. 1998). 
Schizophreniform disorder was assessed 
through a M.I.N.I. diagnosis of psychosis 
(not otherwise specified) complemented 
by a diagnosis of schizophreniform 
disorder according to DSM-IV criteria;  
- Female patients of childbearing 
potential needed to utilize a proper 
method of contraception (the pill, vaginal 
ring, hormonal patch, intrauterine device, 
cervical cape, condom, contraceptive 
injection, diaphragm, abstinence).  
- A time interval between the onset of 
psychosis and study entry exceeding 
two years; 
- Prior use of antipsychotic medication 
longer than two weeks in the previous 
year and/or six weeks lifetime; 
- Intolerance/contraindications to one of 
the study drugs; 
- Patients who were coercively treated 
at a psychiatric ward (based on a 
judicial ruling); 
- Patients who were represented by a 
legal guardian or under legal custody; 
- Pregnancy, as determined through a 
pregnancy test, or lactation. 
Healthy 
controls 
- Matched to the patient sample for age, 
gender, ethnicity, and education. 
- A history of past diagnosis and/or 
treatment for neurological or psychiatric 
disorder. 
 
2.2.3 Sample characteristics 
All but one participant (n=46; 24 patients and 22 healthy controls) participated in the 
cASL component of the study at baseline, with 41 undergoing cASL at follow up (19 
patients and 22 healthy controls). A subset of participants consented to take part in the 
fMRI component (n=43; 22 patients and 21 healthy controls), with 41 undergoing fMRI 
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at follow up (20 patients and 21 healthy controls). At recruitment, patients were 
minimally treated (all had received less than two weeks antipsychotic medication in the 
previous year, and less than six weeks in their lifetime). At baseline MRI, patients had 
received an average of 8.76 days (S.D. 7.74; range 0–24 days) of antipsychotic 
treatment. Patients receiving scans at two time points were scanned a mean 31.86 
(S.D. 8.94) days after baseline.  
The flow chart in Figure 4 and Table 4, illustrate the inclusion of patients in each part of 
the study, and the reasons for non-inclusion where relevant.  
Figure 4: Flow chart illustrating patients in each study component 
This flowchart illustrates the patients recruited for screening, and the final numbers in each 
group in the study. Details regarding reasons for withdrawal are given in the table below. 
Participants excluded from the analysis after data had been acquired are highlighted in the 










Reason for withdrawal 
n=1 Personal reasons 
n=2 Did not consent to MRI 
n=1 Not eligible for MRI due to eye surgery 
n=1 Too unwell 
n=1 Did not want to take medication 
n=1 Patient did not have time for study visits 
 
Table 5 provides a summary of the baseline demographic characteristics for all patients 
and healthy controls (n=47), who took part in either scanning protocol or both. The 
majority of participants were male (72% of patients; 86.4% of healthy controls). Our 
patients had a mean age of 26.76 years (S.D. 5.31) and our healthy controls had a 
mean age of 24.91 years (S.D. 4.12). The majority of participants were white (40.0% of 
patients; 54.5% of healthy controls). Our patients had been ill for a mean 9.85 months 
(S.D. 10.58). 
Patients and healthy participants did not differ significantly in age, gender, ethnicity or 
education level (all n.s., p>0.05). However, despite attempts to match our two groups, 
the healthy controls were more often employed (χ2=4.397, p=0.038) than were our 
patients. This might be expected given that the illness itself (including the prodromal 
period) may affect functioning, and therefore affects an individual’s ability to complete 
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 University (finished) 
University (unfinished) 
Professional training (finished) 
Professional training (unfinished) 
High school (finished) 
High school (unfinished)  





















 Schizophrenia, undifferentiated 
 Schizophreniform disorder 
 Schizoaffective disorder 
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             Schizophrenia, paranoid 



















Antipsychotic administered (%) 
 Amisulpride 
 Other (olanzapine n=2 and 
















2.2.4 Safety considerations 
Several procedures were in place to ensure the safety of participants included in the 
study. Informed consent from patients was taken only by a psychiatrist, following an 
assessment of capacity to consent. Prior to the provision of study medication 
(amisulpride), we took patients for an ECG, which was performed and assessed for 
abnormalities by a cardiologist at King’s College Hospital. This avoided known potential 
cardiac side effects of this medication. In addition, we monitored all side effects 
throughout study participation using the Udvalgfor Kliniske Undersogelser side effects 
scale (UKU).  Patients met weekly with researchers during the provision of study 
medication, in addition to receiving usual care from their clinical teams. We ensured 
close communication between the study team and clinical teams regarding any 
adverse effects. Occurrences of serious adverse events (SAEs) and suspected 
unexpected serious adverse reactions (SUSARs) were closely monitored, and we 
followed strict reporting guidelines, according to local laws and regulations. All patients 
were provided with a card to carry with them, detailing their involvement in the trial and 





2.3 Procedures  
2.3.1 Patient recruitment 
All patients presenting to SLAM (or WLMHT) services with a FEP were identified and 
judged for eligibility in consultation with their clinical team. If suitable, patients were 
approached to participate in the study. Willing participants signed informed consent in 
the presence of a consultant psychiatrist who assessed for capacity to consent. 
Following this, we screened patients to ensure they met study inclusion and exclusion 
criteria (Table 3). Diagnosis of schizophrenia, schizophreniform disorder or 
schizoaffective disorder was confirmed using the Mini International Neuropsychiatric 
Interview (M.I.N.I) Plus (Sheehan et al., 1998). Those meeting study criteria underwent 
an ECG examination prior to drug administration and were cleared as normal by a 
cardiologist before initiating amisulpride. For patients recruited within TreatFEP, 
consent was obtained by a researcher, and the details of their antipsychotic treatment 
were recorded from clinical notes or discussion with their responsible clinician.  
2.3.1.1 Baseline visit 
Baseline assessments were carried out within a week of identifying the patient. During 
this visit, we completed the MRI scan, completed clinical assessments, and dispensed 
study medication (4 weeks open-label amisulpride), for those enrolled in OPTiMiSE. 
For these patients, the dose was increased gradually to a target of 400mg (in a split 
dose across the day) at day 12, following a specified titration schedule:  
Day 0: 100mg (half a tablet) 
Day 4: increase to 200mg 
Day 8: increase to 300mg (one and a half tablets) 
Day 12: increase to 400mg 
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Whilst the above guidelines were provided in the protocol, clinical teams determined 
the actual dose, based on their assessment of patient requirement. Variations to the 
specified schedule were permitted within the OPTiMiSE protocol but preferably a dose 
of 200, 400, 600 or 800 was reached by the end of 4 weeks (to ease potential transition 
to a double-blind phase, not relevant to the current project). Patients could not take any 
other antipsychotic during the study. However, concomitant medications of other kinds 
(mood stabilisers, benzodiazepines, antidepressants, and anticholinergic medications) 
were permitted but always recorded.  
2.3.1.2 Demographic information 
At the first visit, we recorded demographic variables including age, gender, ethnicity, 
marital status, occupation (past and present), parents’ occupations, education, and 
current living arrangements. General clinical characteristics were recorded including 
DSM IV diagnostic category, duration of untreated psychosis (DUP; dated from first 
experience of psychotic symptoms as reported clinically up until first treatment, whether 
prescribed as part of the study or otherwise), treatment setting, and prognosis. In 
addition, data regarding alcohol and drug abuse, adverse events, concomitant 
medication, and drug accountability were collected throughout. 
2.3.1.3 Clinical Measures  
We completed several clinical assessments at baseline, as outlined below:   
a) Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987): The PANSS is a 
well-validated measure of the symptoms of schizophrenia, and is the most widely used 
scale for this purpose. Ratings are based on a trained rater-led clinical interview of 
about 45 minutes. Three subsections are assessed: positive symptoms, negative 
symptoms, and general psychopathology. For each symptom, the rating takes into 
account both the presence and severity, as well as the degree to which it interferes in 
daily life. There is a total of 30 items, each of which is rated on a scale of 1 to 7, 
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representing absent through to extreme experience of each symptom. Therefore, 
scores range between 30 and 210. All raters underwent the same training, and were 
tested to ensure inter-rater reliability by the sponsor. The PANSS was used to monitor 
symptoms throughout the study and to determine remission status at follow up (see 
below). 
b) Clinical Global Impressions Scale of severity (CGI (severity); Guy, 1976): The CGI is 
a 7-point scale representing the clinician’s assessment of severity of a patient’s illness. 
This is a subjective rating based on the clinician’s past experience of individual’s with 
the same diagnosis. Ratings are as follows: 1, normal, not at all ill; 2, borderline 
mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely 
ill. 
c) Personal and Social Performance Scale (PSP; Morosini et al., 2000): The PSP is a 
clinician-rated measure of personal and social dysfunction, rated in four areas: socially 
useful activities (work/study), personal and social relationships, self-care, and 
disturbing and aggressive behaviours. Each area is scored as absent, mild, manifest, 
marked, severe or very severe. A final score is then obtained from 1 – 100, according 
to specified criteria that take into account the frequency of problems, and the effects on 
functioning.  
d) Calgary Depression Scale for Schizophrenia (CDSS; Addington et al., 1992): Levels 
of depression aside from negative symptoms or drug-induced side effects are rated 
using the CDSS. Nine categories are scored as 0, absent; 1, mild; 2, moderate; or 3, 
severe, to obtain a final score of between 0 and 27.  
e) Udvalgfor Kliniske Undersogelser side effects scale (UKU; Lingjaerde et al., 1987): 
This assessment of drug-induced side effects was administered at baseline and weekly 
throughout the four-week antipsychotic treatment period. The UKU is a clinician-rated, 
48 item, semi-structured interview, that rates the experience of side effects, 
independent of whether they are drug-induced. Experience of the side effect is rated 
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from 0 (“not or doubtfully present”), through 1, 2, and 3 which represent mild, moderate, 
and severe, respectively.  Each item is also rated on the probability that it is caused by 
the medication (“impossible”, “possible” or “probable”), which can then inform the need 
for subsequent action. Side effect profiles can be assessed by the subscales for 
psychic, neurologic, autonomic, and other. A final ‘global assessment of interference by 
existing side effects with patient’s daily performance’ is assessed by the patient and the 
clinician.   
2.3.1.4 Four-week follow up  
At week four, patients were assessed for remission using the symptom remission 
criteria outlined by the Schizophrenia Working Group (Andreasen et al., 2005). Four 
weeks was chosen for pragmatic reasons, as a period in which stable treatment could 
be established. Remission was defined as a score of 3 or less (mildly present and does 
not interfere with daily life functioning) on the following PANSS items – delusions (P1), 
conceptual disorganisation (P2), hallucinations (P3), blunted affect (N1), 
passive/apathetic social withdrawal (N4), lack of spontaneity and flow of conversation 
(N6), mannerisms and posturing (G5) and unusual thought content (G9). A score of 
greater than 3 on any one of these items determined non-response. This 
operationalization of remission has shown good clinical validity and is associated with 
patient outcomes (e.g. Ciudad et al., 2009). The European First Episode Schizophrenia 
Trial (EUFEST) suggested that 40% of FEP patients reached these criteria within four 
weeks, suggested that it would be a realistic goal of antipsychotic treatment and within 
the timeframe of the current study. In addition to assessing remission, CGI (severity 
and improvement scores), PSP, CDSS, and UKU assessments were carried out at four 




Figure 5: Stages completed by patients in the OPTiMiSE trial, relevant to the current 
project  
 
Patients classed as in remission at four weeks remained on amisulpride, whilst those 
who were not in remission continued to a double-blind phase of the OPTiMiSE trial (not 
relevant to the current study). Between 4 and 12 weeks, all patients (for whom clinical 
notes were available) were medicated with a second generation antipsychotic. Of 
these, 57.1% remained on amisulpride (mean dose [chlorpromazine equivalent]: 
115.63 mg). The remaining patients were treated with olanzapine (28.7%), aripiprazole 
(7.1%) or quetiapine (7.1%).  The flow diagram in Figure 5 summarises the stages of 
the trial.  
Given that there was a relatively small number of non-responders in the present study, 
I also calculated a continuous score of response at four weeks. This represented a 
percentage change in PANSS score between baseline and follow up, and was 





For individual PANSS items, the same formula was used but 7 rather than 30 was 
subtracted from the scores. In both cases, this subtraction accounted for the fact that a 
score of 7 for each individual item, or 30 for total scores, would be obtained with no 
psychopathology present.  
2.3.1.5 Twelve-week follow up 
To assess longer-term antipsychotic treatment response, I also assessed the clinical 
status of patients at 12 weeks. Again, this period was chosen for pragmatic reasons as 
suitable for completion of the Personal and Psychiatric History Schedule (PPHS). This 
clinical evaluation was completed using clinical notes as clinical measures, such as the 
PANSS, were not available for all patients. The PPHS is a standardized instrument 
developed by the World Health Organization (WHO) for use in multi-centre studies of 
incidence and outcome in schizophrenia (Jablensky et al., 1992). It assesses the 
presence and severity of a variety of symptoms, as well as the course of illness, and 
dysfunction in several related functional and occupational domains.  
For current purposes, I was interested only in the items that related to the Andreasen 
criteria for remission using the PANSS. Seven items on the PPHS relate to the seven 
PANSS items listed in the remission criteria (see table 6), and therefore these were the 
items I used. I assessed all patients with a baseline MRI scan using the PPHS, 
regardless of whether or not they had 12-week follow up assessments. This allowed 
me to analyse, for those with both 12-week PANSS and PPHS assessments, the 
reliability of the PPHS in classifying response. This calculation suggested substantial 




Table 6: PPHS items and their corresponding PANSS items (Jablensky et al., 1992) 
PPHS Item PANSS Item 
Delusions P1 – Delusions 
Hallucinations P3 – Hallucinations 
Thought Disorder G9 – Unusual thought content 
Psychomotor Disorder G5 – Mannerisms and posturing 
Flat Affect N1 – Blunted affect 
Apathy 
N6 – Lack of spontaneity and flow of 
conversation 
Social Withdrawal N4 – Social Withdrawal 
 
Patient clinical information was accessed using the SLAM NHS Foundation Trust 
electronic Patient Journey System, on which clinicians record all contact with the 
patient concerned. Information is recorded only whilst patients remain under the care of 
services in this Trust, and therefore information was not available for some patients 
who had been transferred to care in a different Trust. In a period of one week prior to 
the 12-week interview date, I extracted any information relevant to the 7 items relating 
to the 7 PANSS remission criteria as outlined above. Where no notes were available 
for the calculated period, notes for the dates closest to this period were used. Rating of 
the 7 items followed the PPHS specified criteria. A score of 0 – 2 was recorded, where 
0 indicated ‘absent’, 1 indicated ‘mild or occasional’, and 2 indicated ‘severe or 
frequent’.  
To categorise patients as responders or non-responders according to the Andreasen 
criteria, PPHS ratings were converted to corresponding PANSS item scores as follows: 
PPHS Rating PANSS score 
0 1, 2 or 3 
1 5 or 6 




Therefore, a responder at 12 weeks had a score of 0 in all the Andreasen items, which 
corresponds with a score of 3 (mild) or less on the PANSS. Non-responders had a 
score of either 1 or 2 in any one or more of the Andreasen items. This provided a 12-
week categorisation of response to treatment.  
2.3.2 Healthy controls  
2.3.2.1 Baseline visit 
Once identified and screened for study criteria (see Table 3), healthy controls 
underwent a brain scan with the same imaging protocol as for patients and using the 
same scanner. Healthy controls had no history of past diagnosis and/or treatment for 
neurological or psychiatric disorder. 
2.3.2.2 Demographic information 
At the first visit, demographic variables were recorded including age, gender, ethnicity, 
occupation, parents’ occupations, and education. In addition, participants were asked 
about their caffeine and alcohol consumption, previous use of illicit substances, and 
any medication that there were currently taking.  
2.3.3 Behavioural measures of salience attribution  
The salience attribution task (SAT) was used to investigate salience attribution in all 
participants (Roiser et al. 2009). Initially, participants completed a tutorial out of the 
scanner to familiarise them with the task. A mean reaction time (RT) and standard 
deviation (SD) were also extracted from this tutorial to individually calibrate difficulty of 
the task in the scanner. The mean RT from the tutorial was used as the mean probe 
duration, calibrating difficulty to individual performance. The minimum and maximum 
probe duration was calculated using the SD (mean from practice +/- 2xSD). In the 
scanner, participants underwent another practice block before completing a single 
block of 64 trials. No rewards were available during the practice sessions.  
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The SAT is a speeded-response task offering monetary rewards and providing 
measures of salience attribution. Participants fixate on a cross and 1000ms later are 
presented with a cue either side of the cross in one of four categories (blue animals, 
red animals, blue household objects or red household objects). 1000–2000ms later, a 
black square (the probe) appears to which participants must respond as quickly as 
possible. The duration of the probe depends on the individual’s reaction times during 
practice, as described above. 
Following their response, written feedback is given. If they respond during presentation 
of the probe on a rewarded trial, they receive the message ‘Good’ or ‘Very Quick’, and 
information on how much money they have won. Should they respond before or after 
presentation of the probe, they receive the message ‘Try to respond faster’ or ‘Missed’, 
respectively. On trials that are unrewarded, where they respond during presentation of 
the probe they receive the message ‘No money available’. Auditory feedback is also 
given, with the tone of the beep related to the amount won (higher beeps signalling 
larger amounts of money). Figure 6 illustrates the task. 
 
Figure 6: Diagram showing a single trial in the SAT task.  
Fixation is followed by the conditioned stimulus. After a short delay, the participant must respond 
to the black square as quickly as possible. They then receive feedback as to how much money 




In this task, half of all trials are rewarded with money (between 5 and 100 pence). 
Whether or not money is received depends on the stimulus presented before the 
probe, whilst the amount won depends on the speed of response (Table 7). Missed 
trials where money was available earn 5 pence. On trials in which participants respond 
during the presentation of the probe, the money won increases based on speed of 
response up to one pound.  
There are four versions of the task, which each differ on the stimulus dimension that is 
rewarded (red, blue, animal or household object). In each of these, probability of 
reward is dependent on cue stimulus dimensions (colour or form) with money rewarded 
at a fixed probability for each stimuli combination. The task-relevant dimension is that 
in which the dimension categories differ in their relationship with reward, such that one 
category is rewarded on 87.5% of trials and the other on 12.5% of trials. The other 
dimension is task-irrelevant and rewarded equally, such that both stimulus categories 
are rewarded on 50% of trials. These probabilities remain constant for a full block of 64 
trials. Table 8 illustrates this for a ‘blue block’.  
Table 7: Feedback and reward given during the SAT 
Outcome on reinforced trials was determined by the speed of response to the probe. On non-
reinforced trials, outcome was always the same, regardless of speed of response.  
Trial Type Response Feedback Reward 
Reinforced None/after probe ‘Missed: five pence’ Five pence 
Premature – <100ms after 
probe onset 
‘Too early: five pence’ Five pence 
During probe but slower than 
mean RT 
‘Hit – good: ten pence’ Ten pence 
During probe and faster than 
mean RT by up to 1.5 SD 
‘Quick – very good: X 
pence’ 
 
Up to max 100 pence 
During probe and faster than 
mean RT by more than 1.5 
SD 










The different block types were numbered 1 to 4 and the choice of block type depended 
on the block that was used for the previous subject, in ascending order and circling 
back to 1 from 4. This meant that participants scanned at two time points may or may 
not receive the same block type. 
Table 8: Example of a ‘blue block’ in which colour is the relevant domain 
 Cue dimension Cue category Rewarded (% trials) 
Task relevant Colour 
Blue 87.5 
Red 12.5 
Task irrelevant Form 
Household objects 50 
Animals 50 
 
The differential rewards depending on block type allow measures of both adaptive 
salience and aberrant salience to be obtained based on the participant’s performance. 
Two measures are calculated, adaptive and aberrant salience, both of which are 
defined implicitly using reaction times (RT) to the probe and explicitly using visual 
analogue scale ratings (VAS). In the latter, after completing the task participants gave 
estimates of the percentage of time each stimulus category (blue, red, household 
objects, animals) were associated with reward. Responses where participants pressed 
the button prior to the probe (premature errors) and missed targets (omissions) are 
also recorded for each stimulus type. These measures represented the accuracy of 
participants, and allowed those making many mistakes to be excluded from the 
analysis (NB no participants had to be excluded for this reason). 
Adaptive salience is the ability to correctly attribute salience to relevant stimuli. In this 
task, this is the ability to differentiate between the stimuli categories on the task-
relevant dimension that are rewarded at high probability and those rewarded at low 
probability, disregarding the task-irrelevant dimension categories. Thus, adaptive 
implicit salience is calculated as RT on high probability-reinforcement trials relative to 
RT on low probability-reinforcement trials (collapsed across task-irrelevant stimulus 
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dimensions). Similarly, adaptive explicit salience is the increase in VAS rating for high 
probability-reinforcement trials relative to low probability-reinforcement trials (collapsed 
across task-irrelevant stimulus dimensions). This essentially shows whether 
participants respond differently to the stimulus categories that are relevant to reward in 
the expected direction. Thus, high scores of adaptive salience will be achieved by 
having lower RT to the high probability of reward category (e.g. responding more 
quickly to blue stimuli in a ‘blue block’) or rating the rewarded category as more 
associated with reward on the VAS. Responding equally or responding to the low 
probability of reward category more quickly will result in zero or negative adaptive 
salience scores, respectively.  
For aberrant salience scores, the direction of difference is unimportant because any 
deviation from equal response (either in RT or VAS rating) shows an aberrant 
attribution of salience. Therefore, aberrant implicit salience is the absolute difference in 
RT between the two levels of the task-irrelevant stimulus dimension (collapsed across 
the task-relevant stimulus dimension). Aberrant explicit salience is the absolute 
difference in VAS rating between the two levels of the task-irrelevant stimulus 
dimension (collapsed across the task-relevant stimulus dimension). This measure gives 
an indication of whether the participant is responding differentially to stimulus 
categories where they should not be (i.e. where the probability of reward is equal).  
2.3.4 Magnetic Resonance Imaging Acquisition 
Neuroimaging was carried out in a General Electric Signa HDX 3 Tesla scanner at the 
Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and 
Neuroscience. Participants underwent a brain scan at two time points: baseline and 
four-weeks follow up. All scans for all participants were obtained using the same 
scanner for a scan time of approximately 15 minutes. Handedness of participants was 
not recorded, and this should be borne in mind when considering the results.  
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Prior to the scan, patients completed a tutorial on a laptop in preparation for the 
functional MRI task. During the scan, high-resolution structural T1 images, functional 
MRI (EPI) BOLD images, and continuous arterial spin labelling images of CBF at rest 
were obtained. Structural images were acquired first, followed by functional images, 
and finally CBF images. During scan acquisition, four dummy scans were acquired to 
allow for T1 saturation. These were not recorded or included in the analysis.  
2.3.4.1 Structural MRI  
Structural data collected were 3D T1-weighted sagittal images, using a MP-RAGE 
sequence based on the protocol from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI). (http://adni-info.org/.) This provided high-resolution whole brain T1-weighted 
images to facilitate co-registration and normalisation of the BOLD fMRI and cASL data.  
2.3.4.2 BOLD fMRI  
Images depicting BOLD contrast were acquired during the SAT to investigate neural 
correlates of salience attribution. Fifty slices of 2.4mm thickness were acquired to 
produce 237 volumes across the task. A TR of 2500ms and TE of 25ms were used 
throughout the task. The task was projected onto a screen, which participants viewed 
via a prismatic mirror.  
2.3.4.3 Continuous Arterial Spin Labelling  
The projector used during fMRI BOLD was switched off prior to the resting continuous 
arterial spin labelling (cASL) protocol, during which participants were told to rest awake 
with their eyes open. cASL is used to image CBF. This method uses a continuous 
inversion pulse to magnetically label flowing blood in the regions of interest. Perfusion-
weighted images are produced by subtraction of a labelled image (with magnetically 
tagged inflowing blood) and a control image (in which inflowing blood has not been 
magnetically tagged). The result of this computation represents the amount of blood in 
a brain region at a particular point in time (ml/100g/min). Images were obtained using a 
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pseudo-continuous flow-driven, adiabatic inversion scheme and a 3D interleaved spiral 
FSE readout. We acquired 64 slices of 3mm thickness using a TR of 5500ms and a TE 
of 32.256ms.  
2.3.5 Data Analysis 
2.3.5.1 Clinical and behavioural data 
Analysis of behavioural and demographic data was carried out in the Statistical 
Package for the Social Sciences (SPSS 16: SPSS Inc., Chicago, IL), which was also 
used to explore relationships between these variables and the imaging data. Initial 
descriptive statistics were used to explore the data and assess normality and the 
existence of outliers. Non-normal clinical data were transformed to improve normality or 
explored using non-parametric statistics, where appropriate. 
Following the calculation of salience behavioural measures, as outlined above, the data 
was subjected to a one-sample t-test against 0 to investigate the acquisition of reward 
contingencies. The effect of omission errors and premature responses was assessed 
using repeated measures t-tests. Non-normal data were transformed using a square-
root transformation before analysis. Untransformed scores are presented in this thesis 
for clarity and ease of interpretation.   
Comparisons of patients and healthy controls were carried out using independent 
samples t-tests to assess whether the groups differ on measures of salience, both at 
baseline and follow-up. Further, paired samples t-tests were used to assess changes in 
salience scores from baseline to follow-up within patients. Where ANOVAs were used, 
equality of variance amongst the factors was assessed using Mauchley’s test of 
sphericity. Where the assumption of equality of variance was violated, corrected 
statistics are reported (Greenhouse Geisser). Post hoc planned comparisons were 
implemented where significant main effects existed following ANOVA, to characterise 
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the effect seen. Due to potential increased type 1 error rate from such post-hoc testing, 
Bonferroni corrections are reported. 
Correlational analyses were conducted for behavioural variables that were significantly 
altered by the antipsychotic treatment. Relationships between clinical measures and 
behavioural performance were explored using Pearson’s r, or Spearman’s r where data 
were non-normal. 
2.3.5.2 Image Analysis  
All images were analysed in the Statistical Parametric Mapping suite (SPM, version 8), 
which was developed by the Functional Imaging Laboratory of University College 
London (www.fil.ion.ucl.ac.uk/spm). Where correlations or extracted values of CBF 
were explored the Statistical Package for the Social Sciences (SPSS, version 15.0) 
was used.  
2.3.5.2.1 Preprocessing 
Both cASL and fMRI images were pre-processed prior to the main analysis.  
a) cASL 
Normalisation parameters were derived using a high-resolution T1 structural scan. The 
rCBF images were normalised to standard MNI space in a three-step procedure using 
the ASLToolbox of SPM-5. Extra-cerebral signal was removed using the ‘Brain 
Extraction Tool’ (BET) of the Functional Software Library (FSL) (Smith, 2002). This 
produced a binary mask, which along with the stripped T1 image was co-registered 
with the rCBF image. Co-registered images were multiplied by the rCBF map to 
remove extra-cerebral signal from this image. The result of this process and the skull-
stripped T1 image were co-registered onto the original structural scan. The original T1 
scan was normalised to the MNI T1 template provided by SPM, and the transformation 
matrix resulting from this was applied to both the T1 and the rCBF images. Lastly, 
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manual quality assurance was carried out, before smoothing using a 10mm Gaussian 
kernel.  
b) fMRI BOLD 
Functional MRI images were reorientated to the anterior and posterior commissures 
(AC-PC). Initially, this was carried out manually using 
http://imaging.mrccbu.cam.ac.uk/imaging/FindingCommissures as a guide. Linear 6-
parameter rigid body transformation was then used within-subjects to align all the 
scans in the time series with one another. Images were first aligned to each other, then 
to a mean image from the time series. This produced movement parameters, which 
were used as covariates in the first level analysis.  
A halfway registration process was used to provide a structural scan for co-registration 
with the EPI images using the longitudinal pairwise registration tool in SPM-12. 
Antipsychotic treatment has been associated with changes in structural brain imaging 
parameters and so halfway registration provides a mean between the baseline and 
follow up scans for each individual. Using this image to co-register with the EPI time 
series from baseline and follow up scans ensures that changes observed are due to 
functional alterations and not to structural changes. The normalised halfway structural 
scan was co-registered with the EPI time series, to allow the application of 
normalisation parameters to the EPI images. Finally images were smoothed using a 
Gaussian kernel of 10mm.  
Movement was assessed using a script developed locally to provide plots of movement 
across the fMRI time course, which were assessed manually. Scans with large 
amounts of movement were submitted to a process of movement correction or 
discarded if necessary. Interpolation was used to correct for large spikes by taking the 




2.3.5.2.2 cASL Image Analysis 
cASL data were analysed using a fixed effects general linear regression model 
conducted with the locally developed ASLToolbox extension to SPM-5. T-tests were 
used to compare resting perfusion between groups and the effect of antipsychotic 
medications longitudinally within patients. Global perfusion was included as a covariate 
in this model. A priori ROIs, defined using wfupickup atlas, were explored based on 
previous studies investigating the changes elicited by antipsychotic treatment, including 
the hippocampus, caudate, and putamen (Rodriguez et al., 1996, 1997; Lahti et al., 
2009; Ertugrul et al., 2009; Goozee et al., 2014). Mean perfusion values were extracted 
using the wfupickup atlas to define regions and functions in the ASLToolbox to extract 
mean values.   
Clusters of regions in which I detected significant differences (between-subjects) or 
significant alterations with treatment (within-subjects) in rCBF were extracted. Using 
these clusters, I explored correlations with clinical and behavioural measures.  
2.3.5.2.3 fMRI Image Analysis 
Event-related univariate analysis was used to detect individual predictors of treatment 
response at baseline. Baseline measures were compared between those subsequently 
classified as responders and those classified as non-responders.  
The fMRI images were evaluated in an event-related design with SPM8 in the context 
of the general linear model. Following realignment, normalization and smoothing, a 
GLM was built with a regressor for each cue and a regressor for the outcome. For each 
participant, a contrast image of activity related to adaptive reward prediction and 
another of aberrant reward prediction was produced. Second-level group differences 
were calculated from the results of the first-level analysis. As well as a whole brain 
analysis, regions of interest (ROIs), chosen on the basis of findings from Roiser’s group 
(Roiser et al., 2012, Roiser et al., 2010), were investigated in the hippocampus, 
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striatum, and PFC. ROIs were identified using the wfupickatlas tool of SPM and were 
tested bilaterally. Images were corrected for multiple comparisons using FWE-
correction with p<0.001. Following procedures developed by Roiser and his 
colleagues, cues for which participants fail to respond entirely were excluded, as they 
may result from a lack of attention during the trial (Roiser et al., 2009). 
2.3.6 Power calculations 
2.3.6.1 Power calculation for cASL 
Previous research has shown that 12–18 patients are sufficient to detect a 10% change 
in perfusion in placebo-controlled crossover designs (the striatal size of change 
observed following haloperidol administration) (Murphy et al, 2011). This is consistent 
with findings from our group of highly statistically significant changes in rCBF using 
whole-brain ASL in just 18 subjects. Therefore, at the region of interest level, a sample 
only 18 subjects would be sufficient to detect a significant (p<0.05) 10% difference in 
between-group CBF means. This sample size is smaller than I had at baseline and 
follow up. 
2.3.6.2 Power calculation for fMRI 
A sample size of 16 participants is required to have 80% power at p=0.05 to detect an 
effect size of 0.9, between response groups at baseline on the SAT. This is less than 
the effect reported by Roiser et al. (2009) comparing patients with and without positive 
psychotic symptoms (d=1.6). 
In the responder group alone, we would have 96% power to detect normalization of the 
SAT up to 4 weeks. The sample sizes in consideration are discussed at page 287 of 




3.1 The effects of antipsychotics on clinical measures  
In this chapter, I report the clinical characteristics and changes in clinical presentation 
of patients in my study. I first present clinical measures for the whole patient group, 
describing their clinical characteristics at baseline and follow up, and then changes to 
these measures over four weeks of antipsychotic treatment.  
I next present the clinical characteristics of patients, separated according to treatment 
response at four weeks. I present cross-sectional comparisons of responders and non-
responders at baseline and at follow up, and longitudinal effects of antipsychotic 
medication on clinical measures in each group after four weeks treatment. I also 
investigate any relationships between the demographics and sample characteristics 
and response to antipsychotic treatment at four weeks. The number of non-responders 
in my sample was small. As such, in addition to categorical comparisons of response I 
also assess relationships between the demographic and clinical characteristics and a 
continuous measure of response, the PANSS percentage change score. 
Finally, to assess longer-term outcomes, I present clinical follow-up data at 12 weeks. I 
explore relationships between the demographic and clinical characteristics at baseline 
and follow up and clinical variables at 12 weeks. For patients without 12-week follow up 
PANSS scores, I used the PPHS to obtain scores from clinical notes where available 
(see page 122 of Methods for details). Where participants are not included in any 
analyses, I provide details as to the number of participants and the reasons for their 
non-inclusion. 
I expected to see improvement in clinical symptoms over time, with greater 
improvements demonstrated in the treatment responders. I expected a good response 
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to be associated with female gender, a shorter DUP, and less severe symptom 
presentation at baseline.  
3.1.1. Demographic and clinical characteristics of patients 
Clinical symptoms were assessed at baseline and follow up (after four weeks of 
treatment) using the PANSS, CGI (severity), PSP, and CDSS (Table 9). A follow-up 
PANSS assessment was completed for all 25 patients to determine response to 
treatment, but not all patients completed the other clinical assessments. Numbers for 
each measure are provided in the appropriate section below. Demographic measures 
for the entire patient group are provided in the description of the sample, Table 5, 
Methods, page 115. 
3.1.1.1 Clinical characteristics of patients at baseline 
Clinical characteristics of the whole patient group (n=25) at baseline are shown in 
Table 9. Before treatment, patients had a mean total PANSS score of 65.76 (S.D. 
14.16) and the majority were designated by the CGI as “moderately ill” (52.0%). The 
group had a mean PSP score of 53.86 (S.D. 11.79), indicating varying degrees of 
difficulty in daily functioning but not so low as to require intensive supervision (Morosini 
et al., 2000). Depressive symptom scores were relatively low, with a mean CDSS score 
of 4.41 (S.D. 3.65).  
My sample differs from some samples in previous longitudinal imaging studies that 
have investigated treatment response. This is partly due to the aims of this study to 
recruit FEP patients who have not been previously treated. This means that patients 
were in general younger and less severely ill than many previous samples (e.g. 




3.1.1.2 Clinical characteristics of patients at follow up 
Table 9 shows the clinical characteristics of the whole patient group (n=25) at follow up 
following four weeks of antipsychotic treatment. At follow up, patients had a mean total 
PANSS score of 50.32 (S.D. 19.05) and most were designated as “mildly ill”, 
“borderline mentally ill” or “normal/not ill at all” (68.0%) on the CGI. Most patients were 
considered “very much improved” (28.0%) or “much improved” (36.0%) using the CGI 
improvement scale. The mean PSP score was 69.35 (S.D. 14.73), not far off the 
threshold of 71 for mild degree of difficulties in functioning. As at baseline, depressive 
symptom scores were low, with a mean CDSS of 3.11 (S.D.3.93). 
 
Table 9: Clinical scores for total patient group at baseline and 4-week follow up 
 
Patients Baseline Follow up (4 weeks) 
PANSS, mean (SD) 
 Positive 
 Negative 












CGI severity (%) 
 Normal/Not ill at all 
 Borderline mentally ill 
 Mildly ill 
 Moderately ill 
 Markedly ill 
 Severely ill 
 Missing 
CGI improvement (%) 
 Very much improved 
 Much improved 
 No change 











































3.1.1.3 Longitudinal effects of four-week antipsychotic treatment on clinical measures 
in patients  
Here, I assess the effect of antipsychotic treatment on the clinical presentation of the 
entire patient group, comparing scores in symptom measures at baseline and follow 
up.  
a) PANSS 
(i) Raw scores  
For the whole patient group, there was a decrease in positive, negative, and general 
psychopathology scores over the four weeks of antipsychotic treatment. As the data 
were not normally distributed, I conducted nonparametric Wilcoxon signed-rank tests to 
see whether these changes were significant. The results showed statistically significant 
decreases in positive (Z=-3.97, p<0.0001), general psychopathology (Z=-3.58, 
p<0.0001), and total (Z=-3.74, p<0.0001) PANSS scores. However, the change in 
negative symptoms was not statistically significant (Z=-1.65, p=0.099).  
These results suggest that amisulpride treatment in this patient group led to statistically 
significant improvements in overall symptoms, and that this improvement is primarily in 
positive and general psychopathology symptoms, but is not seen in negative 
symptoms.  
(ii) Percent change scores 
Percent change scores reflect the degree of change in PANSS scores over time, which 
can be more easily related to clinically significant change in symptoms than can raw 
scores. The relationship between changes on the PANSS and clinical presentation has 
been explored in a number of studies that related PANSS percent change scores with 
clinician-rated CGI scores (Cramer et al., 2001; Leucht et al., 2005 a/b). These studies 
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suggest that change scores of between 19% and 28% correspond to “minimally 
improved”, whilst 40% to 53% corresponds to “much improved”.  
In our total sample, there was a mean change of 60.94%, 19.31%, 25.00%, and 
46.07% in positive, negative, general psychopathology, and total scores, respectively. 
Wilcoxon signed-rank test against 0 suggests that all of these changes were 
statistically significant (positive: p<0.0001; negative: p=0.032; general 
psychopathology: p<0.0001; total: p<0.0001). Clinically, these changes suggest less 
than “minimal improvement” in negative and general psychopathology scores, whilst 
positive and total PANSS scores were “much improved”. 
In agreement with the results from the raw scores, these data suggest that amisulpride 
treatment in this patient group leads to statistically and clinically significant 
improvements in positive symptoms, but less improvement in general psychopathology 
symptoms. They suggest more modest but statistically significant changes in negative 
symptoms. Overall, there is an improvement in psychotic symptomatology for the 
patient group as a whole.   
b) CGI 
At baseline, the majority of patients scored 4 (“moderately ill”) or above on the CGI, 
whilst at follow up, the majority of patients scored 3 (“mildly ill”) or below. There was a 
decrease in median score from 4.87 (S.D. 1.14; “mildly ill”) to 3.23 (S.D. 1.21; 
“borderline mentally ill”), indicating a decrease in illness severity. Scores were non-
normally distributed so non-parametric tests were employed. Following four weeks 
antipsychotic treatment, Wilcoxon signed-rank tests suggested a significant decrease 
in the CGI severity scores (Z=-3.53, p<0.0001). Furthermore, the majority of patients 
(64.0%) had a CGI improvement score of either 2 or 1, indicating they were “much 
improved” or “very much improved”, respectively. 
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The changes in CGI scores across four weeks of treatment support the patterns seen 
in PANSS scores, with a general improvement of symptoms for all patients, such that 
the severity of illness lessened with treatment.  
c) PSP 
Four weeks of antipsychotic treatment led to an increase in PSP total score, from 53.86 
(S.D. 11.79) to 69.35 (S.D. 14.74), indicating an improvement in functioning. PSP 
scores were non-normally distributed and as such, I conducted a Wilcoxon signed-rank 
test, which indicated that this increase was statistically significant (Z=-3.14, p=0.002).  
d) CDSS 
Overall, there was a small decrease in CDSS scores from 4.41 (S.D. 3.65) to 3.11 
(3.93), indicating a small improvement in symptoms of depression. However, a 
Wilcoxon signed-rank test revealed that this decrease was not statistically significant 
(n.s., p>0.05). The literature suggests that a score of 6–7 on the CDSS indicates major 
depression, whilst a score of 4–5 indicates minor depression (Bressan et al., 1998; 
Sarro et al., 2004). Patients in my sample were not very depressed and only just 
reached the threshold for minor depression even at baseline. Therefore, the lack of a 
significant change is probably due to a low level of depression symptoms experienced 
by the patients at any time point.  
3.1.2 Demographic and clinical characteristics of responders and non-responders 
In these sections, I present the demographic and clinical data for patients in relation to 
response to treatment at four and twelve weeks, to assess the associations of these 
variables with short- and longer-term treatment response.  
3.1.2.1 Treatment response at four weeks 
I conceptualised treatment response at four weeks in two ways. Firstly, as described in 
Methods (page 99), patients were categorised after four weeks treatment into 
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responders and non-responders using the Andreasen (2005) criteria. Secondly, I 
calculated percent change in PANSS scores for all patients at four weeks to provide a 
continuous measure of treatment response. I explored categorical data using Chi-
squared tests. Where continuous data were normal, I conducted independent samples 
t-tests to investigate between group differences. Where data was non-normal, I 
employed nonparametric alternatives (e.g., Mann Whitney-U).  
3.1.2.1.1 Cross-sectional comparisons of baseline demographic and clinical 
characteristics in four-week responders and non-responders  
I first assessed whether there were any differences at baseline between future four-
week responders and non-responders. Table 10 provides baseline demographic and 
clinical characteristics of these two groups. These data were investigated to assess 
whether those patients who were later categorised as a responder differed significantly 






















 Range  
 Mean (S.D.) 
 
21 – 40  
28.12 (5.21) 
 


















 Schizophrenia, undifferentiated 
 Schizophreniform disorder 
 Schizoaffective disorder 
             Schizophrenia, disorganised 
             Schizophrenia, paranoid 















DUP (months) (mean, S.D.) 6.47 (6.82) 16.63 (13.76) 
PANSS (mean, S.D.) 
 Positive 
 Negative 










37.38 (3.50)  
76.75 (8.58) 
CGI severity (%) 
 Normal/not ill at all 
 Borderline mentally ill 
 Mildly ill 
 Moderately ill 
 Markedly ill 


















PSP (mean, S.D.)  54.13 (13.73) 53.29 (6.80) 
CDSS (mean, S.D.)  4.40 (3.94) 4.43 (3.21) 
Antipsychotic dose, mg (mean, S.D.)* 166.92 (42.50) 183.33 (160.20) 





a) Demographics  
Four-week responders and non-responders did not differ significantly in terms of 
gender, diagnosis or ethnicity, nor did they differ in terms of employment level, 
education level or antipsychotic dose (all n.s., p>0.05). Whilst the mean age of 
responders was higher (28.12 years) than non-responders (23.88 years), this trend 
was not significant (n.s., p=0.061). Duration of untreated psychosis (months) was not 
normally distributed and so it was investigated using a non-parametric Mann Whitney-U 
test. This suggested that there was a significant difference in DUP between responders 
and non-responders (Z=-2.07, p=0.038), such that non-responders had been ill and 
untreated for longer than the responders.  
b) PANSS  
At baseline, four-week non-responders had significantly higher positive symptom 
scores (t(23)=-2.37 p=0.027), higher general psychopathology scores (t(23)=-2.90, 
p=0.008), and higher total PANSS scores (t(23)=-3.10, p=0.005) than responders. 
There was no significant difference between responders and non-responders on 
negative symptom scores (t(23)=-2.03, p=0.055).  
b) CGI  
Whilst non-responders had slightly higher mean CGI (severity) scores than responders 
at baseline, the difference in scores was not significant (Z=-1.55, p=0.185). 
Furthermore, a chi-square test for independence indicated no significant association 
between treatment response status and CGI scores (Χ2=4.74, p=0.32).  
c) PSP 
Four-week responders and non-responders did not have significantly different PSP 





Four-week responders and non-responders did not have significantly different CDSS 
scores at baseline (Z=-0.32, p=0.783). 
3.1.2.1.2 Cross-sectional comparisons of demographic and clinical characteristics in 4-
week responders and non-responders at follow up 
I also assessed whether there were any differences between four-week responders 
and non-responders at follow up. Table 11 provides clinical measures at follow up for 
these two groups. As treatment response was determined by PANSS scores, I 
expected responders and non-responders to differ on this measure at follow up. 
However, I investigated all clinical scores at follow up, to assess whether responders 
and non-responders differed on all or only some measures of symptomatology.  
a) PANSS  
At follow up, PANSS scores were used to designate response to treatment. Therefore, 
as expected four-week non-responders had significantly higher scores than responders 
on all PANSS measures: positive (Z=-3.92, p<0.0001), negative (Z=-2.88, p=0.003), 
general psychopathology (Z=-3.65, p<0.0001), and total PANSS score (Z=-3.82, 
p<0.0001).  
b) CGI  
As expected, mean CGI (severity) scores at follow up were significantly different (Z=-
3.13, p=0.001), suggesting non-responders were more ill than were responders. 
Furthermore, a Chi-square test for independence indicated a significant association 
between treatment response status and CGI scores (Χ2=13.60, p=0.009).  
There was also a significant difference in mean CGI (improvement) scores between 
responders and non-responders (Z=-2.44, p=0.019), with responders showing greater 
improvement. Again, a Chi-square test for independence indicated a significant 
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association between treatment response status and CGI improvement (Χ2=9.04, 
p=0.029). 
 
Table 11: Clinical characteristics of 4-week responders and non-responders at 4-week 
follow up. 
 
Follow up characteristic Responders Non-responders 
PANSS (mean, S.D.) 
 Positive 
 Negative 












CGI severity (%) 
 Normal/Not ill at all 
 Borderline mentally ill 
 Mildly ill 
 Moderately ill 
 Markedly ill 
 Severely ill 
 Missing 
CGI improvement (%) 
 Very much improved 
 Much improved 
 No change 










































At follow up, there was a significant difference in PSP scores between the groups 






There was not a significant difference between responders and non-responders on 
CDSS scores at follow up (Z=-1.61, p=.273). 
3.1.2.1.3 Associations between baseline demographic and clinical measures and a 
continuous measure of treatment response  
As there were relatively few non-responders in our sample, I also assessed a 
continuous measure of treatment response in the form of percent change scores. This 
provides a continuous measure of the extent to which symptomatology changed in 
patients. As reported above, there were improvements in all subscales and total 
PANSS scores, with a mean change of 60.93% (S.D. 37.74), 19.31% (S.D. 84.12), 
25.00% (S.D. 28.69), and 46.07% (S.D. 43.66) in positive, negative, general 
psychopathology, and total scores, respectively. 
The following analyses assessed the association of baseline demographic and clinical 
measures with percent change in PANSS scores following treatment (as a continuous 
measure of response). Percent change scores were non-normally distributed and so 
non-parametric analyses were employed. Spearman’s r was used to explore 
correlations and Mann Whitney-U or Kruskal-Wallis tests were used to explore the 
effects of categorical variables on percent change in PANSS.  
a) Demographics 
There was no relationship between age and percent change scores on the PANSS for 
any of the subscales or for the total PANSS score (all n.s., p>0.05). DUP showed a 
significant negative relationship with percent change in positive symptoms (r=-0.435, 
p=0.033), such that as DUP increased there was a decrease in the improvement of 
positive symptoms. This suggests that those with a longer DUP at baseline experience 
less improvement in their positive psychotic symptoms. There was a similar significant 
negative relationship between DUP and percent change in total PANSS score (r=-
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0.453, p=0.026). This is likely driven by the change in positive scores as there were no 
significant correlations between DUP and percent change in negative (r=-0.378, 
p=0.069) or general psychopathology scores (r=-0.343, p=0.101). These results 
suggest that a shorter DUP is associated with a better response to treatment, 
manifested in an improvement in positive symptoms.  
Percent change on total PANSS score and each subscale did not differ significantly 
between different ethnicities, DSM-IV diagnoses or education levels (all n.s., p>0.05). 
However, there was a significant difference in percent change in positive symptoms 
between employed and unemployed patients (Z=-2.072, p=0.038), but not on any other 
subscale or on total PANSS score. Employed patients showed a greater improvement 
in positive symptoms (median 87.5% change) than did unemployed patients (median 
40.0% change).  
b) PANSS 
Total PANSS, positive, negative, and general psychopathology scores at baseline were 
not correlated with percent change in PANSS total or any subscale after four weeks’ 
treatment (all n.s., p>0.05). This suggests that baseline severity of symptoms was not 
related to later degree of symptomatic improvement.  
c) CGI 
There was a significant relationship between CGI at baseline and percent change in 
total PANSS score (r=-0.47, p=0.028). There was no significant relationship between 
CGI at baseline and percent change in any PANSS subscale (all n.s., p>0.05). 
d) PSP 
There was no significant relationship between PSP total score at baseline and percent 




e) CDSS  
There was no significant relationship between CDSS total score at baseline and 
percent change in PANSS total or any PANSS subscale (all n.s., p>0.05). 
3.1.2.1.4 Longitudinal effects of four-week antipsychotic treatment on clinical measures 
in four-week responders  
I assessed the effect of four weeks of antipsychotic treatment on clinical measures in 
patients who went on to be designated as a responder at four weeks.  
a) PANSS 
(i) Raw scores  
In four-week responders, there was a decrease in positive, negative, and general 
psychopathology scores over the four weeks of antipsychotic treatment. Due to non-
normality of data, I performed nonparametric Wilcoxon signed-rank tests on positive 
symptoms scores, whereas all other changes were investigated using paired samples 
t-tests. The results showed statistically significant decreases in all scores: positive (Z=-
3.52, p<0.0001), negative (t(16)=2.99, p=0.009), general psychopathology (t(16)=5.53, 
p<0.0001), and total (t(16)=6.22, p<0.0001) PANSS scores.  
These results suggest that amisulpride treatment in responders led to statistically 
significant improvements in overall symptoms, with significant improvements in all 
subscales.  
(ii) Percent change scores  
As above, I calculated percent change scores to investigate the degree of change in 
scores over time in responders, which can be more easily related to clinically significant 
change in symptoms than can raw scores.  
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In four-week responders, there were mean changes of 77.90%, 44.88%, 34.76%, and 
65.22% in positive, negative, general psychopathology, and total scores, respectively. 
Wilcoxon signed-rank test against 0 for non-normal data and one sample t-tests 
against 0 for normal data suggest that all of these changes were statistically significant 
(positive: p<0.0001; negative: p=0.008; general psychopathology: t(16)=7.37, 
p<0.0001; total: t(16)=10.72, p<0.0001). Clinically, all of these scores suggest that the 
changes in all PANSS scores were “much improved”. 
In agreement with the results from the raw scores, these data suggest that amisulpride 
treatment in this patient group leads to statistically and clinically significant 
improvements in PANSS scores, with improvements in all subscales.  
b) CGI 
At baseline, the majority of patients who later showed a good response were given a 
score of 3 (“mildly ill”) or 4 (“moderately ill”) on the CGI. At follow up, all patients scored 
less than 3, with the majority scoring 1 (“normal/not ill at all”). Mean CGI scores 
showed a decrease with treatment from 4.81 (S.D. 0.24; “mildly ill”) to 2.73 (S.D. 0.21; 
“borderline mentally ill”), indicating a decrease in illness severity. Scores were non-
normally distributed so non-parametric tests were employed. Following four weeks 
antipsychotic treatment, Wilcoxon signed-rank tests suggest a significant decrease in 
the CGI severity scores (Z=-3.37, p=0.001). Consistent with this, the majority (72.4%) 
of responders were given a CGI improvement score of either 2 or 1, indicating they 
were “much improved” or “very much improved”, respectively. 
The changes in CGI scores across four weeks of treatment support the patterns seen 
in PANSS scores, with a general improvement of symptoms for responders, such that 





In responders, four weeks of antipsychotic treatment led to an increase in PSP total 
score, from 54.13 (S.D. 3.54) to 74.73 (S.D. 3.15), indicating an improvement in 
functioning. PSP scores were non-normally distributed and as such, I conducted a 
Wilcoxon signed-rank test, which indicated that the increase was statistically significant 
(Z=-3.21, p=0.001).  
d) CDSS 
Responders showed a small decrease in CDSS scores from 4.50 (S.D. 1.09) to 2.50 
(1.04), indicating a small improvement in symptoms of depression. Similarly to the 
whole patient group, this decrease was not statistically significant (Wilcoxon signed-
rank test, n.s., p>0.05).  
3.1.2.1.5 Longitudinal effects of four-week antipsychotic treatment on clinical measures 
in four-week non-responders  
I assessed the effect of four weeks of antipsychotic treatment on clinical measures in 
patients who went on to be designated as a non-responder at four weeks.  
a) PANSS 
(i) Raw scores  
In four-week non-responders, there appeared to be little change in PANSS scores. 
Positive, general psychopathology, and total PANSS scores showed negligible small 
decreases, whilst negative PANSS scores actually showed a slight increase after 
treatment. Paired sample t-tests suggest that there were no significant changes in 
positive, negative, general psychopathology or total PANSS scores (all n.s., p>0.05).  
As expected, these results suggest that amisulpride treatment in this patient group did 
not lead to statistically significant improvements in overall symptoms and there were no 
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improvements on any subscale. This lack of improvement is reflected in the 
designation of these patients to the non-responders group.  
(ii) Percent change scores  
In non-responders, there were mean changes of 24.89%, -35.05%, 4.25%, and 5.38% 
in positive, negative, general psychopathology, and total scores, respectively. Wilcoxon 
signed-rank test against 0 for non-normal data and one sample t-tests against 0 for 
normal data suggest that all of these changes were not statistically significant (positive: 
t(7) = 2.09, p=0.075; negative: p=0.499; general psychopathology: t(7)=0.34, p=0.74; 
total: p=0.26). Clinically, all of these scores suggest that the changes in all PANSS 
scores were “minimally improved” or less. Negative symptoms worsened over the 
course of treatment.  
In agreement with the results from the raw scores, these data suggest that amisulpride 
treatment in this group of non-responders did not lead to statistically or clinically 
significant improvements in symptoms, with no significant changes on any subscale.  
b) CGI 
At baseline, the majority of patients who later showed a poor response were given a 
score of 4 (“moderately ill”) or 5 (“markedly ill”) on the CGI. At follow up, most non-
responders scored 3 (“mildly ill”) and none scored 1 (“normal/not ill at all”). Mean CGI 
scores did not show a significant change with treatment (baseline: 5.29, S.D.0.49; 
follow up: 4.80, S.D. 0.37; p=0.62). Improvement scores were more variable than in 
responders, with 25% showing much improvement, but 37.5% showing no change or 
worsening. Furthermore, the mean improvement score was 4.40 (S.D. 0.60), which 
indicates no change. 
The lack of significant changes in CGI scores across four weeks of treatment support 
the patterns seen in PANSS scores, with little improvement in the symptoms of non-
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responders, such that the severity of illness remained relatively stable despite 
treatment.  
c) PSP 
In non-responders, there was not a significant change in PSP score with treatment 
(baseline: 54.20, S.D. 3.96; follow up: 53.20, S.D. 8.73; p=0.78).  
d) CDSS 
Responders showed no change in CDSS scores, with the mean total score remaining 
stable at 4.80 throughout four weeks treatment.  
3.1.2.2 Treatment response at 12 weeks 
As described in Methods (page 122), remission status at 12 weeks after baseline was 
assessed using the PPHS. This allowed me to categorise patients into responders and 
non-responders at 12 weeks. Using this categorisation, I assessed the associations of 
demographic variables and baseline clinical scores with treatment response at 12 
weeks. A continuous score was not available for this time point and so only categorical 
treatment response was explored. Categorical data were explored using chi-square 
tests. Where continuous data were normal, independent samples t-tests were applied 
to investigate between group differences. Where data was non-normal, nonparametric 
alternatives were employed (Mann Whitney-U).  
PPHS scores were not available at 12 weeks for six patients (Table 12), as clinical 
notes were not available for these participants. All patients for whom data was not 
available at 12 weeks, were responders at four weeks. Data was available for PPHS 





Table 12: Reasons for non-inclusion at 12-weeks follow up  
 
Patient ID Reason for non-inclusion 
2208 
Patient discharged to GP, no access to 
clinical notes. 
2231 Patient not yet at 12 weeks. 
TR33 
Patient moved to another NHS Trust, no 
access to clinical notes. 
2401 
Patient recruited from another NHS 
Trust, no access to clinical notes. 
2402 
Patient recruited from another NHS 
Trust, no access to clinical notes. 
2404 
Patient recruited from another NHS 
Trust, no access to clinical notes. 
 
Whilst at four weeks there were 17 responders (68.0%) and 8 non-responders (32.0%), 
at 12 weeks, there were 11 responders (58.0%) and 8 non-responders (42.0%). 
Response was relatively stable, with one responder at four weeks categorised as a 
non-responder at 12 weeks and one non-responder at four weeks categorised as a 
responder at 12 weeks. For all other participants, remission status was the same at 12 
weeks as it was at four weeks.  
Between four and 12 weeks, all patients (for whom clinical notes were available) were 
medicated with a second generation antipsychotic. Of these, 57.1% remained on 
amisulpride (mean dose [chlorpromazine equivalent]: 115.63 mg). The remaining 
patients were treated with olanzapine (28.7%), aripiprazole (7.1%) or quetiapine 




3.1.2.2.1 Cross-sectional comparisons of demographic and clinical characteristics in 
12-week responders and non-responders at baseline 
Table 13 provides demographic and baseline clinical characteristics of the patient 
sample according to response to treatment at 12 weeks. These data were investigated 
to assess whether those patients who were categorised as a responder at 12 weeks 
differed significantly from non-responders at 12 weeks in demographics and baseline 
clinical measures.  
a) Demographics  
Twelve-week responders and non-responders did not differ significantly in terms of 
age, gender, diagnosis, ethnicity or education (n.s., p>0.05). Duration of untreated 
psychosis (months) was not normally distributed and so I investigated it using a non-
parametric Mann Whitney-U test. DUP did not seem to be related with long-term 
response as there was no significant difference in DUP between 12-week responders 
and non-responders (Z=-0.92, p=0.395).  
b) PANSS  
At baseline, 12-week non-responders had significantly higher general psychopathology 
symptom scores (t(17)=-4.07, p=0.001) and total PANSS scores (t(17)=-2.67, p=0.016) 
than responders. There was no significant difference between 12-week responders and 
non-responders in either positive (t(17)=-1.26, p=0.23) or negative symptom scores 
(t(17)=-1.15, p=0.27).  
c) CGI 
There was no significant difference between 12-week responders and non-responders 
in baseline mean CGI scores (Z=-1.84, p=0.13). Furthermore, a chi-square test for 
independence indicated no significant association between twelve-week treatment 




There was no significant difference in PSP total score at baseline between 12-week 
responders and non-responders (Z=-0.75, p=0.48). 


















 Range  
 Mean (S.D.) 
 
21 – 34 
27.18 (4.58) 
 


















 Schizophrenia, undifferentiated 
 Schizophreniform disorder 
 Schizoaffective disorder 
             Schizophrenia, disorganised 
             Schizophrenia, paranoid 















DUP (months) (mean, S.D.) 9.05 (8.31) 14.13 (14.05) 
PANSS (mean, S.D.) 
 Positive 
 Negative 












CGI severity (%) 
 Normal/Not ill at all 
 Borderline mentally ill 
 Mildly ill 
 Moderately ill 
 Markedly ill 


















PSP (mean, S.D.)  54.80 (10.63) 50.43 (10.89) 
CDSS (mean, S.D.)  4.20 (4.05) 5.14 (4.06) 
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e) CDSS  
There was no significant difference in CDSS total score at baseline between 12-week 
responders and non-responders (Z=-0.59, p=0.60). 
3.1.2.2.2 Cross-sectional comparisons of baseline demographic and clinical 
characteristics in 12-week responders and non-responders  
I also investigated whether clinical scores after four weeks of treatment were 
significantly different, to assess whether there were differences already evident 
between 12-week responders and non-responders at this point (Table 14).  
a) PANSS  
When 12-week responders and non-responders were compared on PANSS scores 
after four weeks of treatment, non-responders had significantly higher positive 
symptoms scores (Z=-2.96, p=0.002), general psychopathology scores (Z=-2.52, 
p=0.009), and total PANSS scores (Z=-2.73, p=0.005) than responders. There was no 
significant difference between responders and non-responders in negative symptom 
scores (Z=-1.70, p=0.091).  
b) CGI 
As expected, mean CGI (severity) scores at follow up were significantly different (Z=-
2.90, p=0.003), suggesting 12-week non-responders were more ill than were 
responders. Furthermore, a chi-square test for independence indicated a significant 
association between treatment response status and CGI scores (Χ2=10.50, p=0.033).  
There was, however, no significant difference in mean CGI (improvement) scores 
between responders and non-responders (Z=-1.13, p=0.25). Consistent with this, a 
Chi-square test for independence indicated no significant association between 
treatment response status and CGI improvement (Χ2=5.52, p=0.14). 
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Table 14: Clinical characteristics of 12-week responders and non-responders after four 
weeks of treatment  
 





PANSS (mean, S.D.) 
 Positive 
 Negative 












CGI severity (%) 
 Normal/Not ill at all 
 Borderline mentally ill 
 Mildly ill 
 Moderately ill 
 Markedly ill 
 Severely ill  
 Missing 
CGI improvement (%) 
 Very much improved 
 Much improved 
 No change 






























PSP (mean, S.D.)   69.40 (15.35) 57.2 (5.85) 
CDSS (mean, (S.D.)   3.4 (4.50) 4.4 (3.91) 
 
c) PSP 
There was no significant difference in PSP total score at four weeks follow up between 
12-week responders and non-responders (t(13)=1.69, p=0.12). 
d) CDSS  
There was no significant difference in CDSS total score at four weeks follow up 




3.1.2.2.3 Longitudinal effects of four-week antipsychotic treatment on clinical measures 
in responders at twelve weeks 
I assessed the effect of four weeks of antipsychotic treatment on clinical measures in 
patients who went on to be designated as a responder at 12 weeks.  
a) PANSS 
(i) Raw scores 
In 12-week responders, there was a decrease in positive, negative, and general 
psychopathology scores over the four weeks of antipsychotic treatment. Due to non-
normality of data, I conducted nonparametric Wilcoxon signed-rank tests on all scores. 
The results showed statistically significant decreases in positive (Z=-2.94, p=0.003), 
general psychopathology (Z=-2.54, p=0.011), and total (Z=-2.80, p=0.005) PANSS 
scores. The change in negative PANSS scores was not significant (Z=-1.47, p=0.14).  
These results suggest that amisulpride treatment in 12-week responders led to 
statistically significant improvements in overall symptoms, with significant 
improvements in all subscales except for negative symptoms.  
(ii) Percent change scores  
As above, I calculated percent change scores to investigate the degree of change in 
scores over time in 12-week responders, which can be more easily related to clinically 
significant change in symptoms than can raw scores.  
In these responders, there were mean changes of 79.87%, 29.88%, 27.15%, and 
58.48% in positive, negative, general psychopathology, and total scores, respectively. 
Wilcoxon signed-rank test against 0 for non-normal data and one sample t-tests 
against 0 for normal data suggested that changes were statistically significant in 
positive (p=0.003), general psychopathology (t(10)=3.97, p=0.003) and total 
(t(10)=5.97, p<0.0001) PANSS scores. The mean change in negative symptoms was 
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not significant (t(10)=1.53, p=0.16). Clinically, these scores corresponded to “minimally 
improved” or “much improved”.  
In agreement with the results from the raw scores, these data suggest that amisulpride 
treatment in this patient group leads to statistically and clinically significant 
improvements in overall PANSS scores, but not in negative symptoms.  
b) CGI 
At baseline, the majority of patients who later showed a good response at 12 weeks 
were given a score of 3 (“mildly ill”) or 4 (“moderately ill”) on the CGI. After four weeks 
of treatment, all patients scored less than 3. Mean CGI scores showed a decrease with 
treatment from 4.90 (S.D. 0.57; “moderately ill”) to 2.80 (S.D. 0.79; “borderline mentally 
ill”), indicating a decrease in illness severity. Scores were non-normally distributed so 
non-parametric tests were employed. Following four weeks antipsychotic treatment, 
Wilcoxon signed-rank tests suggest a significant decrease in the CGI severity scores 
(Z=-2.87, p=0.004). Consistent with this, the majority (81.8%) of responders were given 
a CGI improvement score of either 2 or 1, indicating they were “much improved” or 
“very much improved”, respectively. 
The changes in CGI scores across four weeks of treatment support the patterns seen 
in PANSS scores, with a general improvement of symptoms for responders, such that 
the severity of illness lessened with treatment.  
c) PSP 
In 12-week responders, four weeks of antipsychotic treatment led to an increase in 
PSP total score, from 54.80 (S.D. 10.63) to 69.40 (S.D. 15.35), indicating an 






Twelve-week responders showed a small decrease in CDSS scores from 4.20 (S.D. 
4.05) to 3.40 (4.50), indicating a small improvement in symptoms of depression. As 
before, this decrease was not statistically significant (Wilcoxon signed-rank test, Z=-
0.74, p=0.46).  
3.1.2.2.4 Longitudinal effects of four-week antipsychotic treatment on clinical measures 
in 12-week non-responders  
I assessed the effect of four weeks of antipsychotic treatment on clinical measures in 
patients who went on to be designated as a non-responder at 12 weeks.  
a) PANSS 
(i) Raw scores  
In 12-week non-responders, there appeared to be little change in PANSS scores. 
Positive, general psychopathology, and total PANSS scores showed small or negligible 
changes after treatment. Paired sample t-tests suggest that there were no significant 
changes in positive, negative, general psychopathology or total PANSS scores (all n.s., 
p>0.05).  
As expected, these results suggest that amisulpride treatment in this patient group did 
not lead to statistically significant improvements in overall symptoms and there were no 
improvements on any subscale. This lack of improvement is reflected in the 
designation of these patients to the non-responders group.  
(ii) Percent change scores  
In 12-week non-responders, there were mean changes of 30.10%, -21.66%, 12.05%, 
and 14.53% in positive, negative, general psychopathology, and total scores, 
respectively. Wilcoxon signed-rank test against 0 for non-normal data and one sample 
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t-tests against 0 for normal data suggest that all of these changes were not statistically 
significant (positive: t(7)=2.24, p=0.060; negative: p=0.87; general psychopathology: 
p=0.16; total: p=0.16). Clinically, all of these scores suggest that the changes in all 
PANSS scores were “minimally improved” or less. Negative symptoms worsened over 
the course of treatment.  
In agreement with the results from the raw scores, these data suggest that amisulpride 
treatment in this group of non-responders did not lead to statistically or clinically 
significant improvements in symptoms, with no significant changes on any subscale.  
b) CGI 
At baseline, the majority of patients who later showed a poor response were given a 
score of 4 (“moderately ill”) or 5 (“markedly ill”) on the CGI. At follow up, most non-
responders scored 3 (“mildly ill”) or worse and none scored 1 (“normal/not ill at all”). 
Mean CGI scores did not show a significant change with treatment (baseline: 5.40, 
S.D.0.89; follow up: 4.80, S.D. 0.84; p=0.41). Improvement scores were more variable 
than in responders, with 25% designated as much or very much improved, but 37.5% 
showing no change or worsening. Furthermore, the mean improvement score was 4.20 
(S.D. 1.64), indicating no change. 
The lack of significant changes in CGI scores across four weeks of treatment support 
the patterns seen in PANSS scores, with little improvement in the symptoms of non-
responders, such that the severity of illness remained relatively stable despite 
treatment.  
c) PSP 
In 12-week non-responders, there was not a significant change in PSP score with 





Twelve-week non-responders showed a small decrease in CDSS scores, but this 
change was not significant (baseline: 5.80, S.D. 4.76; follow up: 4.40, S.D. 3.91; 
p=0.41).  
3.1.3 Chapter summary 
In this chapter, I have described the effects of antipsychotic treatment on clinical 
measures in patients with FEP. Furthermore, I have explored the relationships between 
baseline and four-week demographic/clinical factors and treatment response as 
assessed at four and 12 weeks. Four-week treatment response was assessed in two 
ways. Firstly, patients were divided categorically into responders and non-responders, 
according to the Andreasen criteria (Andreasen et al., 2005). Secondly, percent change 
in PANSS score was used as a continuous measure of treatment response. Grouping 
patients in this way is a novel approach, that can clarify the relationships between 
clinical measures and outcomes.  
To summarise, in the entire patient group, symptoms improved with treatment, with 
significant decreases in all PANSS subscales, apart from negative symptoms. These 
improvements were confirmed by the mean percent change scores on the PANSS, as 
well as changes in CGI and PSP ratings. At an individual level, not all patients 
improved with treatment, with 17 (68%) showing a good response to treatment and 8 
(32%) showing a poor response to treatment at four weeks.  
Grouping patients according to response showed that not only was a shorter DUP 
associated with a better response to treatment, but there was also a significant 
difference between responders and non-responders, such that non-responders had a 
longer DUP. Comparisons of responders and non-responders also suggest that non-
response was associated with a greater severity of illness at baseline. These results 
may indicate that early intervention, during a milder stage of the disorder, could lead to 
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better response. Alternatively, there may be differences in both the underlying 
pathophysiology and the resulting symptomatology observed that determines whether 





3.2 The effects of antipsychotics on behavioural measures of 
salience attribution and related neural function measured using fMRI 
In this chapter, I present behavioural and related neural function (fMRI) data for the 
salience attribution task in patients and healthy controls.  
I begin by presenting behavioural data for antipsychotic-naïve patients and healthy 
controls. I assess these using cross-sectional comparisons to explore differences in 
salience measures before treatment and following four weeks of amisulpride treatment. 
I also present longitudinal analyses of behavioural measures to assess the effect of 
antipsychotic medication on measures of salience attribution in patients. Finally, I 
assess relationships between response to treatment (at four and 12 weeks) and 
measures of salience attribution.   
In the second part of the chapter, I present data representing the neural function 
underlying salience attribution measured using fMRI in patients and healthy controls. I 
begin by presenting cross-sectional data comparing antipsychotic-naïve patients with 
healthy controls. This explores whether activation related to salience attribution in 
patients before treatment differs from that of healthy individuals (suggesting that 
potential differences seen may relate to illness pathophysiology). I then present a 
cross-sectional analysis of the neural function of patients after four weeks of treatment 
in comparison to that of healthy controls. This explores whether any differences 
between these groups, that may have been present at baseline, are still present 
following four weeks’ treatment with amisulpride.  
Subsequently, I present longitudinal analyses exploring the effect of antipsychotic 
medication on salience activation in patients. In these analyses, I compare SPM maps 
at baseline and follow up in the same patients. For completion, I also present 
longitudinal assessments of healthy individuals, comparing baseline and follow up 
scans for any altered patterns of neural function. 
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Next, I assess the relationship between antipsychotic treatment response at four weeks 
and salience activation. I do this by first exploring patterns of activation in responders 
and non-responders cross-sectionally at baseline and follow up (after four weeks of 
treatment), with one another and with healthy controls. I then assess longitudinal 
changes in neural function seen in each of these groups individually. Finally, to assess 
longer-term outcomes, I assess the relationship between neural activation and 
antipsychotic treatment response at 12 weeks, both cross-sectionally and 
longitudinally.  
For all imaging analyses, I first evaluated global brain volumes, before assessing any 
regions of interest defined a priori. I discuss all effects surviving either voxel- or cluster-
level family-wise error (FWE) correction for whole brain multiple comparisons.  
Some participants did not consent to take part in the fMRI arm of the study (see 
Methods, Table 4, page 114 for reasons). Any participants who completed the fMRI 
protocol but are missing from an analysis are reported in each relevant section. Unless 
otherwise stated, all participants who completed the fMRI paradigm (n=22) were 
included in the analysis.   
Hypotheses explored: 
 At baseline, patients will show greater aberrant salience but reduced adaptive 
salience compared with healthy controls. 
 Aberrant salience processing will be associated with ventral striatal and 
dorsolateral PFC activation.  
 At follow up, there will be a normalisation of abnormal salience attribution and 
the associated activation, such that patients become more like healthy controls. 
However, this change will be specific to treatment responders, such that 
behavioural and neural measures in responders and non-responders differ at 
follow up. Patients who do not respond to treatment will continue to exhibit 
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altered salience attribution and ventral striatal activation to irrelevant stimulus 
features. 
3.2.1 Salience attribution scores in patients and healthy controls  
I first considered behavioural measures of salience attribution for the entire patient 
group and the healthy controls. These analyses try to identify any abnormalities in 
salience attribution processes in patients with FEP, which might support the salience 
attribution hypothesis. They also investigate the effects of antipsychotic treatment in a 
group of previously untreated patients with FEP. 
I carried out cross-sectional comparisons of patients and healthy controls on measures 
of salience attribution (implicit aberrant and adaptive salience, explicit aberrant and 
adaptive salience, premature/omission errors, and money won) at baseline (where 
patients were minimally treated) and at follow up (after four weeks of antipsychotic 
treatment). I also investigated longitudinal changes in these measures in patients.  
3.2.1.1 Cross-sectional comparisons of salience attribution scores in patients and 
healthy controls at baseline 
Table 15 provides an overview of baseline SAT scores for patients and healthy 
controls.  
At baseline, all participants responded more quickly on high- relative to low-probability 
reinforced trials (t(42)=3.04, p=0.004). Analysis of the groups separately revealed that 
healthy controls showed significant implicit adaptive salience (t(20)=3.01, p=0.007) but 














RT adaptive salience (ms) 8.24 (27.67) 16.47 (25.11) t(41)=1.02, p=0.31 
VAS adaptive salience 
(mm) 
17.52 (31.69) 57.40 (32.87) 
t(41)=-4.05, 
p<0.0001* 
RT aberrant salience (ms) 19.52 (16.39) 14.41 (10.87) t(41)=1.01, p=0.32 
VAS aberrant salience 
(mm) 
11.61 (10.89) 11.17 (9.51) t(41)=0.14, p=0.89 
Omission errors 0.50 (1.92) 0.33 (0.66) Z=-0.83, p=0.41 
Premature errors 2.45 (2.79) 1.43 (1.75) Z=-1.31, p=0.19 
Money won (£) 10.19 (4.30) 11.16 (5.46) t(41)=-0.65, p=0.52 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; * p<0.05 
 
At baseline, patients had lower adaptive salience scores (implicit and explicit) and higher 
implicit aberrant salience scores than healthy controls, and similar explicit aberrant 
salience scores. However, the only significant group difference was for scores of explicit 
adaptive salience (t(41)=-4.051, p<0.0001), indicating that patients had significantly 
lower levels of explicit adaptive salience. Patients and healthy controls also did not differ 
on the number of errors they made or on the amount of money won. 
3.2.1.2 Cross-sectional comparisons of salience attribution scores in patients and 
healthy controls at four-week follow up  
Table 16 provides an overview of follow up SAT scores for patients and healthy 
controls (after four weeks).  
Again, I first investigated whether the participants as a whole were able to use reward 
associations to guide how they responded (comparing responses on high-probability 
trials to those on low-probability trails). At four-week follow up, participants responded 
more quickly on high- relative to low-probability reinforced trials (t(39)=3.43, p=0.001). 
At follow up, the distribution of implicit adaptive salience measures were non-normal, 
so I conducted a one-sample Wilcoxon Signed-Rank Test against 0 to assess whether 
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patients and healthy controls exhibited significant implicit adaptive salience 
(significantly different to zero). As at baseline, healthy controls showed significant 
implicit adaptive salience at follow up (p<0.0001). However, in contrast to baseline, the 
patients now did too (p=0.028), indicating that both groups were able to differentiate 
between high- and low-probability cues. 
 








RT adaptive salience (ms) 11.17 (31.62) 18.12 (22.84) t(39)=-0.81, p=0.42 
VAS adaptive salience (mm) 32.26 (30.89) 72.90 (25.75) 
t(24)=-3.21, 
p=0.004* 
RT aberrant salience (ms) 12.04 (11.57) 12.16 (7.74) t(39)=-0.37, p=0.72 
VAS aberrant salience (mm) 15.79 (13.21) 11.10 (17.34) t(38)=1.70, p=0.097 
Omission errors 0.25 (0.55) 0.29 (0.64) Z<0.0001, p=1.00 
Premature errors 1.10 (1.52) 1.52 (1.63) Z=-1.02, p=0.31 
Money won (£) 12.07 (6.08) 11.74 (5.86) t(39)=0.17, p=0.86 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; * p<0.05 
 
Nevertheless, at follow up, patients still showed significantly lower explicit adaptive 
salience scores than healthy controls (t(24)=-3.21, p=0.004). There were no significant 
differences between the groups in any other salience score, including in errors made or 
money won (all n.s., p>0.05).  
3.2.1.3 Longitudinal effects of four-week antipsychotic treatment on behavioural 
measures of salience attribution in FEP patients  
Table 17 shows the longitudinal measures for patients and healthy controls who were 
scanned at two time points. I examined the effects of antipsychotic treatment on 
behavioural measures of salience attribution within the patient group by considering the 
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changes in these measures longitudinally. For comparison, I examined the stability of 
the measures in healthy controls across a similar period.  
 
Table 17: Measures of salience attribution over four weeks in patients and healthy 
controls scanned at two time points 
 
Salience measure Baseline Follow up Test, sig. 
Patients    
RT adaptive salience (ms) 11.18 (26.93) 11.17 (31.62) t(19)=-0.71, p=0.49 
VAS adaptive salience 
(mm) 
21.66 (31.60) 32.26 (30.89) t(18)=-1.36, p=0.19 
RT aberrant salience (ms) 18.23 (15.50) 12.04 (11.57) t(19)=1.55, p=0.14 
VAS aberrant salience 
(mm) 
13.13 (10.96) 15.79 (13.21) t(18)=-0.91, p=0.37 
Omission errors 0.50 (2.01) 0.25 (0.55) Z=-0.14, p=0.89 
Premature errors 2.50 (2.91) 1.10 (1.52) Z=-2.50, p=0.012* 
Money won (£) 10.15 (4.50) 12.07 (6.08) Z=-0.67, p=0.50 
Healthy controls    
RT adaptive salience (ms) 16.24 (25.74) 18.12 (22.84) t(20)=-0.59, p=0.56 
VAS adaptive salience 
(mm) 
56.35 (33.36) 72.90 (25.75) t(20)=-1.40, p=0.18 
RT aberrant salience (ms) 14.35 (11.15) 12.16 (7.74) t(20)=0.76, p=0.45 
VAS aberrant salience 
(mm) 
10.95 (9.71) 11.10 (17.34) t(20)=0.56, p=0.58 
Omission errors 0.25 (0.55) 0.29 (0.64) Z=-0.18, p=0.86 
Premature errors 1.45 (1.79) 1.52 (1.63) Z=-0.57, p=0.57 
Money won (£) 11.17 (5.60) 11.74 (5.86) Z=-0.15, p=0.88 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; * p<0.05 
 
When baseline and follow-up scores were compared in patients, there was a significant 
decrease in the number of premature errors committed after treatment (Z=-2.50, 
p=0.012). There were no significant differences in any other measures. There were no 
significant differences between baseline and follow up scores in healthy controls, 













Figure 9: Longitudinal changes in explicit adaptive and aberrant salience over four weeks, in patients and healthy controls 
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3.2.2 Salience attribution measures in responders and non-responders 
In these sections, I present the salience attribution scores for patients in relation to 
response to treatment at four and 12 weeks, to assess the associations of these 
variables with short- and longer-term treatment response.  
3.2.2.1 Treatment response at four weeks 
To investigate the relationship between treatment response and measures of salience 
attribution, I carried out cross-sectional and longitudinal analyses of these measures to 
compare responders and non-responders (and healthy controls). I also assessed 
whether there was a relationship between baseline and longitudinal salience attribution 
measures and continuous measures of response (percent change in PANSS scores). 
3.2.2.1.1 Cross-sectional comparisons of baseline salience attribution in four-week 
responders and non-responders  
a) Four-week responders versus non-responders 
I first assessed whether there were any baseline differences between four-week 
responders and non-responders. Table 18 provides salience measures for responders 
and non-responders at baseline. These data were investigated to assess whether 
salience attribution processing at baseline differed in patients who were categorised as 
responders at four weeks compared with non-responders. 
At baseline, responders had significantly higher implicit adaptive salience than non-
responders (t(16)=2.82, p=0.012). There were no other differences between the two 















Test, sig.  
RT adaptive salience (ms) 17.25 (30.99) -7.52 (8.30) t(16)=2.82, p=0.012* 
VAS adaptive salience 
(mm) 
26.71 (35.32) 1.44 (15.20) t(19)=1.76, p=0.10 
RT aberrant salience (ms) 22.98 (17.45) 13.46 (13.23) t(20)=1.47, p=0.16 
VAS aberrant salience 
(mm) 
10.07 (11.12) 14.31 (10.62) t(20)=-1.05, p=0.31 
Omission errors 0.71 (2.40) 0.13 (0.354) Z=-0.17, p=0.92 
Premature errors 2.43 (2.95) 2.50 (2.67) Z=-0.28, p=0.82 
Money won (£) 11.33 (3.52) 8.20 (5.04) t(20)=1.71, p=0.10 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
b) Four-week responders versus healthy controls  
I next assessed whether there were any baseline differences between four-week 
responders and healthy controls. Table 19 provides salience measures for responders 
and healthy controls at baseline.  
 








Test, sig.  
RT adaptive salience (ms) 17.25 (30.99) 16.47 (25.11) t(33)=0.081, p=0.94 
VAS adaptive salience 
(mm) 
26.71 (35.32) 57.40 (32.87) t(33)=-2.63, p=0.013* 
RT aberrant salience (ms) 22.98 (17.45) 14.41 (10.87) t(33)=1.75, p=0.090 
VAS aberrant salience 
(mm) 
10.07 (11.12) 11.17 (9.51) t(33)=-0.56, p=0.58 
Omission errors 0.71 (2.40) 0.33 (0.66) Z=-0.60, p=0.68  
Premature errors 2.43 (2.95) 1.43 (1.75) Z=-0.99, p=0.34 
Money won (£) 11.33 (3.52) 11.16 (5.46) t(33)=0.098, p=0.92 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
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At baseline, four-week responders had significantly lower implicit adaptive salience 
than did healthy controls (t(33)=-2.63, p=0.013). There were no significant differences 
in any other measures of salience at baseline between responders and healthy 
controls.  
c) Four-week non-responders versus healthy controls 
Lastly, I assessed whether there were baseline differences between four-week non-
responders and healthy controls. Table 20 provides salience measures for non-
responders and healthy controls at baseline.  
 
Table 20: Measures of baseline salience attribution in 4-week non-responders and 







Test, sig.  
RT adaptive salience (ms) -7.52 (8.30) 16.47 (25.11) t(27)=-3.86, p=0.001* 
VAS adaptive salience (mm) 1.44 (15.20) 57.40 (32.87) t(27)=-4.41, p<0.0001* 
RT aberrant salience (ms) 13.46 (13.23) 14.41 (10.87) t(27)=-0.29, p=0.77 
VAS aberrant salience (mm) 14.31 (10.62) 11.17 (9.51) t(27)=0.71, p=0.48 
Omission errors 0.13 (0.354) 0.33 (0.66) Z=-0.73, p=0.62 
Premature errors 2.50 (2.67) 1.43 (1.75) Z=-1.20, p=0.26 
Money won (£) 8.20 (5.04) 11.16 (5.46) t(27)=-1.33, p=0.20 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
At baseline, four-week non-responders had significantly lower levels of both implicit 
and explicit adaptive salience than did healthy controls (t(27)=-3.86, p=0.001 and 
t(27)=-4.41, p<0.0001, respectively). There were no significant differences between the 
groups on aberrant salience scores, errors or money won at baseline.  
3.2.2.1.2 Cross-sectional comparisons of salience attribution in four-week responders 
and non-responders at four-week follow up  
a) Four-week responders versus non-responders 
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I first assessed whether there were differences between four-week responders and 
non-responders at follow up after four weeks of treatment. Table 21 provides salience 
measures for responders and non-responders at baseline.  
 








Test, sig.  
RT adaptive salience (ms) 17.30 (25.58) 1.98 (39.03) t(18)=1.065, p=0.30 
VAS adaptive salience 
(mm) 
32.46 (28.94) 31.93 (36.44) t(17)=0.035, p=0.97 
RT aberrant salience (ms) 7.16 (4.63) 19.37 (15.08) 
t(18)=-2.78, 
p=0.013* 
VAS aberrant salience 
(mm) 
18.46 (15.12) 11.21 (8.12) t(17)=1.011, p=0.33 
Omission errors 0.33 (0.65) 0.13 (0.35) Z=-0.72, p=0.62 
Premature errors 1.17 (1.75) 1.00 (1.20) Z=-0.083, p=0.97 
Money won (£) 11.12 (3.66) 13.50 (8.69) t(18)=-0.85, p=0.41 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
After four weeks of treatment, there was no longer a significant difference between 
responders and non-responders in adaptive salience (t(18)=1.065, p=0.30), although 
adaptive salience in responders was still higher than that of non-responders (mean 
17.3ms versus 1.98ms). However, responders after treatment showed significantly 
lower implicit aberrant salience than did non-responders (t(18)=-2.77, p=0.013). There 
were no other differences between the two patient groups in measures of salience, 
including errors and money won (all n.s., p>0.05). 
b) Four-week responders versus healthy controls 
I next assessed whether there were any differences between four-week responders 
and healthy controls at four-week follow up. Table 22 provides salience measures for 
responders and healthy controls at follow up.  
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Test, sig.  
RT adaptive salience (ms) 17.30 (25.58) 18.12 (22.84) t(31)=-0.20, p=0.84 
VAS adaptive salience 
(mm) 
32.46 (28.94) 72.90 (25.75) 
t(12.6)=-2.40, 
p<0.033* 
RT aberrant salience (ms) 7.16 (4.63) 12.16 (7.74) t(31)=-2.03, p=0.051 
VAS aberrant salience 
(mm) 
18.46 (15.12) 11.10 (17.34) t(31)=1.73, p=0.093 
Omission errors 0.33 (0.65) 0.29 (0.64) Z=-0.34, p=0.81 
Premature errors 1.17 (1.75) 1.52 (1.63) Z=-0.88, p=0.41 
Money won (£) 11.12 (3.66) 11.74 (5.86) t(30.66)=-0.38, p=0.71 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
After four weeks of treatment, four-week responders still had lower implicit adaptive 
salience than healthy controls (t(12.6)=-2.40, p<0.033). There were no significant 
differences in any other measures of salience at follow up between responders and 
healthy controls. 
c) Four-week non-responders versus healthy controls 
Finally, I assessed whether there were any differences between four-week non-
responders and healthy controls at four-week follow up. Table 23 provides salience 
measures for non-responders and healthy controls at follow up.  
At follow up, four-week non-responders still had lower implicit adaptive salience scores 
than did healthy controls but this was no longer significant (t(27)=-1.39, p=0.18). 
However, explicit adaptive salience scores remained significantly lower in non-
responders than in healthy controls (t(27)=-3.29, p=0.003). There were no significant 
differences between the groups on aberrant salience scores, errors or money won at 





Table 23: Measures of follow up salience attribution in four-week non-responders and 







Test, sig.  
RT adaptive salience (ms) 1.98 (39.03) 18.12 (22.84) t(27)=-1.39, p=0.18 
VAS adaptive salience (mm) 31.93 (36.44) 72.90 (25.75) t(27)=-3.29, p=0.003* 
RT aberrant salience (ms) 19.37 (15.08) 12.16 (7.74) t(27)=1.53, p=0.14 
VAS aberrant salience (mm) 11.21 (8.12) 11.10 (17.34) t(26)=0.78, p=0.45 
Omission errors 0.13 (0.35) 0.29 (0.64) Z=-0.48, p=0.76 
Premature errors 1.00 (1.20) 1.52 (1.63) Z=-0.76, p=0.49 
Money won (£) 13.50 (8.69) 11.74 (5.86) t(27)=0.63, p=0.54 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres 
 
3.2.2.1.3 Longitudinal effects of four-week antipsychotic treatment on clinical measures 
in four-week responders  
To assess whether there were changes in any measures of salience within four-week 
responders during four weeks of treatment, I compared baseline and follow up 
measures in this group (Table 24 and Figure 10).  
In four-week responders there was a significant decrease in implicit aberrant salience 
(t(11)=3.095, p=0.01) and the number of premature errors (Z=-2.13, p=0.033). There 
were no significant changes in any other salience measures or in the amount of money 
won by responders.  
3.2.2.1.4 Longitudinal effects of four-week antipsychotic treatment on salience 
measures in four-week non-responders  
To assess whether there were changes in any measures of salience within four-week 
non-responders during four weeks of treatment, I compared baseline and follow up 
measures in this group (Table 24 and Figure 11). 
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In four-week non-responders there was a significant increase in explicit adaptive 
salience (t(6)=-2.73, p-0.034) but no changes in any other measure of salience, errors 
or money won. This suggests that following treatment non-responders were better able 
to differentiate between high and low probability cues but that this learning was not 
reflected in their reaction times.  
 
Table 24: Measures of baseline and follow up salience attribution in four-week 
responders and non-responders 
 
Salience measure Baseline Follow up Test, sig.  
Responders (n=14)    
RT adaptive salience (ms) 17.25 (30.99) 17.30 (25.58) t(11)=-0.77, p=0.46 
VAS adaptive salience (mm) 26.71 (35.32) 32.46 (28.94) t(11)=0.066, p=0.95 
RT aberrant salience (ms) 22.98 (17.45) 7.16 (4.63) t(11)=3.10, p=0.01* 
VAS aberrant salience (mm) 10.07 (11.12) 18.46 (15.12) t(11)=-1.42, p=0.18 
Omission errors 0.71 (2.40) 0.33 (0.65) Z=0.00, p=1.00 
Premature errors 2.43 (2.95) 1.17 (1.75) Z=-2.13, p=0.033* 
Money won (£) 11.33 (3.52) 11.12 (3.66) t(11)=0.22, p=0.83 
Non-responders (n=8)    
RT adaptive salience (ms) -7.52 (8.30) 1.98 (39.03) t(7)=-0.64, p=0.54 
VAS adaptive salience (mm) 1.44 (15.20) 31.93 (36.44) t(7)=-2.73, p=0.034* 
RT aberrant salience (ms) 13.46 (13.23) 19.37 (15.08) t(7)=-0.90, p=0.40 
VAS aberrant salience (mm) 14.31 (10.62) 11.21 (8.12) t(6)=0.89, p=0.41 
Omission errors 0.13 (0.354) 0.13 (0.35) Z=-0.00, p=1.00 
Premature errors 2.50 (2.67) 1.00 (1.20) Z=-1.28, p=0.20 
Money won (£) 8.20 (5.04) 13.50 (8.69) t(7)=-1.70, p=0.13 























3.2.2.1.5 Associations between salience attribution measures and a continuous 
measure of treatment response at four weeks 
As there were relatively few non-responders in our sample, I also assessed a 
continuous measure of treatment response (at four weeks) in the form of percentage 
change scores, using the same methods as described for the clinical measures (see 
Methods, page 101). I investigated the relationships between baseline and four-week 
follow up measures of salience and percentage change in PANSS score using 
Spearman’s Rho.  
There was no relationship between baseline implicit adaptive salience or 
implicit/explicit aberrant salience and percentage change in any of the subscales or the 
total PANSS scores (all n.s., p>0.05). Baseline explicit adaptive salience was positively 
correlated with percentage change on all subscales and total PANSS scores (positive: 
R=0.44, p=0.044; negative: R=0.56, p=0.008; general psychopathology: R=0.46, 
p=0.036; and total: R=0.56, p=0.008). This was such that higher scores of explicit 
adaptive salience before treatment were related to bigger changes in all symptom 
scores following four weeks of treatment. 
Four-week follow up implicit/explicit adaptive salience and explicit aberrant salience 
scores were not related to percent change in any of the subscales or the total PANSS 
scores (all n.s., p>0.05). Follow up implicit aberrant salience scores were significantly 
negatively correlated with percent change in positive, general psychopathology, and 
total PANSS scores (R=-0.51, p=0.024; R=-0.57, p=0.011; and R=-0.58, p=0.010, 
respectively) but not negative PANSS scores (n.s., p>0.05).  
Errors made and money won at either baseline or follow up were not significantly 





3.2.2.2 Treatment response at 12 weeks 
To investigate the relationship between longer-term treatment response and measures 
of salience attribution, I carried out cross-sectional and longitudinal analyses of these 
measures to compare responders and non-responders defined at 12 weeks (and 
healthy controls).  
3.2.2.2.1 Cross-sectional comparisons of baseline salience attribution in 12-week 
responders and non-responders  
a) Twelve-week responders versus non-responders 
I first assessed whether there were any baseline differences between 12-week 
responders and non-responders. Table 25 provides salience measures for 12-week 
responders and non-responders at baseline.  
 








Test, sig.  
RT adaptive salience (ms) 11.54 (27.25) 6.67 (34.00) Z=-0.32, p=0.80 
VAS adaptive salience 
(mm) 
15.56 (27.71) 6.07 (25.73) Z=-1.42, p=0.16 
RT aberrant salience (ms) 28.53 (19.94) 9.37 (4.61) t(14)=2.58, p=0.022* 
VAS aberrant salience 
(mm) 
11.25 (11.78) 14.57 (11.79) Z=-0.58, p=0.57 
Omission errors 0.13 (0.35) 0.00 (0.00) Z=-1.00, p=0.72 
Premature errors 2.50 (3.74) 2.71 (2.81) Z=-0.60, p=0.57 
Money won (£) 12.80 (4.49) 7.51 (3.55) t(14)=2.74, p=0.016* 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
At baseline, 12-week responders had significantly higher implicit aberrant salience than 
did later non-responders (t(14)=2.58, p=0.022). Twelve-week responders also won 
more money than non-responders (t(14)=2.74, p=0.016). There were no other 
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differences between the two patient groups in measures of salience, including errors 
committed (all n.s., p>0.05).  
b) Twelve-week responders versus healthy controls  
I next assessed whether there were any baseline differences between 12-week 
responders and healthy controls. Table 26 provides salience measures for 12-week 
responders and healthy controls at baseline.  
 








Test, sig.  
RT adaptive salience (ms) 11.54 (27.25) 16.47 (25.11) t(29)=-1.14, p=0.26 
VAS adaptive salience 
(mm) 
15.56 (27.71) 57.40 (32.87) t(29)=-3.90, p=0.001* 
RT aberrant salience (ms) 28.53 (19.94) 14.41 (10.87) 
t(11.67)=2.22, 
p=0.046* 
VAS aberrant salience 
(mm) 
11.25 (11.78) 11.17 (9.51) Z=-0.91, p=0.37 
Omission errors 0.13 (0.35) 0.33 (0.66) Z=-0.35, p=0.82 
Premature errors 2.50 (3.74) 1.43 (1.75) Z=-0.62, p=0.57 
Money won (£) 12.80 (4.49) 11.16 (5.46) t(29)=0.61, p=0.55 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
At baseline, 12-week responders had significantly lower explicit adaptive salience than 
did healthy controls (t(29)=-3.90, p=0.001). There were no significant differences in any 
other measures of salience at baseline between responders and healthy controls.  
c) Twelve-week non-responders versus healthy controls 
Lastly, I assessed whether there were any baseline differences between 12-week non-
responders and healthy controls. Table 27 provides salience measures for 12-week 
non-responders and healthy controls at baseline.  
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Table 27: Measures of baseline salience attribution in 12-week non-responders and 







Test, sig.  
RT adaptive salience (ms) 6.67 (34.00) 16.47 (25.11) Z=-1.90, p=0.059 
VAS adaptive salience (mm) 6.07 (25.73) 57.40 (32.87) Z=-3.20, p=0.001* 
RT aberrant salience (ms) 9.37 (4.61) 14.41 (10.87) t(27)=-1.13, p=0.27 
VAS aberrant salience (mm) 14.57 (11.79) 11.17 (9.51) Z=-.0.29, p=0.79 
Omission errors 0.00 (0.00) 0.33 (0.66) Z=-1.48, p=0.35 
Premature errors 2.71 (2.81) 1.43 (1.75) Z=-1.20, p=0.26 
Money won (£) 7.51 (3.55) 11.16 (5.46) t(270=-1.82, p=0.080 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
At baseline, 12-week non-responders had significantly lower levels of explicit adaptive 
salience than healthy controls (Z=-3.20, p=0.001). There were no significant 
differences between the groups on implicit adaptive salience, aberrant salience scores, 
errors or money won at baseline.  
3.2.2.2.2 Cross-sectional comparisons of follow up salience attribution in 12-week 
responders and non-responders  
a) Twelve-week responders versus non-responders 
I first assessed whether there were any follow up differences (after four weeks of 
treatment) between 12-week responders and non-responders. Table 28 provides 
salience measures for responders and non-responders at baseline.  
At follow up, 12-week responders and non-responders still differed on implicit aberrant 
salience scores (t(14)=-2.42, p=0.030) but there was no longer a significant difference 
the groups in money won (t(14)=-1.20, p=0.25). There were no other significant 
differences in adaptive salience, explicit aberrant salience or errors made. This 
suggests that despite treatment non-responders still had higher levels of aberrant 
salience than did responders.  
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Table 28: Measures of follow up salience attribution in 12-week responders and non-
responders  
 
Salience measure Responders (n=8) 
Non-responders 
(n=8) 
Test, sig.  
RT adaptive salience (ms) 21.92 (28.25) 5.31 (42.67) t(14)=1.06, p=0.31  
VAS adaptive salience 
(mm) 
26.44 (26.95) 34.79 (38.80) Z=-0.58, p=0.61 
RT aberrant salience (ms) 6.45 (4.65) 19.52 (15.97) 
t(14)=-2.42, 
p=0.030* 
VAS aberrant salience 
(mm) 
15.31 (11.84) 9.07 (2.04) t(13)=1.28, p=0.22 
Omission errors 0.00 (0.00) 0.00 (0.00) - 
Premature errors 1.13 (2.10) 0.71 (0.95) Z=-1.00, p=0.72 
Money won (£) 9.91 (3.14) 15.38 (8.26) t(14)=-1.20, p=0.25 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
b) Twelve-week responders versus healthy controls  
I next assessed whether there were any follow up differences between 12-week 
responders and healthy controls. Table 29 provides salience measures for responders 
and healthy controls at follow up.  
 
Table 29: Measures of follow up salience attribution in 12-week responders and healthy 
controls 
 
Salience measure Responders (n=8) 
Healthy 
controls (n=21) 
Test, sig.  
RT adaptive salience (ms) 21.92 (28.25) 18.12 (22.84) t(27)=0.38, p=0.71 
VAS adaptive salience 
(mm) 
26.44 (26.95) 72.90 (25.75) 
t(27)=-4.29, 
p<0.0001* 
RT aberrant salience (ms) 6.45 (4.65) 12.16 (7.74) t(27)=-1.95, p=0.062 
VAS aberrant salience 
(mm) 
15.31 (11.84) 11.10 (17.34) t(27)=0.63, p=0.53 
Omission errors 0.00 (0.00) 0.29 (0.64) Z=-1.30, p=0.46 
Premature errors 1.13 (2.10) 1.52 (1.63) Z=-1.12, p=0.30 
Money won (£) 9.91 (3.14) 11.74 (5.86) 
t(23.44)=-1.083, 
p=0.29 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
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After four weeks of treatment, 12-week responders still had lower explicit adaptive 
salience than healthy controls (t(27)=-4.29, p<0.0001). There were no significant 
differences in any other measures of salience at follow up between 12-week 
responders and healthy controls. 
c) Twelve-week non-responders versus healthy controls 
Finally, I assessed whether there were any follow up differences between 12-week 
non-responders and healthy controls. Table 30 provides salience measures for non-
responders and healthy controls at follow up.  
 
Table 30: Measures of follow up salience attribution in 12-week non-responders and 







Test, sig.  
RT adaptive salience (ms) 5.31 (42.67) 18.12 (22.84) t(27)=-1.23, p=0.23 
VAS adaptive salience (mm) 34.79 (38.80) 72.90 (25.75) Z=-2.39, p=0.014* 
RT aberrant salience (ms) 19.52 (15.97) 12.16 (7.74) t(27)=1.80, p=0.083 
VAS aberrant salience (mm) 9.07 (2.04) 11.10 (17.34) t(26)=-0.30, p=0.77 
Omission errors 0.00 (0.00) 0.29 (0.64) t(27)=-0.66, p=0.51 
Premature errors 0.71 (0.95) 1.52 (1.63) Z=-0.76, p=0.49 
Money won (£) 15.38 (8.26) 11.74 (5.86) t(27)=0.76, p=0.45 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
 
After four weeks of treatment, 12-week non-responders still had significantly lower 
explicit adaptive salience scores than healthy controls (Z=-2.39, p=0.014). There were 
no significant differences in any other measures of salience at follow up between 12-




3.2.2.2.3 Longitudinal effects of four-week antipsychotic treatment on clinical measures 
in 12-week responders  
To assess whether there were changes in any measures of salience within 12-week 
responders during four weeks of treatment, I compared baseline and follow up 
measures in this group (Table 31).  
In 12-week responders there was a significant decrease in implicit aberrant salience 
after four weeks of treatment (t(7)=3.37, p=0.012). There were no significant changes 
in any other salience measures, errors made or the amount of money won by 12-week 
responders. This suggests that in responders four weeks of antipsychotic treatment led 
to decreased levels of aberrant salience.  
 
Table 31: Measures of salience attribution at baseline and follow up in 12-week 
responders and non-responders 
 
Salience measure Baseline Follow up Test, sig.  
Responders  (n=10) (n=8)  
RT adaptive salience (ms) 11.54 (27.25) 21.92 (28.25) t(7)=-1.48, p=0.18 
VAS adaptive salience (mm) 15.56 (27.71) 26.44 (26.95) t(7)=-1.23, p=0.26 
RT aberrant salience (ms) 28.53 (19.94) 6.45 (4.65) t(7)=3.37, p=0.012* 
VAS aberrant salience (mm) 11.25 (11.78) 15.31 (11.84) Z=-0.70, p=0.48 
Omission errors 0.13 (0.35) 0.00 (0.00) Z=-1.00, p=0.32 
Premature errors 2.50 (3.74) 1.13 (2.10) Z=-1.83, p=0.068 
Money won (£) 12.80 (4.49) 9.91 (3.14) t(7)=2.040, p=0.081 
Non-responders  (n=8) (n=8)  
RT adaptive salience (ms) 6.67 (34.00) 5.31 (42.67) Z=-0.56, p=0.58 
VAS adaptive salience (mm) 6.07 (25.73) 34.79 (38.80) Z=-2.37, 0.018* 
RT aberrant salience (ms) 9.37 (4.61) 19.52 (15.97) t(7)=-1.87, p=0.10 
VAS aberrant salience (mm) 14.57 (11.79) 9.07 (2.04) t(6)=1.14, p=0.30 
Omission errors 0.00 (0.00) 0.00 (0.00) t(7)=-1.00, p=0.35 
Premature errors 2.71 (2.81) 0.71 (0.95) Z=-1.28, p=0.201 
Money won (£) 7.51 (3.55) 15.38 (8.26) t(7)=-2.35, p=0.051 
RT=reaction time; ms=milliseconds; VAS=visual analogue scale; mm=millimetres; *p<0.05 
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3.2.2.2.4 Longitudinal effects of four-week antipsychotic treatment on clinical measures 
in 12-week non-responders  
To assess whether there were changes in any measures of salience within 12-week 
non-responders during four weeks of treatment, I compared baseline and follow up 
measures in this group (Table 31). 
In 12-week non-responders there was a significant increase after four weeks of 
treatment in explicit adaptive salience (Z=-2.37, 0.018) but no changes in any other 
measure of salience, errors or money won. This suggests that whilst treatment does 
not decrease levels of aberrant salience in non-responders, it does increase their ability 
to differentiate between high- and low-probability cues at an explicit level.  
3.2.3 Associations between salience attribution measures and delusions 
Given that Roiser and colleagues (2009) reported a relationship between delusions and 
aberrant salience in treated patients with FEP, I also investigated whether there were 
differences in salience measures between patients with delusions and those without 
delusions at both baseline and four-week follow up. There was a trend for those with 
delusions at follow up to have higher implicit aberrant salience at follow up (t(18)=2.08, 
p=0.052), but this did not reach significance. I also found that patients without 
delusions at follow up had significantly higher baseline implicit adaptive salience than 
patients who were delusional at follow up (t(18.14)=-2.80, p=0.012). 
3.2.4 Neural activation associated with salience attribution in patients and healthy 
controls 
Here, I present the imaging data showing activation associated with measures of 
salience attribution in both patients and healthy controls. These analyses try to identify 
abnormalities in salience activation in patients with FEP. They also investigate the 
effects of antipsychotic treatment on neural activation in a group of previously 
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untreated patients with FEP. I present both cross-sectional and longitudinal analyses of 
neural activation in these groups.   
3.2.4.1 Neural activation associated with salience attribution at baseline 
Initially, random-effects group-level analyses, using a one-sample t-test in patients and 
healthy controls separately, were used to investigate group-level activation at baseline 
associated with each of the contrasts described in Methods (page 108): adaptive 
salience, aberrant salience, and outcome (response to parametrically mediated reward 
in the form of money from 0p – 100p, indicated on the screen). This analysis 
investigates the brain regions activated in association with salience processing in 
patients and healthy controls.  
a) Healthy controls  
Significant clusters of activation associated with adaptive salience, aberrant salience, 
and outcome in healthy controls at baseline are shown in Table 32 and Figure 12.  
 
Table 32: Areas of increased neural activation associated with measures of salience 
and trial outcomes in healthy controls at baseline 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (increases)        
 Superior temporal 
 gyrus 
L -54 -18 0 6.67 1173 <0.0001 
  R 68 -30 12 4.65 1120 <0.0001 
Adaptive salience (decreases)        
 Middle temporal gyrus R 56 -58 16 5.08 533 0.009 
Outcome (increases)        
 Middle frontal gyrus R 42 42 10 6.11 597 0.003 




At baseline, in healthy controls adaptive salience was associated with activation in two 
clusters (Table 32), in the superior temporal gyrus, bilaterally, and with a cluster of 
decreased activation in the posterior part of the right middle temporal gyrus, extending 
into the angular gyrus (Fig 12a). The outcome of trials (Table 32) was associated with 
activation in the right middle frontal gyrus and the left medial frontal gyrus (Fig 12b).  
 
 
Figure 12: Areas of increased (red) and decreased (blue) neural activation associated 
with a) adaptive salience and b) trial outcomes in healthy controls at baseline 
a) Healthy controls showed increased activation in superior temporal regions and decreased 
activation in middle temporal gyrus during adaptive salience processing at baseline; b) when 
presented with the outcome of trials, there was increased activation in frontal regions of healthy 
controls at baseline.  
 
b) Patients 
Significant clusters of activation associated with adaptive salience, aberrant salience, 










Table 33: Areas of increased neural activation associated with measures of salience 
and trial outcomes in patients at baseline. 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Outcome (increases)         
 Cingulate gyrus L -10 32 32 6.52 1007 <0.0001 
 Middle frontal gyrus R 36 6 44 5.11 580 0.003 
 Precentral gyrus L -38 0 36 5.06 580 0.032 
 Inferior frontal gyrus  L -46 22 -10 4.95 402 0.016 
 
At baseline, aberrant salience was not associated with any regions of significantly 
increased or decreased activation associated with aberrant salience in patients. 
Similarly, adaptive salience was not associated with any regions of significantly 
increased or decreased activation.  
In contrast, trial outcome in patients was associated with activation in four clusters 
(Table 33). The first was centred on the left cingulate, extending into the right medial 
frontal gyrus. The second was centred on the right middle frontal gyrus, extending into 
the right inferior frontal gyrus. The third was centred on the left precentral gyrus, 
extending into regions of the inferior frontal gyrus. The final cluster was centred on the 
left inferior frontal gyrus, extending into the middle temporal gyrus and temporal pole.  
 
Figure 13: Areas of increased activation associated with baseline outcomes in patients  
At baseline, when presented with the outcome of trials, there was increased activation in 
parietal, temporal, and frontal regions of patients.  
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3.2.4.2 Cross-sectional comparisons of salience activation in patients and healthy 
controls at baseline  
I compared patients and healthy controls at baseline using an exploratory voxel-wide 
search (paired t-test) with p<0.001, uncorrected. Clusters identified were then explored 
for suprathreshold statistics accepted at p<0.05 (FWE-corrected). These analyses 
explored between-group differences in activation when comparing patients and healthy 
controls, whilst completing the SAT at baseline.  
At baseline, there were no significant differences in activation between patients and 
healthy controls for adaptive salience, aberrant salience or outcome.  
3.2.4.3 Neural activation associated with salience attribution at four-week follow up 
Initially, random-effects group-level analyses, using a one-sample t-test in patients and 
healthy controls separately, were used to investigate group-level activation at follow up 
associated with each of the contrasts described in Methods (page 108): adaptive 
salience, aberrant salience, and outcome. 
a) Healthy controls  
Significant clusters of activation associated with adaptive salience, aberrant salience, 











Table 34: Areas of activation associated with measures of salience and trial outcomes 
in healthy controls at follow up 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (increases)        
 Superior temporal 
 gyrus 
R 62 -34 6 8.88 2295 <0.0001 
   L -40 -38 8 6.29 1339 <0.0001 
 Inferior occipital gyrus L -36 -70 -6 6.91 980 <0.0001 
 Precentral gyrus R 44 -2 48 5.38 915 <0.0001 
 Parahippocampal  L -14 -30 -14 5.34 822 0.001 
Outcome (increases)        
 Inferior parietal lobe R 46 -50 50 8.71 444 0.009 
  L -48 -40 50 5.22 526 0.004 
 Inferior temporal gyrus L -54 -54 -12 5.74 1985 <0.0001 
 Middle temporal gyrus  R 62 -50 -10 5.35 333 0.027 
 
At follow up, in healthy controls there was increased activation associated with 
adaptive salience in five significant clusters (Table 34). There were two clusters of 
significant activation in the superior temporal gyrus, one in each hemisphere. There 
was a third cluster centred on the left inferior occipital lobe, extending into the left 
middle occipital gyrus. A fourth cluster centred on the right precentral gyrus of the 
frontal lobe, extending into the inferior frontal lobe. A final cluster centred on the left 
parahippocampal region, extending into the midbrain close to the substantia nigra. 
There were no regions of significantly decreased activation associated with adaptive 
salience in healthy controls at follow up. There were no regions of significantly 
increased or decreased activation associated with aberrant salience in healthy controls 
at follow up.  
Several regions were activated in association with the outcome of trials (Table 34). 
Four clusters of significantly increased activation were found. There were two clusters 
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of significantly increased activation in the inferior parietal lobule, one in each 
hemisphere. There was also a cluster in the left inferior temporal gyrus, extending into 
the right vermis of the cerebellum. A further cluster was found in the right middle 
temporal gyrus including the fusiform gyrus and also extending into the right declive of 
the cerebellum.  
 
 
Figure 14: Areas of activation associated with a) adaptive salience and b) trial outcomes 
in healthy controls at follow up 
At follow up, a) healthy controls showed increased activation in temporal, occipital and frontal 
regions during adaptive salience processing; b) when presented with the outcome of trials, there 
was increased activation in parietal and temporal regions of healthy controls.  
 
b) Patients 
Significant clusters of activation associated with adaptive salience, aberrant salience, 









Table 35: Areas of increased neural activation associated with measures of salience 
and trial outcomes in patients at follow up 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (increases)        
 Superior temporal 
 gyrus 
R 60 -24 8 5.90 581 0.011 
  L -42 -36 10 7.41 834 0.002 
Outcome (increases)        
 Superior temporal 
 gyrus 
R 58 -12 -12 7.55 1184 <0.0001 
  L -32 4 -16 6.39 967 <0.0001 
 Inferior temporal 
 gyrus 
R 54 -52 -16 6.14 323 0.046 
    L -56 -66 -10 6.76 519 0.009 
 Inferior parietal lobe R 52 -46 50 7.03 692 0.002 
 Inferior frontal gyrus R 44 48 4 6.08 418 0.02 
 
At follow up, in patients there was increased activation associated with adaptive 
salience in two significant clusters (Table 35). These two clusters of significantly 
increased activation were centred in the superior temporal gyrus, one in each 
hemisphere, with activation on the left extending into the insula. There were no regions 
of significantly decreased activation associated with adaptive salience in patients at 
follow up. There were no regions of significantly increased or decreased activation 
associated with aberrant salience in patients at follow up.  
Several regions were activated in association with the outcome of trials (Table 35). Six 
clusters of significantly increased activation were found in patients. There were two 
clusters of significantly increased activation in the superior temporal gyrus, one in each 
hemisphere. There were also two clusters, one in each hemisphere, of significantly 
increased activation in the inferior temporal gyrus, extending on both sides into middle 
temporal gyrus. There were further regions of activation in the right inferior parietal lobe 
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and right inferior frontal gyrus. There were no regions of significantly decreased 
activation associated with outcome in patients at follow up. 
 
Figure 15: Areas of activation associated with a) adaptive salience and b) trial outcomes 
in patients at follow up 
At follow up, a) patients showed increased activation bilaterally in temporal cortex during 
adaptive salience processing; b) when presented with the outcome of trials, there was 
increased activation in parietal, temporal, and frontal regions of patients.  
 
3.2.4.4 Cross-sectional comparisons of salience activation in patients and healthy 
controls at four-week follow up 
I compared patients and healthy controls at follow up using an exploratory voxel-wide 
search with p<0.001, uncorrected. Clusters identified were then explored for 
suprathreshold statistics accepted at p<0.05 (FWE-corrected). These analyses 
explored between-group differences in neural activation when comparing patients and 
healthy controls, whilst completing the SAT at follow up.  
At follow up, there were no significant differences between patients and healthy 
controls for adaptive salience, aberrant salience or outcome.  
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3.2.4.5 Longitudinal effects of four-week antipsychotic treatment on neural activation 
underlying salience attribution 
To explore the effects of antipsychotic medications on neural activation, changes from 
baseline to follow up (after four weeks of treatment) were identified using an 
exploratory voxel-wide search performed with p<0.001, uncorrected. Clusters identified 
were then explored for suprathreshold statistics accepted at p<0.05 and FWE 
corrected.  
In patients, follow up scans, after four weeks of treatment, were compared with 
baseline scans, at which patients were antipsychotic-naïve/minimally treated, to identify 
any activation changes across treatment. Healthy controls were also analysed 
longitudinally, at baseline and four weeks later, to ensure that there were no changes 
between time points that might be due to practice effects or other confounders of no 
interest. As my results indicate, there were no changes in healthy controls 
longitudinally, which suggests a lack of learning effects.  
Patients at follow up relative to baseline showed no increases or decreases in neural 
activation associated with adaptive or aberrant salience, and no changes in activation 
associated with the outcome of trials. Across four weeks, healthy controls also showed 
no increases or decreases in neural activation in any region during adaptive or aberrant 
salience or during outcome.  
3.2.4.6 Region of interest analyses 
To specifically assess my proposed hypotheses, a ROI analysis was also executed to 
explore ventral striatal and dorsolateral PFC activation during aberrant salience 
processing in patients and healthy controls. No significant clusters were observed 




3.2.5 Neural activation underlying salience attribution in responders and non-
responders 
In these sections, I present data for neural activation underlying salience attribution for 
patients in relation to response to treatment at four and 12 weeks, to assess the 
associations of this measure with short- and longer-term treatment response. These 
analyses will reveal any potential differences in the activation patterns of responders 
and non-responders at both baseline and follow up, which could aid prediction of 
treatment response. I also explore the longitudinal changes seen in responders and 
non-responders, which will reveal whether antipsychotics affect the functional brain 
activity in these groups differently.  
3.2.5.1 Treatment response at four weeks 
Treatment response in the following analyses was determined at four weeks and 
defined according to the Andreasen (2005) criteria.  
3.2.5.1.1 Baseline neural activation associated with measures of salience attribution in 
four-week responders and non-responders  
Initially, I conducted random-effects group-level analyses using a one-sample t-test in 
four-week responders and non-responders separately to investigate group-level 
activation at baseline associated with each of the contrasts described in Methods (page 
108): adaptive salience, aberrant salience, and outcome. This analysis investigates the 
brain regions activated in association with salience processing in responders and non-
responders.  
a) Four-week responders  
Significant clusters of baseline activation associated with adaptive salience, aberrant 




Table 36: Areas of increased neural activation associated with measures of salience 
and trial outcomes in four-week responders at baseline 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (increases)        
 Inferior frontal gyrus L -38 28 16 7.80 490 0.006 
 Insula R 46 8 14 7.02 424 0.011 
 R 34 24 12 5.84 308 0.033 
Outcome (increases)        
 Medial frontal gyrus L -4 62 24 7.02 509 0.005 
 
At baseline, four-week responders had increased activation associated with adaptive 
salience in three significant clusters (Table 36). The first was centred on the left inferior 
frontal gyrus. The second and third centred on the insula, one of which extended into 
the right inferior and middle frontal gyri. There were no regions of significantly 
increased or decreased activation associated with aberrant salience in responders at 
baseline. At baseline, there was just one region of significantly increased activation 
associated with the outcome of trials in responders (Table 36). This cluster was centred 






Figure 16: Areas of activation associated with a) adaptive salience and b) trial outcomes 
in four-week responders at baseline 
At baseline, a) responders showed increased activation unilaterally in frontal cortex and the 
insula during adaptive salience processing; b) when presented with the outcome of trials, there 
was increased activation in the frontal cortex of responders.  
 
b) Four-week non-responders 
Significant clusters of baseline activation associated with adaptive salience, aberrant 
salience, and outcome in four-week non-responders are shown in Table 37 and Figure 
17.  
 
Table 37: Areas of increased baseline neural activation associated with measures of 
salience in 4-week non-responders  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE 
P 
value 
Adaptive salience (decreases)        
 Cerebellum (declive) R 14 -70 -28 7.06 367 0.004 
 
At baseline, there was one cluster of decreased activation associated with adaptive 
salience in four-week non-responders (Table 37). This was centred on the right 
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cerebellum in the declive, extending into the vermis of the cerebellum. There were no 
regions of increased activation associated with adaptive salience.  
There were no regions of significantly increased or decreased activation associated 
with aberrant salience or outcome in non-responders at baseline.  
 
 
Figure 17: Areas of decreased neural activation associated with trial outcomes in four-
week non-responders at baseline 
At baseline, non-responders showed decreased activation in the declive of the cerebellum 
during the outcome of trials.  
 
3.2.5.1.2 Cross-sectional comparisons of baseline salience activation in four-week 
responders and non-responders  
I was also interested in potential baseline differences in neural activation associated 
with response to treatment at four weeks. I explored these differences in two main 
ways. Firstly, I compared four-week responders with non-responders at baseline. 
Secondly, I compared each patient group with healthy controls.  
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To compare the groups, an exploratory voxel-wide search was first performed with 
p<0.001, uncorrected. Clusters identified were then explored for suprathreshold 
statistics accepted at p<0.05 (FWE-corrected).  
a) Four-week responders versus non-responders  
These analyses explored between-group differences in neural activation when 
comparing four-week responders and non-responders, whilst completing the SAT. 
Clusters of significantly different activation between responders and non-responders 
associated with adaptive salience, aberrant salience, and outcome at baseline are 
shown in Table 38 and Figure 18.  
 
Table 38: Areas of significantly different neural activation associated with measures of 
salience and trial outcomes in four-week responders and non-responders at baseline 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE 
P 
value 
Adaptive salience (responders > non-responders)     
 Insula R 44 4 14 5.75 337 0.042 
 Cerebellum (declive) R 4 -60 -22 4.78 360 0.034 
 
At baseline, responders had significantly greater activation than non-responders 
associated with adaptive salience processing in two clusters (Table 38). The first was 
centred on the right insula and extended into the right precentral gyrus and superior 
temporal gyrus. The second cluster was centred on the right declive of the cerebellum, 
extending into the left declive and right culmen. There were no regions of lower 
activation in responders than in non-responders during adaptive salience processing at 
baseline. Furthermore, no significant differences were found between responders and 





Figure 18: Regions of significantly different neural activation during adaptive salience in 
four-week responders compared with non-responders at baseline 
At baseline, responders had greater activation than non-responders in the insula and declive of 
the cerebellum during adaptive salience processing.  
 
b) Four-week responders versus healthy controls 
At baseline, four-week responders compared with healthy controls did not show any 
differences in activation during adaptive or aberrant salience. There were also no 
differences in activation elicited by the outcome of trials at baseline.   
c) Four-week non-responders versus healthy controls 
Clusters of significantly different activation between four-week non-responders and 
healthy controls associated with adaptive salience, aberrant salience, and outcome at 
baseline are shown in Table 39 and Figure 19.  
 
Table 39: Areas of significantly different neural activation associated with measures of 
salience and trial outcomes in non-responders and healthy controls at baseline 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (non-responders < healthy controls)    




At baseline, there was one region of significantly lower neural activation in four-week 
non-responders compared with healthy controls during adaptive salience (Table 39). 
This cluster was centred on the posterior lobe of the right cerebellum (declive) and 
extended into the left declive. There were no regions of greater neural activation in 
non-responders compared with healthy controls during adaptive salience at baseline. 
There were also no significant differences in neural activation between non-responders 
and healthy controls during aberrant salience or outcome before treatment.  
 
 
Figure 19: Regions of significantly different neural activation during adaptive salience in 
four-week non-responders compared healthy controls at baseline 
At baseline, non-responders had lower activation than healthy controls in the cerebellum during 
adaptive salience processing.  
 
3.2.5.1.3 Neural activation associated with measures of salience attribution in four-
week responders and non-responders at four-week follow up 
Initially, random-effects group-level analyses, using a one-sample t test in four-week 
responders and non-responders separately, were used to investigate group-level 
activation at follow up associated with each of the contrasts described in Methods 
(page 108): adaptive salience, aberrant salience, and outcome. 
a) Four-week responders  
Significant clusters of activation associated with adaptive salience, aberrant salience, 
and outcome in four-week responders after four weeks of treatment are shown in Table 
40 and Figure 20.  
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Table 40: Areas of increased neural activation associated with measures of salience 
and trial outcomes in four-week responders at four-week follow up. 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (increases)        
 Insula L -44 -20 2 6.63 393 0.026 
Outcome (increases)        
 Middle temporal gyrus R 52 -16 -12 12.92 1939 <0.0001 
  L -56 -68 2 7.64 1349 <0.0001 
 L -52 2 -22 7.36 776 <0.0001 
 Inferior parietal lobe R 48 -38 44 8.67 964 <0.0001 
   L -38 -44 34 5.14 259 0.04 
 Inferior frontal gyrus R 48 36 8 8.25 909 <0.0001 
 L -42 42 0 6.18 409 0.007 
 Posterior cingulate L -4 -54 10 7.34 1632 <0.0001 
 Putamen R 28 -4 10 6.88 330 0.017 
 
At follow up, in responders there was increased activation associated with adaptive 
salience in one significant cluster (Table 40). This cluster of significantly increased 
activation was centred on the left insula, extending into the superior temporal gyrus and 
the middle occipital gyrus. There were no regions of significantly decreased activation 
associated with adaptive salience in responders at follow up. There were no regions of 
significantly increased or decreased activation associated with aberrant salience in 
responders at follow up.  
Several regions were activated in association with the outcome of trials in four-week 
responders at follow up (Table 40). Nine clusters of significantly increased activation 
were found in these patients. Both left and right middle temporal gyri were activated, 
with a single cluster on the right extending into temporal pole and two clusters on the 
left, one of which extended into the thalamus and the other extending into superior 
temporal gyrus. The inferior frontal gyrus was also activated in both hemispheres, 
186 
 
extending into middle frontal gyrus on both the left and right. Similarly, there were two 
clusters of significantly increased activation in the inferior parietal lobe, one in each 
hemisphere. Another significant cluster of activation was seen in the left posterior 
cingulate of the limbic lobe, extending into the thalamus. The final cluster was centred 
on the right putamen, extending into the caudate. There were no regions of significantly 
decreased activation associated with outcome in responders at follow up. 
 
 
Figure 20: Areas of activation associated with a) adaptive salience and b) trial outcomes 
in four-week responders at four-week follow up 
At follow up, responders showed greater activation than non-responders a) during adaptive 
salience processing in the left temporal cortex and b) in multiple regions in temporal, parietal, 
and frontal cortex, and in the putamen when presented with the outcome of trials,.  
 
b) Four-week non-responders 
Significant clusters of activation associated with adaptive salience, aberrant salience, 
and outcome in four-week non-responders at follow up are shown in Table 41 and 
Figure 21.  
187 
 
Table 41: Areas of increased neural activation associated with measures of salience 
and trial outcomes in four-week non-responders at 4-week follow up. 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE 
P 
value 
Aberrant salience (decreased)        
 Superior occipital lobe L 0 -84 12 8.73 236 0.017 
 
After four weeks of treatment, in four-week non-responders there were no regions of 
increased or decreased activation associated with adaptive salience.  
There was one cluster of decreased activation associated with aberrant salience (Table 
41). This cluster was centred in the cuneus of the superior occipital lobe, extending into 
the middle occipital gyrus. There were no regions of significantly increased activation 
associated with aberrant salience in non-responders after treatment. 
There were no regions of significantly increased or decreased activation associated 
with outcome in non-responders at follow up.  
 
 
Figure 21: Areas of increased neural activation associated with aberrant salience in four-
week four-week non-responders at four-week follow up 




3.2.5.1.4 Cross-sectional comparisons of four-week follow up salience activation in 
four-week responders and non-responders  
As with baseline data, I also investigated potential differences in neural activation 
associated with response to treatment at four weeks in two main ways. Firstly, I 
compared four-week responders with non-responders at follow up. Secondly, I 
compared each patient group with healthy controls.  
To compare the groups, an exploratory voxel-wide search was first performed with 
p<0.001, uncorrected. Clusters identified were then explored for suprathreshold 
statistics accepted at p<0.05 (FWE-corrected).  
a) Four-week responders versus non-responders  
These analyses explored between-group differences in activation when comparing 
four-week responders and non-responders, whilst completing the salience attribution 
task (SAT). Clusters of significantly different activation between responders and non-
responders associated with adaptive salience, aberrant salience, and outcome after 
four weeks of treatment are shown in Table 42 and Figure 22.  
 
Table 42: Areas of significantly different neural activation associated with measures of 
salience and trial outcomes in four-week responders and non-responders at four-week 
follow up. 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE 
P 
value 
Adaptive salience (responders > non-responders)     
 Midbrain R 6 -2 -12 4.84 739 0.004 
 
After four weeks of treatment, there was one significant cluster of greater activation in 
four-week responders than in non-responders during adaptive salience processing 
(Table 42). This cluster was centred on the brain stem, extending across the midbrain, 
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close to the hypothalamus and substantia nigra. There were no regions of lower 
activation in responders than in non-responders during adaptive salience processing. 
Furthermore, no significant differences were found between responders and non-
responders in activation during aberrant salience or outcome after treatment.   
 
 
Figure 22: Regions of significantly different neural activation during adaptive salience in 
four-week responders compared with non-responders at four-week follow up 
At follow up, responders had greater activation than non-responders in the midbrain during 
adaptive salience processing.  
 
b) Four-week responders versus healthy controls 
Clusters of significantly different activation between four-week responders and healthy 
controls associated with adaptive salience, aberrant salience, and outcome at four-





Table 43: Areas of significantly different neural activation associated with measures of 
salience and trial outcomes in four-week responders and healthy controls at four-week 
follow up. 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE 
P 
value 
Outcome (responders > healthy controls)     
 Middle temporal lobe L -44 -42 8 5.80 375 0.027 
 
After four weeks of treatment, neural activation in four-week responders compared with 
healthy controls did not differ during adaptive or aberrant salience. There was one 
cluster in which responders had higher activation than healthy controls associated with 
the outcome of trials (Table 43). This cluster was centred on the middle temporal lobe, 
extending across the superior temporal gyrus and putamen. There were no regions in 
which responders had lower activation than healthy controls associated with the 








Figure 23: Areas of significantly different neural activation associated with trial outcomes 
in 4-week responders and healthy controls at four-week follow up  
At follow up, responders had greater activation than healthy controls in the middle temporal 
gyrus during presentation of the trial outcomes.  
 
c) Four-week non-responders versus healthy controls 
Clusters of significantly different activation between four-week non-responders and 
healthy controls associated with adaptive salience, aberrant salience, and outcome at 
four-week follow up are shown in Table 44 and Figure 24.  
 
Table 44: Areas of significantly different activation associated with measures of 
salience and trial outcomes in four-week non-responders and healthy controls at four-
week follow up. 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (non-responders < healthy controls)    




After four weeks of treatment, there was one region of significantly lower activation in 
non-responders compared with healthy controls during adaptive salience (Table 44). 
This cluster was centred on the brain stem close to the substantia nigra, extending into 
the right parahippocampal region. There were no regions of greater neural activation in 
non-responders compared with healthy controls during adaptive salience. There were 
no significant differences in neural activation between non-responders and healthy 
controls during aberrant salience or outcome at follow up.  
So in responders, normal midbrain dopamine function is maintained following D2 
blockade (no difference between responders and controls), whereas in non-responders 
the midbrain is underactive following treatment, relative to both responders and 
controls In other words, in non-responders, antipsychotics fail to maintain normal 
dopamine function. Because this difference wasn’t evident at baseline, it must reflect a 
differential effect of antipsychotic treatment on midbrain dopamine function in 
responders and non-responders.  
 
 
Figure 24: Areas of significantly different neural activation associated with trial outcomes 
in 4-week non-responders and healthy controls at four-week follow up  
At follow up, non-responders had lower activation than healthy controls in the midbrain 








3.2.5.1.5 Longitudinal effects of four-week antipsychotic treatment on neural activation 
underlying salience attribution in four-week responders  
Neural activation in responders after four weeks of treatment was compared with 
baseline scans at which patients were antipsychotic-naïve/minimally treated, to identify 
any activation changes related to a good response to treatment.  
During four weeks of treatment, four-week responders showed no increases or 
decreases in neural activation associated with adaptive or aberrant salience, and no 
changes in activation associated with the outcome of trials.  
3.2.5.1.6 Longitudinal effects of four-week antipsychotic treatment on neural activation 
underlying salience attribution in four-week non-responders  
Neural activation in four-week non-responders after four weeks of treatment was 
compared with baseline scans at which patients were antipsychotic-naïve/minimally 
treated, to identify any activation changes related with a poor response to treatment.  
Clusters of significantly changed activation in responders associated with adaptive 
salience, aberrant salience, and outcome are shown in Table 45 and Figure 25. 
  
Table 45: Areas of significantly altered neural activation following treatment associated 
with measures of salience and trial outcomes in four-week responders and non-
responders  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
a) Responders        
 No suprathreshold clusters       
b) Non-responders        
Adaptive salience (baseline < follow up)    
 Cerebellum (declive) L -20 -70 -34 19.68 958 <0.0001 




During four weeks of treatment, four-week non-responders had increased neural 
activation at follow up compared with baseline in two clusters during adaptive salience 
processing (Table 45). These clusters were both in the cerebellum, with one in each 
hemisphere. There were no regions of decreased activation at follow up associated 
with adaptive salience. There were also no regions of either increased or decreased 




Figure 25: Areas of significantly altered neural activation following treatment associated 
with adaptive salience in four-week non-responders  
Non-responders showed decreases in bilateral cerebellum during adaptive salience processing 
following four weeks of antipsychotic treatment.  
 
3.2.5.1.7 Region of interest analyses 
To specifically assess my proposed hypotheses, a ROI analysis was also executed to 
explore ventral striatal and dorsolateral PFC activation during aberrant salience 
processing in four-week responders and non-responders. No significant clusters were 
observed following this analysis at baseline or four-week follow up.  
3.2.5.2 Treatment response at 12 weeks 





3.2.5.1.1 Baseline neural activation associated with measures of salience attribution in 
12-week responders and non-responders  
Initially, random-effects group-level analyses, using a one-sample t test in 12-week 
responders and non-responders separately, were used to investigate group-level 
activation at baseline associated with each of the contrasts described in Methods (page 
108): adaptive salience, aberrant salience, and outcome.  
a) Twelve-week responders 
At baseline, there was no significant activation in 12-week responders during adaptive 
salience, aberrant salience or outcome.  
b) Twelve-week non-responders 
At baseline, there was no significant activation in 12-week non-responders during 
adaptive salience, aberrant salience or outcome.  
3.2.5.1.2 Cross-sectional comparisons of baseline salience activation in 12-week 
responders and non-responders  
I was also interested in potential differences in neural activation associated with 
response to treatment at 12 weeks. I explored these differences in two main ways. 
Firstly, I compared 12-week responders with non-responders at baseline. Secondly, I 
compared each patient group with healthy controls.  
To compare the groups, an exploratory voxel-wide search was first performed with 
p<0.001, uncorrected. Clusters identified were then explored for suprathreshold 
statistics accepted at p<0.05 (FWE-corrected).  
a) Twelve-week responders versus non-responders 
These analyses explored between-group differences in neural activation when 
comparing 12-week responders and non-responders, whilst completing the salience 
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attribution task (SAT). Clusters of significantly different activation between responders 
and non-responders associated with adaptive salience, aberrant salience, and outcome 
at baseline are shown in Table 46 and Figure 26.  
 
Table 46: Areas of significantly different neural activation associated with measures of 
salience and trial outcomes in 12-week responders and non-responders at baseline 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE 
P 
value 
Adaptive salience (responders > non-responders)     
 Superior temporal 
 lobe 
L -56 -34 20 6.67 539 0.004 
 Middle occipital lobe L -20 -78 18 5.87 293 0.042 
 
At baseline, responders had significantly greater activation than non-responders 
associated with adaptive salience processing in two clusters (Table 46). The first was 
centred on the left superior temporal lobe in the region of the insula, extending into the 
left supramarginal gyrus and left postcentral gyrus. The second cluster was centred on 
the left middle occipital lobe extending into the cuneus. There were no regions of lower 
activation in responders than in non-responders during adaptive salience processing at 
baseline. Furthermore, no significant differences were found between responders and 
non-responders in activation during aberrant salience or outcome before treatment.  
 
Figure 26: Areas of significantly different neural activation associated with adaptive 
salience in 12-week responders and non-responders at baseline 
At baseline, responders had greater activation than non-responders in the superior temporal 
lobe and middle occipital lobe during adaptive salience processing.  
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b) Twelve-week responders versus healthy controls 
At baseline, 12-week responders compared with healthy controls did not show any 
differences in activation during adaptive or aberrant salience. There were also no 
differences in activation elicited by the outcome of trials at baseline.   
c) Twelve-week non-responders versus healthy controls 
Clusters of significantly different activation between 12-week non-responders and 
healthy controls associated with adaptive salience, aberrant salience, and outcome at 
baseline are shown in Table 47 and Figure 27.  
 
Table 47: Areas of significantly different neural activation associated with measures of 
salience and trial outcomes in 12-week non-responders and healthy controls at 
baseline 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (non-responders < healthy controls)    
 Cerebellum (declive) L -16 -76 -26 5.48 3810 <0.0001 
 
At baseline, there was one region of significantly lower neural activation in 12-week 
non-responders compared with healthy controls during adaptive salience (Table 47). 
This cluster was centred on the declive of the left cerebellum and extended into the left 
lingual gyrus. There were no regions of greater neural activation in non-responders 
compared with healthy controls during adaptive salience at baseline. There were also 
no significant differences in neural activation between non-responders and healthy 




Figure 27: Areas of significantly different neural activation associated with adaptive 
salience in 12-week non-responders and healthy controls at baseline 
At baseline, non-responders had lower activation than healthy controls in the cerebellum during 
adaptive salience processing.  
 
3.2.5.1.3 Neural activation associated with measures of salience attribution in 12-week 
responders and non-responders at four-week follow up 
Initially, random-effects group-level analyses, using a one-sample t-test in 12-week 
responders and non-responders separately, were used to investigate group-level 
activation at four-week follow up associated with each of the contrasts described in 
Methods (page 108): adaptive salience, aberrant salience, and outcome. 
a) Twelve-week responders 
Significant clusters of activation associated with adaptive salience, aberrant salience, 
and outcome in 12-week responders after four weeks of treatment are shown in Table 












Table 48: Areas of increased neural activation associated with measures of salience 
and trial outcomes in 12-week responders at 4-week follow up. 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Adaptive salience (increases)        
 Superior temporal 
 lobe 
L -42 -26 2 10.84 507 <0.0001 
Adaptive salience (decreases)        
 Superior frontal gyrus L -14 42 36 7.75 214 0.017 
Outcome (increases)        
 Cerebellum R 2 -82 -28 11.60 423 <0.0001 
 Middle temporal gyrus R 62 -50 -4 12.20 207 0.02 
  R 64 -18 -12 15.47 157 0.057** 
 Inferior parietal lobe R 50 -40 38 8.84 162 0.051** 
 Inferior frontal gyrus R 48 42 4 12.22 160 0.053** 
 
At follow up, in responders there was increased activation associated with adaptive 
salience in one significant cluster (Table 48). This cluster of significantly increased 
activation was centred on the left superior temporal lobe. There were also one 
significant cluster of significantly decreased activation associated with adaptive 
salience in responders at follow up. This cluster was centred on the left superior frontal 
gyrus. There were no regions of significantly increased or decreased activation 




Figure 28a: Areas of significantly increased (red) and decreased (blue) neural activation 
associated with adaptive salience in 12-week responders at four-week follow up 
At follow up, adaptive salience processing in responders was associated with a) increased 
activation in superior temporal lobe and b) decreased activation in the superior frontal gyrus. 
 
There were two regions of significantly increased activation in association with the 
outcome of trials in responders at follow up, as well as three clusters of activation that 
neared significance (Table 48). The first significant cluster was centred on the 
cerebellum. The second was centred on the right middle temporal gyrus. There was 
also another cluster of activation that neared significance in the right middle temporal 
gyrus. A cluster of activation in the right supramarginal gyrus of the inferior parietal 
gyrus neared significance, as did a cluster of activation in the right inferior frontal gyrus, 
which extended into the middle frontal gyrus. There were no regions of significantly 





Figure 28b: Areas of significantly increased neural activation associated with the 
outcome of trials in 12-week responders at four-week follow up 
At follow up, the outcome of trials in responders was associated with increased activation in the 
cerebellum, middle temporal gyrus, inferior parietal lobe, and inferior frontal gyrus. 
 
b) Twelve-week non-responders 
At follow up, there was no significant activation in 12-week non-responders during 
adaptive salience, aberrant salience or outcome.  
3.2.5.1.4 Cross-sectional comparisons of salience activation in 12-week responders 
and non-responders at four-week follow up 
As with baseline data, I also investigated potential differences in neural activation 
associated with response to treatment at 12 weeks in two main ways. Firstly, I 
compared 12-week responders with non-responders at four-week follow up. Secondly, I 
compared each patient group with healthy controls.  
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To compare the groups, an exploratory voxel-wide search was first performed with 
p<0.001, uncorrected. Clusters identified were then explored for suprathreshold 
statistics accepted at p<0.05 (FWE-corrected).  
a) Twelve-week responders versus non-responders 
After four weeks of treatment, 12-week responders compared with non-responders did 
not show any differences in activation during adaptive or aberrant salience. There were 
also no differences in activation elicited by the outcome of trials at follow up.   
b) Twelve-week responders versus healthy controls 
After four weeks of treatment, 12-week responders compared with healthy controls did 
not show any differences in activation during adaptive or aberrant salience. There were 
also no differences in activation elicited by the outcome of trials at follow up. 
c) Twelve-week non-responders versus healthy controls 
Clusters of significantly different activation between 12-week non-responders and 
healthy controls associated with adaptive salience, aberrant salience, and outcome at 
four-week follow up are shown in Table 49 and Figure 29.  
 
Table 49: Areas of significantly different neural activation associated with measures of 
salience and trial outcomes in 12-week non-responders and healthy controls at 4-week 
follow up. 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Aberrant salience (non-responders < healthy controls)    
 Frontal lobe  L -18 -38 30 5.44 903 0.001 
 Posterior 
 cingulate/thalamus 




After four weeks of treatment, there were no regions of significantly different neural 
activation between 12-week non-responders and healthy controls during adaptive 
salience processing. There were two clusters of significantly lower neural activation in 
12-week non-responders compared with healthy controls during aberrant salience 
(Table 49). The first cluster was centred on left frontal lobe, extending into the inferior 
parietal lobule and right precuneus. The second cluster was centred on right posterior 
cingulate, extending into bilateral thalamus. There were no regions of greater neural 
activation in non-responders compared with healthy controls during aberrant salience. 
There were no significant differences in neural activation between non-responders and 
healthy controls during outcome at follow up.  
 
 
Figure 29: Areas of significantly different neural activation in 12-week non-responders 
compared with healthy controls associated with aberrant salience at four-week follow up 
At follow up, the outcome of trials in responders was associated with increased activation in the 





3.2.5.1.5 Longitudinal effects of four-week antipsychotic treatment on neural activation 
underlying salience attribution in 12-week responders  
In 12-week responders, I compared neural activation after four weeks of treatment in 
with baseline scans at which patients were antipsychotic-naïve/minimally treated. This 
aimed to identify activation changes related to a good response to treatment. Clusters 
of significantly changed activation in 12-week responders associated with adaptive 
salience, aberrant salience, and outcome are shown in Table 50 and Figure 30.  
 
Table 50: Areas of significantly altered neural activation following treatment associated 
with measures of salience and trial outcomes in 12-week responders and non-
responders  
Coordinates are shown in MNI space. P values have been corrected for multiple comparisons 
across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
a) Responders        
 No suprathreshold clusters       
b) Non-responders        
Outcome (baseline > follow up)    
 Middle occipital gyrus L -40 -78 0 3.87 186 0.033 
 
During four weeks of treatment, 12-week responders showed no increases or 
decreases in neural activation associated with adaptive or aberrant salience, and no 
changes in activation associated with the outcome of trials.  
3.2.3.1.6 Longitudinal effects of four-week antipsychotic treatment on neural activation 
underlying salience attribution in 12-week non-responders  
After four weeks of treatment, 12-week non-responders had decreased neural 
activation in one cluster during outcome (Table 50). This cluster was centred in the left 
middle occipital gyrus. There were no regions of increased neural activation associated 
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with treatment in non-responders during the outcome of trials. There were also no 
regions of altered activation associated with either adaptive or aberrant salience.  
 
 
Figure 30: Areas of significantly altered neural activation following treatment associated 
with outcome to trials in 12-week non-responders  
Non-responders showed decreases in the middle occipital gyrus following four weeks of 
antipsychotic treatment.  
 
3.2.6 Chapter summary 
In this chapter, I have described the effects of antipsychotic treatment on behavioural 
measures of salience attribution and the associated neural activation. Furthermore, I 
explored the relationships between these measures at baseline and after four weeks of 
treatment, and treatment response assessed at four or 12 weeks.  
At the behavioural level, there were relatively few differences in salience attribution 
measures between the whole patient group and healthy controls at either baseline or 
follow up. Patients had similar levels of implicit adaptive salience but had lower levels 
of explicit adaptive salience at baseline and follow up, suggesting they were less 
conscious of the relationships between cues and reward that their responses indicated 
they had learned, even after treatment. Unexpectedly, there was no evidence of 
increased aberrant salience in the patient group at either baseline or follow up. 
Furthermore, in the patient group overall, treatment was not associated with significant 
longitudinal changes in any of the salience measures.  
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More striking results were evident when patients were subdivided according to their 
response to treatment. A good response at both four weeks and 12 weeks was 
associated with higher implicit adaptive salience scores at baseline. Responders at four 
weeks showed a significant decrease in implicit aberrant salience with treatment, which 
was not seen in non-responders. After four weeks of treatment, responders had 
significantly lower levels of implicit aberrant salience than non-responders. Responders 
at 12 weeks also showed a significant reduction in implicit aberrant salience that was 
not seen in 12-week non-responders.   
In both the total patient group and in healthy controls, trial outcome was associated 
with activation in frontal regions, although the precise location of the regions differed 
between the groups. In healthy controls, adaptive salience was associated with 
activation in the superior temporal gyrus. In patients neither adaptive nor aberrant 
salience were associated with significant activation. Comparison of the patient and 
control groups failed to reveal any significant differences in activation associated with 
any salience measure, either at baseline or follow up.  
As with the behavioural data, differences became much more apparent when the 
patients were subdivided according to therapeutic response at four weeks. When 
compared at baseline, responders showed greater activation than non-responders 
when processing adaptive salience in the insula and cerebellum. At follow up, 
responders had higher activation in association with adaptive salience in the midbrain. 
There were no longitudinal changes in activation with treatment in responders, whereas 
non-responders showed bilateral increases in cerebellar activation. There were no 
significant differences between responders and healthy controls at baseline, but at 
follow up, responders showed greater activation during the presentation of trial 
outcomes in the middle temporal lobe. Non-responders showed lower activation during 
adaptive salience than healthy controls in the cerebellum at baseline, and in the 
brainstem at four-week follow up. 
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When patients were subdivided by their response at 12 weeks, responders and non-
responders differed in activation during adaptive salience processing in the superior 
temporal and middle occipital lobes at baseline, but there were no differences at follow 
up. Similar to four-week responders, those designated as responders at 12 weeks did 
not show any differences compared with healthy controls at either baseline or follow 
up. Non-responders, however, had lower activation during adaptive salience compared 
with healthy controls at baseline and follow up. At baseline, this was found in the 
cerebellum, but at follow up there was lower activation in the frontal lobe and posterior 
cingulate.  
The results in this chapter suggest that while there are some differences between 
patients and controls in salience processing, there are more striking behavioural and 
neural differences when patients are subdivided according to their response to 
antipsychotic treatment. Moreover, at both the behavioural and neural level, these 




3.3 The effects of antipsychotics on resting cerebral blood flow (rCBF) 
using continuous spin labelling (cASL) 
In this chapter, I present the results from the analysis of the perfusion data, using a 
resting-state ASL technique that allows the visualisation CBF in patients and healthy 
controls at rest.  
I begin by presenting cross-sectional data comparing antipsychotic-naïve patients with 
healthy controls. This will explore whether rCBF in patients before treatment differs 
from rCBF in healthy individuals (suggesting potential perfusion abnormalities relating 
to the pathophysiology of their illness). I then present a cross-sectional analysis of 
patients after four weeks of treatment compared with healthy controls. This comparison 
will explore whether any differences between these groups, that may have been 
present at baseline, are still present following four weeks treatment.  
In this chapter, I will then present longitudinal analyses exploring the effect of 
antipsychotic medication on rCBF in patients. In these analyses, I compare rCBF maps 
at baseline and follow up in the same patients. For completion, and to check stability of 
rCBF measurements over the duration for which patients were treated, I also present 
longitudinal assessments of healthy individuals, comparing baseline and follow up 
scans for any altered patterns of rCBF over four weeks.  
Finally, I will assess the relationship between antipsychotic treatment response and 
rCBF. I do this by first exploring patterns of rCBF in good and poor treatment 
responders cross-sectionally at baseline and follow up, with one another and with 
healthy controls. I then assess longitudinal changes in rCBF seen in each of these 
groups individually. These analyses are carried out with response to treatment 




For each of these analyses, I first explore the whole brain in a voxel-wise manner. I 
then present region of interest (ROI) analyses for the hippocampus, caudate, and 
putamen. 
Hypotheses tested: 
 At baseline, I would expect to see decreased striatal perfusion and increased 
frontal and hippocampal perfusion in patients compared with healthy controls.  
 At follow up, I would expect increased resting striatal perfusion and decreased 
frontal and hippocampal perfusion in patients compared with healthy controls. 
To assess the relationship between perfusion and clinical or behavioural measures, I 
conducted correlational analyses using extracted values for the whole brain and for the 
clusters where significant increases or decreases were observed. Where variables 
were normally distributed, Pearson’s correlations were calculated. Where variables 
were non-normally distributed, Spearman’s correlations were calculated.   
As previously mentioned, one participant did not take part in the cASL arm of the study 
(Table 51). Unless otherwise stated, all participants who completed the cASL paradigm 
(n=24) were included in the analyses.  
 
Table 51: Patients not included in cASL analysis 
Patient ID Reason for non-inclusion 
2208 
Error in writing image files – images not 





3.3.1 Resting CBF in patients and healthy controls 
I first considered patterns of resting perfusion in the entire patient group and the 
healthy controls. These analyses try to identify the presence of any abnormalities in 
patterns of rCBF in patients with FEP before treatment. They also investigate the 
effects of antipsychotic treatment on rCBF in a group of previously untreated patients 
with FEP. 
3.3.1.1 Global rCBF in patients and healthy controls at baseline 
At baseline, patients had a mean global rCBF of 314.42 ml blood/100g tissue/minute 
(S.D. 74.74), whilst healthy controls had a mean of 312.84 ml blood/100g tissue/minute 
(S.D. 77.80). These values were not significantly different (t(44)=0.031, p=0.98).  
3.3.1.2 Cross-sectional comparisons of rCBF in patients and healthy controls at 
baseline 
Initially, patients and healthy controls were compared at baseline using an exploratory 
voxel-wide search with p<0.01, uncorrected. Clusters identified were then explored for 
suprathreshold statistics and accepted at p<0.05. These were FWE-corrected for 
multiple comparisons, covarying for global rCBF.  
Figure 31 and table 52 show clusters of significantly different rCBF in patients and 










Table 52: Areas of significantly different rCBF in patients and healthy controls at 
baseline  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Patients < Healthy controls 
       
 Middle temporal gyrus L -46 -68 28 6.28 4753 <0.0001 
 Precuneus L -6 -54 38 4.07 1662 0.02 
 
Patients showed no regions of greater rCBF than healthy controls. However, they did 
show two clusters of lower rCBF than healthy controls. The first cluster was centred on 
the left middle temporal gyrus, extending into the superior temporal lobe and the left 
inferior parietal lobe. The second cluster was centred on the left precuneus of the 
parietal lobe, extending into the left frontal lobe.  
 
 
Figure 31: Perfusion differences between patients and healthy controls at baseline  
Lower resting perfusion (blue) in patients compared with healthy controls before treatment was 
seen in temporal and parietal regions 
 
3.3.1.3 Global rCBF in patients and healthy controls at follow up 
Patients and healthy control did not have significantly different global rCBF at follow up 
(t(39)=-0.98, p=0.33). Patients had a mean of 296.64 ml blood/100g tissue/minute 
(S.D. 60.21) and healthy controls had a mean of 316.65 ml blood/100g tissue/minute 
(S.D. 72.22).  
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3.3.1.4 Cross-sectional comparisons of rCBF in patients and healthy controls at follow 
up 
As at baseline, patients and healthy controls were compared at follow up using an 
exploratory voxel-wide search with p<0.01, uncorrected. Clusters identified were then 
explored for suprathreshold statistics and accepted at p<0.05. These were FWE-
corrected for multiple comparisons, covarying for global rCBF. 
 
Table 53: Areas of significant rCBF differences in patients and healthy controls at 
follow up 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE 
P 
value 
Patients > Healthy controls        
 Superior temporal lobe L -44 -6 -12 3.98 2490 0.003 
 
Figure 32 and Table 53 show clusters of significantly different rCBF in patients and 
healthy controls at follow up.  
Patients showed significantly greater rCBF than healthy controls in one cluster. This 
cluster was centred on the left superior temporal lobe and extended into the left 
temporal pole. There were no regions of significantly lower rCBF in patients compared 






Figure 32: Perfusion differences between patients and healthy controls at follow up 
Higher resting perfusion (red) in patients compared with healthy controls after treatment was 
seen in temporal lobe. 
 
3.3.1.5 Correlations between rCBF and clinical measures in patients 
Significant clusters from the above cross-sectional analyses were extracted and 
correlational analyses with clinical and behavioural measures were conducted to 
explore relationships between differences in these regions and clinical changes in 
patients.  
(i) PANSS scores 
There were no significant correlations between PANSS scores and clusters in which 
there was either baseline or follow up rCBF differences between patients and healthy 
controls.   
(ii) CGI 
There were no significant correlations between CGI scores and clusters in which there 






There were no significant correlations between PSP scores and clusters in which there 
was either baseline or follow up rCBF differences between patients and healthy 
controls.  
(iv) CDSS 
Lower perfusion at baseline in the middle temporal gyrus was significantly correlated 
with higher scores on the CDSS at baseline (r=-0.51, p=0.018), indicating that the 
presence of depressive symptoms was associated with lower perfusion in this region. 
There were no significant correlations between any other clusters in which rCBF was 
significantly different in patients compared with healthy controls and CDSS scores at 
either baseline or follow up.   
(v) Antipsychotic dose 
Higher perfusion in the superior temporal lobe at follow up was significantly associated 
with higher antipsychotic dose (n=14, r=0.56, p=0.038). 
(vi) Salience attribution  
There were no significant correlations between clusters in which rCBF was significantly 
different in patients compared with healthy controls and salience scores at either 
baseline or follow up.   
3.3.1.6 Longitudinal effects of four-week antipsychotic treatment on rCBF 
To explore the effects of antipsychotic medications on cerebral perfusion, changes 
from baseline to follow up were identified using an exploratory voxel-wide search 
performed with p<0.01, uncorrected. Clusters identified were then explored for 
suprathreshold statistics accepted at p<0.05 and FWE-corrected for multiple 
comparisons. For completeness, and to ensure that rCBF measurements were stable 
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over time in my healthy control sample, I also implemented longitudinal analyses of 
healthy controls over four weeks to assess for rCBF changes across this period without 
any intervention.   
As reported above, extracted global rCBF values showed that patients had a mean of 
319.77 ml blood/100g tissue/minute (S.D. 72.29) at baseline, and a mean of 296.64 ml 
blood/100g tissue/minute (S.D. 60.21) at follow up. This change represented a 
significant decrease in global rCBF over four weeks treatment (t(18)=2.22, p=0.039). 
Healthy controls had a mean of 312.87 ml blood/100g tissue/minute (S.D. 77.80) at 
baseline and a mean of 316.65 ml blood/100g tissue/minute (S.D. 72.22) at follow up. 
There was no significant change in global rCBF in healthy controls across four weeks 
(t(21)=-0.57, p=0.58). 
Table 54 and Figure 33 show clusters of significantly altered rCBF in patients following 
four-week antipsychotic treatment.  
 
Table 54: Areas of significant rCBF changes in patients after 4 weeks treatment 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE 
P 
value 
Follow up > Baseline  
 Superior parietal 
 lobe 
L -24 -54 58 4.28 2753 0.001 
 
Patients at follow up relative to baseline showed one cluster of significantly increased 
rCBF. This cluster was centred on the left superior parietal lobe and extended into left 





Figure 33: Perfusion differences at follow up compared with baseline in patients 
following four weeks’ treatment 
In patients, four weeks of treatment led to increased perfusion (red) in the parietal lobe. 
 
3.3.1.7 Region of interest analyses 
ROIs were examined to explore a priori hypotheses of expected differences between 
patients and healthy controls in the hippocampus, caudate, and putamen at baseline 
and follow up. There were no significant differences between patients and healthy 
controls in any of these regions, at either baseline or follow up.  
To specifically assess my proposed hypotheses regarding alterations in rCBF following 
treatment, a ROI analysis was also executed to explore changes in patients in striatal, 
frontal, and hippocampal perfusion. There were no significant increases or decreases 
in rCBF in any of the ROIs in patients over the four weeks.  
3.3.2 Resting CBF in responders and non-responders 
In these sections, I present rCBF data for patients in relation to response to treatment 
at four and 12 weeks, to assess the associations of this measure with short- and 
longer-term treatment response. These analyses will reveal any potential differences in 
rCBF patterns in responders and non-responders at both baseline and follow, which 
could aid prediction of treatment response. I also explore the longitudinal changes seen 
in responders and non-responders, which will reveal whether antipsychotics affect 
rCBF in these groups differently.  
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3.3.2.1 Treatment response at four weeks  
Treatment response in the following analyses was determined at four weeks and 
defined according to the Andreasen (2005) criteria.  
3.3.2.1.1 Cross-sectional comparisons of baseline global rCBF in four-week 
responders and non-responders  
Extracted global rCBF values showed that four-week responders had a mean of 315.10 
ml blood/100g tissue/minute (S.D. 66.25) at baseline, whilst four-week non-responders 
had a mean of 313.08 ml blood/100g tissue/minute (S.D. 94.59). These values were 
not significantly different (n.s., p>0.05). Global rCBF values in responders and non-
responders also did not differ significantly from those of healthy controls at baseline 
(n.s., p>0.05). 
3.3.2.1.2 Cross-sectional comparisons of baseline rCBF in four-week responders and 
non-responders  
a) Four-week responders versus non-responders 
Figure 34 and Table 55 show clusters of significantly different rCBF in four-week 
responders compared with non-responders at baseline.  
 
Table 55: Areas of significant baseline rCBF differences in four-week responders and 
non-responders  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Responders > Non-responders 
 Posterior cerebellum L -16 -80 -46 5.59 2505 <0.0001 




At baseline, there were two clusters of significantly greater rCBF in four-week 
responders compared with non-responders. The first cluster was centred on the 
bilateral posterior cerebellum. The second cluster was centred on the bilateral 
thalamus, extending into left parahippocampal regions (BA30). There were no regions 
of lower rCBF in responders compared with non-responders.  
 
 
Figure 34: Baseline perfusion differences in four-week responders and non-responders  
Higher resting perfusion (red) in responders compared with non-responders was observed at 
baseline in the cerebellum and thalamus. 
 
b) Four-week responders versus healthy controls 
Figure 35 and Table 56 show clusters of significantly different rCBF in four-week 
responders compared with healthy controls at baseline.  
 
Table 56: Areas of significant rCBF differences in four-week responders and healthy 
controls at baseline  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
 Brain area L/R x y z t KE P value 
Responders < Healthy controls 
 Parietal (angular 
 gyrus)  




Before treatment, four-week responders had lower rCBF than healthy controls in one 
significant cluster. This cluster was centred on the left parietal lobe (angular gyrus), 
extending into the left middle temporal gyrus and inferior temporal lobe. There were no 
regions of greater rCBF in responders compared with healthy controls at baseline.  
 
 
Figure 35: Perfusion differences between four-week responders and healthy controls at 
baseline  
Lower resting perfusion (blue) in responders compared with healthy controls before treatment 
was commenced seen in the parietal lobe (angular gyrus) 
 
c) Four-week non-responders versus healthy controls 
Figure 36 and Table 57 show clusters of significantly different rCBF in four-week non-
responders compared with healthy controls at baseline.  
 
Table 57: Areas of significant rCBF differences in four-week non-responders and 
healthy controls at baseline  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Non-responders < Healthy controls 
 Inferior parietal lobe  L -48 -40 42 4.72 3758 <0.0001 




Four-week non-responders had lower rCBF than healthy controls in two significant 
clusters. The first cluster was centred on left inferior parietal lobe, extending into the 
supramarginal gyrus and the left angular gyrus of the temporal lobe. The second 
cluster was centred on the left precuneus of the parietal lobe, extending into the left 
thalamus. There were no regions of higher perfusion in non-responders compared with 
healthy controls at baseline.  
 
 
Figure 36: Perfusion differences between four-week non-responders and healthy 
controls at baseline  
Lower resting perfusion (blue) in non-responders compared with healthy controls before 
treatment was commenced seen in the inferior parietal lobe and the precuneus.  
 
3.3.2.1.3 Cross-sectional comparisons of follow up global rCBF in four-week 
responders and non-responders  
At follow up, there was also no difference in global rCBF (n.s., p>0.05), with four-week 
responders having a mean of 313.69 ml blood/100g tissue/minute (S.D. 51.12) and 
four-week non-responders having a mean of 273.21 ml blood/100g tissue/minute (S.D. 
67.12). Global rCBF values in four-week responders and non-responders did not differ 





3.3.2.1.4 Cross-sectional comparisons of follow up rCBF in four-week responders and 
non-responders  
a) Four-week responders versus non-responders 
At follow-up, there were no longer any regions of greater or lower rCBF in four-week 
responders compared with non-responders.  
b) Four-week responders versus healthy controls  
Figure 37 and Table 58 show clusters of significantly different rCBF in four-week 
responders compared with healthy controls at baseline.  
 
Table 58: Areas of significant follow up rCBF differences in four-week responders and 
healthy controls  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
 Brain area L/R x y z t KE P value 
Responders > Healthy controls 
 Superior temporal 
 lobe  
L -44 -4 -14 4.36 3092 0.001 
 
Four-week responders had greater perfusion than healthy controls in one cluster, 
centred in the left superior temporal lobe and extending into the left lateral globus 
pallidus. There were no regions of lower rCBF in four-week responders compared with 





Figure 37: Perfusion differences between four-week responders and healthy controls at  
follow up 
Higher resting perfusion (red) in responders compared with healthy controls after treatment was 
commenced seen in the superior temporal lobe. 
 
c) Four-week non-responders versus healthy controls  
There were no regions of either higher or lower perfusion in four-week non-responders 
compared with healthy controls at follow up. 
d) Extracted values 
It is interesting that the cluster of greater perfusion in responders included the globus 
pallidus (which has previously been shown to be altered by antipsychotic treatment). 
Furthermore, the higher perfusion was seen only in responders and not in non-
responders, suggesting that it is effective antipsychotic treatment that leads to changes 
in this structure. I extracted mean perfusion values for this cluster in four-week 
responders (mean: 368.72 ml blood/100g tissue/minute), four-week non-responders 
(302.97 ml blood/100g tissue/minute), and healthy controls (321.13 ml blood/100g 
tissue/minute).  
These values suggest that perfusion in this region for non-responders was lowest and 
close to healthy control values, whilst responders had greater perfusion in this regions 
than both the other groups. However, there were no significant differences between 
responders and non-responders (t(17)=1.96, p=0.067), responders and healthy 
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controls (t(27)=1.78, p=0.087), or non-responders and healthy controls (t(24)=-0.59, 
p=0.56). 
3.3.2.1.5 Correlations between rCBF and clinical measures in four-week responders 
and non-responders 
Significant clusters from the comparison of responders and non-responders were 
extracted and correlational analyses with clinical measures were conducted to explore 
relationships between the differences in these regions and clinical changes in patients.  
(i) PANSS scores 
Lower perfusion at baseline in the thalamus was negatively correlated with scores on 
the positive subscale of the PANSS at follow up (r=-0.454, p=0.026), indicating that 
those with continued higher positive symptom severity after treatment had lower 
thalamic perfusion at baseline. There were no other significant correlations between 
any of the suprathreshold clusters and PANSS scores at either baseline or follow up.   
(ii) CGI 
There were no significant correlations between clusters in which rCBF was significantly 
different in four-week responders compared with non-responders and CGI scores at 
either baseline or follow up.   
(iii) PSP 
There were no significant correlations between clusters in which rCBF was significantly 
different in four-week responders compared with non-responders and PSP scores at 





There were no significant correlations between clusters in which rCBF was significantly 
different in four-week responders compared with non-responders and CDSS at either 
baseline or follow up.   
(v) Antipsychotic dose 
There were no significant correlations between clusters in which rCBF was significantly 
different in four-week responders compared with non-responders and antipsychotic 
dose.   
(vi) Salience attribution measures 
There were no significant correlations between clusters in which rCBF was significantly 
different in four-week responders compared with non-responders and salience scores 
at either baseline or follow up.   
3.3.2.1.6 Longitudinal effects of four-week antipsychotic treatment on rCBF in four-
week responders  
Extracted global rCBF values showed that four-week responders had a mean global 
value of 315.10 ml blood/100g tissue/minute (S.D. 66.25) at baseline and a mean of 
313.69 ml blood/100g tissue/minute (S.D. 15.41) at follow up. These values were not 
significantly different (t(10)=0.999, p=0.341).  
Table 59 and Figure 38 show clusters of significantly altered rCBF in four-week 







Table 59: Areas of significant altered rCBF in four-week responders after treatment 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Baseline < follow up (with global covariate)  
 Precentral gyrus L -32 -32 56 4.61 1442 0.005 
 
Four-week responders at follow up relative to baseline showed one cluster of 
significantly increased rCBF. The significant cluster was centred on the left precentral 
gyrus (Brodmann area 4), and extended into the left sub-gyral and left superior parietal 
lobe. There were no regions of significantly decreased rCBF.  
 
 
Figure 38: Perfusion differences at four-week follow up compared with baseline in 4-
week responders  
In responders, four weeks of treatment led to increased perfusion (red) in the left precentral 
gyrus. 
 
3.3.2.1.7 Longitudinal effects of four-week antipsychotic treatment on rCBF in four-
week non-responders  
Four-week non-responders with baseline and follow up scans showed a significant 
decrease in rCBF with treatment (t(7)=2.45, p=0.044), with a baseline mean of 313.08 
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ml blood/100g tissue/minute (S.D. 94.59) and a follow-up mean of 273.21 ml 
blood/100g tissue/minute (S.D. 67.12). 
There were no regions of either increased or decreased rCBF in four-week non-
responders at follow up.  
3.3.2.2 Treatment response at 12 weeks 
Treatment response for the following analyses was determined at 12 weeks, using the 
PPHS assessment. 
3.3.2.2.1 Cross-sectional comparisons of baseline global rCBF in 12-week responders 
and non-responders  
Extracted global rCBF values showed that at baseline 12-week responders had a mean 
of 320.58 ml blood/100g tissue/minute (S.D. 55.66), whilst non-responders had a mean 
of 314.72 ml blood/100g tissue/minute (S.D. 93.52). These values were not significantly 
different (t(17)=0.171, p=0.866).  
3.3.2.2.2 Cross-sectional comparisons of baseline rCBF in 12-week responders and 
non-responders  
a) Twelve-week responders versus non-responders 
Table 60 and Figure 39 show clusters of significantly different rCBF in 12-week 








Table 60: Areas of significant baseline rCBF differences in 12-week responders and 
non-responders  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Responders > Non-responders 
 Precuneus L -6 -54 32 5.74 9435 <0.0001 
 
At baseline, 12-week responders had greater rCBF than non-responders in one 
significant cluster. This cluster was centred on the left precuneus, extending into the 
thalamus. There were no regions of significantly lower rCBF in 12-week responders 
compared with non-responders.  
 
 
Figure 39: Baseline perfusion differences in 12-week responders and non-responders  
Higher resting perfusion (red) in responders compared with non-responders is visible at 
baseline before treatment in a large cluster centred on the precuneus and extending into the 
thalamus. 
 
b) Twelve-week responders versus healthy controls 
At baseline, 12-week responders were compared with healthy controls to identify rCBF 
differences before treatment commenced in the patients. Table 61 and Figure 40 show 





Table 61: Areas of significant baseline rCBF differences in 12-week responders and 
healthy controls  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Responders < Healthy Controls 
 Angular gyrus 
 (parietal) 
L -46 -68 30 6.24 3352 <0.0001 
 
Twelve-week responders had lower rCBF than healthy controls in one significant 
cluster. This cluster was centred on the angular gyrus of the left parietal lobe, 
extending into postcentral gyrus and supramarginal gyrus. There were no regions of 




Figure 40: Baseline perfusion differences between 12-week responders and healthy 
controls  
Lower resting perfusion (blue) in responders compared with healthy controls before treatment 
was seen in the left angular gyrus of the parietal lobe. 
 
c) Twelve-week non-responders versus healthy controls 
At baseline, I also compared 12-week non-responders with healthy controls to identify 
rCBF differences before treatment commenced in these patients. Table 62 and Figure 
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41 show regions of significantly different rCBF in non-responders compared with 
healthy controls at baseline.  
 
Table 62: Areas of significant baseline rCBF differences in 12-week non-responders 
and healthy controls  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R X y z t KE P value 
Non-responders < Healthy Controls 
 Inferior parietal lobe  L -46 -66 26 6.36 13241 <0.0001 
 Cerebellum (declive) R 24 -68 -26 3.82 1778 0.017 
 
Twelve-week non-responders had lower rCBF than healthy controls in two significant 
clusters. The first cluster centred on the left inferior parietal lobe, extending into the 
precuneus. The second cluster centred on the declive of the cerebellum, extending into 
fusiform gyrus in the temporal lobe. There were no regions of significantly higher rCBF 
in 12-week non-responders compared with healthy controls at baseline.  
 
 
Figure 41: Baseline rCBF differences between 12-week non-responders and healthy 
controls  
Lower resting perfusion (blue) in non-responders compared with healthy controls before 




3.3.2.2.3 Cross-sectional comparisons of follow up global rCBF in 12-week responders 
and non-responders  
At follow up, there was no difference in global rCBF (t(14)=0.491, p=0.631), with 12-
week responders having a mean of 299.99 ml blood/100g tissue/minute (S.D. 73.51) 
and non-responders having a mean of 283.80 ml blood/100g tissue/minute (S.D. 
57.38).  
3.3.2.2.4 Cross-sectional comparisons of follow up rCBF in 12-week responders and 
non-responders  
a) Twelve-week responders versus non-responders 
At follow-up, there were no regions of significantly different rCBF between 12-week 
responders and non-responders.  
b) Twelve-week responders versus healthy controls  
At follow up, 12-week responders were compared with healthy controls to identify rCBF 
differences following four weeks of antipsychotic treatment in these patients. Table 63 
and Figure 42 show regions of significantly different rCBF in 12-week responders 
compared with healthy controls at follow up.  
 
Table 63: Areas of significant follow up rCBF differences in 12-week responders and 
healthy controls  
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Responders > Healthy Controls       
 Precuneus L -20 -54 30 5.2 1578 0.022 




There were two significant clusters of greater rCBF in 12-week responders than in 
healthy controls. The first significant cluster was centred on the left precuneus, 
extending into the left postcentral gyrus. The second cluster was centred on the left 
temporal cortex subgyrally and extended into the left fusiform gyrus. There were no 
regions of significantly lower rCBF in 12-week responders compared with healthy 
controls at follow up. 
 
Figure 42: Follow up perfusion differences between 12-week responders and healthy 
controls  
Higher resting perfusion (red) in responders compared with healthy controls after treatment was 
seen in the left precuneus and the left temporal lobe. 
c) Twelve-week non-responders versus healthy controls 
At follow up, 12-week non-responders were compared with healthy controls to identify 
rCBF differences following four weeks of antipsychotic treatment in these patients. 
There were no regions of significantly different rCBF between 12-week non-responders 
and healthy controls at follow up. 
3.3.2.2.5 Longitudinal effects of four-week antipsychotic treatment on rCBF in 12-week 
responders  
Extracted global rCBF values showed that 12-week responders with baseline and 
follow up scans had a mean of 316.53 ml blood/100g tissue/minute (S.D. 59.55) at 
baseline and a mean of 299.99 ml blood/100g tissue/minute (S.D. 73.51) at follow up. 
These values were not significantly different (t(7)=1.30, p=0.24).  
Table 64 and Figure 43 show regions of significantly altered rCBF in 12-week 




Table 64: Areas of significant altered rCBF in 12-week responders after four weeks of 
treatment 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Baseline > follow up  
 Parahippocampal 
 gyrus 
L -24 -42 2 17.11 815 0.015 
Baseline < follow up        
 Parietal lobe L -24 -28 50 13.04 2192 <0.0001 
 
In 12-week responders, there was one significant cluster of decreased rCBF at follow 
up. This centred on the left parahippocampal gyrus. There was also a significant cluster 
of increased rCBF, centred in the left parietal lobe and extending into the precentral 
gyrus and temporal lobe.  
 
Figure 43: a) Perfusion decreases and b) increases across 4 weeks of treatment in 12-
week responders  
a) Decreased resting perfusion (blue) in 12-week responders was seen in the parahippocampal 





3.3.2.2.6 Longitudinal effects of four-week antipsychotic treatment on rCBF in 12-week 
non-responders  
Twelve-week non-responders with baseline and follow up scans had a mean of 314.72 
ml blood/100g tissue/minute (S.D. 93.52) at baseline and a mean of 283.80 ml 
blood/100g tissue/minute (S.D. 57.38) at follow up. These values were not significantly 
different (t(7)=1.87, p=0.10). 
Table 65 and Figure 44 shows regions of significantly altered rCBF in 12-week non-
responders after four weeks of antipsychotic treatment.  
 
 
Table 65: Areas of significantly altered rCBF in 12-week non-responders after four 
weeks of treatment 
Coordinates are shown in MNI space. P values have been FWE-corrected for multiple 
comparisons across the whole brain. Values for cluster-level significance are reported. 
 
Brain area L/R x y z t KE P value 
Baseline < follow up  
 Post-central gyrus (parietal)  R 14 -40 68 10.86 923 0.014 
 
In 12-week non-responders, there was one significant cluster of increased rCBF at 
follow up. This was centred in the right post-central gyrus, extending into the 







Figure 44 Resting rCBF increases across four weeks of treatment in 12-week non-
responders  
Increased resting perfusion (red) in 12-week non-responders was seen in the left postcentral 
gyrus of the parietal lobe.  
 
3.3.3 Chapter summary 
In this chapter, I have described the effects of antipsychotic treatment on cerebral 
blood flow in patients with FEP. Furthermore, I have explored the relationship of rCBF 
at baseline and after four-week treatment with treatment response as assessed at four 
or 12 weeks.  
Overall, patients showed differences from healthy controls both before and after 
treatment. Before treatment, patients had lower resting perfusion in temporal and 
parietal regions compared with healthy controls. Lower perfusion in the middle 
temporal gyrus was related to higher baseline CDSS scores of depression. After four 
weeks of treatment, patients had higher perfusion in the left superior temporal gyrus 
compared with healthy controls, and this was positively correlated with antipsychotic 
dose. These results suggest that patients already differ from healthy controls before 
they are treated, and that antipsychotic treatment alters rCBF. 
When treatment response was considered, I observed differences in the perfusion 
patterns of responders and non-responders. At baseline, responders had higher 
cerebellar and thalamic rCBF than non-responders. Furthermore, higher baseline 
thalamic rCBF was positively correlated with lower positive PANSS scores at follow up, 
suggesting an association between thalamic perfusion and response. Both responders 
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and non-responders showed lower perfusion in parietal regions compared with healthy 
controls at baseline, but only responders had higher perfusion in the superior temporal 
gyrus at follow up. Antipsychotic medication led to increased rCBF in the precentral 
gyrus of responders. However, there appeared to be no changes in rCBF in any region 
with treatment in non-responders. The presence of differences evident before 
treatment, and which are associated with response to treatment four or 12 weeks later 
suggests that rCBF may have predictive value.  
I investigated three ROIs, in relation to my specific hypotheses, investigating rCBF in 
the hippocampus, caudate, and putamen. No significant differences were found in any 
of these regions to support the hypotheses.  
The results in this chapter suggest that antipsychotic medication alters rCBF in patients 





In this final chapter, I discuss my findings. Initially, I will summarise the main findings of 
each results chapter in turn, discussing the results within the context of existing 
literature, and considering potential mechanisms and explanations for my findings. I will 
also consider limitations of the study and the implications for the field of schizophrenia. 
Finally, I will present my main conclusions and potential future directions for the field. 
 
4.1 Summary and interpretation of the findings 
In chapters 3.1, 3.2, and 3.3, I report the differences between patients and healthy 
controls on clinical, behavioural, and neurophysiological measures. I also investigated 
the longitudinal effects of antipsychotic medication on these measures. I further 
investigated associations between the effects observed and whether patients showed a 
good or poor response to treatment at four and 12 weeks. The main findings are 
summarised below: 
 
 In general, amisulpride led to improvements in psychotic symptomatology for 
the patient group. At an individual level, not all patients improved, with 17 (68%) 
showing a good response and 8 (32%) showing a poor response to treatment. 
Non-response was associated with a greater severity of illness at baseline and 
a longer duration of untreated psychosis (DUP) at baseline.  
 Overall, patients significantly differed from healthy controls only in terms of 
explicit adaptive salience, both at baseline and follow up. Furthermore, there 
were no significant changes in patients with treatment in any salience 
measures. However, within the patient sample, altered salience attribution 
appeared to be related to treatment response. A good response was associated 
with higher implicit adaptive salience scores at baseline. Successful treatment 
also appeared to be associated with significant decreases in implicit aberrant 
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salience, which was seen in responders but not non-responders. Finally, 
delusions were associated with lower levels of implicit adaptive salience at 
baseline.  
 Salience processing was associated with activation in frontal and temporal 
regions, with a wider range of regions activated in healthy controls. The patient 
group as a whole did not differ from healthy controls at either baseline or follow 
up in activation. There were differences in neural activation patterns of 
responders and non-responders. There was greater activation in the insula and 
midbrain during adaptive salience in four-week responders than in non-
responders before and after treatment, respectively. Responders differed little 
from healthy controls, showing differences during presentation of outcome at 
follow up only, in the middle temporal lobe. Non-responders differed from 
healthy controls at both time points, with lower activation in the cerebellum and 
brainstem. Longer-term response was also associated with differences in brain 
activation, with a good response associated with higher baseline activation in 
superior temporal and middle occipital lobes during adaptive salience. There 
were no differences in neural activation during aberrant salience processing at 
any time point between any of the groups.  
 In terms of brain perfusion, before treatment, the whole patient group showed 
hypoperfusion in temporal and parietal regions compared with healthy controls. 
At follow up, patients compared with healthy controls had higher perfusion in 
the superior temporal gyrus extending into the globus pallidus, and this was 
positively correlated with antipsychotic dose. There were differences in 
perfusion patterns of responders and non-responders, with responders showing 
higher cerebellar and thalamic rCBF at baseline compared with non-
responders. Furthermore, higher baseline thalamic rCBF was positively 
correlated with lower positive PANSS scores at follow up, suggesting an 
association between thalamic perfusion and response. Both responders and 
non-responders showed lower perfusion in parietal regions compared with 
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healthy controls at baseline, but only responders had higher perfusion in the 
superior temporal gyrus at follow up. Antipsychotic medication led to increased 
rCBF in the precentral gyrus of responders. However, there appeared to be no 
changes in rCBF in any region with treatment in non-responders.  
 
4.1.1 The effects of amisulpride on clinical, behavioural, and neurobiological measures. 
Whilst our understanding of the pharmacodynamic effects of antipsychotic medications 
has improved, we still lack a clear understanding of the short and long term effects of 
antipsychotic medications on the brain. However, increasing evidence suggests that 
structural and functional brain changes observed in psychosis are partly a result of 
antipsychotic treatment (Navari and Dazzan, 2009; Ho et al., 2011; Davis et al., 2005; 
Vita and De Peri, 2007; Goozee et al., 2014).  
In this project, I investigated the effect of amisulpride, a second generation 
antipsychotic (SGA), on various clinical, behavioural, and neurobiological measures, in 
a relatively homogeneous sample of patients with first episode psychosis (FEP). These 
patients were either antipsychotic-naïve or minimally treated, and had been ill for less 
than two years. They therefore provide an advantage over samples in previous studies, 
which have recruited heterogeneous groups of patients, often with previous exposure 
to antipsychotic medication and a range of illness durations. These factors may further 
affect clinical, behavioural, and neurobiological factors related to schizophrenia. As 
such, my sample allows the interpretation of neurobiological factors, without the 
influence of previous treatments or illness chronicity. I found that the clinical, 
behavioural, and neurobiological measures I investigated were affected by four weeks 





a) Clinical measures 
Overall, amisulpride led to an improvement in patients’ symptoms, with significant 
decreases in all PANSS subscales, apart from negative symptoms. These 
improvements were confirmed by the mean percent change scores on the PANSS, as 
well as changes in CGI and PSP ratings. The only measure not showing significant 
changes was CDSS, which was likely due to the fact that there were low levels of 
depressive symptoms in the sample to begin with. The improvement seen in symptoms 
is in line with findings from clinical trials. These have reported group-level efficacy of 
current antipsychotic medications, with superiority of SGAs, such as amisulpride, over 
first generation antipsychotics (FGA) (Leucht et al., 2009). Whilst patients tended to get 
better, in my sample there was no significant improvement in negative symptoms 
following treatment with amisulpride. Whilst there has been some debate surrounding 
the efficacy of current treatments to improve negative and cognitive symptoms in 
schizophrenia, previous research has indicated a potential improvement in these 
domains with amisulpride treatment (Curran and Perry, 2001). This may not have been 
detected in our sample due to the sample size or due to our patients presenting with a 
low level of negative symptoms at baseline.  
b) Behavioural measures of salience attribution 
In 2003, Kapur proposed a framework to bridge the gap between the brain and the 
mind in psychosis, which suggested that dysfunctions in attributing importance to 
salient cues and neutral cues underlies psychotic symptoms such as hallucinations and 
delusions (Kapur, 2003). Furthermore, he proposed that the effect of antipsychotic 
medication on psychotic symptoms resulted from an effect on salience processing, 
mediated by the blockade of dopamine receptors. Investigating the effects of 
antipsychotics on salience processing thus provides a powerful way of testing the 
validity of the salience model of psychosis.  
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Initially, I investigated whether participants were able to use reward associations to 
guide how they responded (i.e., whether they responded more quickly to high-
probability trials than low-probability trails). I found that this was the case at both 
baseline and four-week follow up. However, whilst healthy controls showed significant 
implicit adaptive salience (significantly different to zero) at both baseline and follow up, 
patients did not show significant levels of adaptive salience at baseline. However, after 
treatment they did show significant levels of adaptive salience. This suggests that 
antipsychotic treatment can ameliorate impaired reward learning in patients with 
psychosis, presumably through dopamine antagonism.  
In the present project, patients had reduced explicit adaptive salience at baseline and 
follow up, but there were no differences in implicit (reaction time) scores. This suggests 
that patients were able to learn implicitly about the relationships between high-
probability cues and reward, but were not aware or conscious of this learning. These 
findings are consistent with data from a previous study in patients with FEP, which 
found that they showed reduced explicit and implicit adaptive salience compared with 
healthy controls (Roiser et al., 2009). My findings extend these results, in that this 
difference was evident in patients who were medication naïve. Patients in the previous 
study had been treated with antipsychotic medication, and the reduction in adaptive 
salience was attributed to an effect of this on motivational salience, rather than an 
effect of the disorder itself (Roiser et al, 2009). Indeed, Kapur had originally proposed 
that adaptive salience was intact prior to treatment but diminished as a result of 
dopamine blockade following antipsychotic treatment (Kapur, 2003).  
Longitudinal analyses of the whole patient group provided little evidence for a 
modulatory role of antipsychotics on salience attribution, as there were no significant 
changes in any salience measure in patients following treatment with amisulpride. 
There was a significant decrease in the number of premature errors made by patients 
with treatment, but this may have been due to increased familiarity with the task. 
However, healthy controls did not show a corresponding decrease in errors so this is 
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unlikely. Another possibility is that reduced errors reflected a reduction in distracting 
positive symptomatology following treatment.  
In this sample, I found that patients with delusions had lower implicit adaptive salience 
scores at baseline than patients without delusions. It has been hypothesized that 
salience attribution when disrupted could play a particular role in the development of 
delusions. According to the aberrant salience hypothesis (Kapur, 2003), when there is 
disruption of normal salience attribution processes, neutral stimuli can be assigned 
unwarranted importance or salience, i.e., aberrant salience, and thus attract attention 
and influence behaviour inappropriately. It may be that delusions result from attempts 
to explain unusual experiences of heightened salience to neutral stimuli (Kapur, 2003). 
Consistent with this, Roiser and colleagues (2009) reported that delusional 
symptomatology was associated with higher levels of aberrant salience. There was a 
trend in my data for those with delusions at follow up to also have higher implicit 
aberrant salience scores but this was not significant. In contrast, delusions were related 
to lower levels of adaptive salience rather than higher levels of aberrant salience.  
c) Neural activation during salience attribution measured using fMRI 
This study also investigated salience attribution within the context of the salience 
attribution theory at the level of brain activation. I analysed neural activation using fMRI 
BOLD during salience attribution, performing contrasts that represent adaptive and 
aberrant salience, as well as the outcome of trials.  
At baseline, I investigated activation associated with salience processing in healthy 
controls and patients, separately. Previous studies have reported activation associated 
with adaptive salience (i.e., when individuals differentiate between high and low 
probability cues) in the midbrain, ventral tegmental area, medial dorsal thalamus, 
ventral striatum, and prefrontal cortex of healthy controls (Roiser et al., 2010). I found 
that adaptive salience at baseline was associated with activation in the superior 
temporal gyrus (STG) of healthy controls . This region is not often implicated in reward 
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or salience processing, but cues associated with adaptive salience have been shown to 
elicit greater activation in the STG than other cues in healthy controls (Roiser et al., 
2010) and individuals with at-risk mental state (ARMS) (Roiser et al., 2013). In patients, 
I found that no regions were significantly activated during adaptive salience processing 
at baseline. At follow up, activation associated with adaptive salience was found in 
similar regions as at baseline, with the superior temporal gyrus most consistently 
activated in both patients and healthy controls. It is possible that the lack of activation 
found at baseline could be due to my use of a single block during the SAT and fewer 
trials than in previous studies. This may have resulted in a lack of power to detect the 
activation. Nonetheless, further imaging studies of salience attribution processes could 
confirm the networks of regions activated during both adaptive and aberrant salience 
attribution and their contributions to salience processing.  
In this study, there were no significant clusters of neural activation changes associated 
with aberrant salience. Previous studies have found differential dorsolateral PFC and 
medial temporal gyrus (MTG) activation to cues with identical reward properties. The 
relationship between these regions and salience processing remains speculative. 
Roiser and colleagues (2010) suggested that their role in aberrant salience may be 
related to their previously reported role in signalling uncertainty during reward learning. 
However, what is important is that where aberrant salience was present, and identically 
rewarded cues were responded to as if they were differentially rewarded, neural 
activation in the dorsolateral PFC and MTG also reflected this aberrant attribution of 
salience. When participants responded neutrally to cues that were equally rewarded 
(i.e. did not show aberrant salience) this activation was not seen. The presence of 
activation in any region associated with the erroneous attribution of salience to cues 
(treating neutral cues as if they were differentially rewarded) was not seen in our 
participants. This may have been due to generally low levels of aberrant salience in our 
groups. Alternatively, this may have been due to a lack of power resulting from fewer 
trials during the SAT (as described above).  
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When the patients were compared with healthy controls, no significant differences were 
found at either baseline or follow up in adaptive salience activation. Whilst this is not 
the first study to report a lack of difference between patients and healthy controls 
(Simon et al., 2010), most studies in patients with chronic schizophrenia have reported 
reduced striatal and frontal activation during reward and salience processing in patients 
compared with healthy controls (Koch et al., 2010; Walter et al., 2009; Simon et al., 
2010; Waltz et al., 2010; Diaconescu et al., 2011; Gradin et al., 2011/2013; Dowd and 
Barch, 2012; da Silva Alves et al., 2013). Most of the patients in these studies had 
already been treated with antipsychotics, and had been ill for longer than the 
participants in my study. It is possible that antipsychotics modulate salience processing 
and its underlying neural function. Furthermore, there may also be changes in salience 
attribution as the illness progresses (including effects of changes in general cognition). 
However, studies in patients with FEP have also reported functional abnormalities in 
various regions, for example failure to adequately activate midbrain, striatal, and limbic 
regions in response to high-probability cues (Murray et al., 2008). Nonetheless, our 
patients did not differ from healthy controls either at baseline or follow up. This is 
inconsistent with a recent study showing lower adaptive salience responses in FEP 
compared with healthy controls in the right insula (Smieskova et al., 2015). However, 
unlike my sample, the patients in this study were medicated. We also did not find any 
differences between groups in terms of aberrant salience activation. This finding is 
consistent with a recent study that compared ARMS, FEP and healthy controls on the 
SAT using fMRI, finding no differences in aberrant salience measures (Smieskova et 
al., 2015).   
When considering the longitudinal effects of antipsychotics on brain activation during 
salience processing, I found no effect of treatment in our patients. Again, this is not 
consistent with previous studies, although only two have considered the effects of 
antipsychotics prospectively in patients, and both used the monetary incentive delay 
(MID) task rather than the SAT (Schlagenhauf et al., 2008b; Nielsen et al., 2012). Only 
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the patients in one of these studies were medication-naïve before entering the study 
(Nielsen et al., 2012), whereas patients in the other study were medicated with FGA 
and then switched to olanzapine (Schlagenhauf et al., 2008b). Both these studies 
found decreased activation in the ventral striatum of patients during reward 
anticipation, which normalised after treatment, such that patients no longer differed 
from healthy controls. It is possible that the MID task and SAT are measuring 
fundamentally different concepts, and as such differences in findings should be 
expected with them. This highlights the question of what precisely is being measured 
when we discuss adaptive and aberrant salience. Whether these are valid cognitive 
concepts that reflect real-world cognitive processes and how they relate to other 
reward-learning concepts is not entirely clear.  
The lack of difference found in my study could be explained in several ways. It is 
possible that the short period of treatment between scans (four weeks) was not long 
enough for changes to become apparent. However, antipsychotics have been shown to 
have immediate effects on brain function, even after a single dose (e.g. Handley et al., 
2013) and previous studies have used similar treatment periods of between four and 
six weeks (e.g. Honey et al., 1999, Schlagenhauf et al., 2008a/b, 2010). A lack of 
difference may result from the characteristics of the patient sample. As I recruited only 
antipsychotic-naïve FEP patients who had not been compelled to receive clinical care 
or admitted to hospital, whereas previous studies have included patients who had 
already been treated, who had been admitted to hospital, or who were being treated on 
a compulsory basis. It is thus possible that the studies involved different types of 
patient, and those in my study were less severely ill than in the previous samples. 
Similarly, there were few differences in behavioural measures of salience attribution 
when the entire patient group was compared with healthy controls (see above). The 
only difference found was in explicit adaptive salience, i.e., the ability of a patient to 
verbalise the relationship between high-probability cues and reward. Given the lack of 
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neural differences, it is possible that this behavioural difference is due to indirect effects 
of the illness on learning or cognition.  
However, the most parsimonious explanation for the lack of striking differences 
between the overall patient sample and controls is that the findings are closely related 
to the effect of antipsychotic medication. Pooling all patients together may have 
constituted a heterogeneous group which made it harder to detect significant findings. 
Stratifying patients according to treatment response may have generated subgroups 
that were more biologically homogenous, increasing the likelihood of detecting 
correlates of salience abnormalities.  
d) Resting CBF measured using cASL  
Resting CBF is a measure of basal brain activity that is potentially important in 
understanding the effects of antipsychotics on the brain. It has been related to 
antipsychotic use (Pinkham et al., 2011) and the regions affected show overlap with 
those reported elsewhere as altered in psychosis (Miller et al., 2001; Lahti et al., 2003). 
Changes following antipsychotic treatment are seen immediately, within a few hours of 
single-dose administration (Handley et al., 2012), but in this project, longer term 
administration across four weeks was investigated.  
In this project, patients with FEP showed differences in rCBF compared with healthy 
controls before they were treated with an antipsychotic medication. A limited number of 
studies in antipsychotic-naïve or unmedicated patients have been conducted. Such 
studies suggest the presence of perfusion differences in the frontal cortex, basal 
ganglia, and temporal regions (e.g. Scheef et al., 2010; Kim et al., 2000; Andreasen et 
al., 1997). In my sample, I found differences between patients and healthy controls 
before treatment in the temporal and parietal lobes. Furthermore, one cluster of 
decreased perfusion extended into the frontal lobe. However, I did not replicate 
previously reported differences in the basal ganglia. I discuss potential reasons for the 
differences I found and how they may relate to disease pathology below.   
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There are a number of potential explanations as to why there may be inconsistencies 
between my results and those of previous studies. A major potential source of 
variability is sample heterogeneity. As already stated above, a number of variables that 
may affect brain perfusion vary between different studies and often vary to a large 
extent within a study. These include illness chronicity and illness severity, as well as 
previous and current antipsychotic exposure. Indeed, the samples of many previous 
studies reporting perfusion abnormalities in patients with schizophrenia have 
comprised individuals who are more chronically ill and have been previously 
medicated. There is increasing evidence for a modulatory effect of antipsychotic 
medication on brain perfusion (Goozee et al., 2014). As such, it is difficult when using 
samples including those who have been previously medicated to disentangle where 
perfusion abnormalities are primary to the disease pathophysiology or reflect changes 
resulting from treatment. 
The importance of antipsychotic exposure has been highlighted by Vita and colleagues 
(1995). They conducted a perfusion study in which patients were separated according 
to previous antipsychotic exposure. When they compared nine antipsychotic-naïve 
patients with healthy controls, they found hypoperfusion in frontal, temporal, and 
subcortical regions (thalamus, caudate, and putamen). However, the eight 
antipsychotic-free patients (who had undergone a minimum three-week washout) did 
not differ from healthy controls. These results suggest that antipsychotic medications 
have a modulatory effect on rCBF. Furthermore, this effect can be long-lasting, even 
after the withdrawal of medication. In another study, it was found that rCBF in the basal 
ganglia and temporal lobes was inversely related to the duration of washout (Ebmeier 
et al., 1993). Thus, whilst I did not find alterations in the basal ganglia, this may be 
related to the characteristics of my sample, such as their lack of previous antipsychotic 
exposure. These characteristics allow us to more confidently assert that the differences 
observed are primary to the disease pathophysiology, rather than secondary to other 
factors. Samples which include patients with a range of illness durations and previous 
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treatments are difficult to interpret. If we are to understand the effects of antipsychotics 
on the brain and how they modulate the pathophysiology underlying psychotic illness, 
more research is required in samples that are uncontaminated by previous 
antipsychotic use.  
One finding from previous studies that was replicated in this project was altered 
temporal perfusion, particularly in the left hemisphere, of patients with psychosis. At 
baseline, patients had lower perfusion in the middle temporal gyrus. A large body of 
research implicates temporal abnormalities in psychotic illness, with alterations in 
structure, function, and perfusion. A number of studies of rCBF in schizophrenia have 
found decreased perfusion in the temporal cortex (Ebmeier et al., 1993; Catafau et al., 
1994; Steinberg et al., 1995; Vita et al., 1995; Andreasen et al., 1997; Kim et al., 2000; 
Scheef et al., 2010). Differences in the temporal lobes were still observed at follow up, 
after four weeks of treatment. However, at this point, patients had higher rCBF in the 
superior temporal lobe. Higher perfusion in this region was also associated with higher 
antipsychotic dose.  
The temporal lobe plays a role in auditory processing and so has previously been 
implicated in the development of hallucinatory symptoms of psychosis (Shenton et al., 
2001). In particular, it is possible that hallucinations may derive from dysfunction in 
normal auditory and language functions, which are supported by temporal cortex 
activity. It is therefore particularly interesting that the differences seen are invariably in 
the left hemisphere. Lateralisation of language to the left side of the brain has been 
well-established since early work by Broca (Broca, 1865; Hécaen et al., 1981). The 
temporal lobe has extensive interconnections with the frontal lobe, another area often 
associated with abnormalities in schizophrenia. Indeed, the clusters of decreased 
perfusion found in my study also extended into the frontal lobe. It is likely that brain 
alterations in schizophrenia are diffusely distributed across the brain and will affect 
networks, rather than resembling localised lesions or isolated regions of altered 
function (Mourao-Miranda et al., 2012).  
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Temporal lobe deficits in patients with psychosis have previously been reported in 
structural studies, and these may be affected by antipsychotics (Dazzan et al., 2005). 
However, few studies have explored associations between temporal perfusion and 
antipsychotic medications. Where this has been investigated, results have been mixed. 
Some have reported no changes in temporal lobe perfusion following long-term or 
single dose antipsychotic treatment (Yildiz et al 2000; Miller et al. 1997; Vaiva et al., 
2002; Gonul et al., 2004). Others have suggested decreased metabolism or blood 
flow in this region after treatment (Lahti et al., 2003; Lahti et al., 2009; Bartlett et al., 
1998). Conflicting results may result from differences in the length of time between 
administration of a drug and scanning and the type of antipsychotic prescribed. For 
example, haloperidol (a FGA) has been associated with decreased temporal blood 
flow, whilst olanzapine (a SGA) was associated with increased temporal blood flow in 
the same participants (Lahti et al., 2005). The same group reported decreased 
temporal rCBF after one week of treatment with olanzapine, but that after another five 
weeks of treatment there was increased rCBF in this region (Lahti et al., 2009). Studies 
in healthy controls further support the existence of divergent effects dependent on 
antipsychotic type. In a repeated measures, placebo-controlled study of 20 healthy 
volunteers, aripiprazole led to immediate increases in rCBF in the temporal cortex, 
whilst haloperidol led to decreases in this region (Handley et al., 2013). These studies 
highlight the need to consider the treatment type and duration when interpreting 
results.  
Whilst at baseline patients had lower perfusion in the temporal lobe compared with 
healthy controls, and at follow up there was increased perfusion in this region, changes 
in temporal perfusion were not detected by the longitudinal analysis. The only region of 
significantly increased perfusion in patients was seen in the left superior parietal lobe, 
which extended into the left frontal lobe. The parietal cortex is not often implicated in 
the effects of antipsychotics on perfusion, but altered frontal perfusion is reported 
across the literature. Some previous studies have reported increases in frontal regions 
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with antipsychotic treatment (Sabri et al., 1997; Novak et al., 2005). However, not all 
studies have replicated this, with some reporting decreased rCBF in parts of the frontal 
cortex (Warkentin et al., 1990; Livingston et al., 1998). These inconsistencies may be 
due to a number of methodological differences between studies, as well as sample 
heterogeneity within and between studies (Marco et al., 1997). However, our study 
provides a relatively homogeneous sample of antipsychotic-naïve FEP, within the early 
stages of their illness. Therefore, my results would support that there are increases in 
frontal perfusion, alongside parietal increases, following antipsychotic treatment at this 
early stage. Inconsistencies may also be due to oversimplification of the cortical 
regions within the frontal lobe (treating it as a homogeneous region without divisions). 
The frontal lobe is a large brain region, which can be divided into a number of smaller 
sections with distinct cytoarchitecture and function. It is therefore possible that there 
are both increases and decreases within the frontal lobe following antipsychotic 
treatment but occurring in different regions within this lobe.  
Few, if any, studies have previously investigated the effects of antipsychotics on rCBF 
in patients with psychosis longitudinally using ASL. This technique is a relatively novel 
method of imaging perfusion, and has been used to show correlations between rCBF 
and regional brain activity measured by other techniques (Uludag et al., 2004). 
However, interpretation of perfusion data must bear in mind that mechanisms other 
than brain activation may play a role in alterations seen. The role of receptor-level 
factors, such as up- and down-regulation, have been discussed by some authors 
(Jenkins, 2012), whilst others have highlighted the need to consider global, systemic 
effects of drugs, such as direct effects on blood vessels (Viviani et al., 2013). The 
differences seen are therefore complicated to interpret and may not simply reflect 
functional or structural alterations, although it might be expected that there are 
relationships between these neurobiological changes. The direction of these 
relationships remains unclear, however. It is possible that structural changes precede 
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and lead to changes in perfusion, and vice versa. Multimodality longitudinal studies 
across illness progression may provide insight into these relationships.  
My results suggest that patients already differ from healthy controls before they are 
treated, and that antipsychotic treatment alters rCBF. However, it seems probable from 
my analyses that differences in perfusion patterns in schizophrenia also depend upon 
response to treatment. It is possible that the effects of antipsychotic medication on the 
brain differ between those who respond well and those who respond poorly to 
medication. I therefore investigated these two groups of patients in my sample and 
discuss my results below in section 4.1.2.  
4.1.2 Associations between clinical, behavioural, and neurobiological measures and 
treatment response  
Whilst increasing evidence supports the effects of antipsychotics on the brain, it 
remains unclear whether the effects observed are associated with clinical 
improvement. A major focus of this project was to investigate the associations between 
the measures taken (clinical, behavioural, and neurobiological) and response to 
treatment. Whilst antipsychotic medications are the first treatment choice for psychosis 
and show group-level efficacy (Leucht et al., 2013), at an individual level response to 
treatment is variable (Barnes, 2011). Identifying the differences between patients who 
show a good response to treatment and those who show a poor response to treatment 
is key to understanding the mechanisms of treatment response. Furthermore, this may 
allow for prediction of response as outlined later in section 4.1.3. Biological factors may 
be particularly important, and elucidating the biological variation underlying treatment 
resistance and poor response may improve treatment for patients, reduce costs for 
services, and provide potential new treatment targets. In this project, I investigated 
treatment response in several ways, comparing responders and non-responders 
directly, as well as comparing each with healthy controls. One of the main implications 
of my findings is that in patients with psychosis, the neurobiological differences 
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between responders and non-responders are more marked than those between 
patients and controls. This heterogeneity in terms of response to treatment may reflect 
differences in the underlying neurobiology.  
a) Clinical measures 
Whilst there was a general improvement in psychotic symptomatology following 
treatment, at an individual level there were differences in response to treatment among 
patients. Seventeen patients (68%) showed a good response to treatment, meeting the 
Andreasen et al., (2005) criteria for remission. Eight patients (32%) did not meet these 
criteria and so were designated non-responders. These proportions are in line with 
previous estimates of response rates in psychosis (Barnes et al., 2011). 
Interestingly, DUP was longer in those classified as non-responders at four weeks than 
in responders. Furthermore, a longer DUP was associated with a smaller mean percent 
change in total PANSS scores. This is consistent with findings in the literature (Emsley 
et al., 2008). In this study, the relationship was likely driven by changes in positive 
symptoms, as there was a negative correlation between DUP and mean percent 
change in positive symptoms but no relationship with any of the other subscales. 
However, at 12 weeks, treatment response was no longer related to DUP, suggesting 
that this factor may be related to initial response but not longer-term outcomes. The 
only other demographic factor associated with treatment response was employment, as 
being employed was associated with greater improvements in positive symptoms as 
assessed by mean percentage change. This may be related to severity of illness, 
particularly if baseline symptom scores were related to later response, as patients with 
more severe symptoms at baseline might be less able to work and may also be less 
likely to respond to treatment.  
This suggestion was supported by my analysis of the relationships between PANSS 
scores and treatment response. Non-responders at both four and 12 weeks had higher 
total PANSS scores than responders at both baseline and after four weeks of 
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treatment. This suggests that the more severely ill were less likely to have a good initial 
response, as well as being less likely to respond in the longer term. In most cases, 
positive and general psychopathology symptom scores were related with outcome but 
negative symptom scores were not. As such, antipsychotic treatment response 
depends more on severity of positive and general psychopathology symptoms than on 
negative symptoms. Previous studies have shown better premorbid adjustment, less 
severe pre-treatment symptoms, and shorter DUP to be associated with a better 
response to antipsychotic treatment (Perkins et al., 2005). Furthermore, some previous 
results have shown that whilst more severe hallucinations and delusions at baseline 
are associated with poor treatment response, negative and depressive symptoms were 
not related to outcome (Robinson et al., 1999). Furthermore, I found that negative 
scores did not significantly change with treatment. Previously, antipsychotic treatment 
has been found to have a greater effect on positive symptoms than on negative or 
cognitive symptoms of the disorder (Gardner et al., 2005). 
Remission status remained relatively stable, with most patients who were classified as 
a responder at four weeks remaining so at 12 weeks. Furthermore, when I compared 
responders and non-responders classified at 12 weeks on clinical measures of 
psychopathology at four weeks, I found that there were already significant differences 
in positive PANSS and CGI at this stage. Together, these results suggest that patients 
who were less severely ill at four weeks, remained so throughout and continued to be 
good responders at 12 weeks. This is consistent with previous studies that have 
suggested that an early good response to treatment predicts subsequent good 
response (Levine and Leucht, 2012; Giegling et al., 2012; Ruberg et al., 2011). 
However, data were available for fewer patients at 12 weeks than at four weeks. 
Therefore, it is uncertain whether those patients not included in the analysis at 12 
weeks continued to respond in the same way to antipsychotic treatment in the longer 
term. There were no relationships between the other clinical measures and treatment 
response at either four or 12 weeks or with percent change scores. However, CGI 
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severity at four weeks did significantly differ between responders and non-responders 
at 12 weeks. This again suggests that illness severity after four weeks treatment may 
predict longer-term response to treatment. These results show that in line with previous 
research some demographic and clinical characteristics of our patients were related to 
their response to antipsychotic drugs.  
b) Behavioural measures of salience attribution 
Although when comparing salience attribution in the whole patient group versus that of 
healthy controls few differences were found, this may be because salience attribution 
abnormalities are related to response to treatment. I found several differences in 
salience attribution processing between patients who showed a good response to 
treatment and those who showed a poor response to treatment. I also observed more 
differences between patients and healthy controls when patients were separated 
according to response. These results suggest that salience attribution abnormalities 
may differ in patients showing differences in response to treatment, perhaps reflecting 
differences in underlying pathology of their illness. Therefore, dividing patients 
according to treatment response might provide a clearer view of disrupted salience 
attribution processes in psychosis.  
Previous studies have suggested that patients with psychosis have lower levels of 
adaptive salience compared with healthy controls (Roiser et al. 2009) and some 
suggest that this may actually be related to antipsychotic treatment (Smieskova et al., 
2015). Indeed, within the framework of the aberrant salience hypothesis, it has been 
suggested that psychosis is primarily a disorder of aberrant salience processing, in 
which importance (salience) is attributed to neutral stimuli (Kapur, 2003). However, 
Kapur also talks about the dampening of salience by antipsychotic treatment (Kapur, 
2003). It might be that antipsychotic medications reduce aberrant salience, but also 
reduce adaptive salience, leading to “deficit-like states” in which patients exhibit 
negative symptoms including dysphoria, withdrawal and so on. My results suggest that 
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this may be more complicated than previously thought, with response to treatment 
playing a role in determining the patterns of salience attribution seen.  
Comparing responders and non-responders, I found that there were lower levels of 
implicit adaptive salience at baseline in those showing a poor response to treatment at 
baseline. However, this was no longer observed at follow up. When compared 
separately with healthy controls, both responders and non-responders showed 
adaptive salience deficits. However, only non-responders showed such deficits in 
implicit adaptive salience. Responders appeared to be able to differentiate high- and 
low-probability cues implicitly, but were not able to explicitly learn and verbalise the 
relationships between cues and reward at either baseline or follow up. Conversely, 
non-responders showed neither the ability to implicitly differentiate high- and low-
probability cues, or to explicitly learn or verbalise the relationships. However, non-
responders did not show lower implicit adaptive salience scores than healthy controls 
at follow up. Given that patients did not experience a remission of symptoms, it seems 
unlikely that there was an improvement in adaptive salience as a result of the 
antipsychotic treatment. The group of non-responders was small and so it may be that 
the sample size was not large enough to detect any difference at follow up. There was 
still a large difference in implicit adaptive salience scores at this time point (non-
responders mean: 1.98; healthy controls mean: 18.12), but the sample probably lacked 
power and so this difference was not significant. 
Due to the small number of non-responders in my sample, I also investigated a 
continuous measure of treatment response (percent change in PANSS). I found that 
there was a positive correlation between baseline implicit adaptive salience scores and 
percent change in PANSS, such that those showing the greatest improvements had 
higher baseline adaptive salience scores. This supports the assertion that disrupted 
adaptive salience is related to poor response to treatment.  
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My results do not support the idea that adaptive salience is dampened as a result of 
treatment with antipsychotic medications, as the longitudinal analysis showed no 
changes in implicit adaptive salience scores of either responders or non-responders. 
Indeed, the only significant change in adaptive scores across treatment was an 
increase in explicit adaptive salience scores in non-responders. Previous studies have 
not taken into account response to treatment and so this may have affected their 
results. For example, Roiser and colleagues (2009) used treated individuals with FEP 
in their study and found lower adaptive salience in their patients compared with healthy 
controls. Potentially, the reduced salience is dominated by those in their patient group 
showing a poor response to treatment (which in my sample is associated with lower 
adaptive salience scores), whilst those showing a good response to treatment have 
less disturbed salience attribution and contribute little to the differences seen.  
It was originally thought that psychosis would be characterised by the presence of 
aberrant salience, rather than by disruptions in adaptive salience (Kapur, 2003). 
Indeed, work in healthy populations with subclinical psychotic symptoms (Van Os et al., 
2009) and individuals at ultra-high risk (UHR) of psychosis (Roiser et al., 2012) have 
shown a relationship between higher levels of aberrant salience and psychosis. 
However, this finding has not been replicated in FEP, where decreased adaptive 
salience but comparable levels of aberrant salience were reported in patients 
compared with healthy controls (Roiser et al., 2009). Possibly medication may play a 
modulatory role on both aberrant and adaptive salience, dampening both these 
processes. The FEP patients previously studied were mostly medicated, unlike those 
with subclinical symptoms or at UHR. This might mean that the aberrant salience of 
FEP patients had been decreased by the medication they were taking, and that 
simultaneously any adaptive salience they might previously have exhibited was also 
dampened, leading to a decrease in this measure compared with healthy controls. As 
my sample comprises antipsychotic-naïve or minimally treated patients followed over 
256 
 
treatment, it offers an excellent test of the effects of antipsychotic medications over 
time.  
As discussed above, my results do not support an effect of antipsychotics on adaptive 
salience scores when analysed longitudinally. It is possible that this is due to the type 
of antipsychotic (amisulpride) used in this study. Amisulpride is an SGA and FGAs 
might differ in their effects on salience attribution. However, it is also possible that 
patterns of salience attribution depend not only on medication but also on whether or 
not individuals respond to that medication.  
In my sample, although patients did not differ from healthy controls on measures of 
aberrant salience, there were differences when responders and non-responders were 
directly compared. Responders showed non-significantly higher levels of implicit 
aberrant salience at baseline compared with non-responders, which significantly 
decreased with treatment. Therefore at follow up, responders had significantly lower 
levels of implicit aberrant salience than non-responders. It is possible that different 
patients exhibit different patterns of salience attribution when they are untreated. 
Differences in salience disruptions underlying their illness may be associated with 
differences in individuals’ response to treatment. As such, those who have increased 
levels of aberrant salience are more likely to respond well to treatment, whereas those 
who do not show this salience abnormality, but have decreased adaptive salience, are 
likely to respond less well to treatment. This latter may be consistent with the idea that 
non-responders and treatment-resistance is related to a predominance of negative 
symptoms (Stone et al., 2009).  
Furthering this argument, it is possible to speculate that these differences are 
determined by differences in the neurotransmitter disturbances underlying the illness, 
with dopamine or glutamate differentially involved in producing symptoms. Increased 
aberrant salience is purported to result from disturbed dopamine signalling, for example 
increases in dopamine in the mesolimbic system (Kapur, 2003). Furthermore, current 
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antipsychotic medications primarily target dopamine, most acting as D2 antagonists 
that lower dopamine levels, leading to a reduction in psychotic symptoms (Stahl, 2013). 
As such, those who respond well to current treatments may have a primarily dopamine-
based psychosis, which leads to increased aberrant salience. However, this increased 
dopamine (and associated aberrant salience) is dampened by the antipsychotic 
medication. As dopamine levels are reduced, aberrant salience levels would also be 
expected to lower, and if this is related to symptomatology, a good response to 
treatment would be seen. In contrast, those who show a poor response to treatment 
might have an alternative underlying pathology, in which dopamine plays less of a role 
but other neurotransmitter systems, such as glutamate, are involved. Hence, they 
would be less likely to respond to current treatments that target dopamine, as this 
would not be the primary dysfunction causing their symptoms. Studies in treatment-
resistant schizophrenia have suggested that glutamate disruption might play a role in 
the aetiology of the illness of such individuals (Stone et al., 2007).  
As a result, a vast area of research is now investigating the efficacy of medications that 
target glutamate to treat psychosis. A primarily glutamate-based pathophysiology might 
be related to lower levels of adaptive salience but not increases in aberrant salience, 
thus showing a greater predominance of negative symptoms such as withdrawal and 
flat affect. A psychosis associated with glutamate dysfunction would be less likely to 
respond to treatments that target dopamine and so such individuals might be less likely 
to show a good response to treatment. This theory would be supported by my results, 
showing lower levels of adaptive salience in non-responders. However, it is not 
possible to comment on the glutamate signalling in such individuals, or whether there 
are differences in glutamate function between responders and non-responders. These 
arguments are highly speculative and require much further research to support them. 
Positron emission tomographic (PET) studies are required to monitor dopamine levels 
in patients before and after treatment, alongside tasks such as the SAT, which can 
provide measures of salience attribution. In addition, whilst glutamatergic compounds 
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have shown some promise in early clinical trials (Stone, 2011; Noetzel et al., 2013), 
results remain few and inconsistent, and glutamatergic compounds are not yet 
available for regular use in the clinic to treat psychosis (Kahn and Sommer, 2015; 
Singh and Singh 2011). Therefore, further research regarding the pathophysiology 
underlying the illness of treatment non-responders and the reasons for their poor 
response to treatment is warranted. 
Nonetheless, my results suggest that there are abnormalities in salience attribution 
processes of patients with psychosis compared with healthy controls. However, these 
abnormalities differ within patient groups, such that particular patterns of abnormality 
are related to response to treatment. Those who show a good response to treatment 
show greater aberrant salience, whilst those who show a poor response show 
disruptions in adaptive salience processes.  
c) Neural activation during salience attribution measured using fMRI 
Several previous studies have used different types of functional imaging to predict 
treatment response. For example, PET studies have indicated that a good treatment 
response is associated with greater striatal D2 receptor occupancy during treatment 
(Kapur et al., 2001; Nordstrom et al., 1993; Agid et al., 2007) and increased striatal 
dopamine synthesis capacity (Demjaha et al., 2012; Abi-Dargham et al., 2000). BOLD 
fMRI techniques have been used more rarely to investigate relationships between brain 
function and response to treatment. Studies using the n-back (a working memory task) 
have suggested increased PFC activity associated with improved symptoms following 
treatment with CBT (Kumari et al., 2009), as well as atypical antipsychotic medications 
(Honey et al., 1999; Meisenzahl et al., 2006). Unfortunately, these studies have not 
investigated differences between good and poor responders at baseline (before 
treatment commences) and so the results are of limited predictive use.  
Only two studies have investigated the relationship between functional brain activation 
before treatment and later response to treatment (Van Veelan et al., 2011; Nejad et al., 
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2013). Both these studies investigated working memory activation and found that 
particular patterns predicted later response to treatment. Van Veelan and colleagues 
(2011) found left dorsolateral PFC abnormalities in non-responders only, and that 
responders did not differ from healthy controls. Nejad and colleagues (2013) looked at 
functional connectivity, and found activation in a frontoparietal network that predicted 
improvements in negative symptoms. It is difficult to compare these studies to my own 
results as they are investigating a different aspect of brain function. No previous 
studies have investigated salience processing in relation to treatment response within a 
fMRI paradigm. As such, my results provide the first indications of whether measures of 
neural activation underlying salience processing are good potential biomarkers of 
treatment response in FEP.  
Indeed, given the wide range of potential tasks, each tapping a different area of 
cognition, functional imaging provides a huge potential for predictive biomarkers. 
However, there is also a danger that too much variation in task choice prevents 
comparison between studies and makes it difficult to generalise results. It is necessary 
to choose appropriate functional tasks based on theory and a priori hypotheses. The 
use of standardised, commonly used, validated tasks for particular functions is also 
desirable. A good example of this is the n-back task, which is often used to probe 
working memory processes. There is no standard task for the investigation of salience 
attribution. Whilst various tasks are commonly used to provide measures of various 
aspects of reward processing, none offers specific measures of salience attribution, 
both at implicit and explicit levels. The SAT might therefore be good candidate for 
future studies investigating salience attribution in relation to treatment effects and 
treatment response.  
My results showed that whilst there were few differences between healthy controls and 
the entire patient group, several differences became apparent when patients were 
divided according to response. This may suggest that patients showing a good 
response have different underlying pathophysiology to those showing a poor response, 
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as discussed above. This was first illustrated by comparing four-week responders and 
non-responders directly. At baseline, four-week responders had higher activation in the 
insula and cerebellum than non-responders during adaptive salience processing. Four-
week responders also had activation in frontal regions during adaptive salience 
processing that was not seen in non-responders. At follow up, responders had higher 
activation in the midbrain, again associated with adaptive salience.  
The insula is a region of cortex at the base of the lateral sulcus, and plays a role in 
various aspects of emotions, perception, and cognition (Gasquoine, 2014). 
Furthermore, the insula, along with the anterior cingulate cortex, is thought to be part of 
a salience network, which enables switching between the default mode network at rest 
and task-related states of brain activation (Palaniyappan and Liddle, 2012). Structural 
and functional abnormalities in the insula have been reported in a range of psychiatric 
disorders, including autism, eating disorders, anxiety, and schizophrenia (Gasquoine 
2014). Meta-analyses support the existence of bilateral volume reductions in the insula 
in schizophrenia, unrelated to illness stage or sex (Shepherd et al., 2012). 
Furthermore, decreased gyrification in the insula may be related to poor treatment 
response (Palaniyappan et al., 2013). In a functional study, reduced prediction error 
signals in the insula during instrumental reward learning were reported, which 
correlated with positive symptom severity (Gradin et al., 2011). This is consistent with 
my results in which four-week non-responders, who had more severe positive 
symptoms than responders even at baseline, had reduced insula activation during 
salience attribution. Activation in this region could therefore provide a potential 
biomarker for treatment response.  
I also compared responders and non-responders each in turn with healthy controls. 
Consistent with Van Veelan and colleagues (2011), I did not find any differences 
between responders and healthy controls at baseline. However, non-responders did 
differ from healthy controls, with decreased activation in the cerebellum. Whilst the 
cerebellum has traditionally been associated with motor control and coordination, more 
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recent studies have implicated this structure in emotion regulation and cognition 
(Shakiba, 2014). What’s more, cerebellar abnormalities have been implicated in 
several psychiatric disorders, such as bipolar disorder, depression, and anxiety 
disorders, in addition to schizophrenia (Philips et al., 2015). It is interesting that whilst 
four-week responders in my study did not show any activation changes with treatment, 
bilateral increases in the cerebellum associated with adaptive salience processing were 
seen in non-responders. It is not clear how cerebellar activation relates to symptoms, 
as non-responders remained symptomatic despite this increase in activation. 
Furthermore, at follow up they no longer differed from healthy controls in this region.  
Different regions were associated with response to treatment when longer-term 
response was considered. At baseline, the comparisons of 12-week responders and 
non-responders identified differences in the superior temporal and middle occipital 
lobes. At follow up, there were no longer any differences between these two groups. 
Similarly to four-week responders, those designated as responders at 12 weeks did not 
show any differences from healthy controls at either baseline or follow up. Long-term 
non-response appears to be associated with reduced activation during adaptive 
salience in the cerebellum before treatment commences. After four weeks of treatment, 
12-week non-responders had lower activation in the frontal lobe and posterior cingulate 
associated with aberrant salience. These results suggest that altered activation during 
adaptive salience processing is associated with both short- and longer-term poor 
response to treatment. However, those patients showing a good response to treatment, 
both in the short- and longer-term, did not differ significantly from healthy controls. 
These differences are apparent before treatment initiation and so may be potential 
predictive biomarkers for treatment response.  
It is interesting that there were mainly differences during adaptive salience processing, 
and fewer during aberrant attribution of salience. Moreover, there was a clear link 
between adaptive salience abnormalities and treatment response, whether this was 
defined by the Andreasen criteria or by percentage PANSS change. This is consistent 
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with recent currently unpublished research investigating ultra high-risk (UHR) 
participants (Schmidt et al., in prep), where normalisation of adaptive salience 
processing was associated with improvement of delusion-like symptoms. Whilst good 
treatment response is associated with greater abnormalities in dopamine signalling, 
they are here exhibiting less marked abnormalities in adaptive salience processes. This 
may suggest that rather than increased or aberrant dopamine signalling, it is a lack of 
dopamine that underlies adaptive salience abnormalities. This would be consistent with 
my finding that there is underactivation in the midbrain of non-responders after four 
weeks of treatment, potentially suggesting that antipsychotic treatment had failed to 
normalise dopamine function in this region.  
Adaptive salience abnormalities may therefore be more significant in the development 
of psychosis, particularly in those who are unlikely to respond to currently available 
treatments. This is consistent with the argument outlined above, that non-response is 
related to decreased adaptive salience, which may relate to differences in underlying 
neurotransmitter disturbances. Whilst increased aberrant salience may result from 
disturbed dopamine signalling, for example increases in dopamine in the mesolimbic 
system (Kapur, 2003), disturbed adaptive salience attribution may relate to a primary 
glutamate dysfunction, which would not respond well to current treatments targeting 
dopamine. As stated above, such speculation requires much further research to 
establish whether this is the case.  
It is also worth bearing in mind that the sample size was low with both four- and 12-
week response. In particular, there were very few non-responders at either of these 
time points. Therefore, these results are preliminary and should be interpreted with 
caution. Nonetheless, my results suggest that there are differences between 
responders and non-responders at the level of both behaviour and neural activation 




d) Resting CBF measured using cASL  
Few studies have previously investigated the association between rCBF and treatment 
response longitudinally in psychosis. To my knowledge, just four have done so 
(Rodriguez et al., 1996/1997; Lahti et al., 2009; Ertugrul et al., 2009) and none of these 
used ASL. Furthermore, their patient samples have often been previously exposed to 
antipsychotics making it difficult to discern whether the effects reported were the result 
of treatment withdrawal, chronic antipsychotic use or the study drug. Nevertheless, 
there were some similarities between these studies and my results. Similar to previous 
work, I found that the precise pattern of effects of antipsychotic treatment (in this case 
with amisulpride) on brain perfusion depends on treatment response. Furthermore, 
patterns of perfusion observed at baseline differed between those who later showed a 
good response and those who showed a poor response to treatment. As these 
differences were present before treatment had begun, they may potentially provide 
predictive biomarkers of treatment response (see discussion of support vector machine 
learning below). 
At baseline, antipsychotic-naïve/minimally treated patients who later responded well to 
four weeks of amisulpride had higher rCBF in regions of the cerebellum and in the 
bilateral thalamus than those who went on to show a poor response to treatment. This 
is consistent with the work of Rodriguez and colleagues (1996/1997) who found greater 
thalamic perfusion, as well as greater perfusion in the basal ganglia and right PFC at 
baseline associated with a good response to clozapine. In addition, thalamic rCBF 
ratios (relative to homolateral cerebellar rCBF) predicted response correctly in 78.9% of 
cases. However, patients in this study were treated with FGA at baseline, to which they 
had not responded. It is possible that increases in thalamic and basal ganglia perfusion 
resulted from the FGA. Indeed, Lahti and colleagues (2009) reported increases in a 




I also found that higher baseline rCBF in the thalamus of my patients was significantly 
correlated with lower PANSS scores at four-week follow up. Elsewhere, baseline 
thalamic rCBF has been shown to predict percent change in PANSS after eight weeks 
of clozapine treatment (Ertugrul et al., 2009). However, it is worth highlighting that 
percent change scores do not necessarily indicate clinically relevant improvement. As 
such, whilst higher rCBF in this structure might predict bigger changes, it is not 
necessarily associated with remission, and patients exhibiting this trait may therefore 
still be ill following treatment. Nonetheless, the presence of differences associated with 
later clinical improvement evident before treatment has started suggests that rCBF may 
have some value in predicting response to antipsychotic treatment. 
Figure 45: Simplified diagram showing the connectivity between the thalamus and 
cortical and subcortical regions (adapted from Lahti et al., 2009). 
The ventral striatum is an area rich in dopamine (DA) D2-receptors, and is likely a key site of 
initial antipsychotic action. Receiving DA (from the ventral tegmentum) and glutamate (GLU; from 
the anterior cingulate) inputs, the ventral striatum projects GABA efferents to the ventral pallidum, 
which in turn projects to the thalamus. The thalamus has glutamatergic projections to the PFC. 
The action of antipsychotics in responders and non-responders appears to have different effects. 
In responders, it is possible that previously elevated DA is opposed through D2 blockade, which 
restores GLU transmission. In non-responders, this does not occur and GLU transmission 
remains impaired.  
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The thalamus appears to be a key structure in schizophrenia, particularly as part of 
fronto-strital-thalamic networks (Figure 45). It is a highly interconnected structure, with 
projections to and from cortical regions and the brainstem, and it has been posited as a 
“gating” or “filtering” region, playing a major role in human cognition (Andreasen, 1997). 
Furthermore, models of schizophrenia have proposed the thalamus to be a crucial 
brain region that could underlie a broad information processing deficit underlying the 
pathophysiology of schizophrenia (Carlsson and Carlsson, 1990). Aside from the 
studies investigating perfusion described above, abnormalities in thalamic structure 
and function have been reported elsewhere in the literature, including decreased 
neuronal density and volume (Pakkenberg, 1992; Andreasen et al., 1990; Flaum et al., 
1990), decreased white-matter projections to the PFC (Andreasen et al., 1994), and 
abnormal activation during active hallucinations (Sibersweig et al., 1995).  
It has been proposed that the action of antipsychotics on the connections to the 
thalamus may differ in responders and non-responders (Lahti et al., 2009). The ventral 
striatum is a key site of antipsychotic action, rich in dopamine (DA) D2 receptors. PET 
studies have shown increased striatal DA release in drug-free patients (Laruelle et al., 
1996), which is predictive of treatment response (Abi-Dargham et al., 2000). It is 
possible that excessive DA signalling in the ventral striatum leads to increased 
GABAergic signalling via the ventral pallidum, which, in turn, reduces thalamic 
glutamatergic transmission to the PFC. Antipsychotics acting at the ventral striatum site 
would block excessive DA signalling, releasing the inhibitory GABAergic effects on the 
thalamus, and thus restoring glutamate signalling to the PFC and other thalamic 
projection sites. However, this process may only occur in responders, but not in non-
responders, where glutamatergic signalling remains impaired (Lahti et al., 2009). 
Precisely why non-responders would not show the same effect remains a matter of 
speculation. It is possible that the pathophysiology of their symptoms is not primarily 
due to excessive striatal DA signalling, and so drugs targeting this region have little 
effect. As outlined in section 4.1.2. b) above, it has been proposed that in individuals 
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with schizophrenia who show a poor response to current treatments the 
pathophysiology underlying the illness could be influenced by other neurotransmitter 
systems, such as glutamate (Stone et al., 2007). As previously suggested, drugs 
targeting glutamatergic dysfunctions may therefore be more effective in treating those 
who respond poorly to drugs targeting primarily the dopamine system.  
Although in my sample I observed alterations in the thalamus associated with treatment 
response, there was no effect seen in the ventral striatum or other regions connected 
with the thalamus. However, the relationships between imaging parameters is complex 
and it is possible that PET in the same subjects would have revealed increased 
dopamine release in these regions. Multimodal studies in the same subjects would be 
informative in this regard, and could aid the investigation of relationships between the 
alterations seen in different measures, for example how changes in structure or 
metabolism relate to altered perfusion.  
At follow up, there were no longer any differences between responders and non-
responders. This may suggest that as in the studies by Rodriguez and colleagues 
(1997a/b) there is a decrease in thalamic perfusion following treatment. However, in 
their study participants were treated at baseline with FGA and then switched to 
clozapine. It is therefore possible that the FGA treatment was associated with 
increased thalamic perfusion, and that this increase was greater than that associated 
with clozapine. As such, following switching there appeared to be a relative decrease in 
perfusion in this region. This highlights the importance of treatment status at baseline. 
In antipsychotic-naïve individuals, one does not need to consider the complicating 
influence of current treatment on the brain measure of interest.  
Few studies have investigated the relationships between perfusion and antipsychotic 
treatment response, and often the results obtained are conflicting. However, it may be 
unwise to try to pool results from studies looking at the effects of antipsychotics 
because there are likely to be differences in the effects of different types of 
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antipsychotics used. Particularly, FGA and SGA tend to be associated with different 
effects (Goozée et al., 2014). Even within the class of SGA, it is possible that there are 
different effects that reflect the precise mechanisms of action of the specific drug 
studied. Therefore, comparative studies of more than one antipsychotic medication 
administered to the same participant are necessary and may shed light on the 
differences in effects between drugs. This is likely to be a pertinent issue if 
personalised medicine is to develop beyond the prediction of benefit from broad 
categories of drugs. However, given the number of drugs available, to begin by 
comparing broader classes (e.g., FGA and SGA) may be a justifiable approach. Further 
understanding of the mechanisms of action of different antipsychotic medications may 
allow the development of different classification systems that provide some predictive 
value in terms of response to treatment for individual patients.  
Supporting the assertion that studies are needed that compare different types of drugs, 
in a study of patients with schizophrenia treated for six weeks with either olanzapine or 
haloperidol, there were common regions of effects but also regions in which the effects 
of the two drugs differed (Lahti et al., 2009). Both drugs acted to increase rCBF in 
cortico-subcortical and limbic networks. However, in patients treated with haloperidol, 
good response was associated with greater activation in the left thalamus and lower 
activation in the left hippocampus at follow up. In contrast, in patients treated with 
olanzapine, good response was associated with greater activation in the cerebellum 
and lower activation in cortical regions (sensorimotor, middle and medial frontal, 
superior parietal, and anterior cingulate cortex) at follow up.  
In addition to cross-sectional analyses, I also investigated the effects of amisulpride 
longitudinally in responders and non-responders. This revealed differences dependent 
on response to treatment. When responders and non-responders were assessed 
separately, responders were shown to have an increase in rCBF in the precentral 
gyrus, whilst non-responders did not show any changes. However, there was an overall 
decrease in global rCBF in non-responders that was not seen in responders. Increased 
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parietal rCBF was also seen in 12-week responders and non-responders, although the 
precise region differed slightly. These results suggest that there are longitudinal 
changes with antipsychotic treatment, which differ depending on whether patients later 
showed good or poor response to treatment. Furthermore, it suggests that there may 
be fewer effects of antipsychotic medication on patterns of regional brain perfusion in 
non-responders, who also show fewer changes in symptomatology. The global 
decrease in rCBF observed in non-responders may reflect a non-specific, diffuse effect 
of the drug that does not lead to improved symptomatology. Of course, as my group of 
non-responders was small, it is possible that the sample lacked power to detect any 
regional changes in rCBF.  
As discussed above, interpreting perfusion is complex as a number of biological 
mechanisms may play a role. There are several mechanisms by which antipsychotics 
could lead to altered perfusion. It is supposed that perfusion reflects microcirculation 
and glucose consumption, and integrative synaptic processes (mostly postsynaptic) 
rather than spike rates of efferent cells (Lauritzen, 2001). However, this suggests that 
perfusion could reflect any number of events occurring at a synapse, including 
neurotransmitter interactions with receptors, production of second messengers, 
reuptake, and recovery of electrochemical gradients. Some authors have suggested a 
role for receptor-level factors, such as up- and down-regulation (Jenkins, 2012), which 
could provide a link between the dopaminergic changes seen with antipsychotic 
treatment and changes in blood perfusion to serve the altered metabolic associated 
with these changes. Others have highlighted global, systemic effects of drugs, such as 
direct effects on blood vessels (Viviani et al., 2013). However, my results suggest 
regional effects in addition to global effects, which are not adequately accounted for by 
global, systemic antipsychotic effects. Perfusion changes likely reflect functional or 
structural alterations also seen with antipsychotic treatment, and the changes in 
metabolic demand associated with these. Neural activation is coupled with blood 
oxygen use, and so changes in activation will likely be reflected in perfusion changes 
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(Theberge, 2008), although whether this relationship is direct is unclear. The direction 
of these relationships also remains unclear. It is possible that structural changes 
precede and lead to changes in perfusion, and vice versa. Multimodality longitudinal 
studies in humans across illness progression may provide insight into these 
relationships, alongside animal studies to determine the molecular and cellular 
processes underlying changes in blood flow.  
Longitudinal analyses can show the dynamic changes associated with good or poor 
response, and may therefore aid the elucidation of mechanisms of response or new 
treatment targets for those showing a poor response. However, when considering 
prediction of response in a clinical setting, studying baseline differences can be more 
useful. Personalised medicine would benefit most from biomarkers that predict later 
treatment response but are present before treatment begins, allowing clinicians to 
assess the pre-treatment neurobiology of patients and pick a treatment that is likely to 
be successful on this basis. For this, support vector machine learning and other types 




4.2 Limitations of the research 
My sample was recruited from mainly outpatient services, during the first two years of 
illness. Furthermore, I could not recruit patients who were treated or admitted on an 
involuntary basis (under a Section of the Mental Health Act). These factors mean that 
the sample of patients I recruited were unlikely to be severely ill, as they were being 
treated in the community (all except one patient) and were well enough to consent to 
and take part in the study. This may limit the generalizability of the results. It has been 
reported that more than 70% of patients with a FEP are admitted to hospital (Byrne, 
2007) and for many their first contact with services is via an admission often through 
accident and emergency departments (Payne et al., 2006). Furthermore, more severely 
ill patients may have more problems with adherence to treatment, which would affect 
the perceived efficacy of a treatment. Our patients were mostly quite willing to take 
antipsychotic medications, and were more closely supervised (by the research team in 
addition to the clinical team) than they would otherwise have been. Therefore, these 
results may not be applicable to more severely ill inpatients who would be less 
adherent to medication.  
The less severely ill sample we recruited may also explain the relatively small number 
of non-responders (although we were close to the 40% reported by Barnes et al., 
2011), as severity of illness may be related to later treatment response. Indeed, in our 
own sample, we found that baseline severity of illness (PANSS, CGI, and PSP) was 
related to later response to treatment, with non-responders being more severely ill at 
baseline than responders. However, having a small number of non-responders reduces 
the power of the statistical analyses carried out. I have attempted to overcome this by 
using a continuous measure of treatment response alongside a categorical definition, 
to provide further support for any relationships between the characteristics and clinical 
variables in patients and treatment response.  
A further consideration in the interpretation of my results regards the length of time for 
which patients were treated. We assessed treatment response at four weeks. Most 
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patients are treated for much longer with antipsychotic medications. In some cases, a 
patient may take longer than this to show a response to treatment. However, I also 
used the PPHS to assess 12-week treatment response in order to gain an idea of how 
longer term outcome might be affected by the variables studied. However, it is possible 
that between these two time points antipsychotic medication was changed as part of 
the study protocol or by the responsible clinician. Furthermore, 12-week follow up was 
not available for a number of patients, limiting the sample size at this stage. However, 
previous studies have shown that antipsychotic medications have effects on the brain 
early in treatment, and many studies support that early response to treatment is 
strongly predictive of later response (see discussion above).  
Indeed, sample size may be a limitation for the functional imaging results presented in 
this thesis. Nonetheless, the power calculations on page 113 of the Methods suggest 
that a sample size of 16 participants would be required to have 80% power at p=0.05 to 
detect an effect size of 0.9, between response groups at baseline on the SAT. This is 
less than the effect reported by Roiser et al. (2009) comparing patients with and 
without positive psychotic symptoms (d=1.6). This suggests that my sample was 
sufficient. Nonetheless, future studies should aim to recruit larger samples, which could 
be aided by large multicentre trials.   
A major strength of this study was its focus on recruiting a more homogeneous patient 
group than has previously been studied. Ideally, patients who are entirely 
antipsychotic-naïve would be recruited and scanned prior to any medication being 
prescribed. However, in reality this is incredibly difficult to achieve, given pathways to 
care and our ability to identify patients before treatment, as well as ethically dubious if 
we are to arrange study practicalities without delaying much-needed treatment. For this 
reason, most of our patients were in fact minimally treated rather than completely 
naïve. However, even short term and single doses of antipsychotic drugs have been 
shown to affect the brain (Handley et al., 2014). We must therefore be cautious in 
interpreting the findings from baseline brain scans, as they may already reflect changes 
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related to the treatment patients received prior to this. However, the duration of 
previous treatment was limited to a maximum of two weeks, and the mean period of 
treatment prior to the first scan was just 8.76 days (S.D. 7.74). It would be more of a 
concern if there were differences between responders and non-responders regarding 
treatment prior to the first scan, as this might be responsible for differences seen 
between the two groups. However, when this was directly compared, there was no 
significant difference (t(23)=-0.21, p=0.83). 
The longitudinal design of this study is a strength as it enables investigation of changes 
over treatment within the same individuals. However, longitudinal designs, with 
individual patients being followed up over time, invite a risk of drop out. If patients do 
drop out of the study it is worth considering whether there were any differences 
between patients completing follow up and those who dropped out. In this study, we 
had follow up clinical scores for all patients, and cASL imaging for all patients. Only two 
patients completed a baseline fMRI scan and did not complete the follow up. As this is 
a relatively small number of patients, it is unlikely that this would have affected my 
results.  
In this study, the use of a single antipsychotic drug ensured that the effects seen could 
be interpreted more easily within the context of the mechanisms of action of this 
particular medication. However, it limits the generalizability of the results somewhat. 
Patients in real life are treated with a range of antipsychotic medications and these 
results do not allow us to directly apply the predictive biomarkers found to these other 
drugs. Furthermore, the results cannot aid the clinical choice between antipsychotic 
medications by informing us of which patients would benefit from which specific drug. 
Future studies comparing different classes and different specific antipsychotic 
medications are necessary. However, using a single antipsychotic with a relatively pure 
mechanism of action at D2 receptors is a strength at this early stage.  
Finally, this study justifiably focuses on the early stages of psychotic illness. Many 
current patients who have been ill for a long time and previously treated, may also have 
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inadequate management of symptoms and might benefit from medication optimisation 
through predictive biomarkers to avoid the need for more lengthy trials of alternative 
medications. However, the results in this study are only relevant to patients who are 
first beginning treatment. Whilst it is clear we wish to target patients early on and 
prevent chronic illness, the many individuals who are already ill with poorly managed 
treatments may not benefit from this kind of research. Nonetheless, the ultimate aim of 
research into predictive biomarkers is that patients will receive appropriate and 
effective medication early in their illness, preventing the progression of the disease. 
Furthermore, the importance of investigating antipsychotic effects in patients with little 
prior exposure to these medications is clear, when attempting to disentangle disease 




4.3 Implications for future research 
4.3.1 Personalised medicine  
The ultimate aim of research such as that pursued in this thesis is to develop a system 
of personalised treatment for patients with psychosis. Personalised medicine uses 
genetic, proteomic, and neuroimaging biomarkers to inform the diagnosis, treatment, 
and management of illness in individual patients. This approach assumes that 
individuals have unique biological characteristics that influence their diagnosis and 
response to therapies (Ozomaro et al., 2013). Here, I have been particularly concerned 
with the prediction of response to treatment in psychosis. Personalised medicine is an 
approach that has been adopted successfully in various areas of physical health (e.g. 
oncology), and is increasingly a focus in psychiatric illnesses.  
Personalised medicine would hold a number of benefits for both individuals and 
society. Some patients with psychosis do not respond to the first antipsychotic 
prescribed and we cannot currently predict who will respond and who will not (Barnes 
et al., 2011). As such, patients may undergo a series of treatment ‘trials’ until they find 
an antipsychotic that works for them. This can be associated with a degree of suffering 
on the part of the patient, as well as associated detrimental effects on their social and 
occupational functioning. In addition, there is a societal cost associated with poorly 
treated illness, including the extra time and money required to treat residual symptoms 
and associated morbidity, adverse drug reactions and side effects (Piquette-Miller and 
Grant, 2007). Therefore, discovering biomarkers that are predictive of response to 
treatment would allow drug treatments to be tailored to the pathophysiology underlying 
a particular patient’s illness.  
Such biomarkers could be integrated into routine clinical practice, if tools were 
developed that could detect them at an early stage. Thus, a patient diagnosed with a 
first episode psychosis might receive an MRI scan or a blood test as part of their initial 
assessment. The results of such an investigation could then be used to determine 
275 
 
which treatment the patient is likely to benefit from, prior to initiation of treatment. This 
would avoid the need for lengthy treatment trials, in which various medications are 
trialled unsuccessfully before one is found to be effective. I discuss the potential for 
clinical application of such biomarkers below (page 293).  
In this line of research, it is important to not only consider the factors that determine a 
good response to treatment, but also those that are associated with non-response. 
Many studies focus on the clinical or biological variables that predict a favourable 
treatment outcome. It is important that we do not neglect the neurobiological signatures 
of a poor response. The former will allow us to practice personalised medicine, the 
latter will identify those who may not respond to any current treatments. Therefore, 
understanding the mechanisms of their lack of response may provide new treatment 
targets, to allow new drugs to be developed that can provide benefit for those who 
currently show a poor response to all available antipsychotic medications. Research 
that pursues alternative treatments for those who do not respond to current 
dopaminergic drugs is already underway, with the most obvious example being 
glutamatergic compounds. The development of effective alternative treatments will be 
aided by identification of neurobiological alterations that are found in non-responders 
and can be targeted by new compounds.  
Of course, this study only considered a single antipsychotic medication, amisulpride. 
For predictive tools to be useful clinically, future research will need to investigate a 
range of different treatments. It is possible the factors predicting a good response to 
different antipsychotic medications differ, depending on the precise mechanisms of 
action of that drug. Indeed, as we have seen results from several studies in which more 
than one antipsychotic has been investigated suggest that there are differential effects 
of different medications. Whilst a broad division between FGA and SGA can be drawn, 
it is possible that future research will further differentiate between the actions of drugs 
from within these classes to add extra precision to the selection of a medication for an 
individual’s treatment plan.   
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Despite the promises and optimism of research in personalised medicine in psychiatry, 
some have criticised the relative paucity of primary research studies compared with 
reviews and commentaries (Holmes et al., 2009). However, as the field progresses this 
will hopefully change. Others have suggested that personalised psychiatric practice will 
not determine which of a range of drugs a patient should be prescribed but rather will 
exclude those unlikely to have an effect in a small number of patients (De Leon 2009). 
However, it is possible that integrative approaches, using information from 
neuroimaging, as well as genetics and proteomics, may provide more accurate 
predictions (Costa e Silva, 2013). Furthermore, network and multivariate approaches 
are promising new avenues that better reflect the nature of the pathophysiology 
underlying complex psychiatric disorders and will aid our understanding of the 
biological mechanisms of aetiology and treatment response.   
4.3.2 Clinical application 
Currently, personalised approaches to treatment in psychiatry are not at the stage 
where they could be implemented in the clinic. This field is still a burgeoning field, but 
there is promise that the search for useful predictive biomarkers of response to 
treatment will be fruitful. Although much further work is required to identify reliable and 
accurate predictive biomarkers, it is necessary to consider some of the implications of 
this line of research in the clinic, and some of the barriers there may be in applying the 
tools clinically. 
Several biomarkers have been investigated as potential predictive tools for refining 
treatment of individual patients. The neuroimaging techniques proposed, such as those 
used in the current project, hold a number of advantages as potential predictive tools. 
Firstly, they are safe to use and entirely non-invasive. Aside from some 
contraindications (such as claustrophobia and metal implants in the body), most 
patients will be able to undergo an MRI scan. Secondly, these scans can be quick and 
are not taxing for the patient, particularly if resting state measures are used. Of course, 
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the patient’s illness state may be important. It needs to be considered at what stage of 
illness it is optimal to scan a patient to inform treatment. Clearly, it would be desirable 
to scan a patient as early as possible to start treatment as soon as possible, in line with 
early intervention approaches to the treatment of psychosis. However, this would have 
to be balanced with the presence of acute psychotic symptoms that may make a scan 
impractical or particularly uncomfortable for the patient.  
Of course, the uptake of new practice and new tools in the clinic is determined by a 
number of factors beyond simply the effectiveness and availability of the new 
technology. MacQueen (2010) has outlined some of the potential barriers to uptake, 
including policy issues. For example, there must be consideration of how to deal with 
the large amounts of personal and potentially sensitive information created by a 
personalised medicine approach. Furthermore, detailed cost-benefit analyses are yet to 
be conducted. MRI scans can be costly and psychiatric illnesses are relatively 
common, which may mean a high demand for such assessments (MacQueen, 2010). 
Nonetheless, it is possible that compared with the cost of poorly managed psychiatric 
illness, the outlay for such assessments may prove more cost-effective in the long 
term. Detailed cost-benefit analyses are required to answer such questions. 
A hugely influential factor in the uptake of such technologies for the diagnosis, 
treatment, and management of psychiatric disorders will be psychiatrists themselves. 
Indeed, it is possible that a cultural change will be required before such tools could be 
successfully integrated into clinical practice. Psychiatrists are generally trained to take 
a holistic view of their patients, and so may reject the impersonal nature of a scan that 
does not consider other psychosocial factors. Indeed, for many psychiatrists, the term 
‘personalised medicine’ refers to the consideration of other psychosocial factors into 
the treatment of an individual. Therefore, introduction of the technology would require 
some education and training for clinicians, and it would need to be incorporated into the 
holistic approach that is embedded within current psychiatric practice. Importantly, 
some psychiatrists may feel as though new technology, which appears to make 
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decisions on their behalf, threatens the importance of their clinical judgement, gained 
through long-term knowledge of a patient and the insight gained into each individual’s 
unique experience of an illness gained from more traditional psychiatric assessment. 
Indeed, psychiatrists do not currently use laboratory tests in their practice, but as 
suggested by MacQueen (2010) the curriculum for specialty training could be 
developed to reflect recent advances in biological psychiatry and to try to oppose the 
development of ‘neurophobia’ amongst newly qualified psychiatrists (Bullmore et al., 
2009). Such changes may facilitate the incorporation of scanning for predictive 
biomarkers into regular clinical practice.  
4.3.3 Future research directions  
My results suggest that patients with psychosis differ in underlying neurophysiological 
processes, as well as relevant behavioural measures, based on whether they show a 
good or poor response to treatment. There are also differential effects of antipsychotics 
on the brains of responders and non-responders. Personalised medicine hopes to 
discover such associations, and find biological markers that can predict clinical 
improvement before treatment, such that drugs can be targeted to particular individuals 
based on the pathophysiology of their disorder.  
It is particularly important to confirm whether there are differences between these 
patients before treatment commences. I found several differences at baseline between 
patients who later showed a good response and those who later showed a poor 
response. That these differences are present before treatment is important if 
neurobiological measures are to be used to predict treatment response. Whilst it is 
interesting to note the differences in prospective dynamic changes in neurobiological 
measures during treatment depending on response to treatment, these differences 
could not be used to guide treatment choice in a personalised manner that avoids trial 
and error, as discussed elsewhere in this thesis.  
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A new technique that holds particular promise is support vector machine learning 
(SVM), a pattern recognition method that models brain activity as activation within 
distributed networks and can be used to predict outcomes at an individual level 
(Mourao-Miranda et al., 2012). Very few studies have used this technique to predict 
treatment response, although it has shown promise in predicting transition to psychosis 
(Koutsouleris et al., 2009; 2012) or longer-term prognosis (Mourao-Miranda et al., 
2012). Further work on the data used in this thesis will investigate the potential for SVM 
to be applied to measures of resting perfusion and functional activation during the SAT 
to predict outcome to treatment. Patient recruitment in the OPTiMiSE study continues 
until April 2016, which will increase the sample size. This would be an advantage as 
the sample used in this thesis is relatively small for pattern recognition procedures, 
particularly those categorised as non-responders.  
Further research building on the results of this thesis should also consider the 
integration of multiple imaging modalities to further understand the neurophysiology 
underlying psychotic symptoms and response to treatment. In particular, PET imaging 
alongside perfusion imaging could relate dopaminergic alterations reported in patients 
to brain blood flow.  
My results provide promise that neuroimaging markers could be used for the prediction 
of treatment response. They would offer safe, non-invasive tools that enable clinicians 
to improve management of psychosis with pharmacological treatments, by ensuring a 
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a  b  s  t  r  a  c  t
Evaluating  the short-  and  long-term  effects  of  antipsychotics  on  brain  physiology  is  a  key  factor  in  advanc-
ing  our  understanding  of  neurophysiological  changes  in  psychosis  and  improving  prediction  of treatment
response.  Understanding  the  nature  of  such  changes  is crucial  to  the  interpretation  of neuroimaging  ﬁnd-
ings  in patients  with  schizophrenia  and  psychoses  in  general.  This  review  has  systematically  appraised
existing  evidence  on  resting  cerebral  blood  ﬂow  (rCBF)  in schizophrenia,  before  and  after  antipsychotic
treatment,  relating  the  ﬁndings  to symptom  severity.  The  review  shows  that  antipsychotics  exert  regional
effects  on rCBF,  particularly  in frontal  and  basal  ganglia  regions,  and  that  different  antipsychotic  gener-
ations  have  differential  effects  on  rCBF.  These  ﬁndings  are  supported  by an exploratory  meta-analysis  of
a  subset  of studies.  The  review  also  highlights  the  relative  lack  of  studies  that  use a priori  deﬁnitions  of
treatment  response,  which  is an  important  step  in  identifying  testable  hypotheses  and  ensuring  clinical
relevance  of remission  criteria.  Finally,  the  review  highlights  important  considerations  for future  psy-
chopharmacological  studies  investigating  the  potential  for rCBF  to predict  symptomatic  improvement,
which  could  inform  the management  of  treatment  in  schizophrenia.
©  2014  Elsevier  Ltd.  All  rights  reserved.
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1. Introduction
Although our understanding of the pharmacodynamic effects of
different antipsychotics has advanced, the precise nature of their
short and long-term effects on brain physiology remains unclear.
Furthermore, it remains to be established whether physiologi-
cal effects are speciﬁcally associated with clinical improvement.
Understanding the nature of such effects is crucial to the interpre-
tation of neuroimaging ﬁndings in patients with schizophrenia and
psychoses in general.
Growing evidence suggests that some of the brain structural and
functional changes observed in these disorders are partly related to
antipsychotic treatment (Navari and Dazzan, 2009; Ho et al., 2011;
Davis et al., 2005; Vita and De Peri, 2007). This evidence also sug-
gests that different antipsychotics may  be associated with speciﬁc
alterations (Vita and De Peri, 2007), with ﬁrst generation antipsy-
chotics (FGA) particularly associated with increased basal ganglia
(BG) and decreased frontal and temporal cortical volumes, and sec-
ond generation antipsychotics (SGA) less so (Lieberman et al., 1987;
Ho et al., 2011).
Among neuroimaging markers, altered resting cerebral blood
ﬂow (rCBF) is a measure of basal brain activity that has been
related to both antipsychotic use and symptom amelioration
(Pinkham et al., 2011). Most importantly, changes in rCBF pat-
terns following antipsychotic administration have been reported
in the same brain regions reported as altered in psychosis (Miller
et al., 2001; Lahti et al., 2003). Moreover, these changes seem
to occur within a few hours of single-dose administration, pos-
sibly in a generation-speciﬁc manner (Handley et al., 2012),
hence demonstrating sensitivity of rCBF to early antipsychotic
action.
Additionally, rCBF is closely correlated with neuronal metabolic
measures (Raichle et al., 1976) and modern perfusion techniques,
such as arterial spin labelling (ASL), show that rCBF correlates with
regional brain activity measured using other techniques (Uludag
et al., 2004), thus potentially representing a good physiological
measure of antipsychotic effect. However, it should be borne in
mind that changes in rCBF may  not have the same origin as brain
activation, as several other mechanisms may  play a role in altered
perfusion. For example, molecular mechanisms at the receptor
level, including receptor distribution, up-regulation and down-
regulation of receptors will all play a role in determining regional
perfusion patterns (Jenkins, 2012). In addition, systemic effects of
drugs should be considered, such as direct effects on blood vessels,
which may  lead to global effects that need to be considered in the
analysis (Viviani et al., 2013).
Despite growing evidence that rCBF is altered by antipsychotic
administration, its relationship with treatment response remains
unclear. In fact, the few existing studies in this area have employed
different methodologies, including positron emission tomography
(PET), single-photon emission computed tomography (SPECT) and
labelled-Xenon inhalation, and different design procedures (cross-
sectional versus longitudinal). Achieving a better understanding of
this relationship could help in the prediction of treatment outcomes
and prognosis as well as in the identiﬁcation of possible novel tar-
gets for antipsychotic action, while guiding decisions regarding
how long an antipsychotic should be trialled for, or when an ade-
quate dose is achieved (Lahti et al., 2009).
This systematic review aims to address three main questions: (1)
is there consistent evidence that antipsychotic medications induce
changes in global or regional rCBF; (2) if so, how do changes in
rCBF correlate with symptoms prior to and following antipsychotic




Searches were performed in EMBASE, PsycINFO, and Medline
databases for peer-reviewed articles published between January
1980 and March 2013. Search terms used were: [“schizophrenia”
OR “psychosis” OR “schizo$”] OR [healthy controls” OR “normal
volunteers” OR “controls”] AND [“neuroleptic agent” OR “atypical
antipsychotic agent” OR “antipsychotic drug” OR  “typical antipsy-
chotic agent”] OR [“unmedicated” OR “antipsychotic-naïve”] AND
[“Brain blood ﬂow” OR “cerebral blood ﬂow” OR “brain rCBF”] AND
[“rest” OR “resting state” OR “baseline” OR “resting”]. Abstracts
were reviewed to assess the relevance of the papers identiﬁed and
any duplicates were removed. Further, references were also exam-
ined for relevance and included if appropriate.
2.2. Study selection
Studies were selected by the ﬁrst author (R.G.) and checked by
the second author (R.H.). Studies directly measuring resting cere-
bral blood ﬂow (rCBF) in patients with a diagnosis of schizophrenia
in relation to administration of an antipsychotic drug were
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included. Task-related activation, metabolism, receptor function
and electrophysiological studies were excluded. Papers comparing
a medicated with an unmedicated group (cross-sectional) or using
an ‘on’ and ‘off’ medication within-subjects design (longitudinal)
were included. Only studies scanning at rest, with patients sitting
or lying down, with eyes open or closed, were included. Proceedings
from conferences were removed from the search.
2.3. Data extraction
For each study the following information was extracted, if avail-
able: (1) year of publication; (2) study design (cross-sectional,
longitudinal single-dose or longitudinal multiple-dose); (3) par-
ticipant demographics; (4) antipsychotic generation and dose;
(5) duration of previous antipsychotic exposure; (6) duration
of treatment prior to ﬁrst scan and between ﬁrst and second
scans, if applicable; (7) image analysis strategy (region of inter-
est, ROI, versus voxel-wise) and regions investigated; (8) rCBF
quantiﬁcation methodology and contrasts performed; (9) asso-
ciations between rCBF values and symptomatology or treatment
response. For all contrasts and associations, reported estimates of
the strength of the effects were extracted when given (either Pear-
son’s r, or Cohen’s d). Where these were not reported but could be
calculated from the data in the original paper, a Cohen’s d effect size
estimate was calculated using the methods outlined in Appendix A.
2.4. Analysis
There was insufﬁcient homogeneity between studies to allow a
quantitative, meta-analytic approach of region of interest studies.
Therefore, a critical, systematic review was undertaken. Never-
theless, a subset of three VBM studies were subjected to signed
differential mapping (SDM), a meta-analytic technique for voxel-
wise neuroimaging data (Radua et al., 2013).
2.4.1. Study quality
Quality of papers included in the meta-analysis was  scored in
6 key areas, as follows: (1) same scanner and sequence used for
each subject (different scanner or sequence = 0, same scanner and
sequence = 1); (2) patient group was antipsychotic-naïve (yes = 1,
mixed group = 0.5, no = 0); (3) drugs administered according to a
protocol for dose regime (yes = 1, no = 0); (4) drugs administered
according to a protocol for duration (yes = 1, no = 0); (5) with-
drawals explained (yes/none reported = 1, no = 0); (6) global rCBF
controlled for in analysis (yes = 1, no = 0).
2.4.2. Signed Differential Mapping (SDM) meta-analysis
Signed differential mapping (SDM) is a voxel-based meta-
analytic technique developed more recently than commonly used
activation likelihood estimation (ALE) methods, and it has recently
been used in a number of studies (Fusar-poli et al., 2012; Bora et al.,
2011; Palaniyappan et al., 2012). Compared to ALE, it offers sev-
eral advantages: it uses strict criteria to select coordinates, which
avoids the bias of using regions identiﬁed with liberal thresholds; it
weights for intra-study variance; and ﬁnally, it uses the general lin-
ear model allowing the use of covariates and comparisons between
groups.
More speciﬁcally, SDM combines peak coordinates from pub-
lished studies. The technique estimates an effect size map  for
each study from reported coordinates and weights each study by
sample size. The pooled effect size at every voxel is calculated
using standard meta-analytical methods. SDM requires that only
studies reporting coordinates from a whole-brain voxel-wise anal-
ysis be included, discarding region of interest (ROI) studies. A
meta-analysis of ROI studies was not possible due to a lack of homo-
geneity between these studies. The analysis was carried out using
the SDM software freely available at http://www.sdmproject.com/
and full details of the technique can be found elsewhere (Radua
et al., 2013).
We extracted and inputted into the SDM software the coor-
dinates for brain regions showing signiﬁcant rCBF increases or
decreases at follow-up compared to baseline. We  used default ES-
SDM kernel size and thresholds (FWHM = 20 mm,  voxel P = 0.005,
peak height z = 1, cluster extent = 10 voxels), and carried out supple-
mentary analyses including residual heterogeneity and jack-knife
analyses to investigate the robustness of the results (Radua et al.,
2012).
3. Results
We  identiﬁed a total of 47 studies: 12 in unmedicated patients
(Table 1), 10 cross-sectional (Table 2) and 25 longitudinal (Table 3).
3.1. Cross-sectional studies
To understand the effects of medications on the brain in dis-
ease, it is important to consider disease-related pathology, prior to
treatment. Assessing the ways in which patients differ from healthy
controls before they receive medication can help disentangle the
differences in brain perfusion that are primary to the disorder from
those that are a result of treatment. Therefore, we ﬁrst review
studies investigating rCBF in antipsychotic-naïve or unmedicated
patients compared with healthy controls. We  found 12 studies
looking at unmedicated patients with schizophrenia. Four studies
used a sample of antipsychotic-naïve patients and the remaining
8 used a mixture of antipsychotic-naïve and antipsychotic-free
patients. Following this, we present ﬁndings from 11 studies com-
paring medicated and unmedicated patients with schizophrenia
and healthy controls.
3.1.1. Studies investigating rCBF in unmedicated patients
Very few studies have investigated unmedicated patients, and
even fewer have used antipsychotic-naïve patients. The latter
would be most desirable to eliminate the possibility of identifying
effects from long-term medication use, where patients undergo a
washout of medication prior to scanning.
Two studies reported no differences in rCBF in schizophrenia
compared with healthy controls (Günther et al., 1991; Steinberg
et al., 1995b), although both found differences in task-activated
rCBF. The other ten studies did report perfusion differences but the
regions affected varied.
Eight studies reported ﬁndings in the frontal cortex, mostly in
prefrontal, medial and orbital areas. Three studies reported hyper-
frontality (Ebmeier et al., 1993; Catafau et al., 1994; Parellada et al.,
1994) and ﬁve reported hypofrontality (Steinberg et al., 1995a;
Vita et al., 1995; Andreasen et al., 1997; Kim et al., 2000; Scheef
et al., 2010) in the patient group. Interestingly, studies reporting
higher frontal rCBF more often recruited only antipsychotic-naïve
patients, whilst those reporting lower frontal rCBF often had a
mixed group. As suggested by some authors, these different results
may  support the hypothesis that hypofrontality is the result of
chronicity, negative symptoms or long-term medication use, rather
a primary correlate of the disease itself (Catafau et al., 1994).
Perfusion differences in the BG were also reported in sev-
eral studies. Again, some reported higher rCBF (Early et al., 1987;
Ebmeier et al., 1993) whilst others reported lower rCBF (Sheppard
et al., 1983; Vita et al., 1995) in this region in patients. Other sub-
cortical regions showed differences in patients with schizophrenia
when compared with healthy controls, including the thalamus,
which showed higher perfusion in three studies (Andreasen et al.,
1997; Kim et al., 2000; Scheef et al., 2010).
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Table  1
Cross-sectional studies in unmedicated patients with schizophrenia.
Reference Participants (n) and interventions Main ﬁndings
Sheppard et al. (1983) Antipsychotic-naïve (6)
Antipsychotic-free (6): 1–4 previous
doses with day washout (4), 1–3 years
with 7 day washout (2)
Healthy controls (12)
No support for hypofrontality.
↓ rCBF in basal ganglia in patients (d = 0.73, p < 0.05).
Early et al. (1987) Antipsychotic-naïve (10) ↑ rCBF in globus pallidus: whole brain ratio in patients (p = 0.0056).
Günther et al. (1991) Antipsychotic-naïve (14)
Antipsychotic-free (17): washout of
between 1 week and 2 years
Healthy controls (31)
No signiﬁcant rCBF differences between patients and healthy controls.
Ebmeier et al. (1993) Antipsychotic-naïve (10)
Antipsychotic-free (10): washout of
more than 2 weeks for oral and more
than 2 months for depot
Healthy controls (20)
↑ rCBF in frontal regions (p < 0.05) and right putamen in patients (p < 0.05). ↓ rCBF in left
inferior anterior cingulate in patients (p < 0.05).
Catafau et al. (1994) Antipsychotic-naïve (10)
Healthy controls (8)
↑ rCBF in prefrontal cortex in patients (left: p < 0.001; right: p < 0.05).
Parellada et al. (1994) Antipsychotic-naïve (6)
Healthy controls (6)
↑ rCBF in prefrontal cortex in patients (p < 0.05)
Steinberg et al. (1995a) Antipsychotic-naïve (7)
Antipsychotic-free (9): washout of
8–365 days (median 30 days)
Healthy controls (13)
↓ rCBF in “ﬁrst break” patients compared with healthy controls in superior frontal, middle
frontal and middle temporal regions (p < 0.05).
Steinberg et al. (1995b) Antipsychotic-naïve (5)
Antipsychotic-free (12): washout of
more than 8 days
Healthy controls (13)
No signiﬁcant rCBF differences between patients and healthy controls.
Vita et al. (1995) Antipsychotic-naïve (8)
Antipsychotic-free (9): washout of more
than 3 weeks
Healthy controls (12)
Antipsychotic-naïve versus healthy controls: ↑ rCBF in cerebellum (p < 0.05), ↓ rCBF in
putamen (p < 0.05), caudate (p < 0.05) and thalamus (p < 0.003).
Antipsychotic-naïve versus antipsychotic-free: ↑ rCBF in cerebellum (p < 0.05), ↓ rCBF in
putamen (p < 0.05), caudate (p < 0.05) and thalamus (p < 0.05).
Andreasen et al. (1997) Antipsychotic-naïve (17)
Healthy controls (17)
↑ rCBF in patients in left inferior frontal (d = 1.26), thalamus (left: d = 1.12; right: d = 1.12),
retrosplinal cingulate (left: d = 1.35; right: d = 1.56), left parietal/supramarginal (d = 1.46), right
fusiform/occipital (d = 1.59) and cerebellar regions (left: d = 1.21; right: d = 1.36).
↓  rCBF in patients in dorsolateral prefrontal (left: d = 1.34; right: d = 1.22), orbital frontal (left:
d  = 1.18; right: d = 1.43), middle frontal (d = 1.18), inferior temporal (left: d = 1.27; right:
d  = 1.48), mid  cingulate (d = 1.1), precuneus (d = 1.54), left parietal (d = 1.23) and primary visual
regions (d = 1.58).
Kim et al. (2000) Antipsychotic-free (31): washout of 3
weeks
Healthy controls (31)
↑ rCBF in patients in left frontal operculum (d = 0.9), cerebellum (d = 1.48), left thalamus
(d  = 0.93) and precentral regions (left: d = 0.91; right: d = 0.81).
↓  rCBF in patients in left middle frontal gyrus (d = 0.98), right inferior frontal gyrus (d = 1.52),
left orbitofrontal (d = 1.14), anterior cingulate (d = 0.93), right insula (d = 0.9) and fusiform
regions (d = 0.97).
Scheef et al. (2010) Antipsychotic-naïve (8)
Antipsychotic-free (3): washout of 2
weeks
Healthy controls (25)
↑ rCBF in patients in thalamus, cerebellum and brainstem (d = 2.82), right parahippocampus
(d  = 2.27), amygdala (left: d = 1.76: right: d = 1.34), right precuneus (d = 1.31) and right occipital
(d  = 1.27).
↓  rCBF in patients in left and right parietal, frontal and anterior cingulate (d = 3.09), left inferior
temporal gyrus (d = 1.49), cerebellum (d = 1.47), right middle temporal gyrus (d = 1.25) and left
superior frontal gyrus (1.18).
Seven studies reported differences in temporal regions, all of
which showed lower rCBF in patients as compared with healthy
controls (Ebmeier et al., 1993; Catafau et al., 1994; Steinberg et al.,
1995a; Vita et al., 1995; Andreasen et al., 1997; Kim et al., 2000;
Scheef et al., 2010).
Interestingly, one study split their patient group according
to previous antipsychotic exposure with 9 antipsychotic-naïve
patients and 8 antipsychotic-free, who had undergone a washout
of at least 3 weeks (Vita et al., 1995). Their results were revealing,
with antipsychotic-naïve patients showing differences when com-
pared with healthy controls in frontal, temporal and subcortical
regions but antipsychotic-free patients showing no differences.
This suggests that treatment with antipsychotic medication may
make cerebral blood ﬂow patterns in patients more similar to those
of healthy controls, and that these effects may  be long lasting even
after withdrawal of medication.
These studies suggest that unmedicated patients with
schizophrenia compared with controls show rCBF differences
in frontal, temporal and BG regions. However, results are hetero-
geneous with the direction of difference (higher or lower rCBF in
patients) varying between different studies. This heterogeneity
may  result from baseline differences in prior antipsychotic expo-
sure and therefore caution should be taken when interpreting
results from studies investigating the effects of medication.
3.1.2. Schizophrenia patients versus healthy controls
Nine studies compared patients and healthy controls. Only one
of these separated patients according to medication status (med-
icated versus unmedicated) (Hook et al., 1995). The other eight
compared patients as one group with healthy controls (Mathew
et al., 1982, 1988; Gur et al., 1983, 1985; Geraud et al., 1987; Dousse
et al., 1988; Paulman et al., 1990; Mori et al., 1999), making it difﬁ-
cult to disentangle the role of medication from that of illness. Two
studies, both using 133-Xenon inhalation, reported lower global
rCBF in patients with schizophrenia when compared to healthy
controls (Mathew et al., 1982; Dousse et al., 1988).
More speciﬁc hemispheric and regional differences were also
reported, although not always consistently. An early 133-Xenon
inhalation study reported higher rCBF in the global left hemisphere
compared with the right in patients but not in healthy controls (Gur
et al., 1983, 1985). Mathew et al. (1988) reported more speciﬁcally
that schizophrenia was associated with higher right occipital and
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Table 2
Cross-sectional studies in patients and healthy controls; ↑ denotes higher rCBF; ↓ denotes lower rCBF.
Reference Participants (n) and interventions Correlations with clinical measures Main ﬁndings
Medoff et al. (2001) Antipsychotic-treated (10): 0.3 mg/kg/day
Haloperidol
Antipsychotic-free (18): 31 ± 17 days
washout
Healthy controls (12)
Correlations not explored ↑ rCBF in hippocampus in
antipsychotic-free patients (p < 0.05).
Mori et al. (1999) Antipsychotic-treated (118): type not
reported, mean dose
1017.9 ± 1112.6 mg/day CP equivalents
Healthy controls (21)
Correlations not explored ↑ antipsychotic dose associated with ↓
rCBF in the left middle cerebral artery
region (r = −0.167, p < 0.05), left
thalamus (r = −0.231, p < 0.01) and
right thalamus (r = −0.193, p < 0.05).
Hook et al. (1995) Antipsychotic-treated (15): type and dose
not reported
Antipsychotic-free (15): mixture of never
treated, 4 week (oral medication) or 3
month (depot) washout
Healthy controls (15)
Correlations not explored Left hemisphere greater than right
hemisphere ﬂows (d = 0.23, F = 0.386,
p < 0.03) and frontal greater than
posterior ﬂows (d = 0.26, F = 0.480,
p < 0.06; trend to signiﬁcance) in
healthy controls and treated patients
but not unmedicated patients.
Paulman et al. (1990) Antipsychotic-treated (20): type and dose
not reported
Antipsychotic-free (20): one or two  weeks
washout
Healthy controls (31)
Correlations not explored ↑ rCBF in right and left hemisphere
(d  = 0.49, F = 4.01, p < 0.05) and ↓ rCBF
in  left frontal and parietal and right
frontal regions (p < 0.05) in patients
compared with controls.
Goldstein et al. (1990) Antipsychotic-treated (15): type not
reported, mean dose 324 ± 341 mg/day CP
equivalents
Healthy controls (15)
Correlations not explored ↑ antipsychotic dose associated with ↓
global rCBF (r = −0.34, p < 0.05).
Dousse et al. (1988) Antipsychotic-treated (24): type and dose




temporal-occipital rCBF (p < 0.02)
No signiﬁcant rCBF differences
between treated and untreated
patients. ↓ overall rCBF in patients
compared with controls (p < 0.02).
Mathew et al. (1988) Antipsychotic-treated (62): type not
reported, mean dose 556.9 ± 872.9 mg/day
CP  equivalents
Antipsychotic-free (46): two week washout
Healthy controls (108)
Suspiciousness: Left temporal rCBF
(r = 0.26, p < 0.05), right hemisphere
antero-posterior gradient (r = −0.25,
p < 0.05)
Emotional withdrawal: Left parietal rCBF
(r = 0.25, p < 0.05).
Unusual thought content: Bilateral central
rCBF (right: r = 0.30, left: r = 0.27, p < 0.05),
bilateral parietal rCBF (right: r = 0.31, left:
r = 0.28, p < 0.05), bilateral occipital rCBF
(right: r = 0.27, left: r = 0.33, p < 0.05), right
temporal rCBF (r = 0.26, p < 0.05), left
frontal rCBF (r = 0.29, p < 0.05), right
hemisphere antero-posterior gradient
(r  = −0.28, p < 0.05).
No signiﬁcant rCBF differences
between treated and untreated
patients. ↑ right temporal and occipital,
and left central, temporal and occipital
rCBF in patients compared with
controls (d = 0.33, F = 2.86, p < 0.03).
Geraud et al. (1987) Antipsychotic-treated (29): type and dose
not reported
Antipsychotic-free (22): 13 never treated, 9
with 15 days (oral medication) or 45 days
(depot) washout
Healthy controls (36)
Correlations not explored No signiﬁcant rCBF differences
between treated and untreated
patients. ‘Frontal pattern’ signiﬁcantly
↓  in patients (d = 0.2, p < 0.01) in
patients.
Gur et al. (1983, 1985) Antipsychotic-treated (17): Fluphenazine,
Chlorpromazine, Thioridazine, Haloperidol,
Thiothixene or Triﬂuoperazine, dose not
reported
Antipsychotic-free (19): 3 never treated, 5
not treated for one year, 3 not treated for
two  months, 8 with one week washout
Healthy controls (44)
No signiﬁcant relationships between CBF
and clinical measures.
Medication x hemisphere x sex
interaction (d = 0.79, F[1,32] = 5.24,
p  = 0.29).
In men, ↓ left hemisphere ﬂows and ↑
right hemisphere ﬂows in anterior
regions and ↑ ﬂow bilaterally in
posterior regions with antipsychotics.
In women, ↑ ﬂow bilaterally in anterior
and posterior regions with
antipsychotics.
Mathew et al. (1982) Antipsychotic-treated (13): type and dose
not reported
Antipsychotic-free (9): one week washout
Healthy controls (17)
Hallucinatory behaviour: Left parietal rCBF
(r = −0.44, p < 0.02), temporal rCBF
(r = −0.35, p < 0.05), right temporoparietal
rCBF (r = −0.38, p < 0.04), occipital rCBF
(r = −0.41, p < 0.04).
No signiﬁcant rCBF differences
between treated and untreated
patients.
left parietal rCBF than controls in a large group of over 200 patients
and healthy controls.
Findings were more consistent across frontal regions. Compar-
ing values averaged across frontal regions with those averaged
across temporal, parietal and occipital regions, Mathew et al. (1988)
identiﬁed a signiﬁcantly lower anterior to posterior ratio in the
patient group than in controls, indicating frontal hypoperfusion.
Consistent with this, Geraud et al. (1987) reported a non-signiﬁcant
trend for lower frontal ﬂow (as a ratio of ﬂow in the rest of the brain)
in patients with schizophrenia than in controls. Also, Paulman et al.
(1990) reported bilateral frontal and temporal hypoperfusion in





















Longitudinal studies in patients and healthy controls; ↑ denotes higher rCBF; ↓ denotes lower rCBF.
Reference Participants (n) and medication Correlations Main ﬁndings
Studies in healthy controls
Fernández-Seara et al.
(2010)
Healthy controls (18): 10 mg metoclopramide;
placebo across two visits
N/A ↑ rCBF in striatum, particularly the putamen (left:
d  = 0.61, p = 0.003; right: d = 0.57, p = 0.031) and the
thalamus (left: d = 0.56, p = 0.009; right: d = 0.57,
p  = 0.007), ↓ rCBF in insula (d = 1.57) and anterior
temporal lobe (d = 1.07).
Handley et al. (2012) Healthy controls (20): 3 mg  haloperidol; 10 mg
aripiprazole; placebo randomised across three
visits
N/A Haloperidol versus placebo: ↑ rCBF in putamen
(d = 2.83, p < 0.0001) and precentral gyrus (d = 1.74,
p < 0.0001) and ↓ rCBF in inferior temporal gyrus
(d = 2.01, p < 0.0001).
Aripiprazole versus placebo: ↑ rCBF in claustrum
(d  = 2.01, p < 0.0001), putamen (d = 1.83, p = 0.002),
and  anterior cingulate (d = 1.68, p = 0.006). ↓ rCBF
in posterior cingulate (d = 1.86, p = 0.001),
prefrontal cortex (d = 1.67, p = 0.025), superior
parietal lobe (d = 1.62, p = 0.025) and orbitofrontal
cortex (d = 1.35, p = 0.039).
Haloperidol > Aripiprazole: putamen (d = 1.77,
p  = 0.002).
Viviani et al. (2013) Healthy controls (20): 100 mg BD amisulpride for 7
days; placebo double-blind with two  week
washout between scans
N/A ↑ rCBF in putamen (trend: d = 0.43, p = 0.09). ↓ rCBF
in  widespread frontal regions, including anterior
cingulate (d = 2.57, p = 0.01).
Single-dose
Lahti et al. (2005) Patients (12): 10 mg Haloperidol (6), 15 mg
Olanzapine (6); all previously treated,
unmedicated for two  weeks prior to scan
Healthy controls (0)
Correlations not explored Haloperidol: ↑ rCBF in left caudate (z = 5.83), ↓ rCBF
in  medial frontal cortex (z = 5.37), middle temporal
cortex (z = 5.33) and left cerebellum (z = 4.91).
Olanzapine: ↑ rCBF in right middle temporal cortex
(z  = 4.42) and anterior cingulate (z = 4.76), ↓ rCBF in
lingual cortex (z = 4.42).
Goldman et al. (1996) Patients (8): 5 mg Haloperidol; all previously
treated, unmedicated for at least two  weeks prior
to scan
Healthy controls (9): 5 mg Haloperidol
Correlations not explored Patients: no signiﬁcant rCBF changes.
Controls: ↑ global rCBF (F = 5.53, p < 0.05).
Jibiki et al.
(1990–1991)
Patients (2): 0.08 mg/kg IM Haloperidol; previous
antipsychotic exposure not reported
Healthy controls (2): 0.08 mg/kg IM Haloperidol
Correlations not explored Patients: 1/2 exhibited widespread ↓ rCBF across
bilateral cerebral hemispheres.
Controls: 1/2 exhibited widespread ↓ rCBF across
bilateral cerebral hemispheres.
Matsuda et al. (1990) Patients (3): 5 mg IM Haloperidol; all previously
treated
Healthy controls (2): 5 mg IM Haloperidol
Correlations not explored Patients: Left-sided dominance becomes
right-sided dominance and ↑ frontal-to-other
ratios in all areas apart from the striatum.
Controls: Similar alterations to those in patients
but of a smaller magnitude.






















Reference Participants (n) and medication Correlations Main ﬁndings
Multiple dose
Ertugrul et al. (2009) Patients (22): Clozapine for 8 weeks, mean daily
dose 350 ± 234.52 mg/day CP equivalents; all
previously treated and treatment resistant
Healthy controls (0)
Correlations not explored ↑ baseline rCBF in right frontal and thalamus of
responders.
At follow-up, ↑ rCBF in right (d = 1.35, p = 0.007)
and left (d = 1.20, p = 0.013) (superior and medial)
frontal to caudate; trend to signiﬁcant ↑ rCBF in
right (d = 1.05, p = 0.018) and left (d = 1.12,
p  = 0.029) frontal to caudate rCBF in responders. No
signiﬁcant changes in responders.
Lahti et al. (2009) Patients (29): Haloperidol or Olanzapine for 6
weeks, mean daily dose 10.43 ± 3.3 mg and
15.9 ± 4.8 mg  respectively; all previously treated,
medication free for 2 weeks
Healthy controls (0)
Correlations not explored ↑ rCBF in left pre-central (t = 4.58, p = 0.022) and
post-central cortex (t = 4.42, p = 0.047) and ↓ rCBF
in  anterior cingulate cortex (t = 5.60, p < 0.0001)
following treatment.
Responders had ↑ rCBF in right ventral striatum
(t  = 5.86, p = 0.005) with Haloperidol. Responders to
Olanzapine had ↑ rCBF in cerebellum (t = 4.92,
p  = 0.012) and right ventral putamen (t  = 4.78,
p  = 0.001) but ↓ rCBF in sensorimotor (t = 6.32,
p  < 0.0001), middle frontal (t = 4.88, p = 0.003),
superior parietal (t = 4.71, p = 0.002) and medial
frontal (t = 4.91, p = 0.001) regions.
Sharaﬁ (2005) Patients (20): Clozapine or ‘other classical
antipsychotic’, duration not reported, mean
300 mg/day and 600 mg/day CP equivalents




Paranoia: Left temporal rCBF (r = 0.50).
Follow-up
Anergia: Posterior parietal rCBF (r = −0.50 to −0.53)
Thought disturbance: Left superior frontal rCBF
(r  = −0.71), Left thalamic/basal ganglia rCBF (r = 0.55)
Paranoia: Left superior frontal rCBF (r = −0.68)
Depression: Right superior temporal rCBF (r = −0.55).
Patients had ↓ rCBF in superior frontal (p < 0.001),
inferior frontal (p < 0.01), temporal (p < 0.022),
posterior parietal (p < 0.001) and anterior parietal
(p  < 0.002) regions at baseline.
Patients had ↓ rCBF in superior frontal (p < 0.008),
inferior frontal (p < 0.043), posterior parietal
(p  < 0.001) and right anterior parietal (p = 0.013)
regions at follow-up.
Novak et al. (2005) Patients (9): Fluphenazine, Olanzapine or
Risperidone, for median 9 weeks, dosages not
reported; all antipsychotic-naïve
Healthy controls (0)
No signiﬁcant correlations. ↑ rCBF in upper left dl PFC (d = 0.67, p < 0.05) and
upper right dl PFC (d = 0.83, p < 0.05) following
treatment.
Lahti et al. (2003) Patients (6): Haloperidol (for 12 ± 10 weeks) or
Clozapine (for 23 ± 12 weeks), daily doses
12 ± 4.5 mg and 280 ± 135 mg  respectively; all
previously treated, medication free for mean
19.2 ± 4.8 days
Healthy controls (0)
Correlations not explored ↑ rCBF in right ventral striatum (t = 4.38), left
caudate (t = 4.04), dorsolateral frontal (right:
t = 4.09; left: t = 3.39) and left sensory motor
(t = 4.01) regions and ↓ rCBF in left hippocampus
(t  = 3.96), left insula (t = 3.34), ventrolateral frontal
(right: t = 3.28; left: t = 4.22) and right middle
temporal region (t = 3.26) following treatment.
Vaiva et al. (2002) Patients (19): low-dose Amisulpride for 4 weeks,
100 mg/day; 9/19 previously treated, medication
free for 6 weeks, 10/19 antipsychotic-naïve
Healthy controls (0)
Follow-up
Affective withdrawal improvements: posterior frontal
rCBF (r = 0.46 to 0.48, p < 0.054), temporo-parietal
junction rCBF (r = 0.5, p = 0.034)
Anhedonia improvements: Antero-internal frontal
rCBF (r = −0.51, p = 0.003)
↑ rCBF in dlPFC (d = 0.4, p < 0.002) and right
posterior frontal cortex (d = 0.22, p = 0.007)
following treatment.
Corson et al. (2002) Patients (29): Haloperidol or Risperidone, for mean
27 days, all antipsychotic-naïve
Healthy controls (29): no intervention, scanned
only at baseline
Correlations not explored Analysis of a subset of 13 patients showing ↑ rCBF
in  caudate (left: d = 0.17; right: d = 0.70, p < 0.009)
and putamen (left: d = 0.22; right: d = 0.25,




















Miller et al. (2001) Patients (32): Haloperidol or Risperidone for 3
weeks, mean daily doses 11.2 ± 5.0 mg and
4.9 ± 2.8 mg respectively; 15/32 previously treated,
17/32 antipsychotic-naïve
Healthy controls (0)
Correlations not explored ↑ rCBF in left putamen (t = 3.0) and left posterior
cingulate gyrus (t = 4.1) and ↓ rCBF in left dl PFC
(t = 3.2), left frontal regions (t = 3.3), right straight
gyrus (t = 3.7) and left insular (t = 3.00) following
Haloperidol.
↓ rCBF in the left (t = 4.9/3.2) and right (t = 2.9)
cerebellum following Risperidone.
Yildiz et al. (2000) Patients (15): Haloperidol for one month, dosage
dependent on clinical status of patient; 6-15
previously treated, medication free for 1 month,
9/15 antipsychotic-naïve
Healthy controls (10): no intervention, scanned
only at baseline
No signiﬁcant correlations. Patients had ↓ baseline rCBF in left inferior
temporal (d = 2.39, p < 0.05) and left superior
temporal (d = 1.43, p < 0.05) regions than controls.
Following treatment, patients had ↓ rCBF in left
inferior temporal (d = 0.68) and left superior
temporal (d = 1.07) regions than controls.
Livingston et al. (1998) Patients (27): Haloperidol or Risperidone for six
months, dosages not reported, all
antipsychotic-naïve
Healthy controls (38): no intervention, scanned
only at baseline
No signiﬁcant correlations. ↑ rCBF in left putamen (p = 0.0001, mean
difference = 6.17) and right putamen (p = 0.004),
and ↓ rCBF in left inferior lateral frontal (p = 0.006)
and right inferior calcerine (p = 0.02) regions
following treatment.
Erkwoh et al. (1997) Patients (24): various antipsychotics (types not
speciﬁed), duration not reported, mean dose
616 mg/day CP equivalents, all antipsychotic-naïve
Healthy controls (20): patients examined for small
meningiomas, no intervention, scanned only at
baseline
Baseline
Delusions: Anterior cingulate cortex rCBF (r = −0.60)
Formal thought disorder: Inferior frontal rCBF
(r  = 0.64–0.68), left superior temporal rCBF (r = 0.62)
Grandiosity: Inferior frontal rCBF (0.60 to 0.62), right
inferior temporal rCBF (r = 0.68)
Persecution: Inferior frontal rCBF (r = −0.61 to −0.62),
superior left temporal rCBF (−0.64)
Stereotyped thoughts: Left superior temporal rCBF
(r  = −0.66), left parietal rCBF (r = −0.61)
Follow-up
Blunted affect: Left thalamic rCBF (r = −0.62)
Emotional withdrawal: Left basal ganglia rCBF
(r  = −0.60)
Difﬁculties in abstract thinking: Anterior cingulate
rCBF (r = −0.62), right basal ganglia rCBF (r = −0.61),
right thalamic rCBF (r = −0.62)
Lack of spontaneity: Left mesial temporal rCBF
(r = −0.62)
Stereotyped thoughts: Inferior temporal rCBF
(r  = −0.62 to −0.63), left mesial temporal rCBF
(r = −0.61).
At baseline patients showed↓ rCBF in bilateral
inferior frontal (p < 0.05), left superior temporal
(p < 0.05) and left superior temporal (p < 0.05)
regions compared with controls.
At follow-up patients showed ↓ rCBF in left inferior
frontal regions (p < 0.05) compared with controls.
Rodriguez et al. (1997) Patients (39): Clozapine, mean dose 551 mg/day for
six  months, all previously treated, sample includes
24 patients from previous study
Healthy controls (0)
Correlations not explored Responders had ↑ rCBF in thalamus (t = 4.66,
p  = 0.00003), basal ganglia (left: t = 4.12, p = 0.0002;
right: t = 3.28, p = 0.002), left lower prefrontal
cortex (t = 2.98, p = 0.005) and right upper
prefrontal cortex (t = 3.14, p = 0.003) at baseline.
In  responders there was  ↓ rCBF in thalamus
(t  = 3.05, p = 0.009), basal ganglia (right: t = 3.31,
p  = 0.005; left: t = 4.13, p = 0.001), upper
dorsolateral cortex (left: t = 2.67, p = 0.019; right:
t = 2.52, p = 0.025), and anterior prefrontal cortex
(left: t = 3.18, p = 0.007; right: t = 2.79, p = 0.015)
following treatment.
Non-responders showed no signiﬁcant changes.
Miller et al. (1997b) Patients (33): Clozapine, Haloperidol and others,
time between scans – 3 weeks; 25/33 previously
treated, 8/33 antipsychotic-naïve
Healthy controls (0)






















Reference Participants (n) and medication Correlations Main ﬁndings
Miller et al. (1997a) Patients (17): Clozapine, Haloperidol, Loxitane,
Olanzapine, Risperidone, Thiothixene or
Triﬂuoperazine, time between scans – 3 weeks;
14/17 medication free for 3 weeks, 3/17
medication-naïve
Healthy controls (0)
Correlations not explored (Order of scans differed between patients therefore
results reported for on- and off-medication states)
Whilst off medication patients had ↓ rCBF in
anterior cingulate cortex (d = 0.57), left
dorsolateral frontal cortex (d = 0.36), inferior
frontal cortex (d = 0.50) and bilateral cerebellum
(left: d = 0.49, right: d = 0.49).
On medication patients had ↑ rCBF in left basal
ganglia (d = 0.22) and left fusiform gyrus (d = 0.5).
Sabri et al. (1997) Patients (24): Bromperidol, Clozapine, Haloperidol,
Levomepromazine, sulpiride or thioridazine,
848.7 mg/day CP equivalents over an average of
96.8 days; all antipsychotic-naïve
Healthy controls (20): no intervention, scanned
only at baseline
Baseline
Sum positive score: Frontal, cingulate and left
temporal rCBF ratios (r = 0.30)
Sum negative scores: Frontal, cingulate and temporal
rCBF ratios (r = −0.30)
Delusional ideas, hallucinatory behaviour and
suspiciousness: Bifrontal, cingulate, left temporal and
left thalamic rCBF ratios (r = −0.59 to −0.66, p < 0.001
to p < 0.0005)
Formal thought disorder and grandiosity: Bifrontal and
bitemporal rCBF ratios (r = 0.59 to 0.70, p < 0.001 to
p  < 0.0005)
Stereotyped ideas: Left frontal, cingulate, left parietal
and left temporal rCBF ratios (r = −0.59 to −0.65,
p  < 0.001 to p < 0.0005)
Follow-up
Sum negative score: Frontal, cingulate, temporal, basal
ganglia and thalamic rCBF ratios (r = −0.59 to −0.80,
p < 0.001 to p < 0.0005). Affective ﬂattening and
emotional withdrawal: Frontal, temporal, basal ganglia
and thalamic rCBF ratios (r = −0.59 to r = −0.67,
p < 0.001). Difﬁculties with abstract thinking: Right
frontal, cingulate, basal ganglia and thalamic rCBF
ratios on the right (r = −0.63 to −0.74, p < 0.001 to
p < 0.0005). Decreased spontaneity and stereotyped
thinking: Bitemporal rCBF ratios (r = −0.59 to −0.71,
p  < 0.001 to p < 0.0005).
Paranoid subgroup of patients had ↑ baseline rCBF
in left parietal (d = 1.25, p < 0.05), left basal ganglia
(d = 1.00, p < 0.025) and right basal ganglia (d = 1.00,
p  < 0.025) compared with controls. They also
showed ↑ baseline rCBF in left inferior frontal
(d  = 1.95, p < 0.025) and right inferior frontal
(d  = 1.33, p < 0.025) regions compared to
non-paranoid patients.
Following treatment, the paranoid subgroup
showed ↓ rCBF in left inferior frontal regions
(d = 1.41, p < 0.025).
Rodriguez et al. (1996) Patients (24): 600 mg/day Clozapine for six
months; all previously treated
Healthy controls (0)
No signiﬁcant correlations. Non-responders had ↓ rCBF in thalamus (d = 1.85,
p  < 0.05), left basal ganglia (d = 1.34, p = 0.001) and
right prefrontal cortex (d = 1.40, p = 0.001) than
responders at baseline.
Following treatment, responders had↓ rCBF – left
basal ganglia (d = 1.59, p < 0.05) and thalamus
(d  = 1.25, p < 0.05) but non-responders showed no
signiﬁcant rCBF changes.
Warkentin et al. (1990) Patients (17; 10 measured at baseline and follow
up): Haloperidol, Flupenthixol, Perphenazine,
Thioridazine or Zuclopenthixol, duration not
reported; 6/10 medication free for 3–12 months,
4/10 medication-naïve
Healthy controls (10): no intervention, scanned
only at baseline
Baseline
‘Greater behavioural disturbance’: Right frontal to
occipital rCBF ratio (r = 0.916, p < 0.001), right frontal to
parietal rCBF ratio (r = 0.946, p < 0.0001), frontal rCBF
(r  = 0.905, p < 0.002), parietal rCBF (r = −0.881,
p  < 0.004).
↓ rCBF in left frontal-occipital ratio (t = 3.403,
p < 0.01) with left frontal-occipital ratio
signiﬁcantly lower than right (t = 2.661, p < 0.03)
following treatment.
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these differences may  be related to cognitive function, as left
hypofrontality was associated with neuropsychological impair-
ments on the Wisconsin Card Sorting Task (WCST). The authors also
suggested that speciﬁc patterns may  be related to particular symp-
tom complexes, ﬁnding greater frontal deﬁcits in paranoid patients
compared with greater temporal deﬁcits in non-paranoid patients.
Mori et al. (1999) assessed rCBF using Xenon-enhanced com-
puted tomography in 118 patients and 21 controls, reporting
signiﬁcantly smaller rCBF in all regions investigated (bilateral puta-
men, bilateral thalamus and regions around the anterior middle and
posterior cerebral artery) apart from one (right posterior cerebral
artery region).
The only study that compared medicated (n = 15) and unmed-
icated patients (n = 15) separately with 15 controls (Hook et al.,
1995) found that healthy controls and medicated, but not unmed-
icated, patients with schizophrenia had higher rCBF in frontal than
other regions, and higher left than right hemisphere rCBF, par-
ticularly in frontal areas. In contrast, unmedicated patients had
a tendency to greater right than left hemisphere rCBF in frontal
regions, suggesting that medication may  lead to perfusion patterns
more similar to those of healthy controls. Interestingly, medicated
and unmedicated patient groups did not differ on clinical meas-
ures, which may  reﬂect an underrepresentation of more severely
symptomatic patients.
Taken together the above cross-sectional studies suggest the
presence of baseline reductions in global rCBF in patients with
schizophrenia and provide some support for hypofrontality in
schizophrenia. However, most did not divide patients into those
medicated and unmedicated, leaving the precise role played by
antipsychotics on rCBF differences unclear.
3.1.3. Medicated schizophrenia versus unmedicated
schizophrenia
Seven studies directly compared medicated and unmedicated
patients with schizophrenia, with ﬁve reporting no global or
regional rCBF differences (Mathew et al., 1982, 1988; Gur et al.,
1983, 1985; Geraud et al., 1987; Dousse et al., 1988; Paulman et al.,
1990; Medoff et al., 2001).
Two studies found an effect of medication on rCBF. Gur et al.
(1983, 1985) reported an interaction between medication (a vari-
ety of naturalistically prescribed drugs, dose not stated), sex and
hemisphere. In men, higher rCBF was seen in the anterior right
hemisphere and posterior bilateral regions in those medicated than
those unmedicated. Women  showed higher bilateral rCBF both
anteriorly and posteriorly when medicated, but more speciﬁc brain
regions were not identiﬁed.
Medoff et al. (2001) used PET [15O]H2O to compare 10
haloperidol-treated (0.3 mg/kg/day) with 18 unmedicated patients
(mean wash-out 31 ± 17 days). They reported higher hippocampal
rCBF in the unmedicated than in the medicated group. Interest-
ingly, it has recently been reported that hippocampal perfusion
may  be ‘normalised’ or reduced following antipsychotic treatment
(Tamminga et al., 2012).
The remaining ﬁve studies did not ﬁnd rCBF differences between
medicated and unmedicated patients. Of note, there was  great
heterogeneity in illness duration, medication type and exposure
(duration and dosage). Interestingly, negative studies had usually
implemented short wash-out periods (less than two  weeks), leav-
ing open the possibility that antipsychotic effects could have been
still present. One cross-sectional study included medication-naïve
patients, and also reported no differences compared to treated
patients. However, the sample size was so small (n = 3) that it may
have lacked statistical power (Dousse et al., 1988). Instead, lon-
gitudinal studies of antipsychotic-naïve patients provide a more
powerful design to investigate potential effects.
3.1.4. Effects of dosage
Two  cross-sectional studies evaluated the effect of antipsy-
chotic dose on rCBF. Goldstein et al. (1990) reported that higher
dosage was associated with lower global rCBF in 15 patients. In a
larger sample of 118 patients with schizophrenia, Mori et al. (1999)
reported that a higher dose was associated with lower rCBF in the
thalamus. These studies suggest that there may  be a dose-response
relationship in rCBF changes and that dosage is an important vari-
able to consider in the interpretation of brain imaging studies.
3.2. Longitudinal studies
Longitudinal studies conducted over varying time intervals may
be more informative than cross-sectional designs on the direction
of causality. The inclusion of healthy controls allows for between-
subjects analyses, providing supplementary information on areas
affected by treatment independently of any underlying patho-
physiology. It also helps clarifying whether any longitudinal rCBF
change in patients represents normalisation, overcompensation or
continued abnormality. Studies in healthy controls can provide
information regarding the neurobiological changes elicited by
antipsychotics, without the confound of potential disease-related
pathology. However, to our knowledge only three studies inves-
tigating rCBF changes related to antipsychotic drugs in healthy
controls have been published. These are reviewed brieﬂy below.
Following this, we present ﬁndings from 21 longitudinal studies of
patients, 4 of which administered a single-dose of antipsychotic and
17 of which administered multiple-doses of antipsychotic medica-
tion.
3.2.1. Studies in healthy controls
In a longitudinal, placebo-controlled study, Fernández-Seara
et al. (2010) looked at the effects of a single 10 mg oral dose of meto-
clopramide (a dopamine D2 antagonist) in a group of 18 healthy
controls using arterial spin labelling (ASL). Using voxel-wise and
ROI approaches they found increases in the striatum, particularly
the putamen, as well as the thalamus. Meanwhile, decreased per-
fusion was  seen in the insula and anterior temporal lobe. Our group
(Handley et al., 2012) used ASL to investigate the effects of single-
dose haloperidol (3 mg)  or aripiprazole (10 mg) on rCBF using a
placebo-controlled, repeated measures design in a group of 20
healthy males. We found that both drugs were associated with
signiﬁcant rCBF increase in putamen and anterior cingulate when
compared with placebo. Aripiprazole was  also associated with rCBF
decrease in several regions, including the posterior cingulate, supe-
rior frontal and superior parietal areas. Finally, a third study looked
at low-dose amisulpride in 20 healthy men  and found an increase
in putamen perfusion, albeit at a trend level (Viviani et al., 2013).
They also reported widespread decreases in frontal cortical regions
and the anterior cingulate.
The very few studies that have been carried out in healthy con-
trols suggest that antipsychotics may  be associated with increased
perfusion in the striatum and other subcortical regions, and
decreased perfusion in cortical regions. However, different antipsy-
chotics appear to induce different patterns of perfusion change and
therefore dose, type and duration of treatment are all important
considerations when interpreting results.
3.2.2. Single-dose studies
Four studies reported on rCBF minutes or hours after a single-
dose of haloperidol or olanzapine (Jibiki et al., 1990–1991; Matsuda
et al., 1990; Goldman et al., 1996; Lahti et al., 2005).
A small study used 99mTcHMPAO SPECT in two  unmedicated
patients and two  healthy controls before and after a single dose
of 0.08 mg/kg IM haloperidol and found hemispheric perfusion
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reduction in one patient and one control but little or no effect in
the others (Jibiki et al., 1990–1991).
Another study administered 5 mg  IM haloperidol to three
patients with schizophrenia and two healthy controls (Matsuda
et al., 1990). Post-treatment all subjects showed increased frontal-
to-temporal, frontal-to-parietal and frontal-to-occipital ratios,
more extensive in patients. No change was found in the frontal-
to-striatal ratios. Patients also changed from higher left-than-right
rCBF in all cortical areas at baseline to higher right-than-left rCBF
following haloperidol. Of note, no test for signiﬁcance was  reported
for these changes.
The largest study used PET [15O]H2O in 12 patients with
schizophrenia administered a single-dose of either 10 mg  haloperi-
dol or 15 mg  olanzapine (Lahti et al., 2005). Both antipsychotics
were associated with an increase in rCBF in the caudate (as well as
differential effects as below).
Finally, one study failed to ﬁnd any rCBF changes after admin-
istration of 5 mg  haloperidol in patients with schizophrenia, but
reported increased global rCBF in controls (Goldman et al., 1996).
It is possible that acute effects are not seen in individuals chron-
ically exposed to antipsychotics after a wash-out period of two
weeks. Inconsistencies may  also be explained by Goldman’s use
of 133Xenon inhalation to gain crude global measures of rCBF as
opposed to the voxel-by-voxel analysis of PET used by Lahti’s
group. Additionally, Goldman’s group investigated changes over
three hours whereas Lahti’s group considered individual drug phar-
macokinetics to capture changes, incorporating the plasma Tmax,
which may  further explain some of these inconsistencies.
Longitudinal single-dose studies suggest an effect of antipsy-
chotics on brain physiology within hours of administration.
However, changes in clinical measures are not seen within hours
of antipsychotic administration and so cannot be investigated by
acute studies. In addition, these few studies, with small, heteroge-
neous samples and variable methodologies make it difﬁcult to draw
conclusions.
3.2.3. Multiple-dose studies
Seventeen studies assessed rCBF longitudinally, before and after
treatment lasting between three weeks to six months, and are dis-
cussed here. Studies that divided patients according to treatment
response are discussed later.
3.2.3.1. Pre- and post-treatment scans within patients. Eleven longi-
tudinal studies reported within group pre- and post-treatment rCBF
changes in patients with schizophrenia (Warkentin et al., 1990;
Sabri et al., 1997; Rodriguez et al., 1996, 1997; Miller et al., 1997a,
1997b, 2001; Livingston et al., 1998; Corson et al., 2002; Lahti et al.,
2003; Novak et al., 2005).
Seven studies identiﬁed frontal perfusion changes following
antipsychotic treatment. Two reported an increase in perfusion
in the dorsolateral prefrontal cortex and inferior frontal regions
following several weeks of treatment in previously antipsychotic-
naïve patients (Sabri et al., 1997; Novak et al., 2005). In contrast,
two studies reported decreased frontal rCBF following treatment
(Warkentin et al., 1990; Livingston et al., 1998). Interestingly, Miller
et al. (1997a, 1997b, 2001) reported increases in frontal perfusion
following withdrawal from antipsychotics.
Sample heterogeneity and methodological differences (includ-
ing location and extent of regions investigated, imaging modality
and previous antipsychotic exposure in addition to antipsychotic
type) may  account for these inconsistencies (Marco et al., 1997).
Alternatively, hypofrontality may  be associated only with cer-
tain subtypes of schizophrenia. Consistent with this, frontal rCBF
increases after treatment have been reported in paranoid patients
(Sabri et al., 1997) and in those with prominent negative symptoms
and poor treatment response (Vaiva et al., 2002).
Changes in rCBF have also been reported in the BG.  Five reported
increased rCBF following both ﬁrst and second generation antipsy-
chotics (Livingston et al., 1998; Miller et al., 1997a, 1997b, 2001;
Corson et al., 2002; Lahti et al., 2003). However, one study reported
a decrease in rCBF following a switch from ‘classical’ antipsychotics
to clozapine, indicating differential effects in this region (Rodriguez
et al., 1996, 1997). Three studies did not report rCBF changes in the
BG at all following antipsychotics (Vaiva et al., 2002; Novak et al.,
2005; Ertugrul et al., 2009).
Evidence for perfusion changes in temporal regions has been
inconsistent. One study showed hyperperfusion of the temporal
lobe, which changed to be more similar to that of healthy controls
following treatment (Sabri et al., 1997). Increased fusiform gyrus
rCBF was  seen following treatment in a pilot but not in a larger
follow-up study (Miller et al., 1997b, 2001). Lahti et al. (2009) found
decreased rCBF in various temporal regions following treatment
with haloperidol. Further divisions of the temporal lobe may eluci-
date a more complicated pattern of rCBF changes associated with
treatment.
In summary, within-subjects comparisons suggest an associa-
tion between antipsychotic administration and frontal perfusion
changes, although the direction of change may  depend on the sub-
region or even the subtype of schizophrenia investigated. The most
consistent ﬁnding in these studies is the increase in BG rCBF follow-
ing treatment. The inclusion of a control group might help elucidate
which patterns of abnormality are associated with the disorder.
3.2.3.2. Pre- and post-treatment scans in patients compared with
single scan in healthy controls. Six studies compared pre- and post-
treatment rCBF in patients with schizophrenia with healthy control
scans taken at a single time point (Warkentin et al., 1990; Erkwoh
et al., 1997; Sabri et al., 1997; Livingston et al., 1998; Yildiz et al.,
2000; Corson et al., 2002).
Results for frontal regions have varied. In a group of 27
antipsychotic-naïve patients, hypofrontality was evident before
treatment in medial frontal regions and remained evident follow-
ing six months of haloperidol or risperidone (Livingston et al.,
1998). Erkwoh et al. (1997) found lower frontal rCBF in patients
compared with controls at baseline that, however, only remained
evident in the left hemisphere following treatment with various
antipsychotics. In contrast, Warkentin et al. (1990) found lower left
frontal-occipital rCBF ratios in patients following treatment only.
Interestingly, another study reported hypofrontality in some
patients (n = 3) but hyperfrontality in others (n = 9) at baseline
compared with healthy controls (Sabri et al., 1997). At follow-up,
two-thirds of subjects in each group had perfusion values similar to
those of controls, with the other third showing only a tendency to
similar values. The subgroup of patients with paranoid symptoms at
baseline had higher parietal and BG rCBF than healthy controls, and
higher inferior frontal rCBF than paranoid-hallucinatory patients.
Following treatment, rCBF in this region decreased in the paranoid
subgroup.
Two multiple-dose longitudinal studies reported increased BG
rCBF following antipsychotics (Corson et al., 2002; Livingston et al.,
1998). Interestingly, Corson et al. (2002) did not ﬁnd differences
in BG rCBF between antipsychotic-naïve and healthy controls at
baseline, supporting the notion that some rCBF alteration in this
brain region may  be underpinned by antipsychotic action.
Differences in rCBF have also been reported in temporal regions.
Fifteen patients (six with one month antipsychotic wash-out and
nine antipsychotic-naïve) showed lower rCBF in left superior and
inferior temporal regions compared with ten controls both at base-
line and follow-up (Yildiz et al., 2000). Previous antipsychotic
exposure may  have masked some alterations. Indeed, another
study in antipsychotic-naïve patients showed that lower superior
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temporal regions perfusion seen at baseline in patients disappeared
following antipsychotic treatment (Erkwoh et al., 1997).
In summary, longitudinal studies provide more robust evi-
dence of changes following treatment, but are subject to similar
methodological criticisms as cross-sectional studies, including
heterogeneity in prior antipsychotic exposure, illness chronicity,
clinical presentation and methodology. Nevertheless, rCBF in BG
and frontal regions appears to be affected by treatment, whilst
evidence is less consistent for temporal regions.
3.3. Differential effects of antipsychotics
Elucidating areas of commonality and difference by controlled
comparison of different antipsychotics may  allow drug-speciﬁc
clinical effects to be attributed to regional brain effects. We  found
six studies directly comparing antipsychotics: three compared
haloperidol and a SGA other than clozapine (Corson et al., 2002;
Miller et al., 2001; Lahti et al., 2009), three compared FGAs with
clozapine (Lahti et al., 2003, 2005; Sharaﬁ, 2005).
A ROI study investigated caudate and putamen perfusion,
reporting no differences between haloperidol and risperidone
administered for approximately four weeks (Corson et al., 2002).
However, participants were prescribed relatively high doses of
risperidone (mean 5.5 mg/day) at which the drug may  act simi-
larly to FGAs (Nyberg et al., 1999). Indeed, four studies reported
that FGAs are associated with greater striatal rCBF increases (Miller
et al., 2001; Lahti et al., 2003, 2005, 2009), which may  also explain
their different side effect proﬁles (Davis et al., 2005; Vita and De
Peri, 2007).
Cortical areas also demonstrate susceptibility to antipsychotic-
generation speciﬁc effects. One study reported greater frontal
decreases with FGAs (Miller et al., 2001), with SGAs associated with
greater increases in frontal, parietal, temporal and occipital cortical
rCBF (Lahti et al., 2003, 2005, 2009; Sharaﬁ, 2005).
Antipsychotic generation should therefore be considered when
investigating treatment effects on brain physiology.
3.4. rCBF and clinical measures
Although most studies reported measures of symptomatology,
these were not always related to measures of resting rCBF before
or after treatment.
3.4.1. Cross-sectional studies
Five cross-sectional studies correlated rCBF with symptom
scores, some ﬁnding none signiﬁcant (Gur et al., 1983, 1985).
Mathew et al. (1988) reported small positive correlations between
total Brief Psychiatric Rating Scale (BPRS) and parietal, central and
temporal rCBF whilst Paulman et al. (1990) reported mean positive
symptom scores moderately positively correlated with absolute
right and left hemisphere ﬂows, whilst negative symptom scores
moderately positively correlated with left parietal rCBF ratio.
Correlations with speciﬁc symptoms have been also reported in
three cross-sectional studies. Two studies reported negative asso-
ciations between hallucinations and temporal and occipital rCBF
(Mathew et al., 1982; Dousse et al., 1988), perhaps consistent
with suggestions that hallucinations are associated with changes
in cortical regions underlying the sensory modality of the hallu-
cination (Allen et al., 2008). Temporal rCBF was  also positively
correlated with suspiciousness, whilst left parietal rCBF correlated
with withdrawal and several regions correlated positively with
unusual thought content (Mathew et al., 1988).
3.4.2. Longitudinal studies
Unlike cross-sectional designs, longitudinal studies allow
changes in symptoms during treatment to be investigated. Five
longitudinal studies reported no signiﬁcant correlations between
rCBF at either baseline or follow-up and psychotic symptom scores
(Miller et al., 1997a, 1997b; Livingston et al., 1998; Novak et al.,
2005; Yildiz et al., 2000). One study reported greater frontal rCBF
in more ‘behaviourally disturbed’ patients (Warkentin et al., 1990).
Six longitudinal studies reported clinical improvement follow-
ing antipsychotic treatment (Warkentin et al., 1990; Sabri et al.,
1997; Erkwoh et al., 1997; Livingston et al., 1998; Yildiz et al.,
2000; Sharaﬁ, 2005) although four found improvement in posi-
tive but not negative symptoms (Sabri et al., 1997; Erkwoh et al.,
1997; Livingston et al., 1998; Miller et al., 2001). In two  studies
rCBF in several regions correlated with positive symptoms before
but not after treatment (Sabri et al., 1997; Erkwoh et al., 1997).
In these studies, higher severity of delusions, hallucinations and
suspiciousness correlated with lower frontal, cingulate, temporal
and thalamic rCBF, whilst more severe formal thought disorder and
grandiosity were associated with higher frontal and temporal rCBF
at baseline. Stereotypy was the only negative symptom associated
with rCBF at baseline, with reported positive associations in left
frontal, parietal and temporal regions. Following treatment, posi-
tive symptoms tended to have remitted, although several regions
showed associations with negative symptoms. Also, frontal, tempo-
ral, thalamic and BG ﬂow was negatively correlated with ﬂat affect,
withdrawal, abstract thinking and stereotypy (Sabri et al., 1997;
Erkwoh et al., 1997).
In summary, presence of positive symptoms has been con-
sistently associated with rCBF in several regions and tended to
remit following antipsychotic treatment. In contrast, fewer neg-
ative symptoms were associated with rCBF at baseline, although
several were associated with regional rCBF at follow up. Nega-
tive symptoms remain difﬁcult to treat, despite the introduction of
SGAs, reported to have greater efﬁcacy in this symptom domain. In
addition, there may  be aetiological heterogeneity amongst negative
symptoms, which may  explain inconsistencies in the association
with brain physiology measures.
3.5. Perfusion and treatment response
A priori deﬁnitions of treatment response may  reveal regions
important for antipsychotic action and potentially facilitate pre-
diction of response. Four longitudinal studies looked at treatment
response in this manner (Rodriguez et al., 1996, 1997; Lahti et al.,
2009; Ertugrul et al., 2009).
In two studies of refractory patients switched from FGA to cloza-
pine for six months, good response to clozapine was associated
with higher baseline (FGA-treated) BG rCBF, which decreased fol-
lowing switching (Rodriguez et al., 1997). In contrast, non-response
to clozapine was  associated with lower BG rCBF, which remained
unaltered following treatment, suggesting that baseline and change
carry some predictive value in response to this antipsychotic.
Importantly, patients were receiving antipsychotics at the time
of the baseline scan and therefore the possibility that antipsy-
chotic action could already be associated with some elevation in
BG rCBF in responders cannot be dismissed. In line with this, a
placebo-controlled, blind and randomised trial, demonstrated that
increased ventral striatal rCBF was  associated with a good response
after one week and six weeks treatment with both haloperidol and
olanzapine (Lahti et al., 2009). Increased thalamic and lower hip-
pocampal rCBF were also related to good response to haloperidol at
six weeks, whilst higher cerebellar rCBF and lower medial frontal,
parietal and anterior cingulate cortex rCBF were related to response
to olanzapine.
Associations between rCBF in the thalamus and frontal cortex
with ‘response’ or symptoms were also reported. Rodriguez et al.
(1997) reported that increased baseline rCBF in the dorsolateral
prefrontal cortex (dlPFC) was  evident in responders and decreased
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Table 4























Miller et al. (1997a) 1 0.5 0 0.5 1 1 4
Lahti et al. (2003) 1 0 1 0 1 0 3
Lahti et al. (2009) 1 0 1 1 1 0 4
Each criteria was  scored as follows: (1) same scanner and sequence used for each subject (different scanner or sequence = 0, same scanner and sequence = 1); (2) patient
group  was  antipsychotic-naïve (yes = 1, mixed group = 0.5, no = 0); (3) drugs administered according to a protocol for dose regime (yes = 1, no = 0); (4) drugs administered
according to a protocol for duration (yes = 1, no = 0); (5) withdrawals explained (yes/none reported = 1, no = 0); (6) global rCBF controlled for in analysis (yes = 1, no = 0).
with treatment. Thalamic and prefrontal rCBF ratios (using the
homolateral cerebellar hemisphere value as a reference) correctly
predicted response in 78.9% of cases. Ertugrul et al. (2009) reported
that baseline frontal/thalamus rCBF predicted percentage change
in Positive and Negative Syndrome Scale of Schizophrenia (PANSS)
score following eight weeks of clozapine. It is noteworthy that
the remission criteria used in this study did not relate to clinical
remission and therefore ‘treatment responders’ may have still been
severely ill.
Previous exposure to antipsychotics makes it difﬁcult to discern
whether these effects resulted from treatment withdrawal, chronic
antipsychotic use or the study drug. Further work should elucidate
which biomarkers can predict treatment response to translate such




Table 4 shows the results of the quality assessment. Studies
scored on average 3.7 out of 6. Most studies did not recruit an
antipsychotic-naïve patient group, but this is not unusual, as it can
be methodologically difﬁcult to recruit a large enough sample of
this kind. No study was considered of such poor quality that they
should be excluded from the meta-analysis, especially consider-
ing the exploratory nature of this analysis. However, caveats stated
elsewhere in this paper should be borne in mind when interpreting
the results.
3.6.2. Meta-analysis results
Three longitudinal studies were identiﬁed for inclusion in
a meta-analysis (Miller et al., 1997a; Lahti et al., 2003, 2009).
Although the number of studies was small, data of ﬁve groups
of patients was available and it was judged that supplementing
the above qualitative review with quantitative coordinate-based
data was of value in determining brain regions with associations
with rCBF and antipsychotic use. However, results should be inter-
preted with caution, due to the small number of datasets and the
exploratory nature of the analysis.
Five groups of patients were available for analysis, as one study
presented data for one group of patients (Miller et al., 1997a)
and two studies presented data for two groups of patients each
treated with different antipsychotics (Lahti et al., 2003, 2009). The
data were resampled in this manner to allow extraction of peak
coordinates from the papers, which were presented separately for
each antipsychotic administered. Coordinates for these groups of
patients as a whole were not available.
Lahti et al. (2003) recruited six patients, four of which were
scanned at baseline, then following haloperidol and again after
treatment with clozapine, thus giving data for two overlapping
groups of ﬁve patients. Lahti et al. (2009) treated patients with
either haloperidol or olanzapine in two independent samples. This
gave ﬁve patients groups (Table 5), two  (non-independent) groups
from Lahti et al. (2003), two independent groups from Lahti et al.
(2009) and a single group from Miller et al. (1997a). The ﬁnal sample
included 56 patients scanned before and after treatment.
Results (Table 5) revealed a large cluster in the left caudate rep-
resenting increased rCBF following treatment with antipsychotic
medication (Z = 2.981; p < 0.0001). Decreases in rCBF after treat-
ment were evident in the right medial frontal gyrus (Z = −3.597;
p < 0.0001), cerebellum (right uvula; Z = −3.539; p < 0.0001 and
left declive; Z = −2.231; p < 0.001) and right thalamus (Z = −2.052;
p < 0.01). These regional alterations are shown in Fig. 1 overlaid on
a template (Table 6).
3.6.3. Robustness of the results
Robustness of the results was tested via two  supplementary
analyses: heterogeneity analysis and jack-knife analysis. The jack-
knife analysis is a type of sensitivity analysis which supplements
the main meta-analytical ﬁndings and indicates how robust they
are with respect to study inclusion. Jack-knife resampling deter-
mines how sensitive the ﬁnal results are to leaving different studies
out of the analysis. The number of jack-knife resampling analyses
is equal to the number of datasets included, and in each analysis a
dataset is excluded in turn.
Additionally, the analysis was separately rerun excluding both
patient groups from Lahti et al. (2003) and then again excluding
both patient groups from Lahti et al. (2009) to ensure that the
methodology of particular studies did not drive the results.
Heterogeneity analysis reveals regions showing between-study
variability. This analysis showed two  of the regions identiﬁed had
high heterogeneity: the right medial frontal gyrus and the right
uvula. This suggests that reductions in these regions are perhaps
less robust.
In the jack-knife analysis the left caudate remained signiﬁcant
in three out of ﬁve analyses. The most replicable decrease in rCBF
was in the right medial frontal gyrus, which only failed to remain
signiﬁcant in one combination out of ﬁve. Decreases in rCBF in
the right thalamus also remained signiﬁcant in three out of ﬁve
combinations. Other signiﬁcant clusters from the main analysis
failed to remain signiﬁcant in more than two  combinations. Rerun-
ning the analysis excluding all patients from Lahti et al. (2003),
showed all changes remained signiﬁcant except the left declive
decrease. When excluding all patients from Lahti et al. (2009), only
the right medial frontal gyrus cluster remained signiﬁcant, sug-
gesting the other ﬁndings may  be driven by this study. Thus overall
the decrease in the right medial frontal gyrus was the most robust
ﬁnding followed by increases in the right thalamus. However the
cerebellar ﬁndings were less reliable.
These analyses support some of the ﬁndings seen in the system-
atic review and suggest antipsychotics are robustly associated with






















Subset of studies included in an exploratory meta-analysis, with reported regions and co-ordinates.
Study Patients (n) Antipsychotic prescribed Coordinates and region identiﬁed with increased CBF Coordinates and region identiﬁed with decreased CBF
Lahti et al. (2003) 5 Haloperidol 28, 8, −12 Right ventral striatum 28, −40, −6 Right hippocampus
−20,  16, 6 Left caudate −46, 12, −2 Left insula/ventrolateral frontal
−30,  −4, 6 Left putamen 52, 16, 16 Right dorsolateral frontal
46, 32, 42 Right dorsolateral frontal 8, −80, −16 Right occipital
−18, −98, −14 Left occipital
Lahti et al. (2003) 5 Clozapine 32, 4, −12 Right ventral striatum −30, −28, −10 Left hippocampus
−14,  8, 16 Left caudate 50, 34, −4 Right ventrolateral frontal
34,  22, 22 Right dorsolateral frontal −44, 34, −6 Left ventrolateral frontal
−50,  −8, 26 Left dorsolateral frontal 10, 64, 2 Superior frontal
−26,  16, 36 Left dorsolateral frontal −38, 2, 52 Left sensory motor
Lahti et al. (2009) 12 Haloperidol −22, 12, 6 Left putamen/ventral striatum 34, −78, −26 Right cerebellum
−20,  4, −10 48, −48, −38
34, −40, 44 Right inferior parietal 22, −76, −28
34, −34, 50 50, 6, −2 Right insula/superior temporal/inferior frontal
28,  8, 6 Right putamen 40, 14, −14
18,  16, −6 Ventral striatum −46, −66, −46 Left cerebellum
28,  0, −10 −14, −74, −32
−44, −14, 30 Left post central cortex −14, −84, −28
−38, −18, 18 −46, 6, −8 Left superior temporal
−16,  −14, 0 Left thalamus 28, 38, 38 Right superior frontal
−6,  6, −4 Left caudate 60, −22, −28 Right inferior temporal
−8, 2, 4 10, 58, 18 Anterior cingulate cortex/medial frontal cortex
−18,  −24, 58 Left post central cortex 4, 60, 0
−48, −44, 32 Left inferior parietal −34, 12, 10 Left insula/superior temporal/inferior frontal
−42,  −40, 44 54, −60, 38 Right inferior parietal/gyrus angularis
58, −60, 38
64, −50, −6 Right middle temporal
62, −42, −14
58, −2, −30 Right middle temporal
24, −24, −12 Right parahippocampus
−8, −14, −18 Midbrain
Lahti et al. (2009) 17 Olanzapine 66, −14, 16 Right post central cortex 0, 52, 22 Anterior cingulate cortex/medial frontal
58,  −46, 38 Right inferior parietal 14, −18, 12 Right thalamus
60,  −30, 36 20, −20, 2
16,  −56, 66 Right superior
parietal/superior
occipital
10, −78, −22 Cerebellum
30,  −62, 60 14, −92, −14
24, −72, 46 12, −66, −18
50, −36, −2 Right middle temporal −10, −12, −14 Midbrain
58,  −32, −12 −12, −26, 2 Left thalamus
−28,  −54, 64 Left superior parietal
−22, −60, 60
−42, 22, 28 Left middle/inferior frontal
8, 4, −10 Right ventral striatum
Miller et al. (1997a,
1997b)
17 Various (65% ﬁrst generation, 35%
second generation)
−13, 5, −6 Left putamen −27, 18, 38 Left dorsolateral frontal
−28,  −83, −2 Left fusiform 10, 36, −28 Inferior frontal
3, 43, 16 Anterior cingulate cortex
−24, −84, −26 Left cerebellum
26, −80, −24 Right cerebellum
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Fig. 1. Main (a) increased (red) rCBF in left caudate and (b) decreased (blue) rCBF in medial frontal gyrus, cerebellum and right thalamus, following antipsychotic treatment
in  patients with schizophrenia. Signiﬁcant regions are overlaid on a template from MRIcron (www.mricro.com/mricron) for illustration.
Table 6
Regions identiﬁed by the SDM analysis as showing signiﬁcant increases or decreases
in rCBF following antipsychotic treatment.
Brain region Talairach
coordinates
Z score p value
Increased rCBF
Left caudate −6, 8, −2 2.981 p < 0.0001
Decreased rCBF
Right medial frontal gyrus 6, 42, 24 −3.597 p < 0.0001
Cerebellum (right uvula) 16, −76, −24 −3.539 p < 0.0001
Cerebellum (left declive) −16, −86,
−22
−2.231 p < 0.001
Right thalamus 20, −24, 0 −2.052 p < 0.01
4. Conclusions
These studies do suggest that antipsychotic medications induce
changes in rCBF, particularly in striatal, frontal and temporal
regions, which are also reported to show structural changes
(Dazzan et al., 2005; Navari and Dazzan, 2009). This review also
provides further evidence that different antipsychotics have dif-
ferent regional effects on rCBF. Although some of these changes
appear to be associated with clinical improvement, the ways in
which patterns of brain physiology relate to symptoms is still not
clear. Altogether, this evidence suggests rCBF is a good candidate
biomarker for treatment response to antipsychotics, although very
few studies have investigated this potential thus far.
4.1. Differential antipsychotic effects on regional rCBF
Various study designs and methodologies have shown global
and regional alterations in rCBF following administration of a
number of antipsychotic drugs. Longitudinal studies provide the
most consistent evidence that antipsychotics affect rCBF regionally,
within hours and even minutes after administration. Longer term
changes are also observed in multiple-dose studies, with striatal,
frontal and temporal regions most consistently implicated. Still,
studies have been small and tended to produce mixed ﬁndings. Evi-
dence from cross-sectional studies is less strong, with many studies
failing to account for medication status or ﬁnding no differences
when medicated and unmedicated patients are compared. This may
be due to methodological inconsistencies and subject heterogene-
ity, including differences in previous antipsychotic exposure or the
use of multiple antipsychotics.
The mechanisms by which antipsychotic medications lead to
alterations in rCBF remain unclear. The concept of neurovascu-
lar coupling suggests that rCBF reﬂects metabolism, such that
areas of enhanced post-synaptic activity have a greater metabolic
demand, and that perfusion is modulated to meet this demand
(Logothetis et al., 2001). Rather than reﬂecting spiking activity,
haemodynamic changes may  depend upon synaptic processes,
with postsynaptic metabolism making the greatest contribution
(Lauritzen, 2001).
All currently licensed antipsychotics antagonise the D2
dopamine receptor and treatment response has been shown to be
related to the level of D2 occupancy (Kapur et al., 2000). It would
be expected therefore that changes occur in areas more densely
populated with D2 receptors, such as the striatum. Antagonism
at these receptors would lead to alterations in neurotransmit-
ter turnover, in turn inducing metabolic and perfusion changes.
It is possible that increased rCBF reﬂects increased presynaptic
synthesis and release of dopamine due to decreased negative feed-
back via autoreceptors. Meanwhile, decreased rCBF in frontal and
temporal regions may  reﬂect either inhibitory or excitatory down-
stream effects, in areas that are innervated by densely D2 populated
regions.
Furthermore, antipsychotics from different generations may
induce different effects on rCBF, with indications that atypicality
may  be responsible for some of these differences. Our results sup-
port this assertion, as greater subcortical effects (particularly in
the BG) are evident following treatment with FGAs and greater
cortical effects following treatment with SGAs. These differences
may  reﬂect the receptor binding proﬁles of FGAs and SGAs. Com-
pared to FGA, SGAs tend to bind with less afﬁnity to D2 receptors
and show more afﬁnity for the serotoninergic system, particularly
5HT2A receptors. The balance between the effects at each of these
receptors decreases the effective occupancy at D2 receptors of a
particular dose (Stahl, 2003).
Understanding differences in the mechanisms underlying
antipsychotic action of different medications could aid clinical
management in schizophrenia. It can illuminate the different clin-
ical characteristics of the drugs, for example changes induced by
FGA in the BG may underlie the motor side effects more frequently
associated with these drugs. Furthermore, it may  facilitate strati-
ﬁed medicine, whereby treatment could be more targeted, taking
into account individual neurobiology. Finally, it also highlights the
importance of carefully considering dose and duration of treatment
and type of antipsychotic used in the design and interpretation of
neuroimaging studies.
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4.2. Correlations between rCBF and clinical measures
If antipsychotics do have speciﬁc, regional effects on rCBF, it can
be questioned how these changes relate to clinical variables. The
evidence reviewed suggests a relationship between rCBF and either
composite symptom scores (such as total BPRS score) or speciﬁc
symptoms, with positive symptoms particularly related to frontal
and temporal perfusion at baseline but few negative symptoms
showing correlations with rCBF before treatment.
Furthermore, longitudinal studies suggest that following treat-
ment positive symptoms tend to remit, whilst negative symptoms
are seen at follow up and are associated with frontal, temporal, tha-
lamic and BG perfusion. Clinical reports and research both suggest
that negative symptoms often fail to remit following antipsychotic
treatment. The underlying aetiology and neurobiological dysfunc-
tion associated with negative symptoms must be elucidated in
order to develop new medications that can effectively treat them.
Measures of physiology such as rCBF have the potential to allow
stratiﬁcation of patients according to symptomatology and related
perfusion patterns. In addition, understanding the brain physiology
underlying psychotic symptoms and alterations with treatment is
also a prerequisite for establishing rCBF as a marker of treatment
response.
Unfortunately, relating imaging measures to clinical measures
in schizophrenia has proven difﬁcult, with small sample sizes, poor
measurement reliability and validity, difﬁculties inferring causa-
tion and medication impeding attempts to uncover the primary
pathophysiology of symptoms (Mathalon and Ford, 2012). Inter-
preting localised alterations in perfusion in relation to symptoms
should be done with care. Medication may  have an effect on the
neurovasculature that is widespread across the brain. Yet, even
when global changes are accounted for (as, for example, in Handley
et al., 2012) regional changes remain, suggesting speciﬁc vascular
effects occur in areas such as the BG. What exactly these regional
changes represent and how best to relate them to psychiatric
symptoms is still a matter of contention. One should be wary of
interpreting such changes in perfusion as altered patterns of activa-
tion, as several factors can inﬂuence brain haemodynamics besides
neural activity.
4.3. Predicting treatment response
The evidence reviewed suggests that neurophysiological meas-
ures such as perfusion of the BG, thalamic and frontal regions may
relate to the effect of antipsychotic treatment, and thus prove useful
in predicting later response to treatment. However, very few stud-
ies investigated the predictive value of rCBF using predetermined
deﬁnitions of treatment response. Conceptualising good response
is important in order to standardise across studies, to provide
testable a priori hypotheses and to ensure clinical applicability of
remission criteria. Advancing our knowledge on the potential pre-
dictive role of rCBF could inform attempts to personalise treatment
of schizophrenia and provide novel targets for development of new
medications.
4.4. Implications for future research
rCBF may  provide a useful predictive biomarker for treatment
response to antipsychotics in schizophrenia. While functional mag-
netic resonance imaging (fMRI) data represent a complicated mix
of parameters (rCBF, cerebral blood volume and oxygen consump-
tion), perfusion imaging can provide absolute quantiﬁcation of a
single parameter either at rest or within an activation paradigm.
Resting CBF provides information on basal brain activity and
understanding the effects of antipsychotics on this physiological
marker may  also help clarifying which mechanisms underlie other
(structural and functional) illness-related brain changes (Scheepers
et al., 2001). Of note, changes in rCBF patterns following antipsy-
chotic administration occur in the same brain regions reported as
altered in psychosis. Additionally, CBF is closely correlated with
neuronal metabolic measures (Raichle et al., 1976) and modern
perfusion techniques such as arterial spin labelling (ASL) provide
measures of CBF that correlate with regional brain activity mea-
sured using other techniques (Uludag et al., 2004). Furthermore,
ASL is non-invasive and since it does not require ionising radia-
tion, is ideally suited to the multiple-point, longitudinal evaluation
required in pharmaco-imaging studies. This review suggests that
baseline patterns of rCBF and changes with treatment in rCBF
are related to treatment response to antipsychotics and there is
promise that these differences predict clinical outcomes.
Identifying biomarkers to predict treatment response in
schizophrenia is a major goal of translational psychiatry and could
inform interventions, allowing the illness course to be altered early
on. The hope for the future however is that much subtler differences
in brain structure, physiology and chemistry will be identiﬁed to
aid differential diagnosis and allow individualised prescribing and
treatment planning depending on individual biology and clinical
presentation of patients.
Appendix A.
A.1. Estimation of effect sizes
For all contrasts and associations, reported estimates of the
strength of the effects were extracted when given (either Pearson’s
r, or Cohen’s d). Where these were not reported but could be cal-
culated from the data in the original paper, a Cohen’s d effect size
estimate was calculated using the formulae below (Thalheimer and
Cook, 2002). Otherwise, the statistical test and p value are reported
as in the original paper.
For independent groups:
Mean rCBF of experimental group − Mean rCBF of control group
Pooled standard deviation
For dependent groups:
Although effect sizes would be ideally calculated using a mean
rCBF change score in patients and controls, together with a pooled
standard deviation of the change, rCBF change scores are rarely
reported for both patients and controls. In most studies, controls are
only scanned on one occasion and so change scores cannot always
be calculated. For these studies, the following formula was used to
calculate an effect size estimate for the change in patients (Dunlop
et al., 1996):
Mean rCBF (baseline) − Mean rCBF (follow-up)
Pooled standard deviation (baseline and follow-up)
When an effect size could not be calculated from the data avail-
able, the statistical test and the p value were reported as in the
original paper. When papers reported t-tests or F-tests, we  calcu-
lated effect sizes (Thalheimer and Cook, 2002).
We grouped studies according to study design: cross-sectional,
longitudinal single-dose, and longitudinal multiple-dose. Results
of the cross-sectional studies are presented for each compari-
son (schizophrenia patients versus healthy controls, medicated
schizophrenia versus unmedicated schizophrenia). Longitudinal
studies contrast pre-treatment and post-treatment rCBF in a single
group or compare patients and controls before and after treatment.
We  also report results for studies comparing treatment with differ-
ent antipsychotic generation and those reporting associations with
clinical variables or treatment response.
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